BTN3A3 evasion promotes the zoonotic potential of influenza A viruses | Nature Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement View all journals Search Log in Explore content About the journal Publish with us Subscribe Sign up for alerts RSS feed nature articles article Article Published: 28 June 2023 BTN3A3 evasion promotes the zoonotic potential of influenza A viruses Rute Maria Pinto1 nAff6, Siddharth Bakshi1 na1, Spyros Lytras ORCID: orcid.org/0000-0003-4202-66821 na1, Mohammad Khalid Zakaria1 na1, Simon Swingler1, Julie C. Worrell ORCID: orcid.org/0000-0001-7754-13642, Vanessa Herder1, Kerrie E. Hargrave2, Margus Varjak1 nAff7, Natalia Cameron-Ruiz1, Mila Collados Rodriguez1, Mariana Varela1, Arthur Wickenhagen1, Colin Loney1, Yanlong Pei3, Joseph Hughes ORCID: orcid.org/0000-0003-2556-25631, Elise Valette1, Matthew L. Turnbull ORCID: orcid.org/0000-0002-7234-58711, Wilhelm Furnon ORCID: orcid.org/0000-0002-5588-42321, Quan Gu ORCID: orcid.org/0000-0002-1201-67341, Lauren Orr ORCID: orcid.org/0000-0002-4553-37031, Aislynn Taggart1, Ola Diebold4, Chris Davis ORCID: orcid.org/0000-0002-7317-32661, Chris Boutell ORCID: orcid.org/0000-0002-2970-77851, Finn Grey4, Edward Hutchinson1, Paul Digard ORCID: orcid.org/0000-0002-0872-94404, Isabella Monne5, Sarah K. Wootton ORCID: orcid.org/0000-0002-5985-24063, Megan K. L. MacLeod2, Sam J. Wilson ORCID: orcid.org/0000-0002-6065-08951 na2 & …Massimo Palmarini ORCID: orcid.org/0000-0001-7007-40701 na2 Show authors Nature volume 619, pages 338–347 (2023)Cite this article 16k Accesses 27 Citations 1778 Altmetric Metrics details Subjects Influenza virusRestriction factorsViral immune evasionViral reservoirsVirus–host interactions AbstractSpillover events of avian influenza A viruses (IAVs) to humans could represent the first step in a future pandemic1. Several factors that limit the transmission and replication of avian IAVs in mammals have been identified. There are several gaps in our understanding to predict which virus lineages are more likely to cross the species barrier and cause disease in humans1. Here, we identified human BTN3A3 (butyrophilin subfamily 3 member A3)2 as a potent inhibitor of avian IAVs but not human IAVs. We determined that BTN3A3 is expressed in human airways and its antiviral activity evolved in primates. We show that BTN3A3 restriction acts primarily at the early stages of the virus life cycle by inhibiting avian IAV RNA replication. We identified residue 313 in the viral nucleoprotein (NP) as the genetic determinant of BTN3A3 sensitivity (313F or, rarely, 313L in avian viruses) or evasion (313Y or 313V in human viruses). However, avian IAV serotypes, such as H7 and H9, that spilled over into humans also evade BTN3A3 restriction. In these cases, BTN3A3 evasion is due to substitutions (N, H or Q) in NP residue 52 that is adjacent to residue 313 in the NP structure3. Thus, sensitivity or resistance to BTN3A3 is another factor to consider in the risk assessment of the zoonotic potential of avian influenza viruses. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution Access options Access through your institution Access through your institution Change institution Buy or subscribe Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 24,99 € / 30 days cancel any time Learn more Subscription info for Korean customersWe have a dedicated website for our Korean customers. Please go to natureasia.com to subscribe to this journal.Go to natureasia.com Buy this article Purchase on SpringerLink Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support Fig. 1: BTN3A3 inhibits avian IAVs.Fig. 2: Specificity of BTN3s restriction.Fig. 3: Determinants of BTN3A3 sensitivity.Fig. 4: BTN3A3 blocks vRNA transcription.Fig. 5: Evasion of BTN3A3 by zoonotic avian IAVs. Similar content being viewed by others A risk marker of tribasic hemagglutinin cleavage site in influenza A (H9N2) virus Article Open access 15 January 2021 Adaptive amino acid substitutions enable transmission of an H9N2 avian influenza virus in guinea pigs Article Open access 24 December 2019 Bat-borne H9N2 influenza virus evades MxA restriction and exhibits efficient replication and transmission in ferrets Article Open access 25 April 2024 Data availability Alignments and raw phylogenetic data related to this study can be found in the following GitHub repository: https://github.com/spyros-lytras/BTN3A3_IAV. Source data related to the animal experiments illustrated in Fig. 3h are available in Supplementary Table 9. Gel source data are available in Supplementary Fig. 1. ReferencesLipsitch, M. et al. Viral factors in influenza pandemic risk assessment. eLife https://doi.org/10.7554/eLife.18491 (2016).Afrache, H., Gouret, P., Ainouche, S., Pontarotti, P. & Olive, D. The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response. Immunogenetics 64, 781–794 (2012).Article CAS PubMed Google Scholar Ye, Q., Krug, R. M. & Tao, Y. J. The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 444, 1078–1082 (2006).Article ADS CAS PubMed Google Scholar Yoon, S.-W., Webby, R. J. & Webster, R. G. in Influenza Pathogenesis and Control Vol. I (eds W. Compans, R. A. & Oldstone, M. B. A.) 359–375 (Springer International Publishing, 2014).Krammer, F. et al. Influenza. Nat. Rev. Dis. Primers 4, 3 (2018).Article PubMed PubMed Central Google Scholar Harrington, W. N., Kackos, C. M. & Webby, R. J. The evolution and future of influenza pandemic preparedness. Exp. Mol. Med. 53, 737–749 (2021).Article CAS PubMed PubMed Central Google Scholar Short, K. R. et al. One health, multiple challenges: the inter-species transmission of influenza A virus. One Health 1, 1–13 (2015).Article PubMed PubMed Central Google Scholar Liu, D. et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 381, 1926–1932 (2013).Article PubMed Google Scholar Wang, X. et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: an epidemiological study of laboratory-confirmed case series. Lancet Infect. Dis. 17, 822–832 (2017).Article PubMed PubMed Central Google Scholar Liu, W. J. et al. Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic. Front. Med. 15, 507–527 (2021).Article PubMed PubMed Central Google Scholar Long, J. S., Mistry, B., Haslam, S. M. & Barclay, W. S. Host and viral determinants of influenza A virus species specificity. Nat. Rev. Microbiol. 17, 67–81 (2019).Article CAS PubMed Google Scholar Rogers, G. N. & Paulson, J. C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 127, 361–373 (1983).Article CAS PubMed Google Scholar Di Lella, S., Herrmann, A. & Mair, C. M. Modulation of the pH stability of influenza virus hemagglutinin: a host cell adaptation strategy. Biophys. J. 110, 2293–2301 (2016).Article PubMed PubMed Central Google Scholar Zaraket, H. et al. Increased acid stability of the hemagglutinin protein enhances H5N1 influenza virus growth in the upper respiratory tract but is insufficient for transmission in ferrets. J. Virol. 87, 9911–9922 (2013).Article CAS PubMed PubMed Central Google Scholar Long, J. S. et al. Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature 529, 101–104 (2016).Article ADS CAS PubMed PubMed Central Google Scholar Blumenkrantz, D., Roberts, K. L., Shelton, H., Lycett, S. & Barclay, W. S. The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets. J. Virol. 87, 10539–10551 (2013).Article CAS PubMed PubMed Central Google Scholar Park, S. et al. Adaptive mutations of neuraminidase stalk truncation and deglycosylation confer enhanced pathogenicity of influenza A viruses. Sci. Rep. 7, 10928 (2017).Article ADS PubMed PubMed Central Google Scholar Mänz, B. et al. Pandemic influenza A viruses escape from restriction by human MxA through adaptive mutations in the nucleoprotein. PLoS Pathog. 9, e1003279 (2013).Article PubMed PubMed Central Google Scholar Riegger, D. et al. The nucleoprotein of newly emerged H7N9 influenza A virus harbors a unique motif conferring resistance to antiviral human MxA. J. Virol. 89, 2241–2252 (2015).Article PubMed Google Scholar Shaw, A. E. et al. Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses. PLoS Biol. 15, e2004086 (2017).Article PubMed PubMed Central Google Scholar Kane, M. et al. Identification of interferon-stimulated genes with antiretroviral activity. Cell Host Microbe. 20, 392–405 (2016).Article CAS PubMed PubMed Central Google Scholar Feeley, E. M. et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 7, e1002337 (2011).Article CAS PubMed PubMed Central Google Scholar Verhelst, J., Parthoens, E., Schepens, B., Fiers, W. & Saelens, X. Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly. J. Virol. 86, 13445–13455 (2012).Article CAS PubMed PubMed Central Google Scholar Wellington, D., Laurenson-Schafer, H., Abdel-Haq, A. & Dong, T. IFITM3: how genetics influence influenza infection demographically. Biomed. J. 42, 19–26 (2019).Article PubMed PubMed Central Google Scholar Rhodes, D. A., Stammers, M., Malcherek, G., Beck, S. & Trowsdale, J. The cluster of BTN genes in the extended major histocompatibility complex. Genomics 71, 351–362 (2001).Article CAS PubMed Google Scholar Kumar, S., Stecher, G., Suleski, M. & Hedges, S. B. TimeTree: a resource for timelines, timetrees, and divergence times. Mol. Biol. Evol. 34, 1812–1819 (2017).Article CAS PubMed Google Scholar Afrache, H., Pontarotti, P., Abi-Rached, L. & Olive, D. Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family. Immunogenetics 69, 379–390 (2017).Article CAS PubMed Google Scholar Pinto, R. M., Lycett, S., Gaunt, E. & Digard, P. Accessory gene products of influenza A virus. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a038380 (2021).Naffakh, N., Tomoiu, A., Rameix-Welti, M. A. & van der Werf, S. Host restriction of avian influenza viruses at the level of the ribonucleoproteins. Annu. Rev. Microbiol. 62, 403–424 (2008).Article CAS PubMed Google Scholar Patrono, L. V. et al. Archival influenza virus genomes from Europe reveal genomic variability during the 1918 pandemic. Nat. Commun. 13, 2314 (2022).Article ADS CAS PubMed PubMed Central Google Scholar van Lieshout, L. P. et al. A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice. Mol. Ther. Methods Clin. Dev. 9, 323–329 (2018).Article PubMed PubMed Central Google Scholar Portela, A. & Digard, P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J. Gen. Virol. 83, 723–734 (2002).Article CAS PubMed Google Scholar Gabriel, G., Herwig, A. & Klenk, H. D. Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog. 4, e11 (2008).Article PubMed PubMed Central Google Scholar Hu, Y., Sneyd, H., Dekant, R. & Wang, J. Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target. Curr. Top. Med. Chem. 17, 2271–2285 (2017).Article CAS PubMed PubMed Central Google Scholar Beaton, A. R. & Krug, R. M. Transcription antitermination during influenza viral template RNA synthesis requires the nucleocapsid protein and the absence of a 5′ capped end. Proc. Natl Acad. Sci. USA 83, 6282–6286 (1986).Article ADS CAS PubMed PubMed Central Google Scholar Chen, Y. et al. Rare variant MX1 alleles increase human susceptibility to zoonotic H7N9 influenza virus. Science 373, 918–922 (2021).Article ADS CAS PubMed Google Scholar Pu, J. et al. Evolution of the H9N2 influenza genotype that facilitated the genesis of the novel H7N9 virus. Proc. Natl Acad. Sci. USA 112, 548–553 (2015).Article ADS CAS PubMed Google Scholar He, J. et al. Genetic characterization of the first detected human case of avian influenza A (H5N6) in Anhui Province, East China. Sci. Rep. 8, 15282 (2018).Article ADS PubMed PubMed Central Google Scholar de Jong, J. C., Claas, E. C., Osterhaus, A. D., Webster, R. G. & Lim, W. L. A pandemic warning? Nature 389, 554 (1997).Article ADS PubMed PubMed Central Google Scholar Neumann, G., Chen, H., Gao, G. F., Shu, Y. & Kawaoka, Y. H5N1 influenza viruses: outbreaks and biological properties. Cell Res. 20, 51–61 (2010).Article CAS PubMed Google Scholar Su, S. et al. Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. Trends Microbiol. 25, 713–728 (2017).Article CAS PubMed Google Scholar Harly, C. et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 120, 2269–2279 (2012).Article CAS PubMed PubMed Central Google Scholar Arnett, H. A. & Viney, J. L. Immune modulation by butyrophilins. Nat. Rev. Immunol. 14, 559–569 (2014).Article CAS PubMed Google Scholar Gu, S., Borowska, M. T., Boughter, C. T. & Adams, E. J. Butyrophilin3A proteins and Vγ9Vδ2 T cell activation. Semin. Cell Dev. Biol. 84, 65–74 (2018).Article CAS PubMed PubMed Central Google Scholar Galão, R. P. et al. TRIM25 and ZAP target the Ebola virus ribonucleoprotein complex to mediate interferon-induced restriction. PLoS Pathog. 18, e1010530 (2022).Article PubMed PubMed Central Google Scholar Kuroda, M. et al. Identification of interferon-stimulated genes that attenuate Ebola virus infection. Nat. Commun. 11, 2953 (2020).Article ADS CAS PubMed PubMed Central Google Scholar Staeheli, P., Grob, R., Meier, E., Sutcliffe, J. G. & Haller, O. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol. Cell. Biol. 8, 4518–4523 (1988).CAS PubMed PubMed Central Google Scholar Guénet, J. L. & Bonhomme, F. Wild mice: an ever-increasing contribution to a popular mammalian model. Trends Genet. 19, 24–31 (2003).Article PubMed Google Scholar Zhang, B. et al. The nucleoprotein of influenza A virus inhibits the innate immune response by inducing mitophagy. Autophagy https://doi.org/10.1080/15548627.2022.2162798 (2023).Philippon, D. A. M., Wu, P., Cowling, B. J. & Lau, E. H. Y. Avian influenza human infections at the human-animal interface. J. Infect. Dis. 222, 528–537 (2020).Article CAS PubMed Google Scholar Adlhoch, C. et al. Avian influenza overview December 2021 - March 2022. EFSA J. 20, e07289 (2022).PubMed PubMed Central Google Scholar Agüero, M. et al. Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022. Euro. Surveill. https://doi.org/10.2807/1560-7917.Es.2023.28.3.2300001 (2023).Bussey, K. A., Bousse, T. L., Desmet, E. A., Kim, B. & Takimoto, T. PB2 residue 271 plays a key role in enhanced polymerase activity of influenza A viruses in mammalian host cells. J. Virol. 84, 4395–4406 (2010).Article CAS PubMed PubMed Central Google Scholar Burke, S. A. & Trock, S. C. Use of influenza risk assessment tool for prepandemic preparedness. Emerg. Infect. Dis. 24, 471–477 (2018).Article PubMed PubMed Central Google Scholar Ramirez, R. D. et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64, 9027–9034 (2004).Article CAS PubMed Google Scholar Wit, E. D. et al. Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res. 103, 155–161 (2004).Article PubMed Google Scholar Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481–485 (2011).Article ADS CAS PubMed PubMed Central Google Scholar Rihn, S. J. et al. TRIM69 inhibits vesicular stomatitis Indiana virus. J. Virol. https://doi.org/10.1128/JVI.00951-19 (2019).Rihn, S. J. et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biol. 19, e3001091 (2021).Article CAS PubMed PubMed Central Google Scholar Kawakami, E. et al. Strand-specific real-time RT-PCR for distinguishing influenza vRNA, cRNA, and mRNA. J. Virol. Methods 173, 1–6 (2011).Article CAS PubMed Google Scholar Bakshi, S., Taylor, J., Strickson, S., McCartney, T. & Cohen, P. Identification of TBK1 complexes required for the phosphorylation of IRF3 and the production of interferon β. Biochem. J. 474, 1163–1174 (2017).Article CAS PubMed Google Scholar Zufferey, R., Donello, J. E., Trono, D. & Hope, T. J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886–2892 (1999).Article CAS PubMed PubMed Central Google Scholar Rghei, A. D. et al. Production of adeno-associated virus vectors in cell stacks for preclinical studies in large animal models. J. Vis. Exp. https://doi.org/10.3791/62727 (2021).MacLeod, M. K. et al. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc. Natl Acad. Sci. USA 108, 7914–7919 (2011).Article ADS CAS PubMed PubMed Central Google Scholar Camacho, C. et al. BLAST+: architecture and applications. BMC Bioinf. 10, 421 (2009).Article Google Scholar Cunningham, F. et al. Ensembl 2022. Nucleic Acids Res. 50, D988–d995 (2022).Article CAS PubMed Google Scholar Mistry, J., Finn, R. D., Eddy, S. R., Bateman, A. & Punta, M. Challenges in homology search: HMMER3 and convergent evolution of coiled-coil regions. Nucleic Acids Res. 41, e121 (2013).Article CAS PubMed PubMed Central Google Scholar Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).Article CAS PubMed PubMed Central Google Scholar Suyama, M., Torrents, D. & Bork, P. PAL2NAL: robust conversion of protein sequence alignments into the corresponding codon alignments. Nucleic Acids Res. 34, W609–W612 (2006).Article CAS PubMed PubMed Central Google Scholar Nguyen, L. T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol. Biol. Evol. 32, 268–274 (2015).Article CAS PubMed Google Scholar Steinegger, M. & Söding, J. MMseqs2 enables sensitive protein sequence searching for the analysis of massive data sets. Nat. Biotechnol. 35, 1026–1028 (2017).Article CAS PubMed Google Scholar Sagulenko, P., Puller, V. & Neher, R. A. TreeTime: maximum-likelihood phylodynamic analysis. Virus Evol. 4, vex042 (2018).Article PubMed PubMed Central Google Scholar Yu, G. Using ggtree to visualize data on tree-like structures. Curr. Protoc. Bioinformatics 69, e96 (2020).PubMed Google Scholar Huerta-Cepas, J., Serra, F. & Bork, P. ETE 3: reconstruction, analysis, and visualization of phylogenomic data. Mol. Biol. Evol. 33, 1635–1638 (2016).Article CAS PubMed PubMed Central Google Scholar Beare, A. S. & Hall, T. S. Recombinant influenza-A viruses as live vaccines for man. Report to the Medical Research Council’s Committee on Influenza and other Respiratory Virus Vaccines. Lancet 2, 1271–1273 (1971).Article CAS PubMed Google Scholar Beare, A. S., Schild, G. C. & Craig, J. W. Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses. Lancet 2, 729–732 (1975).Article CAS PubMed Google Scholar Download referencesAcknowledgementsWe are thankful to the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database on which some of this research is based (Supplementary Tables 7 and 8). We thank P. Murcia (MRC-University of Glasgow Centre for Virus Research) for providing clinical virus isolates and fruitful discussions, and M. Peiris (The University of Hong Kong) who kindly provided Auddy shelduck/Mongolia/963V/2009 (H3N8). We are grateful to S. Bhat, M. Iqbal (The Pirbright Institute), L. Tiley, R. Fouchier (Erasmus MC) and D. Perez (The University of Georgia) for providing the reverse genetics systems of the A/Anhui/1/2013 (H7N9) and A/mallard/Netherlands/10-Cam/1999 (H1N1), A/Puerto Rico/8/1934 (H1N1) and A/California/04-061-MA/2009 (H1N1) viruses, respectively. We acknowledge J. Mccauley (The Crick Institute) for sharing the MDCK-SIAT cells. This work was supported by the UK Medical Research Council (grant no. MC_UU_12016/10) awarded to M.P. and S.J.W. and the following grants: Wellcome Trust grant no. 206369/Z/17/Z (to M.P.); Biotechnology and Biological Sciences Research Council (BBSRC) grant no. BB/P013740/1 awarded to F.G. and P.D.; grant no. BBSRC BB/S00114X/1 awarded to F.G., P.D. and S.J.W.; EU Horizon2020: DELTA-FLU (grant no. 727922) awarded to P.D. and I.M.; Natural Sciences and Engineering Research Council of Canada Discovery grant (no. RGPIN-2018-04737) awarded to S.K.W.; Daphne Jackson Fellowship funded by Medical Research Scotland awarded to S.S.; MRC Career Development Award and Transition Support Award (grant nos. MR/N008618/1 and MR/V035789/1) to E.H.; Wellcome Trust grant no. 210703/Z/18/Z awarded to M.K.L.M. and Medical Research Council grant no. MC_UU_12014/5 awarded to C.B., Q.G. and J.H. are funded by Medical Research Council grant no. MC_UU_12014/12.Author informationAuthor notesRute Maria PintoPresent address: The Roslin Institute, University of Edinburgh, Edinburgh, UKMargus VarjakPresent address: Faculty of Science and Technology, Institute of Technology, University of Tartu, Tartu, EstoniaThese authors contributed equally: Siddharth Bakshi, Spyros Lytras, Mohammad Khalid ZakariaThese authors jointly supervised this work: Sam J Wilson, Massimo PalmariniAuthors and AffiliationsMRC–University of Glasgow Centre for Virus Research, Glasgow, UKRute Maria Pinto, Siddharth Bakshi, Spyros Lytras, Mohammad Khalid Zakaria, Simon Swingler, Vanessa Herder, Margus Varjak, Natalia Cameron-Ruiz, Mila Collados Rodriguez, Mariana Varela, Arthur Wickenhagen, Colin Loney, Joseph Hughes, Elise Valette, Matthew L. Turnbull, Wilhelm Furnon, Quan Gu, Lauren Orr, Aislynn Taggart, Chris Davis, Chris Boutell, Edward Hutchinson, Sam J. Wilson & Massimo PalmariniSchool of Infection and Immunity, University of Glasgow, Glasgow, UKJulie C. Worrell, Kerrie E. Hargrave & Megan K. L. MacLeodDepartment of Pathobiology, University of Guelph, Guelph, Ontario, CanadaYanlong Pei & Sarah K. WoottonThe Roslin Institute, University of Edinburgh, Edinburgh, UKOla Diebold, Finn Grey & Paul DigardIstituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Legnaro, ItalyIsabella MonneAuthorsRute Maria PintoView author publicationsYou can also search for this author in PubMed Google ScholarSiddharth BakshiView author publicationsYou can also search for this author in PubMed Google ScholarSpyros LytrasView author publicationsYou can also search for this author in PubMed Google ScholarMohammad Khalid ZakariaView author publicationsYou can also search for this author in PubMed Google ScholarSimon SwinglerView author publicationsYou can also search for this author in PubMed Google ScholarJulie C. WorrellView author publicationsYou can also search for this author in PubMed Google ScholarVanessa HerderView author publicationsYou can also search for this author in PubMed Google ScholarKerrie E. HargraveView author publicationsYou can also search for this author in PubMed Google ScholarMargus VarjakView author publicationsYou can also search for this author in PubMed Google ScholarNatalia Cameron-RuizView author publicationsYou can also search for this author in PubMed Google ScholarMila Collados RodriguezView author publicationsYou can also search for this author in PubMed Google ScholarMariana VarelaView author publicationsYou can also search for this author in PubMed Google ScholarArthur WickenhagenView author publicationsYou can also search for this author in PubMed Google ScholarColin LoneyView author publicationsYou can also search for this author in PubMed Google ScholarYanlong PeiView author publicationsYou can also search for this author in PubMed Google ScholarJoseph HughesView author publicationsYou can also search for this author in PubMed Google ScholarElise ValetteView author publicationsYou can also search for this author in PubMed Google ScholarMatthew L. TurnbullView author publicationsYou can also search for this author in PubMed Google ScholarWilhelm FurnonView author publicationsYou can also search for this author in PubMed Google ScholarQuan GuView author publicationsYou can also search for this author in PubMed Google ScholarLauren OrrView author publicationsYou can also search for this author in PubMed Google ScholarAislynn TaggartView author publicationsYou can also search for this author in PubMed Google ScholarOla DieboldView author publicationsYou can also search for this author in PubMed Google ScholarChris DavisView author publicationsYou can also search for this author in PubMed Google ScholarChris BoutellView author publicationsYou can also search for this author in PubMed Google ScholarFinn GreyView author publicationsYou can also search for this author in PubMed Google ScholarEdward HutchinsonView author publicationsYou can also search for this author in PubMed Google ScholarPaul DigardView author publicationsYou can also search for this author in PubMed Google ScholarIsabella MonneView author publicationsYou can also search for this author in PubMed Google ScholarSarah K. WoottonView author publicationsYou can also search for this author in PubMed Google ScholarMegan K. L. MacLeodView author publicationsYou can also search for this author in PubMed Google ScholarSam J. WilsonView author publicationsYou can also search for this author in PubMed Google ScholarMassimo PalmariniView author publicationsYou can also search for this author in PubMed Google ScholarContributionsConceptualization was done by R.M.P., S.J.W. and M.P. The methodology was developed by R.M.P., S.B., S.L., M.K.Z., S.S., J.C.W., V.H., K.E.H., L.O., S.K.W. and M.K.L.M. Software was provided by S.L., J.H. and Q.G. Validation was done by R.M.P., S.B., S.L., M.K.Z., J.C.W., V.H. and K.E.H. Formal analysis was carried out by R.M.P., S.B., S.L., M.K.Z., S.S., V.H., M. Varjak, N.C.-R., M.C.R., M. Varela and J.H. The investigation was carried out by R.M.P., S.B., S.L., M.K.Z., S.S., J.C.W., V.H., M. Varjak, N.C.-R., M.C.R., M. Varela, L.O., A.W., C.L., Y.P., E.V., M.L.T., W.F., K.E.H., A.T., O.D. and C.D. Resources were provided by R.M.P., A.T., C.B., E.H., P.D., I.M., S.K.W., S.J.W. and M.P. Data were curated by R.M.P., S.L., M. Varjak, N.C.-R., M.C.R., M. Varela, A.W. and E.V. The original draft preparation and writing were done by R.M.P., S.B., S.L., M.K.Z., J.C.W., V.H., M.L.T., S.K.W. and M.P. Review and editing of the draft were done by R.M.P., S.B., S.L., M.K.Z., S.S., J.C.W., V.H., M.V.k., N.C.-R., M.C.R., M. Varela, A.W., C.L., J.H., E.V., M.L.T., W.F., K.E.H., Q.G., L.O., A.T., O.D., F.G., E.H., P.D., I.M., S.K.W., M.K.L.M., S.J.W. and M.P. Visualization was done by R.M.P., S.B., S.L. and M.P. Supervision was done by R.M.P., J.H., C.B., S.K.W., M.K.L.M., S.J.W. and M.P. Project administration was done by S.J.W. and M.P. Funding was acquired by S.S., C.B., F.G., P.D., I.M., S.K.W., M.K.L.M., S.J.W. and M.P.Corresponding authorCorrespondence to Massimo Palmarini.Ethics declarations Competing interests P.D. is a member of the Science Advisory Council’s Exotic and Emerging Animal Diseases subgroup (SAC-ED) for the UK Government’s Department for Environment, Food & Rural Affairs (Defra) and was part of SAC-ED’s independent expert Scientific Advisory Group in highly pathogenic avian influenza. S.K.W. is an inventor on issued patents in Canada and the United States for the AAV6.2FF capsid, which are owned by the University of Guelph, and licensed to Avamab Pharma Inc., Inspire Biotherapeutics, and Cellastra Inc. M.P. is a member of the Standing Committee on Pandemic Preparedness of the Scottish Government. The remaining authors declare no competing interests. Peer review Peer review information Nature thanks Andrew Mehle, Peter Staeheli, Michael Worobey and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available. Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Extended data figures and tablesExtended Data Fig. 1 Activity and expression of BTN3A1 and BTN3A3 in cell lines and human tissues.a, siRNA knock-down of BTN3A1 in MRC5T and hBEC3-KT. Cells were transfected with scrambled (Neg ctrl) or BTN3A1-targeting siRNAs, and protein levels in the resulting cell lysates were assessed by western blotting. α-Tubulin was used as loading control. Arrows indicate the band corresponding to BTN3A1. For gel source data, see Supplementary Fig. 1. b, Graphs showing the replication kinetics of PR8 and Mallard in siRNA-treated MRC5T and hBEC3-KT cells. Cells were infected with a MOI of 0.001, supernatants were collected at the indicated times post infection and viruses titrated by plaque assay. Data are mean +/− SEM of 3 independent experiments (each using 2 technical replicates). Statistical significance between groups was measured by a 2-way ANOVA. Comparisons were made between area under the curve of the different BTN3A1 siRNA treatment conditions and the average of the two negative controls. No statistically significant differences were found. c, Organ-dependent bulk tissue gene expression. Lung samples are highlighted in blue. d, Lung single cell tissue expression. Data in c and d were obtained from the GTEx Portal (www.gtexportal.org). e, Western blotting of cell lysates obtained from A549, MRC5T, hBEC3-KT and Calu-3 treated with either IFN-γ or universal type-I IFN. Treatment with IFN was for 16h in A549, MRC5T, hBEC3-KT and for 24h in Calu-3 cells. pSTAT1 and RSAD2/Viperin were used as IFN induction controls and α-Tubulin as loading control. For gel source data, see Supplementary Fig. 1.Extended Data Fig. 2 Evolution of BTNs.a, Maximum likelihood phylogeny of concatenated protein domain coding sequences of the Haplorrhini BTN3 genes (K2P+G4 substitution model). Nodes with bootstrap support below 60 have been collapsed. Branches confirmed to have or not have anti-avian IAV activity (described in b) are highlighted in yellow and blue, respectively. Branches not tested were kept black. Relation to more distant tested homologues and orthologous/paralogous gene families are shown as a schematic in grey. IgV homogenization events, major gene duplications and gene subfamilies are annotated on the phylogeny. Presence of each of the four protein domains (IgV, IgC, PRY and SPRY) is annotated on the right of each tree tip and coloured by pairwise amino acid similarity to the respective domain of the human BTN3A3. Species names and taxonomic classification is annotated on the right. The median divergence time between Catarrhini and Platyrrhini was retrieved from TimeTree (http:/imetree.org/). b, Schematic representation of domain organisation and sequence similarity of the indicated proteins.Extended Data Fig. 3 Evolution of antiviral activity of BTNs.a, A549 cells were transiently transduced with SCRPSY lentiviruses expressing the indicated BTN proteins and challenged with PR8- or Mallard-GFP. Eight hours post infection, the percentage of GFP-positive cells was measured by flow cytometry. Data are mean +/− SEM of 2 independent experiments which both gave similar results. b, Western blotting of cell lysates obtained from A549 cells transiently transduced with SCPRSY lentiviruses expressing different BTN proteins. GAPDH was used as loading control. For gel source data, see Supplementary Fig. 1.Extended Data Fig. 4 Phylogeny of BTN3 domains and antiviral activity of BTN orthologues and paralogues.a-d, maximum likelihood Haplorrhini BTN3 gene coding sequence phylogenies of separate domains: IgV (a), IgC (b), PRY (c), SPRY (d) under a K2P+G4 substitution model. Trees are rooted at the C. syrichta branch and node confidence values (10,000 bootstrap replicates) are annotated on each node. Tip shapes are coloured by whether each gene exhibits anti-AIV activity (consistent with Fig. 3a). Phylogenies were visualised using FigTree. e–f, A549 cells were transiently transduced with SCRPSY lentiviruses expressing the indicated BTN proteins and challenged with PR8- or Mallard-GFP. Eight hours post-infection, percentage of RFP-positive cells and its subpopulation of GFP-positive cells was measured by flow cytometry. Data are mean +/− SEM of 2 independent experiments which both gave similar results. Detection of these proteins was not possible using commercially available antibodies, due to their genetic divergence compared to human BTN3A1-3. Therefore, tagging of these BTN genes was attempted by introducing a C-terminal FLAG. Despite their protein expression being successfully detected using an anti-FLAG antibody, the addition of FLAG to human BTN3A3 and other BTN genes resulted in the abolishment of their antiviral activity. Cloning of the genes indicated above was conducted in the same way as those constructs shown in Extended Data Fig. 3.Extended Data Fig. 5 Determinants of BTN3A3 sensitivity.a, PR8:Mallard reassortants and Udorn wild type (WT) were used to perform plaque assays in MDCK cells expressing BTN3A3 and empty vector control cells. Note that reassortant PR8 7:1 Mallard seg 1, Mallard 7:1 PR8 seg 2 and Mallard 7:1 PR8 seg 5 failed to rescue. Reassortant PR8 Mallard 3PNP is formed by PR8 (segments 4, 6, 7 and 8) and segments 1, 2, 3 and 5 from Mallard. Conversely, reassortant Mallard PR8 3PNP contain segments 4, 6, 7 and 8 from Mallard and segments 1, 2, 3 and 5 from PR8. Data are mean +/− SEM of 2 technical replicates from 2 independent experiments. Statistical differences between cells expressing BTN3A3 and control cells were calculated using multiple t-tests and corrected for multiple comparisons using the Holm-Šídák method. NS-Non-significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. b, Identity of amino acid residues in positions 100 (left) and 313 (right) of all NP proteins available in our dataset collected from GenBank. c, Identity of combinations between amino acid residues 100 and 313 (left) and 52 and 313 (right). d, Infectious virus titres obtained in A549-Empty and A549-BTN3A3 cells infected with either Mallard or Cal04 residues 100 and 313 mutants. Cells were infected with an MOI of 0.001 for 48h and viruses were titrated by plaque assay. Data are mean +/− SEM of 2 technical replicates from 3 independent experiments. Statistical analysis was carried out as in (a). e, Viral replication assays in avian cells were carried out in chicken fibroblasts (DF1 cells). Cells were infected an MOI of 0.001 for 48 h. Infectious virus titres were determined by plaque assay. Data are mean +/− standard error of the mean (SEM) of 3 independent experiments (each using two technical replicates).Extended Data Fig. 6 Molecular dating of the F313V NP substitution on the classical swine H1N1 lineage.a, Tip-dated maximum likelihood phylogeny of all classical H1N1 lineage NP sequences annotated by position 313 residue (left) and isolation host (mirrored tree, right). b, Zoomed in snippet of the part of the ML phylogeny shown in A where the F313V change has occurred. Tip shapes are coloured by 313 residue, estimated dates for key nodes are annotated, and strain names are shown on the right of the tips. c, Zoomed in snippet of the part of the BEAST maximum clade credibility phylogeny where the F313V change has occurred. Tip shapes are coloured by 313 residue, median node age and 95% highest posterior density confidence intervals are annotated for key nodes, posterior probability values are shown for each node, and strain names are shown on the right of the tips. The branch where F313V is believed to have taken place on is annotated in colour (pink and green). Phylogenies were visualised using FigTree.Extended Data Fig. 7 BTN3A3 activity and its relation to Mx1 and vRNP complexes.a, Western blotting of cell lysates obtained from A549 cells transfected with the indicated amounts of control or Mx1-targeting pooled siRNAs. Cells were transfected for 48h followed by a 16h type-I IFN treatment. pSTAT1 and α-Tubulin were used as IFN-treatment and loading controls, respectively. For gel source data, see Supplementary Fig. 1. b, Upon siRNA treatment, A549 Empty and BTN3A3 cells were infected with the indicated viruses at an MOI of 0.001. Supernatants were harvested at 48 hpi and infectious viral titres were measured by plaque assay. Data are mean +/− SEM of 2 technical replicates from 3 independent experiments. c, Quantification of cytoplasmic and nuclear levels of vRNP complex proteins at early stages post infection in the presence or absence of BTN3A3. Quantification of 3 independent western blots, one set of which is shown in Fig. 4a. A549-Empty and BTN3A3 overexpressing cells were synchronously infected with PR8 or Mallard at MOI 3. Nuclear/cytoplasm fractionation was performed at 45, 90 mins and 6h post infection. Quantification of vRNP-complex proteins was performed by fluorescence measurements. Cytoplasmic and nuclear viral proteins were normalized to GAPDH and H3, respectively. All values were further normalised to values of A549-Empty cells. Data are mean +/− SEM of 3 independent experiments (each using 2 technical replicates). Statistical significance between groups was measured by a 2-way ANOVA. Comparisons were made between A549-Empty and A549-BTN3A3. NS = non-significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.Extended Data Fig. 8 Minireplicon assays with avian/mammalian NP reassortant RNP complexes.a, 293T-Empty and 293T-BTN3A3 cells were transfected with pcDNA plasmids encoding for PB2, PB1, PA and NP of the indicated viruses alongside firefly luciferase-coding vRNA- or cRNA-like reporter plasmids. A transfection control plasmid expressing Renilla firefly was also added. Forty-eight hours post-transection cells were lysed and firefly and Renilla luciferase activities were measured. Values were normalised to PR8 or Cal04 WT replicons with respective NPs transfected in 293T-Empty cells. Data are mean +/− SEM of 3 independent experiments (each using 2 technical replicates). Statistical differences between Empty and HsBTN3A3 overexpressing cells were calculated using multiple t-tests and corrected for multiple comparisons using the Holm-Šídák method. NS = non-significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. b. Expression levels of PB2, PB1, PA and NP transfected in 293T-Empty (E) or 293T-BTN3A3 (B3) cells were assessed by western blot. α-Tubulin was used as loading control. For gel source data, see Supplementary Fig. 1.Extended Data Fig. 9 Interactions between NP and BTN3A3.a, Western blotting of hBEC3-KT cells infected with IAV Mallard WT or Mallard NP F313Y for 6 h. Expression of NP, PA, PB1, PB2 and GAPDH (loading control) from total cell lysates is shown. b, Total cell lysates of infected cells were used to perform NP immunoprecipitation followed by the detection of the remaining RNP complex-forming proteins. c, Supernatants of the NP immunoprecipitates was used to perform an additional immunoprecipitation using an anti-BTN3A3 antibody followed by the detection of PB2, PB1 and NP. For gel source data, see Supplementary Fig. 1.Extended Data Fig. 10 Correlation between NP signal and nuclear BTN3A3.a, Representative images of confocal microscopy of hBEC3-KT cells infected with Cal04WT or Cal04 NP V313F at MOI 3. Six hours post infection, cells were immunostained with NP (red) and BTN3A3 (green). DAPI staining (blue) was used as a nuclear marker. Scale bar = 35µm. b, Images from >3500 cells from four independent experiments performed as in (a) were used to quantify total NP and nuclear BTN3A3 for Cal04 WT and Cal04 NP V313F. c, Values from b were stratified based on nuclear BTN3A3 intensity (<0.2 or ≥0.2). Data represents relative abundance of total infected cells present in each of the two nuclear BTN3A3 intensities ranges, taking values obtained with Cal04 WT as 100%.Extended Data Fig. 11 Distinct requirements of NP residues for BTN3A3 and Mx1 evasion, and GWAS analysis of H7N9 patients.a, A549 cells overexpressing human Mx1 or BTN3A3 were infected with the mentioned viruses at a MOI of 0.001. Supernatants were harvested at 48 hpi and infectious viral titres were measured by plaque assay. Data are mean +/− SEM of 3 independent experiments (each using 2 technical replicates). Statistical significance between groups was measured by a 2-way ANOVA. NS- non-significant, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. (b-c) GWAS analysis of H7N9-infected patients. Manhattan plots of MX1 (b) and BTN3A3 (c) genomic regions. Gene-level p-values were acquired using RACER in R from data obtained from Chen, et al., Science 373, 918-922, doi:10.1126/science.abg5953 (2021).Extended Data Fig. 12 BTN3A3 restriction by highly pathogenic H5N1.a, Schematic representation of numbers and characteristics of avian IAV NP sequences identified in human spillover events. Total number of sequences was divided into BTN3A3-resistant or sensitive genotypes based on amino acid residues 313 and 52. NP sequences were matched with their respective HA sequences and highly pathogenic avian influenza (HPAI) viruses were separated from the low pathogenic (LPAI) based on the presence of a polybasic cleavage site (only present in HPAI isolates). b, Replication of 7:1 reassortants of PR8 encoding segment 5 from Mallard or H5N1 HPAI viruses in A549-Empty or A549-BTN3A3 expressing cells. Cells were infected at an MOI of 0.001 for 48h and titres were measured by plaque assay. Data are mean +/− SEM of 3 independent experiments (each using 2 technical replicates) with the exception of 52Q which was instead a single technical replicate from 3 independent experiments. Statistical differences between values obtained in empty and BTN3A3 expressing cells were calculated using multiple t-tests and corrected for multiple comparisons using the Holm-Šídák method. NS = non-significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.Supplementary informationSupplementary DiscussionMolecular dating of the F313V NP change.Reporting SummaryPeer Review FileSupplementary Fig. 1Original source images for data obtained by electrophoretic separation.Supplementary Fig. 2Example flow cytometry gating of an IAV-GFP arrayed ISG expression screen.Supplementary Table 1ISG screen results. Percentage of transduced cells and relative virus infectivity are shown for screens illustrated in Figs. 1b and 2e. Mock-transfected and/or mock-infected controls are also included.Supplementary Table 2Dataset of avian IAV isolated from human patients downloaded from the GISAID EpiFlu database. Nature of residues NP 52 and 313, and PB2 271, 590, 591, 627 and 701 for each isolate are shown.Supplementary Table 3Genetic variation of human BTN3A3. Haplotype allelic frequencies of all detected variants of BTN3A3 shown by region. Data were acquired from Ensembl transcript ENST00000244519.7. FLAG definitions: S, Introduction of a STOP codon; D, Deleterious shift or polyphen.Supplementary Table 4Dataset of avian IAV isolated from birds downloaded from GISAID EpiFlu database. Nature of residues NP 52 and 313, and PB2 271, 590, 591, 627 and 701 for each isolate are shown.Supplementary Table 5NCBI accessions of all BTN3 homologues presented in this study.Supplementary Table 6Classical H1N1 swine clade NP sequence NCBI accessions with subclade and BEAST dataset annotations.Supplementary Table 7GISAID EpiFlu acknowledgements for the avian IAV human isolates used in this study.Supplementary Table 8GISAID EpiFlu acknowledgements for the avian IAV bird isolates used in this study.Supplementary Table 9Source data for animal experiments.Rights and permissionsSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.Reprints and permissionsAbout this articleCite this articlePinto, R.M., Bakshi, S., Lytras, S. et al. BTN3A3 evasion promotes the zoonotic potential of influenza A viruses. Nature 619, 338–347 (2023). https://doi.org/10.1038/s41586-023-06261-8Download citationReceived: 17 February 2023Accepted: 25 May 2023Published: 28 June 2023Issue Date: 13 July 2023DOI: https://doi.org/10.1038/s41586-023-06261-8Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative This article is cited by Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants Ann-Kathrin ReuschlLucy G. ThorneGreg J. Towers Nature Microbiology (2024) A human protein that holds bird flu viruses at bay Laura GrafPeter Staeheli Nature (2023) Avian influenza takes flight in humans by evading restriction Andrea Du Toit Nature Reviews Microbiology (2023) Access through your institution Buy or subscribe Access through your institution Change institution Buy or subscribe Associated content A human protein that holds bird flu viruses at bay Laura GrafPeter Staeheli Nature News & Views 28 Jun 2023 Advertisement Explore content Research articles News Opinion Research Analysis Careers Books & Culture Podcasts Videos Current issue Browse issues Collections Subjects Follow us on Facebook Follow us on Twitter Subscribe Sign up for alerts RSS feed About the journal Journal Staff About the Editors Journal Information Our publishing models Editorial Values Statement Journal Metrics Awards Contact Editorial policies History of Nature Send a news tip Publish with us For Authors For Referees Language editing services Submit manuscript Search Search articles by subject, keyword or author Show results from All journals This journal Search Advanced search Quick links Explore articles by subject Find a job Guide to authors Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio About us Press releases Press office Contact us Discover content Journals A-Z Articles by subject protocols.io Nature Index Publishing policies Nature portfolio policies Open access Author & Researcher services Reprints & permissions Research data Language editing Scientific editing Nature Masterclasses Research Solutions Libraries & institutions Librarian service & tools Librarian portal Open research Recommend to library Advertising & partnerships Advertising Partnerships & Services Media kits Branded content Professional development Nature Careers Nature Conferences Regional websites Nature Africa Nature China Nature India Nature Italy Nature Japan Nature Middle East Privacy Policy Use of cookies Your privacy choices/Manage cookies Legal notice Accessibility statement Terms & Conditions Your US state privacy rights © 2024 Springer Nature Limited Close banner Close Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Email address Sign up I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close banner Close Get the most important science stories of the day, free in your inbox. Sign up for Nature BriefingOFFLU's annual report: tackling animal influenza through data sharing Direct access to content Direct access to research Direct access to menu Menu Search enfres Codes and Manuals Publications Documentary Portal Training Platform ANIMUSE PVSIS Bookshop Cart My account enfres Animal Diseases Avian Influenza Antimicrobial resistance Search Who we areToggle submenu Back to menuWho we areWe are the global authority on animal health. Founded in 1924 as the Office International des Epizooties (OIE), in May 2003 we adopted the common name World Organisation for Animal Health. An intergovernmental organisation, we focus on transparently disseminating information on animal diseases, improving animal health globally and thus build a safer, healthier and more sustainable world Mission Advocacy Strategy Structure Members Collaborate with us What we doToggle submenu Back to menuWhat we doWe work to improve animal health and welfare across the globe. By collecting, analysing and disseminating veterinary scientific information, we encourage international solidarity in the control of animal health risks. Furthermore, we work across borders to foster a One Health approach, recognising that the health of animals, humans and the environment are interdependent. Animal Health and WelfareToggle submenu Back to menu Animal Diseases Disease Data Collection Animal Welfare Wildlife Health Official Disease Status StandardsToggle submenu Back to menu Codes and Manuals Standard-Setting Process Observatory Global InitiativesToggle submenu Back to menu Disease Eradication Antimicrobial resistance One Health Biological threat reduction Food Safety Publications What we offerToggle submenu Back to menuWhat we offerWe oversee various programmes, both cross-sectoral ones and those focused on specific needs, to improve the capacities of Veterinary Services and Aquatic Animal Health Services. These programmes are designed to empower and guide countries in the development and implementation of sustainable national plans which go well beyond purely veterinary matters. Improving Veterinary ServicesToggle submenu Back to menu PVS Pathway Vaccine banks Expertise Network Safe Trade and Movement of Animals Self-declared Disease Status Veterinary products Emergency Preparedness Our 100th AnniversaryToggle submenu Back to menuOur 100th AnniversaryCelebrating 100 years of WOAH’s unwavering commitment to global animal health—a legacy of collaboration, innovation, and progress. Join us in honouring WOAH’s past, embracing the present, and charting a sustainable future. WOAH turns 100: A century of improving animal health and welfare Anniversary Reflections Share your anniversary wish Wall of anniversary wishes A century strong: our history Stories and Moments MediaToggle submenu Back to menuMediaFind information related to the animal disease situation in the world, as well to the work of the Organisation. News Events WAHIS Use the search engine below to find a specific content. Search Inicio » News » OFFLU’s annual report: tackling animal influenza through data sharing Joint Press Release OFFLU’s annual report: tackling animal influenza through data sharing Published on 27 June 2023 Share: The page link has been copied to your clipboard View more In a world facing increasing global health challenges, collaboration and data sharing have emerged as powerful tools for combating infectious diseases. As a vital network of experts focused on animal influenza, OFFLU showcases in a recent report their commitment to collaboration and information exchange. The 2022 annual report of the WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) highlights its significant contributions in sharing critical scientific data, advancing pandemic preparedness vaccines, and promoting diagnostic capabilities worldwide. Through collaborative efforts with international organizations, OFFLU strives to enhance global health and preparedness in combating avian, swine, and equine influenza, while safeguarding animal and human populations against the risks posed by these infectious diseases. Sharing critical data with the international community OFFLU aims to promptly identify and analyze emerging strains of influenza viruses in animal populations. By effectively managing known infections, this proactive approach ensures improved management of risks to human health, and contributes to the promotion of global food security, animal health and welfare, and various other community benefits associated with domestic animals and wildlife. Avian influenza has been a major concern throughout 2022, reaching a record number of cases affecting millions of poultry and wild birds across the world. As highlighted in OFFLU’s annual report, the network’s experts have identified H5N1 as the main avian influenza subtype circulating in Africa, the Americas, Asia and Europe, which showed significant genetic variations within the different regions. The report also mentions an increase in infections among both terrestrial and marine mammals. While human infections with H5N1 were sporadic, they were reported in some of the affected continents and low pathogenicity avian influenza (LPAI) viruses of the H9N2 subtype resulted in losses in poultry production. To address the global surge in avian influenza outbreaks, OFFLU experts contributed to risk assessments and actively participated in sharing critical data with the scientific community and policymakers. By working together with experts across sectors, the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (WOAH) and the World Health Organization (WHO), OFFLU has largely contributed to a better understanding of the avian influenza situation and how to best tackle it. Contributing to pandemic preparedness As part of its key mission to collect genetic data on influenza viruses, OFFLU contributed to the WHO Vaccine Composition Meeting (VCM) for avian and swine influenza, in collaboration with WOAH and FAO Reference Centers, research programs, and national veterinary laboratories. The network provided essential genetic, antigenic, and epidemiological data to contribute to development of human candidate vaccine viruses for pre-pandemic preparedness. It helps ensure that, should these animal influenza viruses make the jump from animals to humans, and potentially cause a pandemic, the appropriate vaccines are rapidly developed with the best protection possible. As such, they collected over 1,500 avian influenza virus sequences and 534 swine influenza virus sequences from various regions worldwide. Regarding swine influenza, OFFLU provided valuable information to the WHO VCM for influenza pre-pandemic preparedness, where a new candidate vaccine virus for swine influenza was proposed. The experts group also participated in a Tool for Influenza Pandemic Risk Assessment (TIPRA) exercise to address the detection of swine influenza viruses and human cases across different geographical regions since 2017. In addition, the Expert Surveillance Panel of Equine Influenza, which includes OFFLU and WHO influenza experts, met to review the activity and characteristics of equine influenza viruses. Similar to previous years, the panel issued recommendations on the content of vaccines for the international market. Promoting diagnostic capabilities and monitoring wildlife risks To promote international harmonization of diagnostic capabilities among laboratories, OFFLU conducted proficiency testing rounds. Within the year, the focus was on assessing laboratories’ ability to detect and characterize widely circulating influenza viruses. In order to address the rising number of H5N1 avian influenza cases reported in mammalian species such as mink and sea otters, OFFLU also carried out a monitoring and tracking of the increased risk of avian influenza transmission to mammals in 2022. Experts shared data and collaborated closely with local public health counterparts to enhance the collective knowledge on risk factors, potential prevention and preparedness measures against this growing concern. We are here to provide countries with the best information and guidance to fight animal influenza.Professor Ian Brown, Chair of OFFLU Steering Committee As OFFLU continues its tireless efforts to combat animal influenzas, its collaborative approach and dedication to the One Health framework remain vital in safeguarding animal and human populations against the threats of these infectious diseases. More information OFFLU website Visit the website OFFLU Annual Report 2022 Read the report Our latest news Joint Press Release Quadripartite partners organize High-Level One Health Meeting in collaboration with the Brazil’s Ministry of Health at the G20 Summit Published on 01/11/2024 Joint Press Release New guidelines for disease surveillance released to better protect wildlife Published on 01/10/2024 Joint Press Release World leaders commit to decisive action on antimicrobial resistance Published on 26/09/2024 Joint Press Release Global research network propels Peste des petits ruminants eradication initiatives forward Published on 05/02/2024 Newsletter The monthly newsletter that relays news from the World Organisation for Animal Health (WOAH), as well as from its network and regions. News includes its Members’ self-declarations, articles, upcoming events, publications, communication tools and more. Subscribe to the monthly newsletter and stay informed on the organisation’s latest activities at both global and regional levels. Subscribe Regions Africa Americas Asia and the pacific Europe Middle East WOAH Contact Career Procurement Follow us facebook twitter linkedin instagram youtube flickr Terms and Conditions Privacy Policy Copyright ©WOAH2024 We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent. Cookies settings Accept all Reject allCookies policy Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. CookieDurationDescription__cfduid1 monthThe cookie is used by cdn services like CloudFare to identify individual clients behind a shared IP address and apply security settings on a per-client basis. It does not correspond to any user ID in the web application and does not store any personally identifiable information.viewed_cookie_policy1 yearThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. Others others Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. CookieDurationDescription_gat_UA-190436238-11 minuteNo description_gat_UA-27210936-11 minuteNo description_pk_id.2.ece21 year 27 daysNo description_pk_ses.2.ece230 minutesNo description_pk_testcookie.2.ece2sessionNo descriptionCONSENT16 years 8 months 2 days 15 hoursNo descriptionoKBJgxZFRjc-1 dayNo descriptionXxhSHVdnPFQD1 dayNo description Advertisement advertisement Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads. CookieDurationDescriptionIDE1 year 24 daysUsed by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.test_cookie15 minutesThis cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.VISITOR_INFO1_LIVE5 months 27 daysThis cookie is set by Youtube. Used to track the information of the embedded YouTube videos on a website. Analytics analytics Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. CookieDurationDescription_gasessionThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors._gid1 dayThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form. Functional functional Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features. CookieDurationDescription__cf_bm30 minutesThis cookie is set by CloudFare. The cookie is used to support Cloudfare Bot Management.langThis cookie is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.pll_language1 yearThis cookie is set by Polylang plugin for WordPress powered websites. The cookie stores the language code of the last browsed page. Performance performance Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. CookieDurationDescriptionYSCsessionThis cookies is set by Youtube and is used to track the views of embedded videos. Save & AcceptAdvances in influenza research Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About COVID-19 News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge Newsletters Health & Personal Care eBooks Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Cold, Flu & Cough Eating Disorders Eye Health Gastrointestinal Health Heart Disease High Blood Pressure Lung Cancer Mental Health Mpox Pregnancy Type 1 Diabetes Type 2 Diabetes Sexual Health Sleep View Health A-Z ×Top Health Categories Coronavirus Disease COVID-19 Heart Disease Diet & Nutrition High Blood Pressure Artificial Intelligence Lung Cancer Allergies Mental Health Alzheimer's & Dementia Mpox Arthritis & Rheumatology Pregnancy Breast Cancer Type 1 Diabetes Cold, Flu & Cough Type 2 Diabetes Eating Disorders Sexual Health Eye Health Sleep Gastrointestinal Health View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge Newsletters Health & Personal Care eBooks Contact Meet the Team Advertise Search Become a Member Webinars eBooks Contact Meet the Team Advertise Search Become a Member Advances in influenza research Download PDF CopyView Supplier Profile Sponsored Content by Sino Biological Inc.Reviewed by Emily MageeJun 30 2023 Thought LeadersDr. Mohammad SafiarianAssociate Product ManagerSino Biological This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed. Could you introduce yourself and describe your primary areas of work? I am Dr. Mohammad Safiarian, the Associate Product Manager at Sino Biological. In my role, I am responsible for developing and marketing protein products. I obtained my Ph.D. in biochemistry from Georgia State University and completed my postdoc at the Georgia Institute of Technology and Baylor College of Medicine. My expertise primarily concerns protein science, DNA biochemistry, and enzymology. Throughout my career, I have authored several peer-reviewed papers that have garnered over a hundred citations. Watch the webinar on-demand What are the key aspects of combating influenza, and how do diagnostic tools contribute to timely intervention? Accurate diagnosis, effective prevention, and appropriate treatment are vital in combating influenza. Diagnosing influenza involves various methods, including antigen detection, virus isolation, RT-PCR, immuno/fluorescence assays, and rapid molecular assays. These diagnostic tools help healthcare professionals identify the presence of influenza viruses and determine the specific viral strains causing the infection. Accurate diagnosis is crucial for timely intervention and appropriate management. Prevention is undoubtedly the most effective approach to combat influenza. Vaccination remains the cornerstone of influenza prevention, and influenza vaccines are designed to stimulate the immune system to produce antibodies that recognize and neutralize the specific strains of the virus. Can you provide an overview of the influenza virus’s structure and how it affects diagnosis and vaccine development? Influenza viruses have a unique structure. Hemagglutinin (HA) is a glycoprotein on the surface of the influenza virus. It plays a crucial role in viral entry into host cells by binding to receptors on the surface of respiratory cells. It is a primary target for neutralizing antibodies induced by influenza vaccines and antiviral drugs. Neuraminidase (NA) is another surface glycoprotein that facilitates the release of newly formed virus particles from infected cells. It targets antiviral medications and can also be utilized in vaccine development. Nuclear protein (NP) forms the backbone of the viral particle and is involved in viral replication and packaging of the viral genome. NP is a conserved antigen and is most commonly utilized in diagnostic tests to detect the presence of influenza viruses. Matrix protein two (M2) is a transmembrane protein in viral assembly and release. It is a target of antiviral drugs, and certain influenza vaccines contain M2 antigens to elicit immune responses. Non-structural protein one, or NS1, is a multifunctional protein that helps the virus evade the host's immune response. It is not a target for current influenza vaccines, but it plays a role in diagnostic tests to differentiate between influenza virus subtypes. The influenza virus has three polymerase proteins, PB1, PB2, and PA, essential for virus replication and transcription. These proteins are involved in adapting influenza viruses to new hosts and are targets of new antiviral drugs. The development and application of influenza vaccines have played a pivotal role in our ongoing fight against this ever-changing viral infection. The World Health Organization (WHO) plays a critical role in monitoring and responding to the global threat of influenza. Through its Global Influenza Surveillance and Response System (GISRS), the WHO closely monitors the spread and evolution of flu viruses worldwide. Based on its comprehensive surveillance data, the WHO, in collaboration with experts from various countries, makes annual recommendations for the strains to be included in the seasonal influenza vaccines. These recommendations, communicated through the WHO global influenza updates and consultation meetings, guide vaccine manufacturers in formulating the most appropriate vaccine composition for the upcoming flu season. What methods are currently being used for the manufacture of the influenza vaccine? Two primary technologies are used for influenza vaccine production: egg-based and recombinant methods. Egg-based vaccines have been the traditional method of influenza vaccine production for decades. They involve growing influenza viruses in chicken eggs, a well-established and relatively affordable process. The egg-based approach allows for larger-scale production of vaccines to meet the demand during the flu season. However, it does have some drawbacks. Firstly, the production is time-consuming, taking approximately eight months from strain selection to vaccine availability. This lag time may pose challenges in rapidly responding to emerging antigens or pandemics. Additionally, some individuals may have allergies to egg proteins, limiting the suitability of egg-based vaccines for these individuals. On the other hand, recombinant flu vaccines represent a newer technology that does not rely on eggs for production. Recombinant vaccines are developed using genetic engineering techniques, where specific proteins from the influenza virus are expressed in other cell types, such as mammalian or insect cells. This method offers several advantages. Firstly, recombinant vaccines can be produced relatively quickly, taking around five months from strain selection to vaccine availability. Moreover, recombinant vaccines suit individuals with egg allergies since no eggs are involved in the production. However, there are some drawbacks associated with recombinant vaccines. For example, they can be more expensive than egg-based vaccines, primarily due to the cost of the cell culture system and associated technology. As a newer technology, recombinant vaccines may have limited long-term efficacy data. Both approaches remain valuable in ensuring a sufficient supply of influenza vaccines to protect populations worldwide. What types of flu vaccines are commonly used today? A wide range of formulations and technologies are employed to combat this ever-evolving viral infection, influenza, including the live attenuated influenza vaccine (LAIV), which consists of weakened viral strains. While these strains can still infect and replicate within the body, they are designed to cause only mild or no symptoms. This vaccine is typically administered as a nasal spray and has been approved for use in certain age groups. The advantages include a single dose and strong and long-lasting immunity, and the disadvantage is that it is not recommended for immunocompromised individuals. The second technology is inactivated influenza vaccines, produced by growing the virus in eggs and then inactivating them using chemicals. This process ensures that the virus is no longer capable of causing disease. Inactivated vaccines contain viral components such as hemagglutinin and neuraminidase proteins. Adjuvants, which enhance the immune response, are often added to improve the vaccine's effectiveness. The advantages of these types of vaccines are that they are safe for all ages, and the disadvantages include the requirement for adjuvants and the potential need for multiple doses. The third technology is virosomal vaccines, which utilize reconstituted virus envelopes containing HA, NA, and lipids. These vaccines do not contain the entire virus but focus on essential viral components. The virosomes facilitate the delivery of the components into the immune system and stimulate the immune response against the influenza virus. The advantages of this type are that they are safe and provide an excellent immune response. However, they can be expensive and may require multiple doses. Split-virion is the fourth type of influenza vaccine, which involves the inactivation of the virus followed by the splitting of the virus into its components. These components are then purified, ensuring that only specific viral antigens, such as HA or NA, are present in the vaccine. Split-virion vaccines induce an immune response against these viral components, protecting against the corresponding influenza strain. The advantage of split-virion vaccines includes providing an excellent immune response, and the disadvantage is that they may not cover all strains and require adjuvants. Lastly, subunit vaccines utilize purified HA or NA proteins from the influenza virus. These proteins, the major antigens responsible for stimulating the immune response, are combined with adjuvants to enhance the immune response. Subunit vaccines offer targeted protection against specific strains of influenza. The advantage of this type of vaccine is that they are safe (as they no longer contain live viruses). However, there is a potential need for multiple doses, which provide a weaker immune response than others. Watch the webinar on-demand What are some exciting directions for the future of influenza vaccine development? As we continue to combat influenza and strive for more effective prevention strategies, ongoing research and innovation in vaccine development pave the way for future advancements. In the continuous battle against influenza, scientists and researchers are constantly exploring innovative approaches to improve the selection of seasonal flu strains for vaccine development. Traditional serological methods, which involve testing blood samples for the presence of antibodies, can be labor-intensive and inconsistent. However, with advancements in bioinformatics and computational tools, we now have new avenues to anticipate and track the natural evolution of flu viruses. One such tool is Nextflu, an online platform that utilizes bioinformatics to visualize the genetic evolution of seasonal flu viruses. By analyzing the genetic sequences of flu viruses obtained from surveillance data, Nextflu can provide insights into how these viruses evolve and change over time. This information is crucial for predicting the most likely strains to circulate in upcoming flu seasons, allowing researchers to make informed decisions regarding vaccine composition. Another valuable tool in the selection of seasonal flu strains is antigenic cartography. This tool utilizes the surveillance data provided by the World Health Organization to analyze the antigenic properties of flu viruses. By plotting the antigenic relationships between different strains on the map, researchers can identify clusters of viruses with similar antigenic characteristics. This information helps in understanding how flu viruses evolve and how they may respond to immune pressure, guiding the selection of strains for vaccine formulation. Researchers strive to develop a universal flu shot that provides broad and durable protection against multiple influenza strains by targeting viral components, including the HA Stalk Domain, NP, and NA. These approaches focus on conserved regions of the virus, which have the potential to induce immune responses capable of recognizing and neutralizing a wide range of influenza viruses. One key viral target is the HA Stalk Domain. This region of the HA protein plays a crucial role in cell membrane fusion, allowing the virus to enter the host cell. Compared to the highly variable head domain, the stem domain of the HA stalk is relatively conserved across different influenza strains. Researchers aim to induce immune responses that can neutralize a wide range of influenza viruses by targeting the HA Stalk Domain. Another promising target is Matrix Protein 2, or M2. M2 is highly conserved among different influenza strains, making it an attractive target for universal vaccines. The nuclear protein (NP) of the influenza virus is also an attractive target for a universal vaccine as it is involved in viral replication and highly conserved across different strains. The influenza virus's neuraminidase (NA) protein has been identified as a potential target for universal vaccine development. Scientists have explored various platforms that offer innovative approaches to vaccine development. One such platform is the Virus-Like Particle (VLP) which involves the co-expression of the HA, NA, and M genes together, generating VLPs resembling the influenza virus structure. VLPs mimic the native virus without the genetic material, making them safe for use in a vaccine. By presenting the viral antigens in a highly organized and immunogenic manner, VLP-based vaccines can elicit strong immune responses. Another platform is nanoparticles. In this approach, the ferritin protein and HA of the influenza virus self-assemble into nanoparticles. These nanoparticles display the viral antigens in a highly ordered and repetitive manner, enhancing their immunogenicity. By leveraging the self-assembly property of ferritin and HA, nanoparticle-based vaccines can induce robust and cross-reactive immune responses. The viral vector platform utilizes an adenoviral vector to deliver the required antigen. Adenoviral genomic sequences are engineered to include a gene cassette encoding the desired viral antigens. When administered, the adenoviral vector delivers the antigenic genes into the host cell, stimulating the immune system to generate an immune response. Nucleic acid-based platforms, such as DNA and mRNA vaccines, have also shown promise in universal flu vaccine development. A plasmid carrying the gene cassette encoding the desired immunogen is constructed in the DNA vaccine approach. The plasmid is then delivered into the host cell, allowing it to produce the viral antigen and trigger an immune response. Similarly, mRNA molecules representing the immunogen are formulated and delivered into the host cell in mRNA vaccines. Once inside the cell, the mRNA instructs the production of the viral antigen, initiating the immune response. The pursuit of a universal influenza vaccine has gained significant momentum. As previously mentioned, these vaccine candidates utilize various platforms, including VLPs, nanoparticles, viral vectors, and nucleic acids. Several of these vaccine candidates are currently in various phases of clinical trials, including phases one through two. What are some key hurdles in pursuing universal influenza vaccines, specifically in preclinical trials and evaluation criteria? One major challenge lies in evaluating novel influenza vaccines during preclinical trials. Unlike seasonal influenza vaccines, which can rely on established endpoints such as antibody titers and seroconversion rates, universal vaccines target broader immune responses that extend beyond strain-specific antibodies. There is a lack of uniform evaluation criteria for these novel vaccine candidates, making it challenging to compare their efficacy across different studies. Another obstacle in the development of universal vaccines is the absence of established correlates of protection for broadly cross-reactive immune responses. Traditional measures of vaccine efficacy, such as neutralizing antibody titers, may not fully capture the effectiveness of a universal vaccine that aims to provide broad protection against diverse influenza strains. Furthermore, the funding landscape poses a significant challenge. Watch the webinar on-demand Related StoriesFDA approved PDE4 inhibitor roflumilast for atopic dermatitisSino Biological announces services partnership with Rapid NovorEmpowering oncology research: Transmembrane proteins and cutting-edge production platformsDespite the potential impact and importance of universal influenza vaccines, funding for their development is limited. Resources are often focused on seasonal influenza vaccine production and distribution, leaving a funding gap for research and development of universal vaccine strategies. How has Sino Biological been involved in influenza vaccine development? Sino Biological is dedicated to supporting and advancing the field of influenza vaccine research. As a globally leading biotechnology company, we offer a wide range of high-quality bioreagents that are instrumental in the development of influenza vaccines Sino Biological offers comprehensive solutions for influenza vaccine development and production to vaccine manufacturers. We provide a wide range of influenza virus research reagents, including influenza vaccine antigens, antibody pairs, neutralizing antibodies, and kits. Additionally, we offer high-quality technical services such as kit development, antigen expression, and antibody development. These products and services are suitable for various vaccine development scenarios, such as candidate vaccine strain screening, virus seed batch preparation, vaccine safety, and immunogenicity assessment, and vaccine protective efficacy evaluation. By utilizing Sino Biological's ProVir viral antigen collection, researchers can investigate and characterize the immune response induced by influenza vaccines, paving the way for developing more effective preventive strategies. Influenza antibodies play important roles in vaccine development processes, including vaccine strain screening, seed lot quality control, and preclinical safety evaluation. Sino Biological has developed 200+ influenza antibody products, including pan HA/NP antibodies, pan NP antibody pairs, and neutralizing antibodies, covering various applications such as WB, ELISA, sandwich ELISA, HI, and MN, and providing comprehensive support for influenza vaccine development. In antiviral therapy research and vaccine potency evaluation, cytokines including IFN-γ, IL-4, IL-6, and IL-2 are monitored to assess the cytokine storm triggered by viral infection. Sino Biological has a collection of human and mouse cytokine ELISA kits, each of which undergoes eight QC tests. Sino Biological also offers kit development services and conducts full methodological validation to ensure the validity and stability of the detection. In addition to cytokine ELISA kits, Sino Biological also offers a panel of influenza HA/NP antigen detection kits for the accurate quantification of HA or NP content in samples to support influenza vaccine production and development. Our CRO services are designed to support research and development needs across various fields, including influenza vaccine research. We offer various services, including recombinant protein expression, recombinant antibody production, monoclonal antibody development, and polyclonal antibody development. Our commitment to quality is evident in our ISO certificates. These certifications reflect our dedication to maintaining rigorous quality management systems to ensure the consistency and reliability of our products and services. We are proud to see our products cited in over 10,000 publications as of September 2022, appearing in prestigious and high-impact journals. This recognition demonstrates researchers' trust and confidence in our reagents and services. At Sino Biological, we have established a strong global presence with our headquarters in Beijing, China. In addition to our main office, we have strategically placed branches in various cities to serve our customers better. Our branches can be found in Guangzhou, Shanghai, Taizhou, and Suzhou within China, allowing us to cater to the diverse needs of researchers and scientists nationwide. Sino Biological has expanded internationally with branches in Tokyo, Frankfurt, Pennsylvania, and Texas. These locations enable us to provide efficient and reliable support to our customers worldwide, ensuring the prompt delivery of high-quality bioreagents and comprehensive CRO services. We are a global network facilitating scientific advancements and collaborations across borders. Can you provide an overview and features of ProVir® developed by Sino Biological? Sino Biological, Inc. has launched ProVir®, the world's most extensive collection of recombinant viral antigens. This comprehensive collection comprises over 1000 products representing 90+ virus types/subtypes and 350+ strains. The ProVir® product line offers a diverse selection of high-quality recombinant proteins produced in insect and mammalian cells. These products undergo rigorous testing to ensure their purity and bioactivity. The ProVir® portfolio includes an exceptional coronavirus catalog, encompassing a vast array of antigens from more than 300 strains of influenza, as well as various other elusive viral proteins like RSV, Ebola, and Cytomegalovirus. These reagents are specifically designed to support vaccine research and drug development endeavors. How can AI and recombinant technologies from Sino Biological be applied in influenza vaccine development? Sino Biological and Ainnocence have established an AI-enabled platform for antibody affinity maturation. Powered by a self-evolving artificial intelligence engine, Ainnocence's SentinusAI® is transforming affinity maturation. SentinusAI® effectively ranks up to 1010 antibody sequences based on their predicted affinity toward one or more antigens within a few days. When combined with Sino Biological's high-throughput recombinant antibody development program, top candidates can be expressed recombinantly at a lower cost and shorter lead time, generating affinity data with a high hit rate of 15%. Among the different types of influencer vaccines, which one is known to be more effective and most popular? The effectiveness of influenza vaccines can vary greatly depending on factors such as circulating strains, population demographics, and individual health conditions. However, among the different types of influenza vaccines, inactivated vaccines have been widely used and are a popular choice among healthcare professionals. Inactivated vaccines contain killed influenza viruses and are available as injectable shots. There is a long history of safe and effective use of inactivated vaccines in preventing influenza infections. Recently, these vaccines have been continuously improved to target specific strains and are recommended for different age groups, including children, adults, seniors, and pregnant women. It is important to note that the effectiveness of these influenza vaccines can be significantly influenced by various factors, as mentioned earlier, such as vaccine coverage, public health campaigns, and regional preferences. Consequently, healthcare professionals in different regions may recommend inactivated or live attenuated virus vaccines. Watch the webinar on-demand How do researchers and companies ensure that seasonal flu vaccines are safe and effective when they are usually developed within a relatively short timeframe each year? Vaccine developers need to prioritize safety. They conduct thorough preclinical and clinical studies to evaluate potential side effects. This usually involves extensive testing in animal models for preclinical studies and multiple phases of clinical trials in humans. They also monitor the long-term safety and effectiveness, typically after the vaccine is marketed. Secondly, vaccine efficacy is another critical factor. The vaccine has to work and developers must select appropriate antigens targeting the most prevalent and virulent strains of influenza. Vaccine developers continuously monitor and analyze circulating strains to identify the most suitable candidates for inclusion in their annual vaccines. Optimizing the manufacturing processes is also essential to ensure the timely delivery of vaccines to healthcare professionals without compromising quality. This factor ensures rapid production and distribution. Streamlining regulatory processes is another consideration. In many countries, regulatory bodies collaborate with vaccine developers to streamline these processes, ensuring vaccines reach the market or healthcare professionals promptly. This can expedite vaccine development while maintaining rigorous standards. Finally, ongoing vaccine effectiveness monitoring and evaluation in the post-marketing stage are crucial. Post-marketing surveillance helps identify any potential rare adverse events or changes in virus circulation that may impact vaccine performance. Are antibodies against influenza used only for diagnostic purposes, or do they also have applications in treating influenza? The antibodies against influenza can be utilized for both diagnostic and treatment purposes. In terms of diagnosis, antibodies are employed in various tests, such as rapid diagnostic tests in clinics and serological assays in laboratories, to identify the presence of the influenza virus or influenza-specific antibodies in patient samples. These tests are highly beneficial for healthcare teams in confirming the occurrence of influenza infection in patients. Regarding treatment, specific monoclonal antibodies have been developed to address influenza. These antibodies target and neutralize the influenza virus, reducing viral replication and the severity of symptoms. They bind to specific viral components inhibiting the virus from entering and infecting host cells. These antibodies can be administered as therapeutic options for specific groups of individuals, such as those at higher risk of experiencing severe influenza symptoms due to underlying conditions or compromised immune systems. However, it is essential to note that these antibody-based treatments are typically specific to certain strains or subtypes of influenza, and they do not generally offer broad protection against all influenza viruses. Therefore, this remains a limited option. Is there currently a universal vaccine available? As of now, there is no universally approved influenza vaccine available. However, extensive research is underway to develop a universal vaccine that can provide long-lasting and broad protection against multiple strains of influenza. Several vaccine candidates are currently being investigated in preclinical and clinical trials, showing promising results. Ongoing research efforts are focused on overcoming the challenges of developing an effective universal vaccine for global use. One major obstacle is the lack of a uniform evaluation framework for novel influenza vaccines during preclinical trials. In other words, standardized methods for assessing the efficacy and immune response generated by these vaccines are still being developed. Another challenge is the limited funding available for universal vaccine development. Vaccine research and development processes are costly, requiring extensive testing in clinical trials to ensure safety and effectiveness. Therefore, adequate funding is crucial for conducting robust studies and advancing potential vaccine candidates. Where can readers find more information about Sino Biological? To learn more about Sino Biological, please search www.sinobiological.com, to learn more about influenza vaccine development and production solutions by Sino Biological, please visit the website. Dr. Mohammad Safiarian is the Associate Product Manager at SinoBiological, where he is responsible for product development and marketing of protein products. He earned his Ph.D. in Biochemistry from Georgia State University and completed post-doctoral training at the Georgia Institute of Technology and Baylor College of Medicine. Dr. Safiarian's expertise lies in protein science, DNA biochemistry, and enzymology, and he has authored several peer-reviewed papers with over 100 citations. About Sino Biological Inc. Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Sino Biological's core business Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and produced. In addition, we offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. Our product quality control indicators meet rigorous requirements for clinical use samples. It takes only a few weeks for us to produce 1 to 30 grams of purified monoclonal antibody from gene sequencing. Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments. Posted in: Thought Leaders Tags: Adenovirus, Antibodies, Antibody, Antigen, Arenavirus, Artificial Intelligence, Biochemistry, Bioinformatics, Biotechnology, Blood, Cell, Cell Culture, Cell Membrane, Chemicals, Children, Consultation, Coronavirus, Cytokine, Cytokines, Cytomegalovirus, Diagnostic, DNA, Drugs, Efficacy, ELISA, Evolution, Flu, Fluorescence, Gene, Gene Sequencing, Genes, Genetic, Genetic Engineering, Genome, Genomic, Glycoprotein, H1N1, H3N2, Healthcare, Immune Response, Immune System, immunity, Immunization, Influenza, Interferon, Interferon-gamma, Interleukin, Interleukin-2, Interleukin-6, Labor, Laboratory, Life science, Lipids, Mammalian Cells, Manufacturing, Matched Antibody Pairs, Medicine, Membrane, Monoclonal Antibody, Nanoparticle, Nanoparticles, Nasal Spray, Necrosis, Nucleic Acid, pH, Plasmid, Polyclonal Antibody, Polymerase, Preclinical, Protein, Protein Expression, Public Health, Quality Control, Reagents, Recombinant Protein Production, Research, Respiratory, Seniors, Structural Protein, Syndrome, T-Cell, Technology, Transcription, Tumor, Tumor Necrosis Factor, Vaccine, Viral Vector, Virus Comments (1) Download PDF CopyView Supplier Profile Citations Please use one of the following formats to cite this article in your essay, paper or report:APASino Biological Inc.. (2023, June 30). Advances in influenza research. News-Medical. Retrieved on November 11, 2024 from https://www.news-medical.netews/20230630/Advances-in-influenza-research.aspx.MLASino Biological Inc.. "Advances in influenza research". News-Medical. 11 November 2024. <https://www.news-medical.netews/20230630/Advances-in-influenza-research.aspx>.ChicagoSino Biological Inc.. "Advances in influenza research". News-Medical. https://www.news-medical.netews/20230630/Advances-in-influenza-research.aspx. (accessed November 11, 2024).HarvardSino Biological Inc.. 2023. Advances in influenza research. News-Medical, viewed 11 November 2024, https://www.news-medical.netews/20230630/Advances-in-influenza-research.aspx. Suggested Reading Responding to Mpox: Global outbreak, research innovations, and therapeutic strategiesSino Biological and BioGeometry Deepen Strategic Cooperation to Empower Protein R&D with Generative AIAn ActRIIA fusion protein got FDA approved for PAH treatmentFDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancerSino Biological finalizes the acquisition of SignalChem Biotech, strengthening global presence and expanding product portfolioInDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapyTherapeutic potential of CD20 x CD3 bispecific antibodiesFDA-approved TIVDAK®: Targeting tissue factor in cervical cancer Comments It seemed that the author intended to avoid mentioning mRNA influenza William CHUI says: July 2, 2023 at 12:08 PM It seemed that the author intended to avoid mentioning mRNA influenza vaccine which is inPreclinical or Phase 1 clinical trial. As a scientist with credibility, he or she should provide neutral and unbiased information. 0 0 Reply The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Trending Stories How gut bacteria regulate stress and sleep cyclesGene editing with CRISPR may introduce new defectsGenetic diagnosis solves medical mystery for 30 undiagnosed patientsBerry-flavored vapes impair lung immune responseSpace-grown stem cells show promise for accelerating biotherapies More Content from Sino Biological Inc. Utilizing cytokines in stem cell cultivation: Advances and applications in disease treatment Influenza: Research Tools for the Virus Influenza: Immunodetection and vaccine development See all content from Sino Biological Inc. High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home COVID-19 News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Monday 11 Nov 2024 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2024 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI. Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy. Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms. Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions. Provide Feedback Submit Cancel You might also like... × FDA approves AChEI ALPHA-1062 for Alzheimer’s disease treatmentFigure - Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Domestic Cat, France, 2022 - Volume 29, Number 8—August 2023 - Emerging Infectious Diseases journal - CDC Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People A-Z Index × Submit A-Z Index × Submit A-Z Index Search Dropdown × Submit Emerging Infectious Disease journal ISSN: 1080-6059 Facebook Twitter LinkedIn Syndicate Volume 29, Number 8—August 2023 Research Letter Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Domestic Cat, France, 2022 François-Xavier Briand , Florent Souchaud, Isabelle Pierre, Véronique Beven, Edouard Hirchaud, Fabrice Hérault, René Planel, Angélina Rigaudeau, Sibylle Bernard-Stoecklin, Sylvie Van der Werf, Bruno Lina, Guillaume Gerbier, Nicolas Eterradossi, Audrey Schmitz, Eric Niqueux, and Béatrice Grasland Author affiliations: ANSES, Ploufragan, France (F.-X. Briand, F. Souchaud, I. Pierre, V. Beven, E. Hirchaud, N. Eterradossi, A. Schmitz, E. Niqueux, B. Grasland); Clinique Vétérinaire des Deux Rivières, Mauléon, France (F. Hérault); Clinique Vétérinaire Filiavet, Bressuire, France (R. Planel); Resalab Ouest site de Labovet Analyse, Les Herbiers, France (A. Rigaudeau); Santé publique France, Saint-Maurice, France (S. Bernard-Stoecklin); Université Paris Cité Institut Pasteur National Reference Center, Paris, France (S. Van der Werf); National Reference Center for Respiratory Viruses, Lyon, France (B. Lina); Université de Lyon, Lyon (B. Lina); French Ministry of Food and Agriculture, Paris (G. Gerbier) Main Article Figure Figure. Phylogenetic analysis of highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus detected in domestic cat, France, 2022. Tree was created by using MEGA 7 software (https://megasoftware.net) and the neighbor-joining method with 1,000 bootstrap replicates for complete concatenated HPAI H5N1 virus segments. All sequences belong to the A/duck/Saratov/29-02V/2021–like genotype. Red solid circle indicates virus sequence from cat; black solid circle indicates sequence from a nearby duck farm. Both sequences are available in the GISAID database (https://www.gisaid.org) under accession nos. EPI_ISL_16395206 (cat) and EPI_ISL_16740903 (duck). Red bracket indicates closely related sequences detected during the same period and area in France from domestic bird farms. Scale bar indicates nucleotide substitutions per site. Main Article Page created: June 16, 2023 Page updated: July 20, 2023 Page reviewed: July 20, 2023 The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above. home4EID JournalAbout the JournalexpandGeneral InformationexpandBackground and GoalsEditorsEditorial BoardStaffContactArticlesexpandNovember 2024Infectious Diseases and Carceral Health SupplementEarly ReleasePast IssuesexpandAugust 2023expandHighly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Domestic Cat, France, 2022expandFigureTableAppendixMedscape CMEICEIDSearchexpandAdvanced Article SearchArticles by Country SearchSpotlight TopicsexpandAntimicrobial Resistance SpotlightCoronavirus SpotlightEbola SpotlightEtymologiaFood Safety SpotlightFungal DiseasesHIV/AIDS SpotlightInfluenza SpotlightLyme Disease SpotlightMalaria SpotlightMERS SpotlightMpox SpotlightPneumonia SpotlightRabies SpotlightTicks SpotlightTuberculosis/MycobacteriaZika SpotlightArticle Type SearchEID on PubMed CentralSubscribeAuthor Resource CenterPeer ReviewersPodcastsexpandSearchSocial Media Press & Media Information About CDC Contact Us 800-232-4636 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat CONTACT CDC Contact Us Call 800-232-4636 Email Us ABOUT CDC About CDC Jobs Funding POLICIES Accessibility External Links Privacy Policies No Fear Act FOIA OIG Nondiscrimination Vulnerability Disclosure Policy Public Health Publications CONNECT WITH US Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat Email LANGUAGES Español 繁體中文 Tiếng Việt 한국어 Tagalog Русский العربية Kreyòl Ayisyen Français Polski Português Italiano Deutsch 日本語 فارسی English U.S. Department of Health & Human Services Accessibility External Links Privacy Policies No Fear Act FOIA Nondiscrimination OIG Vulnerability Disclosure Policy Public Health Publications USA.gov file_externalProtein prevents transmission avian influenza viruses in humans Skip to main content Main navigation Contents Reactions Expert voices What we know Resource library Briefings Training SMC Studies Journalists Scientists Press offices About SMC ES About SMC ES The 5Ws +1 Statute Advisory Committee Working Method Governance Team FAQ Global network User account menu - Secondary Search ESEN Breadcrumb Home Reactions Reactions: a protein is identified that prevents transmission and replication of avian influenza viruses in humans This article is 1 year old Reactions: a protein is identified that prevents transmission and replication of avian influenza viruses in humans Although outbreaks of H5N1 avian influenza have reached record numbers in recent years, human infections remain anecdotal. A study published today in Nature identifies a protein responsible for inhibiting the replication of this virus in humans, while 'human' flus are able to evade it. The authors propose that this protein with antiviral activity evolved in primates and consider that resistance or sensitivity to it should be taken into account when assessing the zoonotic potential of avian influenza viruses. SMC Spain 28/06/2023 - 17:00 CEST Versión en castellano Expert reactions Gustavo del Real - gripe aviar proteína EN Gustavo del Real Researcher at the Center for Research on Influenza Pathogenesis and Transmission (CRIPT) at the Icahn School of Medicine at Mount Sinai, New York, USA and researcher at the National Institute for Agrarian and Food Research and Technology (INIA-CSIC) National Institute for Agricultural and Food Research and Technology (INIA-CSIC) Spanish National Research Council (CSIC) Science Media Centre Spain More than three years after the sudden onset of the SARS-CoV-2 covid-19 pandemic, the world population has returned to pre-pandemic normality. Health authorities and infectious disease experts are now trying to guess which agent will be responsible for the next pandemic. It is not known when or where it will emerge, nor what type of micro-organism will surprise us, but all experts agree that sooner or later it will visit us with greater or lesser aggressiveness. Among the most likely candidates are still the viruses that cause avian influenza, belonging to the Influenza A genus. Their threat is not new; they have been causing sporadic infections in humans for almost three decades, but without ever becoming established and spreading efficiently in our species. For the past couple of years, a member of this group of avian viruses, called H5N1, has been causing innumerable highly virulent outbreaks in poultry and wild birds around the world, with very high mortality rates. But of added concern is that this virus has demonstrated the ability to severely infect several mammalian species, which is a first step towards crossing the species barrier and causing effective and virulent infections in humans. Numerous research groups are trying to unravel the factors involved in the adaptation of viruses to different animal species. In this article, the authors describe the identification of the protein BTN3A3 (Butyrophilin subfamily 3, member A3), which acts as a potent inhibitor of avian influenza viruses, but not of human influenza viruses. This protein is expressed in human respiratory tract cells and its inhibitory activity appears to have originated and evolved in primates. Specifically, the researchers show that the mechanism of action of BTN3A3 acts in the early stages of the virus cycle, inhibiting viral RNA replication. However, not all avian influenza viruses are sensitive to this inhibitory protein. For example, viruses of the H7 and H9 subtypes, as well as a high percentage of highly virulent H5N1 strains, are refractory to the inhibitory action of BTN3A3. Specifically, viruses isolated in the H5N1 outbreak that affected a ferret farm in Galicia in 2022 showed a mutation conferring resistance to BTN3A3 that the virus previously acquired in an avian host. In summary, this study provides a breakthrough in the understanding of the innate molecular mechanisms by which humans defend against avian influenza viruses. The authors postulate that this new resistance element could be of high epidemiological value in association with the ability of avian influenza viruses to transmit in humans. The author has not responded to our request to declare conflicts of interest Language EN María Iglesias - gripe aviar proteína EN María Iglesias-Caballero Virologist at the Reference Laboratory for Influenza and Respiratory Viruses of the National Microbiology Centre - Carlos III Health Institute National Microbiology Centre - Carlos III Institute of Health Health Institute Carlos III Science Media Centre Spain Avian influenza is currently a serious animal health problem. Understanding the virus evasion mechanisms and the evolution of proteins involved in evading the immune response is of vital importance, as this provides a tool with great potential to assess the impact of the different bird-to-human virus transmissions that we have been analysing worldwide. The identification of mutations allows us to assess the origin of the virus detected in humans and to understand the impact these changes may have on the population. The rapid and reliable collection of genomic data has now provided great advantages for influenza virus surveillance. Having information on mutations to monitor, even if we then have to verify their actual impact by functional and antigenic assays, is a great advantage that allows us to make rapid and informed decisions. On the other hand, a better understanding of the innate immune response to respiratory viruses is crucial, as this will give us one of the keys to understanding the development and evolution of respiratory infections. In the case of human influenza, some interferon evasion pathways are well characterised. In respiratory infections, the innate immune response plays a key role: if inadequately activated, viral replication can lead to the development of disease, but over-activation can lead to tissue damage that aggravates the disease. A better understanding of all these multiple pathways and the interactions between them is an important field with great potential. The authors of this paper have presented functional and genomic data that are robustly supported by appropriate methodology. The use of different assays provides rigorous support for the results presented. The author has not responded to our request to declare conflicts of interest Language EN Ursula Höfle - proteína gripe aviar Ursula Höfle Associate Professor, SaBio Group of the Institute for Research in Hunting Resources IREC (CSIC-UCLM-JCCLM), University of Castilla-La Mancha Institute for Research in Hunting Resources IREC (CSIC, UCLM, JCCM) Spanish National Research Council (CSIC) University of Castilla-La Mancha Science Media Centre Spain The study published by an established group dedicated to the investigation of zoonotic virus characteristics and host immune response reports the finding of a new gene that adds to the already known mechanisms involved in the so-called species barrier that prevents avian influenza A viruses from easily infecting humans. This extensive study based on solid evidence worked out in great detail adds a gene to the already known factors inhibiting the transmission of avian influenza A viruses to humans - BTN3A3 - and tells how evasion of inactivation by this gene has allowed some avian influenza viruses to acquire zoonotic potential and infect humans, especially in the H7N9 subtype that caused a wave of human infections in 2013. The study is based on the search for genes stimulated by interferon (the substance secreted as an immune response in our body) and combines cell culture studies, animal experiments and in-depth studies of human and primate genomes and avian influenza A viruses. Through the experiments, the researchers identified the BT3A3 gene as a specific inhibitor of avian influenza viruses both in cell culture and in a live mouse model. They also detected that the gene acts at the level of virus replication in the cell nucleus and the amino acid in the sequence of one of the segments of avian [influenza A virus] AIVs that makes avian influenza viruses susceptible to the gene's effect. Finally, they describe two amino acid changes that can make avian influenza A viruses resistant to the gene, one of which is present in most avian influenza viruses that have, at some point in history, made the jump to humans - including the 1918 influenza virus (the misnamed Spanish flu). They conclude that these changes - that is, evasion of the species-hopping barrier constituted by the BTN3A3 gene - are a key mechanism that may confer zoonotic potential to avian influenza A viruses. The author has not responded to our request to declare conflicts of interest Language EN Publications BTN3A3 evasion promotes the zoonotic potential of influenza A viruses Research articlePeer reviewed BTN3A3 evasion promotes the zoonotic potential of influenza A viruses Research articlePeer reviewed Journal Nature Publication date 28/06/2023 Authors María Pinto et al. Study types: Research articlePeer reviewed Download publication Learn more about study types Topics Bird fluzoonoses You may be interested in Reactions: bird flu cases detected in Spain in 2022 were not real infections Reactions: bird flu cases detected in Spain in 2022 were not real infections H5N1 avian influenza: an old acquaintance that is changing fast H5N1 avian influenza: an old acquaintance that is changing fast A brief history of H5N1, an avian influenza virus devastating to birds and low risk to humans A brief history of H5N1, an avian influenza virus devastating to birds and low risk to humans The 5Ws +1 Publish it FAQ Contact Science Media Centre Spain Sobre SMC What is the SMC Spain Statute Advisory Committee CC Licence FAQ Contact the SMC Do you have any questions or suggestions? Write to us Información Legal Notice and Privacy Policy Cookies Policy Accesibilidad © Science Media Centre 2021New insights into influenza A's infiltration of host cells RecommendedNew webinar: Overcoming critical challenges in AI-driven drug discovery Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucomaBrand new Beyond the Lab report on antibodies… Download NOW! About us | Advertise with us | Contact us MenuHomeCancer Research hubNewsArticlesPublicationsVideosPodcastsWebinarsWhitepapers / App NotesContent HubsEventsLiverpool Breakfast BriefingIndustry Events Close Targets Screening Stem Cells Hit-to-Lead Omics Imaging Informatics Regs & Legs Women in Stem news New insights into influenza A’s infiltration of host cells 0SHARES Share via Pinterest Reddit Buffer Xing WhatsApp Flipboard Posted: 28 June 2023 | Izzy Wood (Drug Target Review) | No comments yet US researchers have made a significant breakthrough in understanding how the influenza A virus takes over host cells while minimising damage to itself. By studying the protein PA-X, they found that the virus uses a surgical strike approach, selectively degrading host cell RNA while preserving its own replication, shedding light on the persistent threat of influenza A. Influenza A, one of the primary viruses behind annual flu seasons and occasional deadly pandemics, has long posed a significant threat to humans and animals alike. Scientists have been striving to unravel the mechanisms of this virus, and now a team of researchers at the University of Wisconsin–Madison, US, havr made a breakthrough in understanding how one of the virus’s key proteins operates, uncovering a surprising finding that challenges previous assumptions. The discovery sheds light on how influenza A infiltrates host cells more strategically rather than through brute force. The focal point of the study is a protein called PA-X, which disrupts host cells by degrading their RNA—the genetic material necessary for protein production and defence against invading viruses. PA-X initiates thousands of cuts in the RNA of host cells, rendering their genetic instructions incoherent. However, for the virus to effectively infiltrate host cells while preserving its own RNA, a delicate balance must be maintained. Marta Gaglia, Associate Professor of Medical Microbiology and Immunology at UW–Madison’s Institute for Molecular Virology, led the study. She explains that the virus orchestrates a surgical strike on host cells without compromising its replication. Using high-throughput sequencing and advanced statistical modeling, Gaglia and her team have made significant progress in understanding how PA-X degrades host cell RNA while minimising damage to the virus itself. The researchers found that PA-X exhibits a strong preference for a specific sequence of RNA, which is abundant in the genetic material of humans and other animals infected by influenza A viruses but rarely present in the virus’s own RNA. Although PA-X occasionally affects non-target RNA sequences, it proves sufficiently effective in disrupting host cell functions. The findings, published in the journal Nature Microbiology, provide key insights into PA-X’s mechanism. Additionally, the study suggests that the influenza A virus possesses a mechanism for differentiating between RNA sequences in its hosts’ genetic material and its own—a phenomenon known as selfon-self recognition, commonly observed in host immune responses but previously unacknowledged in viruses. Gaglia highlights the significance of this discovery, noting, “It’s interesting to see the virus also has found a way to do that, flipping the script.” While many aspects of PA-X’s precise function remain unknown, the researchers are now exploring whether their methods accurately capture the position and number of sites in the RNA sequences where PA-X initiates cuts. This ongoing work involves refining their statistical models in collaboration with Christopher Rycroft, a Mathematics Professor at UW–Madison. Gaglia emphasises their intention to develop a robust program that enables other researchers to analyse their data effectively. She states, “We have collected some more datasets that we hope to use to refine the methods so we can make this a really robust program that other people can use to analyse their data as well.” Another unresolved question concerning PA-X relates to its impact on the severity of influenza infections. Previous studies have indicated that influenza A strains with less active PA-X proteins tend to be associated with more severe symptoms. However, researchers have yet to identify specific genetic markers of the PA-X protein that can indicate its level of activity, which could potentially indicate the dangerousness of a particular strain. Gaglia envisions an ideal scenario in which the sequence of a virus could be analysed to determine the activity level of its PA-X protein, providing valuable insights into the potential severity of the infection. Related topicsGenetic Analysis, Proteogenomics, Proteomics, RNAs Related conditionsInfluenza A Related organisationsUniversity of Wisconsin-Madison Related peopleMarta Gaglia By Izzy Wood (Drug Target Review)28 June 2023 No comments yet Shares 0 Share via Pinterest Reddit Buffer Xing Flipboard Related topicsGenetic Analysis, Proteogenomics, Proteomics, RNAs Related conditionsInfluenza A Related organisationsUniversity of Wisconsin-Madison Related peopleMarta Gaglia Most popular...Beyond the lab: antibodiesAlzheimer’s disease: driving advancements with precision medicineOrganoids: the versatile platform for discovery and regenerationUnlocking a new molecular space in rapid drug discoverySpecific HERV expression signatures linked to MS and ALS Read the latest issue All subscriptions include online membership, giving you access to the journal and exclusive content. Download free copy Related content news Breast cancer genetic variants in women of African ancestry By Drug Target Review news CNTN4 modulates factors involved in Alzheimer’s disease By Drug Target Review article Harnessing natural killer cells to combat age-related diseases By Dr Robert Hariri (Celularity), Ellen Capon (Drug Target Review) news Proteogenomics: finding targets for never-smoker lung cancer By Drug Target Review Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Content Articles News Whitepapers & App Notes Corporate Content Webinars Blogs Events Products Issue Archive Topics Targets Screening Stem Cells Hit-to-lead Omics Imaging Informatics Regs & Legs Advertising & Editorial Media Planner Publishing Schedule Advertising Opportunities Advertising Tech Specs Author Information Permission to reuse our content Write for us | Advertise with us Contact Subscribe Today T: +44 (0)1959 563311 F: +44 (0)1959 563123 Company Information Drug Target Review is published by: Russell Publishing Ltd.Court LodgeHogtrough HillBrasted, Kent, TN16 1NUUnited Kingdom About Careers @ Russell Publishing Terms & Conditions Privacy Policy Cookie Policy Manage your cookies © Russell Publishing Limited, 2010-2024. All rights reserved. Terms & Conditions | Privacy Policy | Cookie Policy Website development by e-Motive Media Limited. This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.Manage your cookies I agreeCookie Settings Close Cookie Settings This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as "Necessary" are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies "Advertising & Targeting", "Analytics" and "Performance", these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to 'Enabled' or 'Disabled', then click 'Save and Accept'. View our Cookie Policy page. Necessary Necessary Always Enabled Necessary cookies enable the core functionality of the website, including security, network management and accessibility. These cookies do not store any personal information. You may disable these by changing your browser settings, but this may affect how the website functions. CookieTypeDurationDescriptioncookielawinfo-checkbox-advertising-targetingpersistent1 yearThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".cookielawinfo-checkbox-analyticspersistent1 yearThis cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".cookielawinfo-checkbox-necessarypersistent1 yearThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".cookielawinfo-checkbox-performancepersistent1 yearThis cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".PHPSESSIDsession1 yearThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.viewed_cookie_policypersistent1 yearThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.zmember_loggedsession1 yearThis session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users. Advertising & Targeting advertising-targeting Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns. CookieTypeDurationDescriptionadvanced_ads_browser_widthpersistent1 monthThis cookie is set by Advanced Ads and measures the browser width.advanced_ads_page_impressionspersistent2 yearsThis cookie is set by Advanced Ads and measures the number of previous page impressions.advanced_ads_pro_server_infopersistent1 monthThis cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.advanced_ads_pro_visitor_referrerpersistent1 yearThis cookie is set by Advanced Ads and sets the referrer URL.bscookiepersistent2 yearsThis cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.IDEpersistent2 yearsThis cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.li_sugrpersistent3 monthsThis cookie is set by LinkedIn and is used for tracking.UserMatchHistorypersistent1 monthThis cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.VISITOR_INFO1_LIVEpersistent5 monthsThis cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website. Analytics analytics Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website. CookieTypeDurationDescriptionbcookiepersistent2 yearsThis cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.GPSpersistent30 minutesThis cookie is set by YouTube and registers a unique ID for tracking users based on their geographical locationlangsession1 yearThis cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.lidcpersistent1 dayThis cookie is set by LinkedIn and used for routing.lisscpersistent11 monthsThis cookie is set by LinkedIn share Buttons and ad tags.vuidpersistent2 yearsWe embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.wow.anonymousIdpersistent2 yearsThis cookie is set by Spotler and tracks an anonymous visitor ID.wow.schedulepersistent20 minutesThis cookie is set by Spotler and enables it to track the Load Balance Session Queue.wow.sessionpersistent20 minutesThis cookie is set by Spotler to track the Internet Information Services (IIS) session state.wow.utmvaluespersistent20 minutesThis cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on._gapersistent2 yearsThis cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors._gatpersistent1 minuteThis cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites._gidpersistent1 dayThis cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form. Performance performance Performance cookies include cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information. CookieTypeDurationDescriptioncf_ob_infopersistent1 minuteThis cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.cf_use_obpersistent1 minuteThis cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.free_subscription_onlysession1 yearThis session cookie is served by our membership/subscription system and controls which types of content you are able to access.ls_smartpushpersistent1 monthThis cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.one_signal_sdk_dbpersistentUntil clearedThis cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.YSCsession1 yearThis cookie is set by Youtube and is used to track the views of embedded videos. Save & AcceptHigh body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection | Nature Communications Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement View all journals Search Log in Explore content About the journal Publish with us Sign up for alerts RSS feed nature nature communications articles article High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection Download PDF Download PDF Article Open access Published: 30 June 2023 High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection Minami Nagai1 na1, Miyu Moriyama ORCID: orcid.org/0000-0003-0310-90471 na1, Chiharu Ishii2 na1, Hirotake Mori ORCID: orcid.org/0000-0002-7988-57583, Hikaru Watanabe4, Taku Nakahara4, Takuji Yamada ORCID: orcid.org/0000-0002-9622-18494,5, Dai Ishikawa4,6,7, Takamasa Ishikawa2, Akiyoshi Hirayama ORCID: orcid.org/0000-0002-0440-68202, Ikuo Kimura ORCID: orcid.org/0000-0001-8778-145X8,9, Akihito Nagahara6,7, Toshio Naito3, Shinji Fukuda ORCID: orcid.org/0000-0001-5161-98802,4,6,10,11 & …Takeshi Ichinohe ORCID: orcid.org/0000-0002-6376-28411 Show authors Nature Communications volume 14, Article number: 3863 (2023) Cite this article 11k Accesses 15 Citations 200 Altmetric Metrics details Subjects Influenza virusNeutrophilsPattern recognition receptorsSARS-CoV-2Viral host response AbstractFever is a common symptom of influenza and coronavirus disease 2019 (COVID-19), yet its physiological role in host resistance to viral infection remains less clear. Here, we demonstrate that exposure of mice to the high ambient temperature of 36 °C increases host resistance to viral pathogens including influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). High heat-exposed mice increase basal body temperature over 38 °C to enable more bile acids production in a gut microbiota-dependent manner. The gut microbiota-derived deoxycholic acid (DCA) and its plasma membrane-bound receptor Takeda G-protein-coupled receptor 5 (TGR5) signaling increase host resistance to influenza virus infection by suppressing virus replication and neutrophil-dependent tissue damage. Furthermore, the DCA and its nuclear farnesoid X receptor (FXR) agonist protect Syrian hamsters from lethal SARS-CoV-2 infection. Moreover, we demonstrate that certain bile acids are reduced in the plasma of COVID-19 patients who develop moderate I/II disease compared with the minor severity of illness group. These findings implicate a mechanism by which virus-induced high fever increases host resistance to influenza virus and SARS-CoV-2 in a gut microbiota-dependent manner. Similar content being viewed by others Obesity, the most common comorbidity in SARS-CoV-2: is leptin the link? Article 09 July 2020 Akkermansia muciniphila protects mice against an emerging tick-borne viral pathogen Article 05 January 2023 Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications Article 21 October 2022 IntroductionRespiratory infectious diseases, such as influenza and coronavirus disease 2019 (COVID-19), cause substantial morbidity and mortality. These infectious diseases mostly affect older adults1,2. Increased susceptibility to influenza virus infection in older humans could be explained by the fact that older human monocytes have impaired signaling to induce type I interferons (IFNs) in response to influenza virus infection3,4. However, the role of other age-related changes of host factors in susceptibility to influenza virus infection remains unclear. With respect to age-related changes of host factors, several studies demonstrated that the composition of gut microbiota changes with age in both humans and animals5,6,7. In addition, mean body temperature in humans decrease with age8. Although it has increasingly become evident that gut microbiota and their metabolites are important for protection against influenza virus infection9,10,11,12, the effects of body temperature on host defense to influenza virus infection are largely unknown.In addition to age-related changes of host factors, environmental parameters and eating behavior could affect host susceptibility to influenza virus infection13,14,15,16. A recent study showed that mice housed in 10 or 20% relative humidity succumbed to influenza virus infection more rapidly than those housed in 50% relative humidity13. Further, ketogenic diet-fed mice had improved survival relative to mice on a normal chow diet after influenza virus challenge14. In vitro studies using rhinovirus and influenza virus showed that warm temperature restricts viral replication through type I IFN-dependent and -independent mechanisms17,18,19. In addition, both humidity and temperature affect the frequency of influenza virus transmission among guinea pigs20,21. We previously demonstrated that exposure of mice to the high ambient temperature of 36 °C impairs virus-specific CD8+ T cell responses and antibody production after intranasal challenge with a sublethal dose (30 pfu) of influenza virus11. In contrast, the effects of outside temperature on host resistance to lethal influenza virus challenge remain unknown. The highest temperature during summer reaches 36 °C in Tokyo. In contrast, the average minimum temperature in January goes down to around 4 °C in Tokyo. Thus, here we explore the effects of outside temperatures such as 4 °C or 36 °C on host resistance to influenza virus infection.In this study, we demonstrate that exposure of mice to the high ambient temperature of 36 °C increases body temperature and host resistance to influenza virus or SARS-CoV-2 infection. Moreover, we demonstrate that high body temperature-dependent activation of gut microbiota increases the levels of bile acids in the serum and intestine, and suppresses virus replication and detrimental inflammatory responses following influenza virus and SARS-CoV-2 infection.ResultsTemperature affects severity of influenzaIn mice infected with influenza virus, reduction of body temperature became apparent starting around day 4 p.i. (Supplementary Fig. 1a). Consistent with the reduction of body temperature, the virus-infected mice remained huddled together probably to avoid reducing their body temperature (Supplementary Fig. 1b). These observations prompted us to explore the functional role of body temperature in resistance to influenza virus infection. To this end, we kept mice at 4, 22, or 36 °C for 7 days before influenza virus infection11. We have previously confirmed that cold or high-heat exposure of naïve mice was generally well tolerated11. Cold-exposed naïve mice exhibited significant decrease in body temperature compared with room temperature-exposed group, whereas high-heat exposure of naïve mice significantly increased body temperatures ranged from 38.4 °C to 39.1 °C (Fig. 1a). To examine the role of body temperature in protection against influenza virus infection, cold-, room temperature-, or high heat-exposed mice were infected intranasally with a mouse-adapted influenza A virus strain A/Puerto Rico/8/1934 (PR8) and kept at 4, 22, or 36 °C, respectively, for the entire duration of the experiments. After influenza virus infection, cold-exposed mice succumbed to disease with severe hypothermia faster than room temperature-exposed group, whereas high heat-exposed mice were highly resistant to influenza virus infection at three challenge doses (Fig. 1b, c and Supplementary Fig. 2). Consistent with our previous report11, the virus titers were significantly reduced in the lung of high heat-exposed mice compared with cold- or room temperature-exposed groups at early time points (Fig. 1d). Similar results were observed when mice were challenged with influenza virus intratracheally (Supplementary Fig. 3) or a human isolate of the 2009 pandemic influenza A virus strain A/Narita/1/2009 (pdm09) (Supplementary Fig. 4). These protective effects of high heat-exposed mice against influenza virus infections were dependent on the virus challenge dose (Fig. 1c and Supplementary Figs. 2 and 4).Fig. 1: Body temperature affects severity of influenza virus infection.Mice were kept at 4, 22, or 36 °C for 7 days before influenza virus infection and throughout infection. a, Body temperature of naïve mice kept at 4, 22, or 36 °C were measured (4 °C, n = 16 mice; 22 °C, n = 15 mice; 36 °C, n = 15 mice). b–d Mice kept at 4, 22, or 36 °C were infected intranasally with 1000 pfu of influenza virus. Body temperatures (b; 4 °C, n = 8 mice; 22 °C, n = 8 mice; 36 °C, n = 9 mice), mortality (c; 4 °C, n = 8 mice; 22 °C, n = 8 mice; 36 °C, n = 9 mice), and virus titer in the lung wash (d; 4 °C, n = 4 mice; 22 °C, n = 5–6 mice; 36 °C, n = 6 mice) were measured on indicated days after challenge. e, f, Eight-, 52-, 101-weeks-old mice kept at 22 °C were infected intranasally with 1000 pfu of influenza virus. Body temperatures (e) and mortality (f) were measured on indicated days after challenge (8 weeks, n = 16 mice; 52 weeks, n = 10 mice; 101 weeks, n = 7 mice). g, h Partially hepatectomized or control mice kept at 22 °C were infected intranasally with 1000 pfu of influenza virus. Body temperatures (g) and mortality (h) were measured on indicated days after challenge (control, n = 8 mice; partial hepatectomy, n = 10 mice). Each symbols indicate individual values (a, d, e, g). Data are mean ± s.e.m. Data are pooled from two independent experiments (a) or are representative of two independent experiments (b–h). Statistical significance was analyzed by two-way analysis of variance (ANOVA) (a, d, e), two-tailed unpaired Student’s t test (g), or two-sided log-rank (Mantel-Cox) test (c, f, h). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significant (g; 0 day p.i., p = 0.0023; 4 days p.i., p = 0.0139; 7 days p.i., p = 0.00000044).Full size imageWe next examined the effects of outside temperature on host resistance to SARS-CoV-2, another respiratory virus, infection. Recently, it has been reported that Syrian hamsters are a useful small animal model for SARS-CoV-2 infection22. Consistent with a previous report22, hamsters kept at 22 °C were resistant to infection with an original SARS-CoV-2 strain bearing aspartic acid at position 614 of spike (S) protein (S-614D) (Supplementary Fig. 5a–c). In contrast, cold-exposed hamsters succumbed to diseases with severe hypothermia despite having viral loads similar to room temperature-exposed group (Supplementary Fig. 5). Similarly, cold-exposed K18-hACE2 transgenic mice succumbed to disease with severe hypothermia faster than room temperature-exposed group, whereas the high heat-exposed mice were highly resistant to lethal SARS-CoV-2 infection (Supplementary Fig. 6). Next, we wished to examine the effects of outside temperature on host resistance to non-respiratory viral pathogens such as severe fever with thrombocytopenia syndrome phlebovirus (SFTSV), Zika virus, or encephalomyocarditis virus (EMCV). After infection with SFTSV or Zika virus intravenously, cold-exposed mice succumbed to disease, whereas room temperature-exposed mice were resistant to infection (Supplementary Figs. 7 and 8). In addition, high heat-exposed mice improved survival relative to cold- or room temperature-exposed mice after intraperitoneal EMCV challenge (Supplementary Fig. 9).Next, we wished to setup an experimental condition in which sex-matched mice kept at room temperature have different body temperatures. Since aged mice had lower body temperature than adult mice23, we next examined the effects of age in influenza virus-induced mortality. Consistent with published reports23,24, aged mice had lower body temperature than adult mice and were more susceptible to influenza virus infection (Fig. 1e, f), whereas high-heat exposure of the aged mice had improved survival relative to control mice (Supplementary Fig. 10). Next, we wished to setup an experimental condition in which age- and sex-matched mice have different body temperatures. Since liver plays a key role in thermogenesis and thermoregulation25, we next examined the effects of partial hepatectomy in influenza virus-induced mortality. Notably, decrease in basal body temperature of room temperature-exposed adult mice by partial hepatectomy exacerbated influenza virus-induced mortality (Fig. 1g, h). Together, these data indicated that body temperature significantly affects host resistance to a broad range of viral infections including influenza A virus and SARS-CoV-2.High fever increases gut microbial metabolismNext, we wished to determine the threshold of body temperature required for protection against influenza virus infection. To this end, we kept mice at 22, 28, 34, or 36 °C before influenza virus infection. While most high heat-exposed naïve mice kept at 36 °C had basal body temperature over 38 °C, an average of basal body temperature of naïve mice kept at 34 °C was 37.2 °C ranged from 37.0 °C to 37.7 °C (Fig. 2a). Although all mice kept at 36 °C survived from lethal influenza virus infection, the majority of the virus-infected mice kept at below 34 °C succumbed to disease at two challenge doses (Fig. 2b and Supplementary Fig. 11a). In addition, all 36 °C-exposed mice kept their body temperature over 38 °C during influenza virus infection (Fig. 2c and Supplementary Fig. 11b). Further, the virus titers were significantly reduced in the lung of high heat-exposed group compared with 34 °C-exposed group at 2 and 3 days p.i. (Fig. 2d). These data indicated that high body temperature over 38 °C may increase host resistance to influenza virus infection.Fig. 2: High body temperature increases gut microbiota-dependent host resistance to influenza virus infection.Mice were kept at 22, 28, 34, or 36 °C for 7 days before influenza virus infection and throughout infection. a Body temperature of naïve mice kept at 22, 28, 34, or 36 °C were measured (22 °C, n = 8 mice; 28 °C, n = 8 mice; 34 °C, n = 9 mice; 36 °C, n = 8 mice). The dashed line indicates 38 °C. b–d Mice kept at 22, 28, 34, or 36 °C were infected intranasally with 1000 pfu of influenza virus. Mortality (b; 22 °C, n = 10 mice; 28 °C, n = 10 mice; 34 °C, n = 10 mice; 36 °C, n = 10 mice), body temperatures (c; 22 °C, n = 10 mice; 28 °C, n = 10 mice; 34 °C, n = 10 mice; 36 °C, n = 10 mice), and virus titer in the lung wash (d; 22 °C, n = 10 mice; 34 °C, n = 10 mice; 36 °C, n = 11–12 mice) were measured on indicated days after challenge. e–g Low fiber (LF)-fed, antibiotics (Abx)-treated, and control mice kept at 36 °C were infected intranasally with 1000 pfu of influenza virus. Mortality (e; control, n = 10 mice; LF-fed, n = 7 mice; Abx-treated, n = 10 mice), body temperatures (f; control, n = 10 mice; LF-fed, n = 7 mice; Abx-treated, n = 10 mice), and virus titer in the lung wash (g; control, n = 10 mice; LF-fed, n = 8–11 mice; Abx-treated, n = 10–18 mice) were measured on indicated days after challenge. Each symbols indicate individual values (a, c, d, f, g). Data are mean ± s.e.m. Data are representative of two independent experiments (a–f) or are pooled from two independent experiments (g). Statistical significance was analyzed by two-way analysis of variance (ANOVA) (a, c, d, f, g) or two-sided log-rank (Mantel-Cox) test (b, e). *P < 0.05, **P < 0.01, ***P < 0.001.Full size imageRecent studies have demonstrated that gut microbiota-derived metabolites protect from influenza virus-induced mortality by enhancing type I IFN signaling or attenuating the neutrophil influx into the lung9,26. Thus, we hypothesized that gut microbial activity may be activated by host body temperature over 38 °C27,28. To test whether gut microbiota or microbial metabolites are needed to increase host resistance to influenza virus infection in high heat-exposed mice, we infected high heat-exposed low fiber (LF)-fed or antibiotics (Abx)-treated mice with influenza virus. High heat-exposed LF-fed and Abx-treated mice significantly reduced the amounts of DNA isolated from cecal contents compared with high heat-exposed control group (Supplementary Fig. 12a). In addition, high heat-exposed LF-fed and Abx-treated mice changed the bacterial clusters in the cecum compared with high heat-exposed control group (Supplementary Fig. 12b–e). Strikingly, high heat-exposed LF-fed or Abx-treated mice succumbed to disease despite having body temperature over 38 °C similar to high heat-exposed control mice during influenza virus infection (Fig. 2e, f). However, the viral titers in the lung of high heat-exposed LF-fed or Abx-treated mice were similar to that of high heat-exposed control mice at early time points (Fig. 2g). Next, we examined whether gut microbiota or microbial metabolites are needed to increase host resistance to SARS-CoV-2 infection in hamsters. To this end, we infected room temperature-exposed LF-fed or Abx-treated mice with SARS-CoV-2. Interestingly, we found that Abx-treated naïve hamsters kept at 22 °C exhibited significant decrease in basal body temperature compared with control or LF-fed naïve hamsters (Supplementary Fig. 13a). Consistent with a previous report22, control hamsters kept at 22 °C were resistant to infection with an original SARS-CoV-2 strain bearing aspartic acid at position 614 of spike (S) protein (S-614D) (Supplementary Fig. 13b). In contrast, LF-fed and Abx-treated hamsters succumbed to infection despite having viral loads similar to control hamsters (Supplementary Fig. 13b–d). These data indicated that inability of high heat-exposed LF-fed and Abx-treated mice or room temperature-exposed LF-fed and Abx-treated hamsters to protect against lethal influenza virus or SARS-CoV-2 challenge was not due to their body temperature but may be instead due to reduction of gut microbial fermentation products.To gain insight into the mechanisms underlying gut microbiota-derived metabolites mediated host resistance to influenza virus infection in high heat-exposed mice, we performed capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS), gas chromatography–mass spectrometry (GC-MS), liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolome analysis of cecal contents, serum, and livers of naïve mice kept at 4, 22, or 36 °C for 7 days. The CE-TOFMS-based cecal metabolome profiles were clustered and found that the levels of both primary and secondary bile acids were significantly increased in the high heat-exposed mice or hamsters compared with cold- or room temperature-exposed groups (Supplementary Fig. 14). In contrast, several types of both primary and secondary bile acids were significantly enhanced in the serum and livers of high heat-exposed mice compared with cold- or room temperature-exposed groups (Supplementary Figs. 15 and 16). In addition, both primary and secondary bile acids were significantly reduced in the serum of high heat-exposed LF-fed or Abx-treated mice compared with high heat-exposed control mice (Supplementary Fig. 17).Bile acids-TGR5 axis protects from influenzaThus far, our data indicated that high heat-exposed mice increased host resistance to a broad range of viral infections including influenza A virus and SARS-CoV-2. In addition, high heat-exposed mice may increase gut microbial biotransforming reactions to produce the secondary bile acids. These observations led us to focus on the role of bile acids in resistance to influenza virus infection. We hypothesized that elevated levels of bile acids in the serum of high heat-exposed mice may play an important role in host resistance to viral infection. To address these possibilities, room temperature-exposed mice were given 0.5 mM of primary or secondary bile acids in drinking water for the entire duration of the experiments. After infection with influenza virus, room temperature-exposed mice that had been given cholic acid (CA), deoxycholic acid (DCA), ursodeoxycholic acid (UDCA), or taurine-conjugated deoxycholic acid (TDCA) in drinking water for 7 days prior to infection had improved survival relative to control mice (Fig. 3a, b and Supplementary Fig. 18a, b). The virus titers were significantly suppressed in the lungs of CA-, DCA-, or UDCA-treated mice at 2 days p.i. (Fig. 3c, d and Supplementary Fig. 18c). However, the virus titer in the lungs remained similar in water-fed and CA-treated mice at 3 and 6 days p.i. (Fig. 3c), suggesting that not only suppression of viral load at early time points but also other mechanisms at later time points could explain how treatment of mice with bile acids improve survival after influenza virus infection. In CA-treated mice, the levels of TDCA, glycine-conjugated DCA (GDCA) and glycine-conjugated CA (GCA) but not DCA and UDCA in the serum were significantly elevated compared with water-fed control group (Supplementary Fig. 19), suggesting that not only DCA but also taurine- or glycine-conjugated bile acids in serum play an important role in protection against influenza virus infection.Fig. 3: Bile acids-TGR5 axis protects from influenza virus infection.a–d Room temperature-exposed mice given 0.5 mM of CA (a) or DCA (b) were infected intranasally with 1000 pfu of influenza virus. Mortality (a, b; water, n = 16 mice; CA, n = 17 mice; DCA, n = 17 mice) and virus titer in the lung wash (c, d; water, n = 10 to 16 mice; CA, n = 9 to 16 mice; DCA, n = 10 mice) were measured on indicated days after challenge. e, f MDCK cells were infected with influenza virus PR8 (an amantadine-resistant strain) in the presence or absence of indicated amounts of GW 4064, HY-14229, or amantadine. Cell lysates were collected at 24 h p.i. and analyzed by immunoblotting with indicated antibodies (e). Cell-free supernatants were collected at 24 h p.i. and analyzed for virus titer by standard plaque assay using MDCK cells (f; DMSO, n = 6; GW 4064, n = 6; HY-14229, n = 6). g, h Room temperature-exposed mice given 100 μM of HY-14229 were infected intranasally with 1000 pfu of influenza virus. Virus titer in the lung wash (g; water, n = 8 mice; HY-14229, n = 8 mice) and mortality (h; water, n = 68 mice; HY-14229, n = 73 mice) were measured on indicated days after challenge. Each symbols indicate individual values (c, d, f, g). Data are mean ± s.e.m. Data are pooled from two (a–d) or three (h) independent experiments or are representative of two independent experiments (e–g). Statistical significance was analyzed by two-way analysis of variance (ANOVA) (f), two-tailed unpaired Student’s t test (c, d, g), or two-sided log-rank (Mantel-Cox) test (a, b, h). *P < 0.05, **P < 0.01 (c; 2 days p.i., p = 0.014; d; 2 days p.i., p = 0.0052; 3 days p.i., p = 0.0456; g; 2 days p.i., p = 0.00321).Full size imageSince bile acids are digestive surfactants that promote lipid absorption, it is possible that they directly disrupt enveloped viruses including influenza virus and SARS-CoV-2 by destroying membrane integrity29. To test this possibility, influenza virus, SARS-CoV-2, or encephalomyocarditis virus (EMCV), a non-enveloped RNA virus, were incubated with various concentrations of DCA at 37 °C for 1 h. Indeed, DCA inactivated the influenza virus and SARS-CoV-2, but not EMCV, at 1.25 mM or higher (Supplementary Fig. 20a–c). However, concentrations of DCA higher than 0.25 mM were toxic to cultured cells (Supplementary Fig. 20d, e).Several other possible mechanisms could explain how higher concentration of DCA in the serum might increase host resistance to influenza virus infection. First, detergent properties of bile acids might affect viral entry or budding by modulating the integrity of cellular membranes30,31 (Supplementary Fig. 21a). Second, bile acids activated receptors might regulate virus-induced inflammatory responses32,33,34. First, we examined the direct effects of DCA on influenza virus replication. In the presence of 0.125 mM of DCA, the ratio of influenza virus nucleoprotein (NP)-positive cells was significantly enhanced at 6 h p.i. (Supplementary Fig. 21b, c), which indicated that DCA facilitates influenza virus entry into MDCK cells. However, influenza virus replication was significantly inhibited by DCA at 24 and 48 h p.i. (Supplementary Fig. 21d, e). Next, we wished to determine which bile acid receptors could contribute to inhibition of influenza virus replication. To this end, we infected MDCK cells with influenza virus in the presence or absence of GW 4064 (a FXR agonist) or HY-14229 (a TGR5 agonist) and found that 1 μM of HY-14229 but not GW 4064 inhibited influenza virus replication (Fig. 3e, f and Supplementary Fig. 22). In addition, treatment of the virus-infected cells with 1 μM of HY-14229 by 9 h p.i. inhibited influenza virus replication (Supplementary Fig. 23). Further, HY-14229-treated mice significantly reduced the virus replication at 2 days p.i. and had improved survival relative to water-fed group (Fig. 3g, h).Next, we tested the second hypothesis that bile acids activated receptors might regulate virus-induced inflammatory responses32,33,34. High heat-exposed mice impaired secretion of mature IL-1β in the lung wash following influenza virus infection (Supplementary Fig. 24)11. One of the hallmarks of IL-1 signaling is the recruitment of neutrophils35,36. In addition, previous studies have indicated the detrimental role of neutrophils in influenza virus-induced mortality3,37. Thus, we first examined the recruitment of neutrophils into the lung of high heat-exposed mice during influenza virus infection. Following influenza virus infection, the levels of pulmonary CXCL1, which is one of the major chemoattractant of neutrophils, in the lung of room temperature-exposed mice became apparent starting around day 3 p.i. and peaking around day 4 p.i. (Fig. 4a). In contrast, the levels of pulmonary CXCL1 were significantly suppressed in the lung of high-heat exposed mice compared with room temperature-exposed group at 4 days p.i. (Fig. 4b). Consistent with this observation, both frequency and number of neutrophils were significantly suppressed in the lung of high-heat exposed mice compared with room temperature-exposed group at 7 days p.i. (Fig. 4c, d). In addition, the levels of CXCL1 and neutrophil recruitment were significantly elevated in the lung of high heat-exposed LF-fed and Abx-treated mice compared with high heat-exposed control group (Supplementary Fig. 25). We next examined whether bile acids or their receptors inhibit influenza virus-induced CXCL1 production. Treatment of bone marrow-derived macrophages with 125 µM of DCA (LDH release <1%) but not CA significantly inhibited not only IL-1β, an important mediator of CXCL1 production (Supplementary Fig. 26)38, but also CXCL1 production from influenza virus-infected bone marrow-derived macrophages (Fig. 4e–g). Consistent with this observation, room temperature-exposed mice that had been given DCA in drinking water suppressed neutrophil recruitment into the lung tissue compared with room temperature-exposed water-fed group (Fig. 4h). In addition, HY-14229 but not GW 4064 inhibited influenza virus-induced IL-1β and CXCL1 production from bone marrow-derived macrophages (Fig. 4i, j). Further, depletion of neutrophils or neutrophil extracellular traps digestion in vivo resulted in prolonged survival of room temperature-exposed mice after influenza virus infection (Fig. 4k, l), consistent with previous reports3,26,39. Together, these data suggested that elevated levels of secondary bile acids in the serum of high heat-exposed mice may increase host resistance to viral infection by suppressing influenza virus replication and detrimental inflammatory responses.Fig. 4: Bile acids-TGR5 axis inhibits inflammatory responses following influenza virus infection.a–d, Mice kept at 22 or 36 °C were infected intranasally with 1000 pfu of influenza virus. The lung washes were collected at indicated time points and analyzed for CXCL1 by ELISA (a, n = 5 mice at 0, 1, 2, 4, 5, an 7 days p.i., n = 11 mice at 3 days p.i.; b n = 5 mice for uninfected, n = 17 mice for infected at 22 °C, and n = 15 mice for infected at 36 °C). Leukocytes were isolated from the lung at indicated time points. The number of Ly6C+ Ly6G+ neutrophils were analyzed by flow cytometry (c, d; n = 3 room temperature- or high heat-exposed mice at 0, 1, 2, 3, and 5 days p.i., n = 4 room temperature-exposed mice at 7 days p.i, n = 6 high heat-exposed mice at 7 days p.i). e, f Bone marrow-derived macrophages were infected with influenza virus in the presence or absence of CA or DCA. Cell-free supernatants were collected at 24 h p.i. and analyzed for IL-1β (e; n = 8 mice) or CXCL1 (f; n = 8 mice for uninfected, n = 16 mice for infected) by ELISA. g Uninfected bone marrow-derived macrophages were cultured in the presence or absence of indicated amounts of DCA for 24 h. LDH activity was measured for cytotoxicity (n = 4). h DCA-treated or control mice kept at 22 °C were infected intranasally with 1000 pfu of influenza virus. Leukocytes were isolated from the lung at 7 days p.i.. The number of Ly6C+ Ly6G+ neutrophils were analyzed by flow cytometry (n = 16 mice for water-fed, n = 14 mice for DCA-treated). i, j Bone marrow-derived macrophages were infected with influenza virus in the presence or absence of indicated amounts of HY-14229 or GW 4064. Cell-free supernatants were collected at 24 h p.i. and analyzed for IL-1β (i; n = 6) or CXCL1 (j; n = 4) by ELISA. k, l Mice kept at 22 °C were infected intranasally with 1000 pfu of influenza virus. A group of mice was treated with either a neutrophil-depleting antibody to Ly6G (k; control IgG, n = 6 mice; anti-Ly6G, n = 6 mice) or recombinant DNase intraperitoneally (l; control, n = 8 mice; DNase I, n = 8 mice) at indicated time points (arrows). Survival was monitored for 14 days. Each symbols indicate individual values (a, b, d–j). Data are mean ± s.e.m. Data are representative of two independent experiments (a, c–e, g, i–l) or are pooled from two independent experiments (b, f, h). Statistical significance was analyzed by two-way analysis of variance (ANOVA) (a, b, e–g, i, j), two-tailed unpaired Student’s t test (d, h), or two-sided log-rank (Mantel-Cox) test (k, l). *P < 0.05, **P < 0.01, ***P < 0.001, n.s., not significant (d; 7 days p.i., p = 0.00053; h; p = 0.0246).Full size imageRole of bile acids in COVID-19We next examined inhibitory effect of bile acids against SARS-CoV-2 infection. To this end, we infected VeroE6/TMPRSS2 cells with SARS-CoV-2 in the presence or absence of various bile acids and found that DCA and UDCA inhibited the virus protein synthesis (Fig. 5a). Consistent with this observation, SARS-CoV-2 replication was significantly inhibited by DCA at 48 h p.i. (Fig. 5b). In addition, DCA-treated hamsters had improved survival relative to water-fed group following SARS-CoV-2 B.1.1.7 (alpha) variant infection without affecting the virus titer at 3 days p.i. (Fig. 5c and Supplementary Fig. 27a, b). Although CA did not inhibit SARS-CoV-2 replication in vitro (Fig. 5a), CA-treated hamsters had improved survival relative to water-fed group after infection with SARS-CoV-2 B.1.1.7 (alpha) variant (Fig. 5d and Supplementary Fig. 27c). Cold-exposed hamsters, which exacerbated SARS-CoV-2-induced mortality (Supplementary Fig. 5), exhibited significant decrease in basal body temperature compared with room temperature-exposed group (Supplementary Fig. 28a). In addition, cold-exposed naïve hamsters significantly reduced the levels of glycine-conjugated chenodeoxycholic acid (GCDCA), GDCA, and GCA in the serum compared with room temperature-exposed group (Supplementary Fig. 28b–d). Together, these data suggested that not only DCA but also taurine- or glycine-conjugated bile acids may play an important role in protection against SARS-CoV-2 infection. Interestingly, we found that 100 μM of GW 4064 efficiently blocked SARS-CoV-2 replication in vitro (Fig. 5e and Supplementary Fig. 29). In addition, GW 4064 but not HY 14229 treatment significantly improved survival of hamsters following SARS-CoV-2 B.1.1.7 (alpha) variant infection without affecting the virus titer at early time points (Fig. 5f, g and Supplementary Fig. 30).Fig. 5: Bile acids-FXR axis protects from SARS-CoV-2 infection.a, b, VeroE6/TMPRSS2 cells were infected with original SARS-CoV-2 (S-614D) in the presence or absence of indicated bile acids (a) or DCA (b). Cell lysates were collected at 24 h p.i. and analyzed by immunoblotting with indicated antibodies (a). Cell-free supernatants were collected at 48 h p.i. and analyzed for virus titer by standard plaque assay using VeroE6/TMPRSS2 cells (b; n = 6). c, d DCA- (c) or CA-treated (d) hamsters kept at 22 °C were infected intranasally with 1.5 × 106 pfu of SARS-CoV-2 B.1.1.7 (alpha) variant. Survival was monitored for 14 days (water, n = 16 hamsters; DCA, n = 14 hamsters; CA, n = 16 hamsters). e VeroE6/TMPRSS2 cells were infected with original SARS-CoV-2 (S-614D) in the presence or absence of indicated amounts of GW 4064, HY-14229, or amantadine as a negative control. Cell-free supernatants were collected at 48 h p.i. and analyzed for virus titer by standard plaque assay using VeroE6/TMPRSS2 cells (n = 15 tests for DMSO control, n = 9 tests for 100 μM of GW 4064 and HY-14229, and n = 6 tests for 10 μM of GW 4064 and HY-14229, and 100 μM of amantadine). The lower limit of detection is indicated by the horizontal dashed line. f, g HY-14229 (100 μM)-, GW 4064 (100 μM)-treated or control hamsters kept at 22 °C were infected intranasally with 1.5 × 106 pfu of SARS-CoV-2 B.1.1.7 (alpha) variant. Mortality (f) and body weight (g) were measured on indicated days after challenge (water, n = 13 hamsters; HY-14229, n = 12 hamsters; GW 4064, n = 12 hamsters). The dashed line indicates the limit of endpoint (g). h, i plasma concentration of fibrinogen (h) and GCA (i) in minor (n = 11 patients) versus moderate I/II (n = 35 patients) groups. Each dot represents a unique patient. j, k Control or GCA-treated hamsters kept at 22 °C were infected intranasally with 1.5 × 106 pfu of SARS-CoV-2 B.1.1.7 (alpha) variant. Mortality (j) and body wight (k) were measured on indicated days after challenge (water, n = 16 hamsters; GCA, n = 15 hamsters). The dashed line indicates the limit of endpoint (k). Each symbols indicate individual values (b, e, g–i, k). Data are mean ± s.e.m. Data are representative of two independent experiments (a, b, f, g, j, k) or are pooled from two (c, d) or three independent experiments (e). Statistical significance was analyzed by two-way analysis of variance (ANOVA) (b, e, g, k), a two-tailed Mann-Whitney test (h, i), or two-sided log-rank (Mantel-Cox) test (c, d, f, j). The center line denotes the median value (50th percentile), while the white box contains the 25th to 75th percentiles of dataset. The black whiskers mark the 5th and 95th percentiles (h, i). ***P < 0.001 (h; p < 0.0001; i; p = 0.0029).Full size imageFinally, we examined the relationship between the levels of bile acids in the plasma of COVID-19 patients and severity of the disease. To this end, 46 patients who had been admitted to Juntendo University Hospital were stratified into minor or moderate I/II disease groups on the basis of optimal oxygen saturation, clinical symptoms and chest radiographic findings. Demographics and background information for 46 patients are in Supplementary Table 1. The levels of serum amyloid A and fibrinogen, important biomarkers of COVID-19 disease severity, were significantly elevated in the plasma of patients who developed moderate I/II disease compared with minor illness group (Fig. 5h and Supplementary Fig. 31). Importantly, the levels of GCA, taurine-conjugated CA (TCA), taurine-conjugated chenodeoxycholic acid (TCDCA), and GCDCA were significantly reduced in the plasma of COVID-19 patients who developed moderate I/II disease compared with minor illness group (Fig. 5i and Supplementary Fig. 32). In addition, the levels of the GCA, TCA, TCDCA, and GCDCA in plasma were significantly and negatively correlated with the levels of fibrinogen in plasma but not patients’ age (Supplementary Figs. 33 and 34). Treatment of VeroE6/TMPRSS2 cells with 2 mM of GCA (LDH release <1%) efficiently inhibited the viral protein synthesis and replication compared with TCA, TCDCA, or GCDCA (Supplementary Fig. 35). Thus, we next examined the protective effect GCA against SARS-CoV-2 infection in hamsters. GCA-treated hamsters had improved survival relative to water-fed group following SARS-CoV-2 B.1.1.7 (alpha) variant infection without affecting the virus titer at 3 days p.i. (Fig. 5j, k and Supplementary Fig. 36). Taken together, our data show that body temperature-dependent activation of bile acid metabolism by gut microbiota increases host resistance to influenza virus and SARS-CoV-2 infection by suppressing virus replication and detrimental inflammatory responses through bile acid receptors.DiscussionOur findings here have identified an unappreciated link between body temperature, gut microbial activity, and host resistance to viral infection. Specifically, high heat-exposed mice increased their basal body temperature over 38 °C, which may stimulate gut microbial activity40. Indeed, both primary and secondary bile acids were significantly enhanced in the serum and livers of high heat-exposed mice. Increased mortality in partially hepatectomized mice following influenza virus infection may be explained by the fact that primary bile acids are synthesized from cholesterol exclusively in the liver and further metabolized by the gut microbiota into secondary bile acids41. Because secondary bile acids are produced by microbial biotransforming reactions in the gut42, high heat-exposed LF-fed and Abx-treated mice significantly reduced the secondary bile acids in the serum and succumbed to influenza virus infection. We have also shown that DCA and HY-14229 (a TGR5 agonist) inhibit influenza virus replication and inflammatory responses both in vitro and in vivo.It has increasingly become evident that gut microbiota promotes type I IFNs-dependent innate antiviral immunity and confers host resistance to influenza virus infection. We and others have previously shown that Abx-treated mice are more susceptible to influenza virus infection9,11,43,44. Abt et al. have shown that alveolar macrophages isolated from Abx-treated mice decreased innate antiviral genes expression in the lung at 3 days post influenza virus infection. Thus, intranasal administration of Abx-treated mice with poly(I:C) at −1 and 3 days post influenza virus infection improved survival relative to control group43. In addition, bone marrow chimera experiments showed that gut microbiota-driven IFN priming in the lungs acts on stromal cells to establish an antiviral state during influenza virus infection44. Further, Steed et al. have identified desaminotyrosine as a gut microbiota-derived metabolite that is able to increase interferon-stimulated genes expression in the lungs and host resistance to influenza virus infection9. Recent studies indicated that bile acids also increase type I IFN-dependent innate antiviral immunity45,46. Hu et al. have indicated that both HSV-1 (DNA virus) and Sendai virus (RNA virus) induces accumulation of intracellular bile acids. The accumulated intracellular bile acids activate SRC kinase through the TGR5-GRK-β-arrestin axis to enable tyrosine phosphorylation of multiple innate antiviral signaling components. Therefore, TGR5 knockout mice were more susceptible to HSV-1 and EMCV infections45. Winkler et al. have shown that dysbiosis of gut microbiota increases virus burden in the serum and spleen of Chikungunya virus (CHIKV)-infected mice. However, reconstitution with a single bacterial species, Clostridium scindens, or its derived DCA can restore TLR7 and MyD88-dependent type I IFN responses to restrict systemic CHIKV infection46. Although the roles of gut microbiota or its derived secondary bile acids in type I IFN-dependent innate antiviral immune responses are well-established, role of body temperature in gut microbial activity and host resistance to influenza virus infection remains unknown. We found that high body temperature over 38 °C significantly increased gut microbiota-derived bile acids in high-heat exposed mice. In addition, we showed that HY-14229 (a TGR5 agonist)-treated room temperature-exposed mice improved survival following influenza virus infection.Our findings obtained from influenza virus infection applies to SARS-CoV-2 infection. Specifically, high heat-exposed K18-hACE2 mice were highly resistant to SARS-CoV-2 infection compared with room temperature-exposed group (Supplementary Fig. 6). In addition, CA- or DCA-treated hamsters had improved survival relative to water-fed group following SARS-CoV-2 B.1.1.7 (alpha) variant infection (Fig. 5c, d). While GW 4064 (a FXR agonist) inhibited SARS-CoV-2 replication in vitro (Fig. 5e and Supplementary Fig. 29), the GW 4064 treatment significantly improved survival of hamsters following SARS-CoV-2 B.1.1.7 (alpha) variant infection without affecting the virus titer at early time points (Fig. 5f, g and Supplementary Fig. 30). Importantly, we found that the levels of GCA, TCA, TCDCA, and GCDCA were significantly reduced in the plasma of COVID-19 patients who developed moderate I/II disease compared with minor illness group (Fig. 5i and Supplementary Fig. 32). In addition, GCA-treated hamsters had improved survival relative to water-fed group following SARS-CoV-2 B.1.1.7 (alpha) variant infection (Fig. 5j, k). These observations suggest that secondary bile acids and their receptor signaling may increase host resistance to SARS-CoV-2 infection. Recent studies suggested that gut microbiome dysbiosis during COVID-19 is associated with detrimental host inflammatory responses and severity of the disease47,48. Given that the severity of COVID-19 disease is associated with an influx of innate immune cells and inflammatory cytokines49,50,51, inhibition of detrimental inflammatory responses by a FXR ligand or probiotic therapy may increase host resistance to SARS-CoV-2 infection.Our study identifies several possible mechanisms by which a gut microbiota-derived secondary bile acids can increase host resistance to influenza virus or SARS-CoV-2 infection. Several possible mechanisms could explain how bile acids or their receptors signaling increased host resistance to influenza virus or SARS-CoV-2 infection. First, detergent properties of DCA at high concentrations (1.25 mM or higher) directly disrupted influenza virus or SARS-CoV-2 by destroying envelope membrane (Supplementary Fig. 20a, b)29. Second, a low concentration of DCA (125 μM) inhibited influenza virus replication by modulating the integrity of cellular membranes30,31 (Supplementary Fig. 21a). Third, TGR5 may suppress influenza virus replication (Fig. 3e–g) probably by inhibiting NF-κB activity or adhesion molecule expression52. Fourth, DCA and TGR5 signaling suppressed neutrophil recruitment into the lung tissue by inhibiting influenza virus-induced IL-1β and CXCL1 production from macrophages (Fig. 4e, f, h–j). These data are consistent with a published report showing that bile acids including DCA inhibit the NLRP3 inflammasome-mediated IL-1β secretion from bone marrow-derived macrophages by stimulating TGR5-cAMP-protein kinase A axis-dependent NLRP3 phosphorylation and ubiquitination33. Although bile acids or their receptors signaling inhibited SARS-CoV-2 protein synthesis and replication in vitro (Fig. 5a, b and Supplementary Figs. 29, and 35b, c), they protected hamsters from lethal SARS-CoV-2 infection without affecting the virus titer at early time points (Supplementary Figs. 27b, 30, and 36). Similarly, while the viral titers in the lung of high heat-exposed control mice were similar to that of high heat-exposed LF-fec or Abx-treated mice at 3 days p.i. (Fig. 2g), only high heat-exposed control group survived from lethal influenza virus infection (Fig. 2e). Since excess neutrophil recruitment into the lung exacerbated influenza virus-induced mortality3,37, these data suggests that inhibition of detrimental inflammatory responses rather than viral replication may be important for gut microbiota-dependent host resistance to influenza virus and SARS-CoV-2 infections in high heat-exposed mice or bile acids-treated hamsters.In the present study, we demonstrated that high heat-exposed mice kept at 36 °C are highly resistant to influenza virus and SARS-CoV-2 infection. A recent study showed that mice housed in 10 or 20% relative humidity succumbed to influenza virus infection more rapidly than those housed in 50% relative humidity13. However, the current study could not maintain the constant humidity in cold-(80% relative humidity), room temperature- (53% relative humidity), and high heat-exposed groups (25% relative humidity). In addition, we previously demonstrated that the high heat-exposed mice decreased their food intake and increased autophagy in lung tissue11. Thus, we cannot simply compare the effects of outside and body temperature on host resistance to viral infection. In addition, respiration rates affected by outside temperature could impact the initial viral inoculation53. To rule out this possibility, we infected cold-, room temperature-, and high heat-exposed mice with influenza virus intratracheally and found that high heat-exposed mice were highly resistant to influenza virus infection (Supplementary Fig. 3), suggesting that difference in survival rate of influenza virus-infected cold-, room temperature-, and high heat-exposed mice was not due to the changes of respiration rates or initial viral inoculation. In addition, although treatment of mice or hamsters with 0.5 mM of bile acids or 0.1 mM of HY-14229 or GW 4064 via drinking water was generally well tolerated, it will be important to determine the administration dose and route to maximize the protective effects of bile acids or the agonists against influenza virus or SARS-CoV-2 infection without deleterious impact in vivo. Since high body temperature during fever cause various physiological changes in the body, future studies to dissect other mechanisms by which high body temperature confers host resistance to viral infection will be important extensions of this work.In summary, our findings substantially expand our understanding of how body temperature increases host resistance to influenza virus and SARS-CoV-2 infection. Our detailed mechanistic analysis demonstrates that high body temperature-dependent activation of gut microbiota metabolism increases the levels of bile acids in the serum and intestine, and suppresses virus replication and detrimental inflammatory responses following influenza virus or SARS-CoV-2 infection. Our finding that reduction of certain bile acids in the plasma of patients with moderate I/II COVID-19 may provide insight into the variability in clinical disease manifestation in humans and enable approaches for mitigating COVID-19 outcomes.MethodsEthics statementAll protocols involving specimens from human participants recruited at Juntendo University were reviewed and approved by the Institutional Review of Juntendo University (H20-0222). All animal experiments using mice and hamsters were performed in accordance with University of Tokyo’s Regulations for Animal Care and Use, which were approved by the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo (PA15-92, PA19-87, PA22-33).PatientsThis is a case-control monocentric study that included 46 patients with COVID-19, hospitalized in the Juntendo University Hospital. All patients were recruited from October 2020 to March 2021. Reverse transcription-polymerase chain reaction (RT-PCR) tests using nasal or pharyngeal swabs were performed for diagnosis of COVID-19. This study was approved by the Ethics Committee of Juntendo University (No. H20-0222) and written informed consent was obtained from all participants. Electronic medical records of the patients’ clinical characteristics on admission were collected. Data included self-reported symptoms before PCR testing, the patient’s medical history, comorbidities, medical treatment received, blood examination result on admission, and chest x-ray and CT results. Data on COVID-19 management were collected as well. Self-reported symptoms on the day of the PCR test were collected via a questionnaire. All imaging and blood test results were collected on admission.AnimalsSix-week-old female C57BL/6JJmsSlc mice and 4-week-old female Syrian hamsters obtained from Japan SLC, Inc. were used as WT controls. For some experiments we used aged (52- to 122-week-old) female C57BL/6JJcl mice obtained from CLEA Japan, Inc. (Fig. 1e, f and Supplementary Figs. 7 and 10). B6.Cg-Tg(K18-ACE2)2Prlmn/J (K18-hACE2) mice were purchased from The Jackson Laboratory and subsequently bred at The University of Tokyo. Mice were kept in an incubator (MIR-154, PHCbi, Japan) at 4 °C (80% relative humidity), 22 °C (53% relative humidity), or 36 °C (25% relative humidity). Cold, RT, or high-heat exposures were started 7 days before infection and continued for the entire duration of the experiments. These mice were allowed free access to food and drinking water and kept on a 12 h light/dark cycle. All animals used in this study were fed with a γ-ray-sterilized normal diet (CE-2, CLEA Japan, Inc.) or AIN93G-fomula diet (Oriental Yeast, Japan) as a LF diet. We confirmed that drinking water did not freeze at 4 °C. All animals were euthanized with deep anesthesia and cervical dislocation. All animal experiments were performed in accordance with The University of Tokyo’s Regulations for Animal Care and Use, which were approved by the Animal Experiment Committee of the Institute of Medical Science, The University of Tokyo (PA15-92, PA19-87, PA22-33).Antibiotic treatmentMice were treated with ampicillin (1 g/L; Nacalai Tesque), vancomycin (500 mg/L; Duchefa Biochemie), neomycin sulfate (1 g/L; Nacalai Tesque), metronidazole (1 g/L; Nacalai Tesque), gentamicin (10 mg/L; Nacalai Tesque), 1% penicillin-streptomycin (P/S) (Nacalai Tesque, 09367-34), and 1% amphotericin B (Nacalai Tesque, 02892-54) in drinking water as previously described11,54. Antibiotic-containing water was changed twice a week. Antibiotic treatment was started 2 weeks before infection and continued for the entire duration of the experiments.Bile acids, GW 4064, or HY-14229 treatmentMice or hamsters were treated with 0.5 mM of CA (Nacalai Tesque, 08843-72), DCA (Nacalai Tesque, 10711-22), UDCA (AdipoGen Life Sciences, CDX-U0019-G025), TDCA (Nacalai Tesque, 32740-04), or GCA (Toronto Research Chemicals Inc., G641370) in drinking water. For some experiments, mice or hamsters were treated with 0.1 mM of GW 4064 (MyBioSource.Inc., MBS576846) or HY-14229 (MedChem Express, HY-14229) in drinking water. Bile acids, GW 4064, or HY-14229 treatment was stared 7 days before infection and continued for the entire duration of the experiments.Cell cultureMadin-Darby canine kidney (MDCK) cells were maintained in minimal essential medium (MEM) (Nacalai Tesque, 21443-15) supplemented with 10% v/v fetal bovine serum (FBS) and 1% v/v penicillin (100 units/ml)/streptomycin (100 μg/ml). VeroE6 cells stably expressing transmembrane protease serine 2 (VeroE6/TMPRSS2; JCRB Cell Bank 1819) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (low-glucose) (Nacalai Tesque, 08456-65) supplemented with 10% v/v FBS, 1% v/v penicillin/streptomycin (P/S), and G418 (1 mg ml−1; Nacalai Tesque, 16512-94). L929 cells were maintained in DMEM (high-glucose) (Nacalai Tesque, 08458-45) supplemented with 10% FBS and 1% P/S. To prepare bone marrow-derived macrophages, bone marrows from the tibia and femur were obtained by flushing with DMEM. Bone marrow cells were cultured with DMEM supplemented with 10% FBS, l-glutamine, 1% P/S, and 30% L929 supernatant containing the macrophage colony-stimulating factor at 37 °C for 5 days55.Virus infection in vivoA mouse-adapted influenza A virus strain A/Puerto Rico/8/1934 (PR8) and a human isolate of the 2009 pandemic influenza A virus strain A/Narita/1/2009 (pdm09) were grown in allantoic cavities of 10-d-old fertile chicken egg for 2 days at 35 °C. Viral titers were quantified by a standard plaque assay using MDCK cells and viral stock was stored at −80 °C. For influenza virus infection, mice were infected by intranasal application of 30 μL of virus suspension (500–2000 pfu of influenza virus in PBS) under isoflurane anesthesia. An original SARS-CoV-2 strain bearing aspartic acid at position 614 of spike (S) protein (S-614D) and SARS-CoV-2 B.1.1.7 (alpha) variant were grown in VeroE6/TMPRSS2 cells for 2 days at 37 °C. Viral titers were quantified by a standard plaque assay using VeroE6/TMPRSS2 cells and viral stock was stored at −80 °C. For SARS-CoV-2 infection, K18-hACE2 mice were infected by intranasal application of 50 μL of virus suspension (5 × 104 pfu of SARS-CoV-2 in PBS) under isoflurane anesthesia. Syrian hamsters were infected by intranasal application of 150 μL of virus suspension (1.5 × 106 pfu of SARS-CoV-2 in PBS) under isoflurane anesthesia. ZIKV (ATCC VR-84) was grown in Vero cells for 2 days at 37 °C. Viral titers were quantified by a standard plaque assay using Vero cells and viral stock was stored at −80 °C. For ZIKV infection, mice were injected intravenously with 1.5 × 107 pfu of ZIKV in PBS under isoflurane anesthesia. SFTSV (a gift from S. Morikawa, National Institute of Infectious Diseases, Tokyo, Japan) was grown in Vero cells for 3 days at 37 °C. Viral titers were determined by 50% tissue culture infectious dose (TCID50) assay according to published procedures56 and viral stock was stored at −80 °C. For SFTSV infection, mice were injected intravenously with 5 × 106 TCID50 of SFTSV in PBS under isoflurane anesthesia. EMCV was grown in L929 cells for 15 h at 37 °C. Viral titers were quantified by a standard plaque assay using L929 cells and viral stock was stored at −80 °C. For EMCV infection, mice were injected intraperitoneally with 100 pfu of EMCV in PBS under isoflurane anesthesia.Body temperature was measured by inserting a rodent thermometer (Natsume Seisakusho, KN-91-AD1687) orally. Baseline body weights were measured before infection. Mice and hamsters were deemed to have reached endpoint at 70% of starting weight or after reaching body temperature of 25 °C or lower. Animals were euthanized under anesthesia with an overdose of isoflurane if severe disease symptoms or weight loss were observed. All experiments with SARS-CoV-2 were performed in enhanced biosafety level 3 (BLS-3) containment laboratories at the University of Tokyo, in accordance with the institutional biosafety operating procedures.Virus infection in vitroMDCK cells in 6-well plates were infected with influenza virus PR8 at a multiplicity of infection (MOI) of 0.01 in the presence or absence of bile acids, GW 4064 (a FXR agonist), or HY-14229 (a TGR5 agonist) for 1 h at 37 °C, and cultured with Opti-MEM (Invitrogen, 31985-070) containing acetyltrypsin (10 mg/mL) in the presence or absence of bile acids, GW 4064, or HY-14229 for additional 23 h. VeroE6/TMPRSS2 cells in 6-well plates were infected with SARS-CoV-2 at an MOI of 0.01 in the presence or absence of bile acids, GW 4064, or HY-14229 for 1 h at 37 °C, and cultured with DMEM (low-glucose) supplemented with 5% FBS, 1% P/S, and 1% HEPES buffer (Nacalai Tesque, 17557-94) in the presence or absence of bile acids, GW 4064, or HY-14229 for additional 23 h.Western blot analysisThe virus-infected MDCK or VeroE6/TMPRSS2 cells in 6-well plates were washed with PBS and lysed in 500 μl of 1× TNT buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol). Lysates were centrifuged at 20,630 × g for 10 min at 4 °C. The supernatant was mixed with 4× lithium dodecyl sulfate (LDS) sample buffer (Invitrogen, NP0007) and 10× sample reducing agent (Invitrogen, NP0009). Samples were boiled for 5 min and fractionated by NuPAGE 10% Bis-Tris Protein Gels (Invitrogen, NP0316BOX) and electroblotted onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, 170-4156). The membranes were incubated with mouse anti-influenza A virus NS1 (Santa Cruz, sc-130568; 1:1000), mouse anti-influenza A virus M2 (Santa Cruz, sc-32238; 1:1000), mouse anti-α tubulin (Santa Cruz, sc-32293; 1:2000), or rabbit anti-SARS-CoV-2 nucleocapsid (Cell Signaling, 33336; 1:1000) antibody, followed by incubation with horseradish peroxidase-conjugated anti-mouse IgG (Jackson Immuno Research Laboratories, 115-035-003; 1:10,000) or anti-rabbit IgG (Invitrogen, G-21234; 1:10,000). The PVDF membranes were then treated with Chemi-Lumi One Super (Nacalai Tesque, 02230-30) to elicit chemiluminescent signals, which were detected and visualized using an LAS-4000 Mini apparatus (GE Healthcare).Quantitative PCRTotal RNA was extracted from cells using TRIzol reagent (Invitrogen, 15596018) and reverse transcribed into cDNA using SuperScript III reverse transcriptase (Invitrogen, 18080085) with an oligo (dT) primer. TB Green Premix Ex Taq II (TaKaRa, RR820A) and a LightCycler 1.5 instrument (Roche Diagnostics) were used for quantitative PCR with the following primers: influenza virus NP forward, 5’-agaacatctgacatgaggac-3’, and reverse, 5′-gtcaaaggaaggcacgatc-3′.ELISACell-free supernatants or lung washes were analyzed for the presence of IFN-α (Hycult Biotech, HM1001; PBL Assay Science, 32100-1), IFN-γ (eBioscience, 14-7311-85 and 13-7312-85,), IL-1β (eBioscience, 14-7012-85 and 13-7112-85), and IL-6 (eBioscience, 14-7061-85 and 13-7062-85) using an enzyme-linked immunosorbent assay (ELISA) utilizing paired antibodies. IFN-β (PBL Assay Science, 42400-1), IFN-λ (PBL Assay Science, 62830-1), or CXCL1 (Proteintech, KE10019) ELISA was performed according to the manufacturer’s instructions. Absorbance at 450 nm was measured by using Microplate Manager version 6 (Bio-Rad).LDH releases assayLDH release assays (Promega, G1780) were performed according to the manufacturer’s instructions. LDH release data were used to account for cell death. The data are expressed as percentage of maximum LDH release.Flow cytometryThe single-cell suspensions of lung samples were prepared as previously described57. Briefly, lungs were perfused with 10 ml PBS through the right ventricle, minced using razor blades, and incubated in HBSS containing 2.5 mM Hepes and 1.3 mM EDTA at 37 °C for 30 min. The cells were resuspended in RPMI containing 5% FBS, 1 mM CaCl2, 1 mM MgCl2, 2.5 mM Hepes, and 0.5 mg/ml collagenase D (Roche) and incubated at 37 °C for 60 min. A single-cell suspension was prepared after red blood cell lysis. The resulting cells were filtered through a 70-µm cell strainer (BD). For neutrophil staining, cells were incubated with APC-labeled anti-Ly6G (Invitrogen, 17-9668-82; 1:200) and eFluor 450-labeled anti-Ly6C (Invitrogen, 48-5932-82; 1:200) (Supplementary Fig. 37). For the detection of influenza virus-infected cells, MDCK cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences, 554714), and intracellulary stained with FITC-labeled mouse anti-influenza virus NP (abcam, ab20921; 1:100) antibody. Flow cytometric analysis was performed with a FACSVerse flow cytometer (BD Biosciences). The final analysis and graphical output were performed using FlowJo software (Tree Star, Inc.).Metabolite extraction and CE-TOFMS measurementsMetabolites in the cecal and serum samples were analyzed as previously described58,59. Briefly, cecal and serum metabolites were extracted by vigorous shaking with methanol containing methionine sulfone and D-camphol-10-sulfonic acid (CSA) as the internal standards. Then the mixture was cleaned with chloroform and water extraction. The suspension was centrifuged at 4600 × g for 15 min at 4 °C, and the resulting supernatant was transferred to a 5-kDa-cutoff filter column (Ultrafree MC-PLHCC 250/pk for Metabolome Analysis, Human Metabolome Technologies, Tsuruoka, Yamagata, Japan). The flow-through was dried under vacuum, and the residue then was dissolved in Milli-Q water containing reference compounds (200 μM each of 3-aminopyrrolidine and trimesate). The levels of extracted metabolites were measured in both positive and negative modes by CE-TOFMS as previously described60. All CE-TOFMS experiments were performed using an Agilent capillary electrophoresis system and Agilent G3250AA LC/MSD TOF system (Agilent Technologies, Santa Clara, California, U.S.A).Raw data was analyzed using our proprietary automatic integration software MasterHands ver. 2.19.0.160. Annotation tables were produced from standard compound measurements and aligned with the datasets according to similar m/z values and normalized migration time. Then, peak areas were normalized against the internal standards methionine sulfone and CSA for cationic and anionic metabolites, respectively. Amounts of each metabolite were calculated based on their relative peak areas and the concentrations of the standard compounds. Principal component analysis of CE-TOFMS data was performed using SIMCA 15 (Umetrics, Umea, Sweden). For the analysis, concentrations below the detection limit were substituted with zero, and metabolites whose levels were below the detection limit in all the samples were excluded.Quantification of serum and liver bile acids via LC-MS/MSSerum and liver metabolites were extracted from 50 μL serum or 50 μg liver suspended in 250 µL of 50% methanol in Milli-Q water supplemented with 20 μM CSA as an internal standard. The samples were homogenized using a multi-sample homogenizer (Shake Master Neo, Bio Medical Science) and centrifuged at 20,400 × g for 10 min at 10 °C, and supernatants were harvested. Liquid chromatography was performed using an Agilent 1290 UPLC system (Agilent Technologies) with gradient elution from an ACQUITY UPLC HSS T3 column (1.8 µm, 50 mm × 2.1 mm ID; Waters) maintained at 45 °C with a mobile phase flow rate of 0.3 ml/min61. Gradient elution mobile phases comprised A (water, 50 mM ammonium formate) and B (methanol, 50 mM ammonium formate). The gradient was initiated at 10% B, increasing linearly to 50% at 0.1 min, held at 50% B at 2 min, increasing linearly again to 80% at 9.5 min, and then increasing linearly to 100% at 10.5 min; this was maintained until 12 min, with subsequent re equilibration at 10% B for a further 5 min. The sample temperature was maintained at 4 °C in the autosampler prior to analysis. The sample injection volume was 1 µL. Mass spectrometry (MS) analysis was performed using an Agilent 6490 triple quadrupole mass spectrometer MS (Agilent Technologies) equipped with an Agilent Jet Stream ESI probe in negative-ion mode. A capillary voltage of −3500 V, a source temperature of 200 °C, gas flow of 14 L/min, nebulizer of 50 psi, sheath gas temperature of 250 °C, and a sheath gas flow of 11 L/min were used. Optimized m/z values of precursor and product ions, dwell times, collision voltages, and retention times selected for each compound are indicated previously62. Concentrations of individual BAs were determined from the peak area in the chromatogram detected with MRM relative to the internal standard, CSA.Quantification of cecal organic acids via GC/MSOrganic acid concentrations of cecal contents were determined by gas chromatography–mass spectrometry (GC/MS)63. In brief, 10 mg cecal contents were disrupted using 3 mm zirconia/silica beads (BioSpec Products) and homogenized with extraction solution containing 100 μl of internal standard (100 μM crotonic acid), 50 μl HCl and 200 μl ether. After vigorous shaking using Shakemaster neo (Bio Medical Science) at 1500 r.p.m. for 10 min, homogenates were centrifuged at 1000 g for 10 min and then the top ether layer was collected and transferred into new glass vials. Aliquots (80 μl) of the ether extracts were mixed with 16 μl N-tert-butyldimethylsilyl-Nmethyltrifluoroacetamide (MTBSTFA). The vials were sealed tightly, heated at 80 °C for 20 min in a water bath, and then left at room temperature for 48 h for derivatization. The derivatized samples were run through a 6890 N Network GC System (Agilent Technologies) equipped with HP-5MS column (0.25 mm × 30 m × 0.25 μm) and 5973 Network Mass Selective Detector (Agilent Technologies). Pure helium (99.9999%) was used a carrier gas and delivered at a flow rate of 1.2 ml per min. The head pressure was set at 97 kPa with split 20:1. The inlet and transfer line temperatures were 250 and 260 °C, respectively. The following temperature program was used: 60 °C (3 min), 60–120 °C (5 °C per min), 120–300 °C (20 °C per min). One microliter of each sample was injected with a run time of 30 min. Organic acid concentrations were quantified by comparing their peak areas with the standards.Fecal DNA extractionFecal DNA isolation was performed as described previously, with some modifications64. Each freeze-dried fecal sample was combined with four 3.0 mm zirconia beads, ~100 mg of 0.1 mm zirconia/silica beads, 400 μL DNA extraction buffer (TE containing 1% (w/v) sodium dodecyl sulfate), and 400 μL of phenol/chloroform/isoamyl alcohol (25:24:1) and vigorous shaked (1500 rpm for 15 minutes) using a Shake Master (Biomedical Science, Shinjuku, Tokyo, Japan). The resulting emulsion was centrifuged at 17,800 × g for 10 minutes at room temperature, and bacterial genomic DNA was purified from the aqueous phase by a standard phenol/chloroform/isoamyl alcohol protocol64. RNA was digested in the sample by RNase A treatment; the resulting DNA sample then was purified again, by another round of phenol/chloroform/isoamyl alcohol treatment.16S rRNA gene sequencing16S rRNA genes in the fecal microbiota DNA samples were analyzed using a Miseq sequencer (Illumina, San Diego, California, U.S.A.). The V1–V2 region of the 16 S rRNA genes was amplified from the DNA (~10 ng per reaction) using a universal bacterial primer set consisting of primers 27Fmod with an overhang adapter (5′-AGRGTTTGATYMTGGCTCAG-3′) and 338R with an overhang adapter (5′- TGCTGCCTCCCGTAGGAGT-3′)65. Polymerase chain reaction (PCR) was performed with Tks Gflex DNA Polymerase (Takara Bio, Inc., Kusatsu, Shiga, Japan), and amplification via the following program: one cycle denaturation at 98 °C for 1 min; 20 cycles of amplification at 98 °C for 10 s, 55 °C for 15 s, and 68 °C for 30 s, with final extension at 68 °C for 3 min. The amplified products were purified using Agencourt AMPure XP kits (Beckman Coulter, Atlanta, GA, USA). The purified products were then further amplified using a primer pair as follows: a forward primer (5′-AATGATACGGCGACCA CCGAGATCTACAC-NNNNNNNN-TATGGTAATTGTAGRGTTTGATYMTGGCTCAG-3′) containing the p5 sequence, a unique 8-bp barcode sequence for each sample (indicated by the string of Ns), and an overhang adapter, as well as a reverse primer (5′-CAAGCAGAAGACGGCATACGAGAT-NNNNNNNNAGTCAGTCAGCCTGCTGCCTCCCGTAGGAGT-3′) containing the P7 sequence, a unique 8-bp barcode sequence for each sample (indicated by the string of Ns), and an overhang adapter. After purification using Agencourt AMPure XP kits, the purified products were mixed in approximately equal molar concentrations to generate a 4 nM library pool, after which the final library pool was diluted to 6 pM, including a 10% Phix Control v3 (Illumina, San Diego, California, U.S.A.) spike-in for sequencing. Finally, Miseq sequencing was performed according to the manufacturer’s instructions. In this study, 2 × 300-bp paired-end sequencing was employed. The microbiome analysis data have been deposited in the DDBJ Sequence Read Archive (http:/race.ddbj.nig.ac.jp/dra/) under accession number DRA015846.Analysis of 16S rRNA gene sequences using QIIME 2Analysis of 16S rRNA gene sequences was performed as described with some modifications66. In brief, filter-passed reads were processed using Quantitative Insights into Microbial Ecology (QIIME) 2 (2019.10.0)67. Denoising and trimming of sequences were carried out using DADA2. The first 20 bp and 19 bp were trimmed from the 5’ end of both forward and reverse reads, respectively, to remove primer sequences. The resulting 135-bp and 220-bp reads from the respective 5’ ends were used for subsequent steps. Taxonomy was assigned using the SILVA132 database using the Naive Bayesian Classifier algorithm68,69. Alpha diversity of gut microbiota was analyzed using observed species, Chao 1, and Shannon indices. PCoA based on UniFrac distances and ANOSIM was carried out using QIIME 2.Statistical analysisStatistical significance was tested using nonparametric one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test, non-parametric Mann-Whitney t test, or Student’s two-tailed, unpaired t test where indicated in the figure legend, using PRISM software (version 5; GraphPad software). P < 0.05 was considered statistically significant.Reporting summaryFurther information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Data availability The authors declare that the data supporting the findings of this study are available within the article and its Supplementary Information files, or are available on request. Source data are provided with this paper. The microbiome analysis data have been deposited in the DDBJ Sequence Read Archive (http:/race.ddbj.nig.ac.jp/dra/) under accession number DRA015846. The CE-TOFMS-based metabolome data are available at the NIH Common Fund’s National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where they have been assigned Project ID (ST002476 and ST002479). The data can be accessed directly via the Project https://doi.org/10.21228/M8113P. Source data are provided with this paper. ReferencesThompson, W. W. et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179–186 (2003).Article PubMed Google Scholar Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323, 1239–1242 (2020).Article CAS PubMed Google Scholar Pillai, P. S. et al. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science 352, 463–466 (2016).Article ADS CAS PubMed PubMed Central Google Scholar Molony, R. D. et al. Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. Sci. Signal. 10, eaan2392 (2017).Article PubMed PubMed Central Google Scholar Claesson, M. J. et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc. Natl Acad. Sci. USA 108, 4586–4591 (2011).Article ADS CAS PubMed Google Scholar Xu, C., Zhu, H. & Qiu, P. Aging progression of human gut microbiota. BMC Microbiol. 19, 236 (2019).Article PubMed PubMed Central Google Scholar Shin, J. et al. Ageing and rejuvenation models reveal changes in key microbial communities associated with healthy ageing. Microbiome 9, 240 (2021).Article PubMed PubMed Central Google Scholar Waalen, J. & Buxbaum, J. N. Is older colder or colder older? The association of age with body temperature in 18,630 individuals. J. Gerontol. A Biol. Sci. Med. Sci. 66, 487–492 (2011).Article PubMed Google Scholar Steed, A. L. et al. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science 357, 498–502 (2017).Article ADS CAS PubMed PubMed Central Google Scholar Rosshart, S. P. et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 171, 1015–1028.e1013 (2017).Article CAS PubMed PubMed Central Google Scholar Moriyama, M. & Ichinohe, T. High ambient temperature dampens adaptive immune responses to influenza A virus infection. Proc. Natl Acad. Sci. USA 116, 3118–3125 (2019).Article ADS CAS PubMed PubMed Central Google Scholar Stefan, K. L., Kim, M. V., Iwasaki, A. & Kasper, D. L. Commensal microbiota modulation of natural resistance to virus infection. Cell 183, 1312–1324 (2020).Article CAS PubMed PubMed Central Google Scholar Kudo, E. et al. Low ambient humidity impairs barrier function and innate resistance against influenza infection. Proc. Natl Acad. Sci. USA 116, 10905–10910 (2019).Article ADS CAS PubMed PubMed Central Google Scholar Goldberg, E. L. et al. Ketogenic diet activates protective gammadelta T cell responses against influenza virus infection. Sci. Immunol. https://doi.org/10.1126/sciimmunol.aav2026 (2019).Moriyama, M., Hugentobler, W. J. & Iwasaki, A. Seasonality of respiratory viral infections. Annu. Rev. Virol. 7, 83–101 (2020).Article CAS PubMed Google Scholar Wang, A. et al. Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation. Cell 166, 1512–1525.e1512 (2016).Article CAS PubMed PubMed Central Google Scholar Foxman, E. F. et al. Temperature-dependent innate defense against the common cold virus limits viral replication at warm temperature in mouse airway cells. Proc. Natl Acad. Sci. USA 112, 827–832 (2015).Article ADS CAS PubMed PubMed Central Google Scholar Foxman, E. F., Storer, J. A., Vanaja, K., Levchenko, A. & Iwasaki, A. Two interferon-independent double-stranded RNA-induced host defense strategies suppress the common cold virus at warm temperature. Proc. Natl Acad. Sci. USA 113, 8496–8501 (2016).Article ADS CAS PubMed PubMed Central Google Scholar Boonarkart, C., Suptawiwat, O., Sakorn, K., Puthavathana, P. & Auewarakul, P. Exposure to cold impairs interferon-induced antiviral defense. Arch. Virol. 162, 2231–2237 (2017).Article CAS PubMed Google Scholar Lowen, A. C., Mubareka, S., Steel, J. & Palese, P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 3, 1470–1476 (2007).Article CAS PubMed Google Scholar Lowen, A. C., Steel, J., Mubareka, S. & Palese, P. High temperature (30 degrees C) blocks aerosol but not contact transmission of influenza virus. J. Virol. 82, 5650–5652 (2008).Article CAS PubMed PubMed Central Google Scholar Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020).Article ADS CAS PubMed PubMed Central Google Scholar Sanchez-Alavez, M., Alboni, S. & Conti, B. Sex- and age-specific differences in core body temperature of C57Bl/6 mice. Age (Dordr.) 33, 89–99 (2011).Article CAS PubMed Google Scholar Toapanta, F. R. & Ross, T. M. Impaired immune responses in the lungs of aged mice following influenza infection. Respir. Res. 10, 112 (2009).Article PubMed PubMed Central Google Scholar Abumrad, N. A. The liver as a hub in thermogenesis. Cell Metab. 26, 454–455 (2017).Article CAS PubMed Google Scholar Trompette, A. et al. Dietary fiber confers protection against flu by shaping Ly6c(-) patrolling monocyte hematopoiesis and CD8(+) T cell metabolism. Immunity 48, 992–1005.e1008 (2018).Article CAS PubMed Google Scholar Chevalier, C. et al. Gut microbiota orchestrates energy homeostasis during cold. Cell 163, 1360–1374 (2015).Article CAS PubMed Google Scholar Hupfauf, S. et al. Temperature shapes the microbiota in anaerobic digestion and drives efficiency to a maximum at 45 °C. Bioresour. Technol. 269, 309–318 (2018).Article CAS PubMed Google Scholar Simon, M., Veit, M., Osterrieder, K. & Gradzielski, M. Surfactants - Compounds for inactivation of SARS-CoV-2 and other enveloped viruses. Curr. Opin. Colloid Interface Sci. 55, 101479 (2021).Article CAS PubMed PubMed Central Google Scholar Murakami, K. et al. Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids. Proc. Natl Acad. Sci. USA 117, 1700–1710 (2020).Article ADS CAS PubMed PubMed Central Google Scholar Ito, K. et al. Dual agonist of farnesoid X receptor and takeda G protein-coupled receptor 5 inhibits hepatitis B virus infection in vitro and in vivo. Hepatology 74, 83–98 (2021).Article CAS PubMed Google Scholar Zhang, S., Liu, Q., Wang, J. & Harnish, D. C. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem. Biophys. Res. Commun. 379, 476–479 (2009).Article CAS PubMed Google Scholar Guo, C. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45, 802–816 (2016).Article CAS PubMed Google Scholar Hao, H. et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis. Cell Metab. 25, 856–867.e855 (2017).Article CAS PubMed PubMed Central Google Scholar Schmitz, N., Kurrer, M., Bachmann, M. F. & Kopf, M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 79, 6441–6448 (2005).Article CAS PubMed PubMed Central Google Scholar Dinarello, C. A. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur. J. Immunol. 41, 1203–1217 (2011).Article CAS PubMed Google Scholar Brandes, M., Klauschen, F., Kuchen, S. & Germain, R. N. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell 154, 197–212 (2013).Article CAS PubMed PubMed Central Google Scholar Lee, C. H. et al. Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer. Oncotarget 6, 38866–38880 (2015).Article PubMed PubMed Central Google Scholar Kulkarni, U. et al. Excessive neutrophil levels in the lung underlie the age-associated increase in influenza mortality. Mucosal Immunol. 12, 545–554 (2019).Article CAS PubMed PubMed Central Google Scholar Wen, C. et al. Heat stress alters the intestinal microbiota and metabolomic profiles in mice. Front. Microbiol. 12, 706772 (2021).Article PubMed PubMed Central Google Scholar Ramirez-Perez, O., Cruz-Ramon, V., Chinchilla-Lopez, P. & Mendez-Sanchez, N. The role of the gut microbiota in bile acid metabolism. Ann. Hepatol. 16, S21–S26 (2017).Article CAS PubMed Google Scholar Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259 (2006).Article CAS PubMed Google Scholar Abt, M. C. et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37, 158–170 (2012).Article CAS PubMed PubMed Central Google Scholar Bradley, K. C. et al. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep. 28, 245–256.e244 (2019).Article CAS PubMed Google Scholar Hu, M. M. et al. Virus-induced accumulation of intracellular bile acids activates the TGR5-beta-arrestin-SRC axis to enable innate antiviral immunity. Cell Res. 29, 193–205 (2019).Article CAS PubMed PubMed Central Google Scholar Winkler, E. S. et al. The intestinal microbiome restricts alphavirus infection and dissemination through a bile acid-type I IFN signaling axis. Cell 182, 901–918.e918 (2020).Article CAS PubMed PubMed Central Google Scholar Yeoh, Y. K. et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70, 698–706 (2021).Article CAS PubMed Google Scholar Mizutani, T. et al. Correlation analysis between gut microbiota alterations and the cytokine response in patients with coronavirus disease during hospitalization. Microbiol. Spectr. 10, e0168921 (2022).Article PubMed Google Scholar Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718–724 (2020).Article ADS CAS PubMed PubMed Central Google Scholar Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).Article CAS PubMed PubMed Central Google Scholar Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463–469 (2020).Article CAS PubMed PubMed Central Google Scholar Pols, T. W. TGR5 in inflammation and cardiovascular disease. Biochem. Soc. Trans. 42, 244–249 (2014).Article CAS PubMed Google Scholar Raun, S. H. et al. Housing temperature influences exercise training adaptations in mice. Nat. Commun. 11, 1560 (2020).Article ADS CAS PubMed PubMed Central Google Scholar Ichinohe, T. et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl Acad. Sci. USA 108, 5354–5359 (2011).Article ADS CAS PubMed PubMed Central Google Scholar Moriyama, M., Koshiba, T. & Ichinohe, T. Influenza A virus M2 protein triggers mitochondrial DNA-mediated antiviral immune responses. Nat. Commun. 10, 4624 (2019).Article ADS PubMed PubMed Central Google Scholar Yoshikawa, T. et al. A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome. PLoS Pathog. 17, e1008859 (2021).Article CAS PubMed PubMed Central Google Scholar Ichinohe, T., Lee, H. K., Ogura, Y., Flavell, R. & Iwasaki, A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206, 79–87 (2009).Article CAS PubMed PubMed Central Google Scholar Soga, T. et al. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J. Proteome Res. 2, 488–494 (2003).Article CAS PubMed Google Scholar Mishima, E. et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 92, 634–645 (2017).Article CAS PubMed Google Scholar Sugimoto, M., Wong, D. T., Hirayama, A., Soga, T. & Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6, 78–95 (2010).Article CAS PubMed Google Scholar Hagio, M., Matsumoto, M., Fukushima, M., Hara, H. & Ishizuka, S. Improved analysis of bile acids in tissues and intestinal contents of rats using LC/ESI-MS. J. Lipid Res. 50, 173–180 (2009).Article CAS PubMed Google Scholar Yukawa-Muto, Y. et al. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species. Hepatol. Commun. 6, 2090–2104 (2022).Article CAS PubMed PubMed Central Google Scholar Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013).Article ADS CAS PubMed Google Scholar Murakami, S. et al. The consumption of bicarbonate-rich mineral water improves glycemic control. Evid. Based Complement Altern. Med. 2015, 824395 (2015).Article Google Scholar Kim, S. W. et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res. 20, 241–253 (2013).Article CAS PubMed PubMed Central Google Scholar Ishii, C. et al. A metabologenomic approach reveals changes in the intestinal environment of mice fed on american diet. Int J. Mol. Sci. 19, 4079 (2018).Article PubMed PubMed Central Google Scholar Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 37, 852–857 (2019).Article CAS PubMed PubMed Central Google Scholar Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596 (2013).Article CAS PubMed Google Scholar Yilmaz, P. et al. The SILVA and “all-species living tree project (LTP)” taxonomic frameworks. Nucleic Acids Res. 42, D643–D648 (2014).Article CAS PubMed Google Scholar Download referencesAcknowledgementsWe thank Akiko Iwasaki (Yale University) for critical reading of the manuscript, Yoshihiro Kawaoka (University of Wisconsin and University of Tokyo) for providing SARS-CoV-2/UT-NCGM02/Human/2020/Tokyo, Masayuki Saijo (National Institute of Infectious Diseases) for providing the SARS-CoV-2 QK002 variant. Flow cytometric analysis was performed in the IMSUT FACS Core laboratory. This work was supported in part by research grants from the Japan Agency for Medical Research and Development (JP223fa627001 to T.I.), JSPS KAKENHI (22H03541 to S.F.), AMED-CREST (JP22gm1010009 to S.F.), JST ERATO (JPMJER1902 to S.F.), the Food Science Institute Foundation (to S.F.), the Metagen Therapeutics, Inc. (to S.F. and T.I.), the MSD Life Science Foundation (to T.I.), the Takeda Science Foundation (to T.I.), and the Suzuken Memorial Foundation (to T.I.). M. Moriyama is the Research Fellow of the Japan Society for the Promotion of Science. The metabolomics work is supported by National Institutes of Health grant U2C-DK119886.Author informationAuthor notesThese authors contributed equally: Minami Nagai, Miyu Moriyama, Chiharu Ishii.Authors and AffiliationsDivision of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo, JapanMinami Nagai, Miyu Moriyama & Takeshi IchinoheInstitute for Advanced Biosciences, Keio University, Yamagata, JapanChiharu Ishii, Takamasa Ishikawa, Akiyoshi Hirayama & Shinji FukudaDepartment of General Medicine, Juntendo University Faculty of Medicine, Tokyo, JapanHirotake Mori & Toshio NaitoMetagen Therapeutics, Inc., Yamagata, JapanHikaru Watanabe, Taku Nakahara, Takuji Yamada, Dai Ishikawa & Shinji FukudaDepartment of Life Science and Technology, Tokyo Institute of Technology, Tokyo, JapanTakuji YamadaLaboratory for Regenerative Microbiology, Juntendo University Graduate School of Medicine, Tokyo, JapanDai Ishikawa, Akihito Nagahara & Shinji FukudaDepartment of Gastroenterology, Juntendo University Faculty of Medicine, Tokyo, JapanDai Ishikawa & Akihito NagaharaLaboratory of Molecular Neurobiology, Graduate School of Biostudies, Kyoto University, Kyoto, JapanIkuo KimuraDepartment of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, JapanIkuo KimuraGut Environmental Design Group, Kanagawa Institute of Industrial Science and Technology, Kanagawa, JapanShinji FukudaTransborder Medical Research Center, University of Tsukuba, Ibaraki, JapanShinji FukudaAuthorsMinami NagaiView author publicationsYou can also search for this author in PubMed Google ScholarMiyu MoriyamaView author publicationsYou can also search for this author in PubMed Google ScholarChiharu IshiiView author publicationsYou can also search for this author in PubMed Google ScholarHirotake MoriView author publicationsYou can also search for this author in PubMed Google ScholarHikaru WatanabeView author publicationsYou can also search for this author in PubMed Google ScholarTaku NakaharaView author publicationsYou can also search for this author in PubMed Google ScholarTakuji YamadaView author publicationsYou can also search for this author in PubMed Google ScholarDai IshikawaView author publicationsYou can also search for this author in PubMed Google ScholarTakamasa IshikawaView author publicationsYou can also search for this author in PubMed Google ScholarAkiyoshi HirayamaView author publicationsYou can also search for this author in PubMed Google ScholarIkuo KimuraView author publicationsYou can also search for this author in PubMed Google ScholarAkihito NagaharaView author publicationsYou can also search for this author in PubMed Google ScholarToshio NaitoView author publicationsYou can also search for this author in PubMed Google ScholarShinji FukudaView author publicationsYou can also search for this author in PubMed Google ScholarTakeshi IchinoheView author publicationsYou can also search for this author in PubMed Google ScholarContributionsS.F. and T.Ichi. conceived the study and designed the experiments; M.N., M.M., and T.Ichi. performed animal experiments; T.Ishi., A.H., and S.F. conducted metabolome analysis; H.M. and T.Nai. collected clinical samples; C.I., H.W., T.Nak., and T.Y. analyzed data; I.K., D.I., and A.N. provided reagents and advice; and S.F. and T.Ichi. wrote the paper.Corresponding authorsCorrespondence to Toshio Naito, Shinji Fukuda or Takeshi Ichinohe.Ethics declarations Competing interests T.N., T.Y., D.I., and S.F. are founders and T.N. and D.I. are board members of Metagen Therapeutics, Inc., a company involved in the microbiome-based medical and drug discovery. T.Y. and S.F. are founders and board members of Metagen, Inc., a microbiome-based healthcare company. The other authors declare no competing interests. Peer review Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available. Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary informationSupplementary InformationPeer Review FileReporting SummarySource dataSource DataRights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissionsAbout this articleCite this articleNagai, M., Moriyama, M., Ishii, C. et al. High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection. Nat Commun 14, 3863 (2023). https://doi.org/10.1038/s41467-023-39569-0Download citationReceived: 14 July 2022Accepted: 20 June 2023Published: 30 June 2023DOI: https://doi.org/10.1038/s41467-023-39569-0Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative This article is cited by Prebiotic inulin ameliorates SARS-CoV-2 infection in hamsters by modulating the gut microbiome Isaiah SongJiayue YangShinji Fukuda npj Science of Food (2024) Gut microbiota wellbeing index predicts overall health in a cohort of 1000 infants Brandon HickmanAnne SalonenKatri Korpela Nature Communications (2024) Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in COVID-19 Morgan EssexBelén Millet Pascual-LeoneBastian Opitz npj Biofilms and Microbiomes (2024) Download PDF Advertisement Explore content Research articles Reviews & Analysis News & Comment Videos Collections Subjects Follow us on Facebook Follow us on Twitter Sign up for alerts RSS feed About the journal Aims & Scope Editors Journal Information Open Access Fees and Funding Calls for Papers Editorial Values Statement Journal Metrics Editors' Highlights Contact Editorial policies Top Articles Publish with us For authors For Reviewers Language editing services Submit manuscript Search Search articles by subject, keyword or author Show results from All journals This journal Search Advanced search Quick links Explore articles by subject Find a job Guide to authors Editorial policies Nature Communications (Nat Commun) ISSN 2041-1723 (online) nature.com sitemap About Nature Portfolio About us Press releases Press office Contact us Discover content Journals A-Z Articles by subject protocols.io Nature Index Publishing policies Nature portfolio policies Open access Author & Researcher services Reprints & permissions Research data Language editing Scientific editing Nature Masterclasses Research Solutions Libraries & institutions Librarian service & tools Librarian portal Open research Recommend to library Advertising & partnerships Advertising Partnerships & Services Media kits Branded content Professional development Nature Careers Nature Conferences Regional websites Nature Africa Nature China Nature India Nature Italy Nature Japan Nature Middle East Privacy Policy Use of cookies Your privacy choices/Manage cookies Legal notice Accessibility statement Terms & Conditions Your US state privacy rights © 2024 Springer Nature Limited Close banner Close Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Email address Sign up I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close banner Close Get the most important science stories of the day, free in your inbox. Sign up for Nature BriefingMinnesota officials urge dog owners to consider vaccine as canine influenza spreadsMinneapolis35°FeEditionMinnesota News You Can UseThe Latest17 minutes agoWolves, Blazers play consecutive games on back-to-back nights in Portland35 minutes agoJohn Robinson, successful football coach at USC and with the LA Rams, has died at 8935 minutes agoMinnesota teenager drowns while kayaking on western Wisconsin lake1 Hour agoTrump names former Rep. Lee Zeldin to lead EPA, adviser Stephen Miller to be deputy chief of policy2 Hours agoSouhan: Jones isn't the best Vikings running back, but he might be the most likeable2 Hours agoAnalysis: Patience, precision on Vikings' to-do list for QB Darnold2 Hours agoChristopher Crutchfield, 54, brought joy and compassion to fight for justice3 Hours agoBCA: Man wanted for pregnant ex-wife’s murder aimed gun at St. Paul officers before they killed him3 Hours agoMarvin Haynes files nearly $2 million claim for wrongful murder conviction3 Hours agoHere’s how the community around George Floyd Square is reacting to Minneapolis’ latest redesign plan3 Hours agoGophers soccer lands first NCAA tournament bid since 20184 Hours agoVikings’ Jones feeling pretty good after rib injury vs. Jaguars4 Hours agoHeupel says No. 6 Vols should have QB Nico Iamaleava against 11th-ranked Georgia4 Hours agoJack Del Rio leaving Wisconsin's staff after arrest on charge of operating vehicle while intoxicated5 Hours agoWild’s Boldy displays again his penchant for scoring important goals6 Hours agoGophers women’s basketball aims for 3-0 start, as UMass-Lowell visits7 Hours agoHennepin County pays $3.4 million to settle lawsuit for wrongful death of jail inmate Lucas Bellamy7 Hours agoTwins rookie starter David Festa had interesting second-half numbers8 Hours ago40 must-reads from staffers at Red Balloon, as it throws itself (and you) a 40th birthday party8 Hours agoReview: Grumpiest ‘Grinch’ yet barrels through the audience at Children’s TheatreLocalCases of canine influenza increase in Minnesota, but vaccine in short supplyNearly 300 dogs have been suspected of being infected with canine influenza since an outbreak began in Minnesota in April.By Kelly SmithJune 29, 2023 at 5:20PMDr. Sarah Smith gives “Kai,” Emily Post’s rescue dog a canine influenza vaccine at the St. Paul Pet Hospital in St. Paul, Minn., on Thursday, June 29, 2023. (Elizabeth Flores, Star Tribune/The Minnesota Star Tribune)CommentGiftShareListenCanine influenza is suspected of infecting nearly 300 dogs in Minnesota since April, when the outbreak of the highly contagious virus was first reported. It's the largest canine disease outbreak in decades."For dog disease in Minnesota, it's the biggest news for the past 40 years at least," said Graham Brayshaw, director of veterinarian medicine at the Animal Humane Society.That's why the state Board of Animal Health this month encouraged dog owners to talk to their vets about the canine influenza vaccine to protect their pups and stop the spread.But there's still a widespread shortage of shots in the state and nationwide, though supply has increased. Last week, a canine influenza vaccine clinic at the Animal Humane Society sold out immediately.MacKenna Theis, of St Paul was excited to take home her new adopted lab mix puppy, Peter, from the Animal Humane Society on May 9, 2023 after the nonprofit reopened its Woodbury location. (Glen Stubbe, Star Tribune/The Minnesota Star Tribune)The St. Paul Pet Hospital's canine flu vaccine supply sold out as soon as appointments were announced. Veterinarian Abigail Maynard said it's pretty difficult for clinics to get supplies of the vaccine since only one company makes it and the demand is high.The outbreak began in Minnesota when the Humane Society reported that a dog transported from Oklahoma had infected all of its 200 dogs. The nonprofit shut down its three shelters in Golden Valley, Woodbury and Coon Rapids and paused all pet adoptions until May, making it the Humane Society's longest closure due to an animal-related outbreak.Since then, Brayshaw said, the Humane Society has had zero cases of canine flu, which causes similar symptoms to the flu in humans, and has implemented stricter protocols, testing and isolating any dog with respiratory symptoms for seven days."We've doubled down the best we can to make sure we're not importing anything that's contagious," he said.Of the nearly 300 suspected canine flu cases in Minnesota, 95 are confirmed infections and most of them are in Hennepin County, according to the state Board of Animal Health. It's likely there are many more infected dogs who haven't been tested or visited a veterinarian to confirm the disease.The number of infections is still low, given that there's an estimated half-million dogs in the metro area. Minnesota is reporting far fewer cases of canine influenza than other states, including Texas and Oklahoma."It's at least not exploding in numbers," Brayshaw said.It takes six to eight weeks for the vaccine to be fully effective. Since most dogs stay at the Humane Society's shelters for an average of a few weeks, the nonprofit is focusing its supply of 1,000 vaccine shots on dogs in the community that go to its clinics, Brayshaw said.He encouraged people who take their dogs to boarding facilities, doggy day care or dog parks to consider vaccinating their pups. "This is a disease I would worry about, based on the social activity of my dog," he said.Canine flu is more serious than kennel cough, a respiratory disease that's akin to a mild cold. Puppies, senior dogs and those with weakened immune systems are more susceptible to complications. Vaccinating those dogs can help reduce the severity of the illness, according to the Board of Animal Health.As with humans and COVID-19, all pups play a role in slowing the spread of the disease, said Holly Rudolf, a Mankato veterinarian who owns Halo Pet Care."The community helping to practice avoidance, vaccinating and using good hygiene practices is going to be helpful in keeping our pet population in the state protected," she said.At the University of Minnesota's Veterinary Medical Center, some dogs with canine influenza had to be hospitalized to receive oxygen. But most dogs have mild cases and recover quickly, said Lindsay Merkel, a veterinarian and associate professor. Canine flu has a low mortality rate; according to the Board of Animal Health, two dogs have been euthanized due to complications from the disease.Canine influenza will likely continue to spread before the virus eventually dies out, Merkel said. However, with so many animal rescues in Minnesota, it's likely that dogs transported from other states and countries will bring new infectious diseases to the state's canine community, she said."We are going to see more and more infectious diseases," Merkel said. "It is a concern."Five things dog owners should know about canine fluKnow the symptoms, which include cough, fever, runny eyes and nose, and shortness of breath.Isolate your dog from others if they're symptomatic: If your dog shows signs of a respiratory illness, isolate them from other dogs for 30 days, regardless of whether your pet is vaccinated.Consider vaccinating your dog, especially if they are high-risk or around a lot of other pups. The Board of Animal Health says to consider the dog's age and whether they are boarded often or attend community events. Dogs must receive an initial shot followed by a booster in three to four weeks, and the vaccine can cost $40 to $85 per shot, according to the agency. Talk to your veterinarian.Avoid social settings to reduce risk, such as dog parks, doggy day cares and other places dogs may have direct contact with other dogs — especially if your dog isn't vaccinated.It's not transmittable to most other pets or humans, though it sometimes can be transmitted to cats.ShareCommentabout the writerKelly SmithReporterKelly Smith covers nonprofits/philanthropy for the Star Tribune and is based in Minneapolis. Since 2010, she’s covered Greater Minnesota on the stateegion team, Hennepin County government, west metro suburban government and west metro K-12 education.See MoreMore from LocalSee MoreElectionsHow Minnesota House Republicans ended the DFL’s state government trifectaRyan FairclothElectionsHow Minnesota House Republicans ended the DFL’s state government trifectaRyan FairclothRepublicans across the country benefited from favorable tailwinds as President-elect Donald Trump resoundingly defeated Democrat Kamala Harris. But that wasn’t the whole story in Minnesota.LocalProject 2025 platform proposal aims to allow mining in Boundary Waters watershedLouis KraussLocalProject 2025 platform proposal aims to allow mining in Boundary Waters watershedLouis KraussThe proposal suggests removing the 20-year protection on the Superior National Forest that President Joe Biden’s administration had ordered in 2023.ElectionsAnn Johnson Stewart wins special election, giving DFL control of Minnesota Senate Rochelle OlsonElectionsAnn Johnson Stewart wins special election, giving DFL control of Minnesota Senate Rochelle OlsonWestern Twin Cities suburban candidates Johnson Stewart and Republican Kathleen Fowke were the only Senate candidates on the ballot. ElectionsHow Minnesota House Republicans ended the DFL’s state government trifectaRyan FairclothElectionsHow Minnesota House Republicans ended the DFL’s state government trifectaRyan FairclothRepublicans across the country benefited from favorable tailwinds as President-elect Donald Trump resoundingly defeated Democrat Kamala Harris. But that wasn’t the whole story in Minnesota.CompanyAbout UsContact UsWork for UsNews in EducationMinnesota’s BestHigh School Sports HubsMobile and Tablet AppsPolicies and StandardsADVERTISEGet in TouchAdvertising OpportunitiesMedia KitClassifiedsPublic NoticesObituariesBuyStrib StorePhoto ReprintsFull Page Archive: 150+ yearsBack CopiesCommercial ReprintsLicensingSupportHelp and FeedbackManage Your AccountNewspaper SubscriptionsDigital AccesseEditionText to SpeechWebsiteTerms of UsePrivacy PolicySite IndexRSS© 2024 StarTribune. All rights reserved.CDC Endorses Recommendation for RSV Vaccine for Older Adults | Patient Care Search search close CDC Endorses Recommendation for RSV Vaccine for Older Adults Additional Action on Polio, Influenza and Pneumococcal Vaccines June 29, 2023, News Staff — The CDC today endorsed recommendations from its Advisory Committee on Immunization Practices for two new vaccines (Abrysvo, manufactured by Pfizer Inc., and Arexvy, manufactured by GSK plc) to prevent respiratory syncytial virus in older adults. In two separate votes that addressed different age groups, the advisory committee recommended that adults ages 60 and older may receive a single dose of RSV vaccine based on shared clinical decision-making with a health care professional. AAFP President Tochi Iroku-Malize, M.D., M.P.H., said the Academy “is optimistic that ACIP voted to approve recommendations for new RSV vaccines” and highlighted the crucial role family physicians play in ensuring that people have access to vaccines to prevent infectious diseases. “We trust the science of vaccines and encourage patients to talk to their family doctors to learn more about the recommendations and vaccines, and how getting vaccinated builds a community of immunity,” Iroku-Malize continued. “We now have something to offer our older adults to help prevent lower respiratory infections from a very common viral disease,” added Pamela Rockwell, D.O., of Ann Arbor, Mich., the AAFP’s liaison to the ACIP. “With COVID-19, influenza and RSV viruses often circulating at the same time, we can help prevent disease in our older patients by vaccinating against all three.” The Academy is reviewing the advisory committee’s recommendations and will issue a formal statement soon. Story Highlights Lengthy Discussions The advisory committee approved the recommendation for adults ages 60 to 64 by a 13-0 vote with one abstention, for adults 65 and older by a 9-5 vote. The votes followed lengthy discussions by committee members about the size of clinical trials, prices and administering RSV vaccines along with seasonal vaccines for influenza and COVID-19. As a result, the original language in the recommendations was amended to “may” from “should.” Arexvy and Abrysvo, which are both indicated for the prevention of lower respiratory tract disease caused by RSV, received FDA approval in May. The manufacturers intend to have the vaccines available in time for this year’s RSV season. More on RSV RSV season typically begins in the fall and peaks during winter. However, evidence suggests that the COVID-19 pandemic changed the seasonal activity of respiratory viruses in 2020 and 2021, and it remains uncertain whether typical patterns will return. Although most people who develop an RSV infection experience mild illness and recover in less than two weeks, some people — in particular older adults, infants and young children — are at increased risk for severe illness or complications that may require hospitalization. It should also be noted that the ACIP reviewed data on the use of RSV vaccines in pregnant women to protect infants from RSV during the first six months of life, as well as clinical considerations for the combined use of RSV vaccines and nirsevimab, a monoclonal antibody developed by AstraZeneca and Sanofi to offer broad protection against RSV disease. However, the committee did not vote on these topics. The FDA’s Antimicrobial Drugs Advisory Committee did vote in June to recommend approval of nirsevimab to protect infants from RSV, and a decision from the agency is expected this fall. Other Actions Although RSV vaccines drew much of the attention at the ACIP meeting, the committee took other important action, including the unanimous approval of several recommendations pertaining to vaccines for pneumococcal disease: the use of either 15-valent or 20-valent pneumococcal conjugate vaccine for all children aged 2-23 months, according to recommended PCV dosing and schedules; for young children with incomplete PCV vaccination, the use of PCV15 or PCV20 vaccine, according to recommended PCV dosing and schedules for healthy children aged 24-59 months and children with specified risk conditions aged 24-71 months; for children aged 2-18 years with any risk condition who have completed their PCV vaccination series before age 6, no additional doses of any pneumococcal vaccine if they have received one or more dose of PCV20; but one dose of PCV20 or 23-valent pneumococcal polysaccharide vaccine, using previously recommended doses and schedules, if they received PCV13 or PCV15 (but not PCV20); and for children aged 6-18 years with any risk indication who have not previously received any dose of PCV 13, PCV15 or PCV20, a single dose of PCV15 or PCV20. When PCV15 is used, it should be followed by a dose of PPSV23 at least eight weeks later if not previously given. The committee also added moderate persistent or severe asthma, chronic liver disease and chronic kidney disease (excluding maintenance dialysis and nephrotic syndrome) to the list of conditions that put children at increased risk, to be more consistent with the conditions listed for adults. The ACIP also made the following recommendations: Adults aged 18 and older who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary vaccination series with inactivated polio vaccine. Adults who have received a primary series of trivalent oral polio vaccine or inactivated polio vaccine in any combination and who are at increased risk of poliovirus exposure may receive another dose of inactivated polio vaccine. Data do not indicate the need for more than a single lifetime booster dose with inactivated polio virus for adults. It is no longer necessary for people with egg allergies to receive an influenza vaccine in a medical setting. Any influenza vaccine appropriate for the recipient’s age and health status can be used regardless of whether it is egg-based. Finally, the advisory committee reviewed presentations and received updates on vaccines for dengue, chikungunya, Mpox, meningococcal disease and COVID-19, including clinical guidance on the use of the Jynneos vaccine during Mpox outbreaks, and updates on COVID-19 epidemiology and vaccine effectiveness. “It is clear from data presented that vaccinating persons of all ages against communicable disease helps the entire community with direct and indirect effects,” said Rockwell. Copyright © 2024 American Academy of Family Physicians. All Rights Reserved.Doherty Institute and SK bioscience join forces against influenza | Doherty Website Search Please do not fill-in this field About Our Work Services & Facilities People Education Careers News & Events Support COVID-19 Research Searchss A joint venture between The University of Melbourne and The Royal Melbourne Hospital Search About Overview Laureate Professor Peter Doherty Governance Reports & Publications Brochures Venue Hire Support our work Advocacy Contact Us Our Work Institute Themes Immunology Viral Infectious Diseases HIV Hepatitis Influenza Emerging Infections COVID-19 Antimicrobial Resistance Bacterial and Parasitic Infections Malaria Tuberculosis Buruli Ulcer Cross-Cutting Disciplines Discovery Research Public Health Clinical and health systems research Global Health Education & Professional Development Indigenous Health Computational Science and Genomics Services & Facilities Services Facilities People Education Study at the Doherty Institute Research Projects PhD Clinician Graduate Research Training Meet our graduate researchers Prospective Student Information Session Contacts Careers News & Events News Events Setting it Straight Podcast: Infection and Immunity - Evidence Explained Publications Support COVID-19 Research News 27 Jun 2023 Doherty Institute and SK bioscience join forces against influenza The Peter Doherty Institute for Infection and Immunity (Doherty Institute), home to one of five WHO Collaborating Centres for Reference and Research Influenza (WHOCCRRI) in the world, has signed a research collaboration agreement with vaccine and biotech company SK bioscience, based in South Korea, to support and further research in influenza biology, vaccines and antivirals. The program will include testing of anti-influenza compounds to identify new antivirals, capacity building in low- and middle-income countries of the region and the development of a new influenza vaccine platform. In an online signing ceremony, attended by Professor Kanta Subbarao, Director of the WHOCCRRI at the Doherty Institute, Professor Ian Barr, Deputy Director of the WHOCCRRI at the Doherty Institute, Jaeyong Ahn, CEO of SK bioscience, and Hun Kim, President of Global R&BD of SK bioscience, Doherty Institute Director Professor Sharon Lewin said that this collaboration agreement is a significant milestone in the organisation's shared commitment to tackling infectious diseases and promoting public health "By collaborating with SK bioscience, we will strengthen our ability to respond to global challenges through exchanging knowledge and fostering innovation. Together, we will make a lasting impact in the prevention and treatment of infectious diseases, like influenza, around the world,” said Professor Lewin. Jaeyong Ahn said “We expect a synergy combined with our capability in developing the world's first quadrivalent cell culture-based influenza vaccine and the infrastructure of the Doherty Institute, a leading research institution on global infectious diseases. We will strengthen global partnerships with various organisations and continuously expand cooperative areas to establish a response system against infectious disease pandemics in the world.” Jaeyong Ahn, CEO of SK bioscience (left) and Professor Sharon Lewin, Director of the Doherty Institute at the signing ceremony on June 26, 2023. News Archive 2024 January February March April May June July August September October November 2023 January February March April May June July August September October November December 2022 January February March April May June July August September October November December 2021 January February March April May June July August September October November December 2020 January February March April May June July August September October November December 2019 January February March April May June July August September October November December 2018 January February March April May June July August September October November December 2017 January February March April May June July August September October November December 2016 January February March April May June July August September October November December 2015 June July August October November December KEEP INFORMED Facebook Twitter Instagram Subscribe for the latest news, events and research For any media enquiries, please contact: Communications Team P: +61383441911 E: doherty-media@unimelb.edu.au Contact Us 792 Elizabeth Street Melbourne, 3000 Get Directions doherty-reception@unimelb.edu.au +61 3 9035 3555 Contact Us Facebook Twitter Instagram LinkedIn Keep informed Subscribe for the latest news, events and research First name Last name Email Subscribe We acknowledge the Wurundjeri people of the Kulin Nation as the traditional custodians of the land where our Institute stands. We are committed to collaboration with Aboriginal and Torres Strait Islander communities to reduce the unacceptable burden of infectious disease. We are committed to training the next generation of exceptional Indigenous leaders in infection and immunity. Copyright The Peter Doherty Institute for Infection and Immunity Privacy Policy | Intranet | Site by LemonadeAustralia faces another record flu season – and children’s vaccination rates are alarming | Health | The Guardian Skip to main contentSkip to navigationClose dialogue1/1Next imagePrevious imageToggle captionSkip to navigationPrint subscriptionsSearch jobs Sign inIntInternational editionUK editionUS editionAustralia editionEurope editionThe Guardian - Back to homeThe GuardianNewsOpinionSportCultureLifestyleShow moreHide expanded menuNewsView all NewsWorld newsUS elections 2024UK newsClimate crisisUkraineEnvironmentScienceGlobal developmentFootballTechBusinessObituariesOpinionView all OpinionThe Guardian viewColumnistsCartoonsOpinion videosLettersSportView all SportFootballCricketRugby unionTennisCyclingF1GolfUS sportsCultureView all CultureBooksMusicTV & radioArt & designFilmGamesClassicalStageLifestyleView all LifestyleFashionFoodRecipesLove & sexHealth & fitnessHome & gardenWomenMenFamilyTravelMoneySearch input google-search SearchSupport usPrint subscriptionsSearch jobsHolidaysDigital ArchiveGuardian LicensingAbout UsThe Guardian appVideoPodcastsPicturesNewslettersToday's paperInside the GuardianThe ObserverGuardian WeeklyCrosswordsWordiplyCorrectionsSearch input google-search SearchSearch jobsHolidaysDigital ArchiveGuardian LicensingAbout UsWorldEuropeUSAmericasAsiaAustraliaMiddle EastAfricaInequalityGlobal development The single thing different to pre-pandemic years is the number of younger Australians not getting an influenza vaccine. Photograph: kwanchaichaiudom/Getty Images/iStockphotoView image in fullscreenThe single thing different to pre-pandemic years is the number of younger Australians not getting an influenza vaccine. Photograph: kwanchaichaiudom/Getty Images/iStockphotoHealth This article is more than 1 year oldAnalysisAustralia faces another record flu season – and children’s vaccination rates are alarmingThis article is more than 1 year oldAsha Bowen and Christopher Blyth for the ConversationSince 2023’s influenza season started, children have made up almost 80% of those admitted to hospital Follow our Australia news live blog for the latest updates Get our morning and afternoon news emails, free app or daily news podcast Mon 26 Jun 2023 02.00 BSTLast modified on Mon 26 Jun 2023 07.00 BSTShareThe 2023 flu season may be one of Australia’s largest flu seasons on record and doctors are concerned about its impact on children.You may have seen headlines warning parents about “kindy flu”. These can be misleading. This year’s flu virus does not “target” children. But children are particularly vulnerable for one important reason – low vaccination rates.We are concerned that fewer children have received their annual flu vaccine in 2023, compared with previous years. And it leaves them, and the wider community, at risk of flu and its complications.How bad is this year’s flu season?In 2023 we are on track for a similar influenza season to 2019 – the largest on record in Australia. That’s when there were more than 300,000 recorded influenza cases.Flu cases are on the rise across Australia. Do I need a winter vaccination?Read moreAt the time of writing, we’ve had 107,941 recorded flu cases and the flu season still has months to go. Of these, 48,873 have been in children under 15 and 22,365 in those aged five to nine years.Since the flu season started in late April, children have made up almost 80% of those admitted to hospital at sentinel surveillance sites. Many children’s hospitals are reporting high numbers of children hospitalised with flu.Sadly, one child has died of influenza, a three-year-old in Perth.These large case numbers come after low influenza case numbers seen earlier in the pandemic.Why is this happening?The 2023 flu strains do not seem to be any more severe than in other years, according to a number of measures.In hospitals, the number of those admitted directly to intensive care (now 7%) is similar to previous seasons. Sign up for Guardian Australia’s free morning and afternoon email newsletters for your daily news roundup In the community, the number of those with flu-like illnesses needing to take time off regular duties is also similar.There is also no evidence the strains circulating are more likely to infect children, or for them to infect others, compared with strains circulating in previous years.So something else must be going on.What’s different in 2023?The single thing different to pre-pandemic years is the number of younger Australians not getting an influenza vaccine.In 2020, at this stage of the season, nearly 40% of children aged from six months to under five years were vaccinated, compared with just 20% now. In those five to under 15, 25% were vaccinated in 2020 compared with just 12% now.This makes us worried.skip past newsletter promotionSign up to Afternoon UpdateFree daily newsletterOur Australian afternoon update breaks down the key stories of the day, telling you what’s happening and why it mattersEnter your email address Sign upPrivacy Notice: Newsletters may contain info about charities, online ads, and content funded by outside parties. For more information see our Privacy Policy. We use Google reCaptcha to protect our website and the Google Privacy Policy and Terms of Service apply.after newsletter promotionYoung children, particularly those under five, are the group most likely to be hospitalised with flu.Although children with underlying medical conditions – including chronic disorders of the heart, lungs, nervous and immune system – are most susceptible, more than half of children admitted to hospital each year with flu are otherwise healthy. While rare, flu deaths occur in previously healthy children.We are also worried about influenza making children more vulnerable to secondary bacterial infections. These include invasive group A streptococcus and pneumococccal disease.Another reason to get vaccinatedChildren have large volumes of virus in their nasal secretions and, after infection, shed this for days. They also have poorer hygiene practices, often coughing and spluttering over those closest to them.So children will quickly infect their parents, grandparents and younger siblings. Some will be at higher risk of getting unwell and being hospitalised, such as the elderly, the very young, First Nations people and those with underlying medical issues including heart, lung, kidney and immune problems.Primary school-age children are the group who most frequently transmit flu in the community. In 2023 we expect the largest number of cases in the community to be in five- to nine-year-olds.When to seek medical attentionFlu in children commonly causes high temperatures, sore throats, miserable kids and non-stop runny noses and coughing. Most cases can be safely managed at home.But if you’re worried about your child, seek medical advice, particularly if your child: has difficulty breathing (breathing rapidly or drawing in chest or neck muscles) is vomiting and refusing to drink is more sleepy than normal has pain that doesn’t get better with simple pain relief medication And right now, before they get sick, book in your children for their annual flu vaccine. It prevents more than half of infections. And, even if infected, vaccinated children are less likely to be hospitalised with it. This article was first published by the Conversation. Asha Bowen is program head at the Telethon Kids Institute; Christopher Blyth is a paediatrician, infectious diseases physician and clinical microbiologist at the University of Western AustraliaExplore more on these topicsHealthFluChildrenVaccines and immunisationanalysisShareReuse this contentComments (…)Sign in or create your Guardian account to join the discussionMost viewedMost viewedWorldEuropeUSAmericasAsiaAustraliaMiddle EastAfricaInequalityGlobal developmentNewsOpinionSportCultureLifestyleOriginal reporting and incisive analysis, direct from the Guardian every morningSign up for our emailHelpComplaints & correctionsSecureDropWork for us Privacy policyCookie policyTerms & conditionsContact usAll topicsAll writersDigital newspaper archiveTax strategyFacebookYouTubeInstagramLinkedInXNewslettersAdvertise with usSearch UK jobsBack to top© 2024 Guardian News & Media Limited or its affiliated companies. All rights reserved. (dcr)Tightly Packed Poultry and Pig Farms Could Be Incubating the Next Deadly Flu – Mother Jones Skip to main content Share on Facebook Share on TwitterEmailPrintComments Donate Donate Subscribe Poll Workers Trump Elon Musk’s “Election Integrity Community” Private Prisons Newsletters Politics Environment Criminal Justice Guns Race Gender + Sexuality Food Podcast Video Magazine Poll Workers Trump Elon Musk’s “Election Integrity Community” Private Prisons Subscribe to our magazine Donate Monthly Donate Smart, Fearless Journalism Politics Environment Criminal Justice Guns Race Gender Food Podcast Video Magazine Newsletters membership ticker Donate Now Do you give a damn about the future of this country? The guardrails protecting democracy may have buckled, but they are not broken. Autocratic forces are ascendant in America—yes, it can happen here, and did—but the story isn’t fully written. Truth-telling independent media is one remaining bulwark against Trump’s unrestrained exercise of power. Our nonprofit newsroom is built for what’s ahead. No oligarchs or billionaires can tell us what to publish. Depend on it, and please stand with us. The guardrails protecting democracy may have buckled, but they are not broken. Autocratic forces are ascendant in America, but the story isn’t fully written. Truth-telling independent media is one remaining bulwark against Trump’s unrestrained exercise of power. Our nonprofit newsroom is built for what’s ahead. No oligarchs or billionaires can tell us what to publish. Please stand with us. Donate Now Environment FoodJuly+August 2023 IssueTightly Packed Poultry and Pig Farms Could Be Incubating the Next Deadly FluNo one wants this kind of viral mash-up. Tom PhilpottReporterBio | Follow Share on Facebook Share on TwitterEmailPrintComments Yeye Weller The coronavirus is a rapidly developing news story, so some of the content in this article might be out of date. Check out our most recent coverage of the coronavirus crisis, and subscribe to the Mother Jones Daily newsletter.If you’re like me, you associate pork with the deliciousness of bacon. But lurking behind the pleasure lies something much less savory to think about: the risk of another pandemic. That’s because humans and pigs easily swap influenza viruses. Worse still, pigs can also pick up influenza strains that circulate among birds, whose viruses aren’t well adapted to infecting and spreading among people. Humans don’t have the receptors in our throats and noses that avian flus can easily attach to. Our isolation from avian flus is what makes them dangerous—since our immune systems rarely encounter them, we have little innate ability to fight them off. Enter pigs. They can catch flu strains from birds (often carrying them without symptoms), mash them up with genetic material from human-adapted flus, and create novel varieties capable of flummoxing human immunity and generating pandemics. That’s why virologists call hogs “mixing vessels” for novel influenza strains. In 2009, just such a flu—a new strain of H1N1—emerged from an industrial hog farm in Mexico, combining individual gene segments from humans, birds, North American pigs, and Eurasian pigs. It spread worldwide, inspiring the World Health Organization to declare a pandemic, the first time it had done so since 1968. This strain of H1N1 didn’t prove as virulent as health officials first feared, but even so, it killed more than 284,000 people around the world, including at least 12,000 Americans, and still circulates today. The crisis temporarily gutted demand for US pork, both domestically and abroad, and the Department of Agriculture raced to shore up the industry by buying about $230 million worth of pork to distribute in aid programs. It was no coincidence an enormous hog operation was the culprit. Humans domesticated pigs at least 9,000 years ago, and we’ve probably been swapping flus with them ever since. But for almost that entire history, hog farming was essentially a backyard activity, with few animals per operation, and broad genetic diversity in the pig population. That diversity meant some pigs would carry a genetic mutation that could block a particular pathogen, an “immune firebreak to keep the virus from going from hog to hog or barn to barn,” says Rob Wallace, an evolutionary biologist with the Agroecology and Rural Economics Research Corps, and author of Big Farms Make Big Flu. All of that changed in the early 1980s, when US hog farming got supersized. In 1982, 330,000 farms raised 55 million hogs. By 2017, just 66,000 farms were churning out more than 72 million genetically similar pigs. Nearly 80 percent of those hogs were raised on the 3,600 largest US operations, each averaging more than 14,000 animals. Richard Webby, professor of infectious diseases at St. Jude Children’s Research Hospital and director of a WHO group that studies animal flus, put it like this: It’s a “numbers game. These viruses throw out mutations every time they replicate, so the more chances the virus gets, the more interactions with humans, it increases the chance that one day the stars will align in the right order, the virus will get the right mutation, and take off.” As if trying to boost those odds, the US livestock industry has chosen to place mammoth numbers of chickens in the very regions where hog farming is most concentrated. Iowa leads the nation in both pig (23 million) and laying-hen (56 million) populations, while also housing nearly 12 million turkeys. Meanwhile, in North Carolina, neighboring Sampson and Duplin counties are home to about 1,200 large hog operations and nearly 800 industrial-scale poultry farms—with more popping up every year. As if trying to boost those odds, the US livestock industry has chosen to place mammoth numbers of chickens in the very regions where hog farming is most concentrated. It doesn’t have to be this way. In February, Sen. Cory Booker (D-NJ) rolled out the Farm System Reform Act, which would place a moratorium on new and expanded factory-scale livestock facilities and devote $10 billion over a decade to promoting pasture-based models involving fewer animals. The bill has zero chance of passing in the current Congress, and faces an uphill climb anyway, given the power of the $296 billion meat industry. But such reform proposals offer a path to a future that should be broadly popular: one where we can enjoy our bacon—albeit less of it—­without ramping up the risk of unleashing the next pandemic pathogen. Looking for news you can trust? Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox. Close Thank you for subscribing! E32CB By signing up, you agree to our privacy policy and terms of use, and to receive messages from Mother Jones and our partners. DONALD TRUMP & DEMOCRACYMother Jones was founded to do journalism differently. We stand for justice and democracy. We reject false equivalence. We go after stories others don’t. We’re a nonprofit newsroom, because the kind of truth-telling investigations we do doesn’t happen under corporate ownership. And we need your support like never before, to fight back against the existential threats American democracy faces. Fundraising for nonprofit media is always a challenge, and we need all hands on deck right now. We have no cushion; we leave it all on the field. It’s reader support that enables Mother Jones to report the facts that are too difficult, expensive, or inconvenient for other news outlets to uncover. Please help with a donation today if you can—even a few bucks will make a real difference. A monthly gift would be incredible. DONATE NOW DONALD TRUMP & DEMOCRACYMother Jones was founded to do journalism differently. We stand for justice and democracy. We reject false equivalence. We go after stories others don’t. We’re a nonprofit newsroom, because the kind of truth-telling investigations we do doesn’t happen under corporate ownership. And we need your support like never before, to fight back against the existential threats American democracy faces. Fundraising for nonprofit media is always a challenge, and we need all hands on deck right now. We have no cushion; we leave it all on the field. It’s reader support that enables Mother Jones to report the facts that are too difficult, expensive, or inconvenient for other news outlets to uncover. Please help with a donation today if you can—even a few bucks will make a real difference. A monthly gift would be incredible. DONATE NOW More about:AgricultureAnimalsClimate ChangeCoronavirusCory BookerGreen New DealHealthHealth CareIowaMeatPandemic-Proofing America Related Blood, Soil, and Grass-Fed BeefEamon Whalen Industrial Hog Farms Are Breeding the Next PandemicTom Philpott Bird Flu Is Slamming Factory Farms But Sparing Backyard Flocks. Why?Tom Philpott The Renewable Energy Revolution Is UnstoppableEric Holthaus We Recommend Trump Puts the Father of Family Separation in Charge of Mass DeportationIsabela Dias What It’s Like to Be a Poll Worker With a DisabilityJulia Métraux Exclusive: RFK Jr. Is Crowdsourcing Cabinet Picks for TrumpKiera Butler Elon Musk’s “Election Integrity Community” Turns Its Attention to ArizonaJulianne McShane Latest Press Freedom Groups Warn of the Threat Posed by TrumpJulianne McShane A Cool New Ally in the Fight to Reduce Atmospheric Carbon: ChonkusSachi Kitajima Mulkey The Other Big Election Winners? Private Prisons.Julia Lurie This Week on Reveal: From Victim to SuspectJamilah King Sign up for our free newsletter Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox. Close Thank you for subscribing! E32CB By signing up, you agree to our privacy policy and terms of use, and to receive messages from Mother Jones and our partners. Get our award-winning magazine Save big on a full year of investigations, ideas, and insights. Subscribe Support our journalism Help Mother Jones' reporters dig deep with a tax-deductible donation. Donate RHC membership for blog posts view comments Mag Promo Independent. In print. In your mailbox. Inexpensive, too! Subscribe today and get a full year of Mother Jones for just $19.95. Subscribe December 2024 October 2024 August 2024 Bold. Brave. Beautiful. Award-winning photojournalism. Stunning video. Fearless conversations. Follow us on Instagram > Looking for news you can trust? Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox. Close Thank you for subscribing! E32CB By signing up, you agree to our privacy policy and terms of use, and to receive messages from Mother Jones and our partners. About Our Staff DEI&B Financials Careers Freelance Guidelines Contact Us Support Ways to Give Advertise With Us Licensing / Reprints Store Subscribe Magazine Subscriptions Give a Gift Subscription Email Newsletters Customer Service This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Privacy Manager Copyright © 2024 Mother Jones and the Center for Investigative Reporting. All Rights Reserved.Terms of Service Privacy Policy We Noticed You Have An Ad Blocker On. Can you pitch in a few bucks to help fund Mother Jones' investigative journalism? We're a nonprofit (so it's tax-deductible), and reader support makes up about two-thirds of our budget. We noticed you have an ad blocker on. Can you pitch in a few bucks to help fund Mother Jones' investigative journalism? Donate Not Now close Don't let an algorithm decide what news you see. Sign up for the free Mother Jones Daily newsletter and follow the news that matters. Close Thank you for subscribing! E32CBAvian Influenza A(H5N1) virus infections detected in cats in Poland Discover About FAO News Multimedia Main topics Statistics Members Publications English العربية 中文 Français Русский Español Share Close Animal health Areas of work Our programmes Animal diseases Highly pathogenic avian influenza Foot-and-mouth disease Situation updates FAO Reference Centres About Application and requirements Reporting News and Events News Stories Events Resources Publications Videos Webinars Tools Avian Influenza A(H5N1) virus infections detected in cats in Poland 29/06/2023 Avian Influenza A(H5N1) virus infections have been detected in domestic cats in Poland, according to a recent statement from the WOAH/FAO Network of Expertise on Animal Influenza (OFFLU). Multiple households across the country have reported unusual deaths of cats, drawing significant media attention. These concerning occurrences align with previous studies highlighting the vulnerability of both wild and domestic Felidae to Influenza A(H5N1) viruses, often contracted through the ingestion of infected wild bird carcasses. A report from the Polish Chief Veterinary Officer issued on 26 June 2023 revealed that nine out of 11 tested cats were confirmed to be infected with the Influenza A(H5N1) virus. The infection follows a severe and rapid course, consistent with previous cases in Felidae. Clinical signs include listlessness, loss of appetite, depression, fever, neurological symptoms, respiratory and gastrointestinal issues, jaundice, and even death. Symptoms typically manifest within a few days after exposure to the virus. Fatal cases of Influenza A(H5N1) in cats have been reported in Europe and North America, with exposure to infected wild birds or poultry as the likely modes of infection. Investigations are currently underway by Polish authorities to understand the outbreak, determine the links between cases, identify routes of exposure, conduct additional testing, and characterize the detected viruses. Initial reports suggest that direct transmission from infected wild birds may not be the primary source, and cat-to-cat transmission is unlikely. Infected cats are believed to shed the virus through the gut and respiratory tract, necessitating the isolation of suspected cases and the use of appropriate personal protective equipment. OFFLU will continue to closely monitor the situation and provide updated information. WeChat Follow us on FAO Organizational Chart Worldwide offices Regional Office for Africa Regional Office for Asia and the Pacific Regional Office for Europe and Central Asia Regional Office for Latin America and the Caribbean Regional Office for the Near East and North Africa Country Offices Jobs Contact us Terms and Conditions Data protection and privacy Scam Alert Report Misconduct Transparency and accountability © FAO 2024Influenza transmissibility among patients and health-care professionals in a geriatric short-stay unit using individual contact data | Scientific Reports Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement View all journals Search Log in Explore content About the journal Publish with us Sign up for alerts RSS feed nature scientific reports articles article Influenza transmissibility among patients and health-care professionals in a geriatric short-stay unit using individual contact data Download PDF Download PDF Article Open access Published: 29 June 2023 Influenza transmissibility among patients and health-care professionals in a geriatric short-stay unit using individual contact data Marie-Paule Gustin1, Laurent Pujo-Menjouet2 & Philippe Vanhems3 Scientific Reports volume 13, Article number: 10547 (2023) Cite this article 1098 Accesses 2 Altmetric Metrics details Subjects Dynamical systemsEpidemiologyInfectious diseasesPublic health AbstractDetailed information are lacking on influenza transmissibility in hospital although clusters are regularly reported. In this pilot study, our goal was to estimate the transmission rate of H3N2 2012-influenza, among patients and health care professionals in a short-term Acute Care for the Elderly Unit by using a stochastic approach and a simple susceptible-exposed-infectious-removed model. Transmission parameters were derived from documented individual contact data collected by Radio Frequency IDentification technology at the epidemic peak. From our model, nurses appeared to transmit infection to a patient more frequently with a transmission rate of 1.04 per day on average compared to 0.38 from medical doctors. This transmission rate was 0.34 between nurses. These results, even obtained in this specific context, might give a relevant insight of the influenza dynamics in hospitals and will help to improve and to target control measures for preventing nosocomial transmission of influenza. The investigation of nosocomial transmission of SARS-COV-2 might gain from similar approaches. Similar content being viewed by others Assessing respiratory epidemic potential in French hospitals through collection of close contact data (April–June 2020) Article Open access 14 February 2024 Regional patient transfer patterns matter for the spread of hospital-acquired pathogens Article Open access 09 January 2024 Investigating healthcare worker mobility and patient contacts within a UK hospital during the COVID-19 pandemic Article Open access 23 December 2022 IntroductionSeasonal influenza can cause critical illnesses, hospitalisation and even death, especially in the elderly and people with severe underlying diseases. Patients falling into these categories were shown to have about a 1.5 times higher risk of death related to influenza-like illness (ILI)1. According to the Canadian Nosocomial Infection Surveillance Program, the influenza A (H1N1) caused a sharp rise in the 30-day mortality attributable to influenza starting from 25 to 62% after the pandemic of 20092. The impact on medical costs is substantial while hospitalisation of influenza-confirmed patients lasted significantly longer compared with other patients (12.3 days vs. 24.7 h)3. During seasonal influenza, a large number of admitted influenza-confirmed patients with a subsequent long length of stay provide a favourable context for nosocomial transmission. This consequently needs appropriate control measures4,5.During flu season, nosocomial outbreaks of influenza are reported in different patient populations (i.e. in Intensive Care Units, in internal medicine wards, in surgery wards, in geriatric units) but also within health care professionals (HCP)5. Hospitalized influenza-infected patients lead to a significant amount of extra work for HCP for controlling potential viral spread and disorganisation of care might occur. Then, the contact patterns for care will influence the risk of transmission between patients and HCP but also within each population (patient, nurse or medical doctor).Models of transmission of healthcare associated infections will help to guide hospital infection control policies and to simulate the prevention effects6. Van Der Dool et al. used a stochastic agent-based model and contacts between HCP or patients in order to study i) the effect of vaccination of HCP on influenza infection among patients7 and ii) the effect of oseltamivir prophylaxis without and with resistant influenza virus strain8. With the same objectives, dynamic modelling, applied to COVID-19, was recently used in a hospital setting. Smith et al. analysed surveillance strategies against COVID-19 using agent-based model and electronically collected contact data from the I-Bird project in long-term care facility9,10.In a hospital environment, no one is expected to be equally in contact with every other individual: the contact rate between subjects will depend on their roles. Patients and HCP mixed differently because of their status and related daily tasks. Therefore, the potential transmissibility of influenza between patients and different categories of hospital staff has to be precisely quantified to suggest the best strategies to reduce the viral spread. Figure 1 illustrates the 9 possible ways an infection can be transmitted from a contagious individual towards a susceptible one during contact according to their roles: patients, nurses and medical doctors. These 9 transmission patterns could be estimated and written in a 3 × 3 "who acquires infection from whom" matrix of transmission rates (\(\beta\) matrix). It should be noted that transmission rates (\(\beta\)s) are derived from the number of contacts and the probability that the transmission of infection occurs when a susceptible and a contagious individual enter into contact (probability of transmission given contact). This probability varies according to the duration of the contact11.Figure 1Different types of contacts from a contagious individual towards a susceptible individual.Full size imageThe numbers of contact in a heterogeneous population are commonly estimated either from self-report logs, questionnaires, surveys7,8 or contacts recorded by proximity-sensing technology based on wearable sensors10,12,13. Some studies comparing methods have highlighted the most objective and exhaustive information provided by wireless sensors14,15,16. It has been shown that only 72% of short contacts (< 5 min) recorded by wireless sensors were actually reported by the participants16. In infectious disease modelling, the probability of transmission given contact is usually assumed17, drawn from the literature9 or fitted so that it is possible, from the model, to estimate a basic reproduction number \({R}_{0}\) compatible with those observed in the literature7.The objective of this pilot study was to develop a dynamical model that allows us to estimate the probability of transmission given contact directly from digital data of contact, recorded in a short-term Acute Care for the Elderly Unit during a 10 days period at the peak of the 2011–2012 influenza season. Various scenarios were tested. We analysed the best scenarios to predict the incidence number of influenza cases over the study period using a stochastic approach and a Susceptible-Exposed-Infectious-Removed (SEIR) model.ResultsStudy populationThis analysis relies on contact data collected by our group in a short-stay geriatric unit (20 beds)18 of a university hospital counting approximately 1,000 beds, located in Lyon, France. The study period was from Tuesday February 28, 2012 to Friday, March 9, 2012, during the peak of seasonal influenza in France19. The included data were recorded during the 10 days spanning from the 28th February 2012, at 1:00 a.m., to the 9th March 2012, at 1.00 a.m. Individuals were differentiated into 3 groups according to their role in the unit: patients (PAT), nurses (NUR) (nurses, nurses’ aides, a social counsellor and paramedical staff) and medical doctors (MD) (physicians and residents). They all received personal electronic badges to wear with an anonymous identification number.The study protocol is detailed elsewhere19. Briefly, nasopharyngeal swabs were systematically collected for influenza detection by polymerase chain reaction (PCR) at the beginning and the end of the study participation time for each individual. In the case of an individual presenting one or more symptoms usually associated with influenza-like infection (ILI), additional swabs were taken for patients and HCP at onset19. Age, gender, influenza vaccination status, presence of ILI were recorded. Each individual was identified by his or her badge number. The infectious periods, defined in Voirin et al.19 for each of the individuals having confirmed infections were taken into account during the 10-day study period.Table 1 shows the characteristics of the 3 observed groups. A total of 82 individuals took part in the study: 35 PAT and 47 HCP (32 NUR and 15 MD). All patients were 77 years old or older and 70% female. Their length of stay was 8.4 days on average with a median of 7 days. A total of 15 participants (10 PAT and 5 HCP) had confirmed influenza A (H3N2). Six individuals (3 PAT, 1 NUR and 2 MD) were prevalent contagious cases at the beginning of the study period. Four individuals contracted confirmed influenza during their stay or work schedule (3 PAT and 1 NUR). Nurses exhibited a vaccine coverage of 30%, MD 50% and PAT 55%.Table 1 Characteristics of participants according to their category: PAT (patients), NUR (nurses and paramedical staff) and MD (medical doctors: physicians and residents).Full size tableContact dataNetwork contact data were collected using Radio Frequency IDentification (RFID) technology referenced previously13,20. Badges were worn individually. The system was tuned so that pairwise face-to-face close encounters (less than 1 m) were recorded only when they lasted longer than 20 s (s). This setup was consistent with the real case scenario leading to respiratory virus transmission. However, in this setting, two people talking next to each other might not end up in a recorded contact. The duration of the contact might be underestimated as 51% of the contacts lasted only 20 s. The distribution of their duration is reported in Fig. 2 and Table 1 of the Supplementary Information page 5. This duration would be multiplied by a factor \(\left({f}_{\beta }\right)\) whose values would minimise the prediction quality of our model as explained in supplementary information pages 2 and 3. The starting and ending times of the events were recorded for each pair of established contacts. A total of 17,947 contacts were recorded during the study period with a recorded cumulative duration of 875,300 s (i.e. 243 h or 10.1 days). More detailed contact data were analysed in previous publications19,21.Figure 2Schematic links of disease transmission and diagram of all possible transitions between the states of a SEIR model for the 3 populations: patients (1), nurses (2) and medical doctors (3). Each square corresponds to a specific state: susceptible (S), exposed (E) i.e. infected but not yet contagious, (I) infectious i.e. contagious and Removed (R) i.e. immune. Solid arrows indicate transition between the states and dotted arrows the influence of contagious individuals on the rate of transmission. The subscripts "1", "2", and "3" denote the patient, nurse and medical doctor populations, respectively. The infection rate for population \(i\) is denoted by \({\lambda }_{i}\), the number of new patients entering into K2 unit (or leaving K2 unit) per day by \({z}_{1}\), the probability for patients of being in a contagious state on admission at time \(t\) by \(\phi\), the average duration of latent period in population \(i\) by \({\sigma }_{i}^{-1}\), and the average infectious period in population \(i\) by \({\gamma }_{i}^{-1}\). Patient population is stable and patients leaving K2 unit each day had same chance to be in any state.Full size imageTransitions between states using a SEIR modelInfluenza transmission in the ward is illustrated by a graphical representation of the possible transitions between different states (Fig. 2). An individual can be in 4 exclusive states: (1) Susceptible (at risk of contracting the disease), (2) Exposed to the virus (i.e. contaminated but not yet contagious), (3) Infectious (i.e. contagious) and (4) Removed (no longer able to become infected i.e. immune). Each state is represented by a compartment defining the so-called SEIR (Susceptible-Exposed-Infectious-Removed) model for each population (PAT/NUR/MD) and individuals could progress successively from one state to the next.Any susceptible individual \(i\) of any category (PAT, NUR, MD) can be infected by any contagious individual \(j\) of any category (PAT, NUR, MD) at a specific transmission rate \({\beta }_{ij}\) per day. The number of newly infected individuals depends on these beta rates. The computation of each element \({\beta }_{ij}\) of the \(\beta\) matrix is detailed in the "Method" section. We assumed no-change in the staff team during the short study period. In this first approach, we tried to keep the model as simple as possible. Then, we assumed that the random mixing inside each population and between two different ones was homogeneous, while possibly differing in vaccination status or exposition to precaution measures.Model parametersTable 2 summarizes the model parameters. We estimated some parameters from the 10-day observed data and others from contact data. The average daily number of patients in the ward was estimated at 13. A mean of 2 new patients \(\left({z}_{1}\right)\) entered the ward during the study and about 20% of them were already contagious. We considered that only 1/3 \(\left(\tau \right)\) of the susceptible HCP were on duty at the same time and then susceptible to become infected at the same time (data taken from HCP timetable, not shown here).Table 2 Definition of model parameters with their estimated value or their varying range.Full size tableFigure 3Matrices estimated from contact data and matrix of the transmission rates. (a) Daily average cumulative number \(\left({\overline{c} }_{ij}\right)\) of contacts for an \(i\)-individual in line with group (Gp) \(j\) in column whatever his or her state (susceptible, exposed, infectious/contagious or removed); (b) Average duration \(\left({T}_{ij}^{\#}\right)\) per "contagious" contact during the 10-day study period, i.e. between an \(i\)-susceptible (S-) individual and an \(j\)-infectious/contagious (I-) individual, expressed in second; (c) Transmission probability \(\left({P}_{ij}\right)\) matrix in case of "contagious" contact between two individuals (must be multiplied by 10–3) and (d) Average transmission rate per day for an \(i\)-susceptible (S-) individual in case of contact with any \(j\)-infectious (I-) individual over the 84 scenarios with a relative error less than 5% on the incidence cases number. Example of interpretation: (a) *A hospitalized patient had on average 22.17 contacts with nurses per day, (b) *A susceptible patient and a contagious nurse had contacts of 45 s on average, (c) *A susceptible patient had 1.17 × 10–3 chances of becoming infected in case of contact with a contagious nurse, (d) *A susceptible patient may be infected by any contagious nurse at a 1.04 rate i.e. every 23 h of "contagious" contact.Full size imageParameters derived from the contact dataTheir estimation is described in the "Method" section. The \(\beta\) matrix of transmission rates depends on the number and duration of contacts between individuals and on the probability of transmission given contact.Average contact number \({\overline{{{c}}} }_{{{i}}{{j}}}\) (Fig. 3a)The matrix of the daily average cumulative numbers of contact \({\overline{c} }_{ij}\) between an individual \(i\) from one of the 3 groups and all members of a group \(j\) is reported in Fig. 3a. For instance, based on this matrix, a hospitalized patient had an average of 22.17 contacts per day with nurses, whereas a nurse had an average of 10.81 contacts per day with patients. The amount of contact for an individual with a given group is specific to the category of both the individual and the group, as shown by an asymmetric matrix. The most frequent daily contacts (61.1 contacts) were within-nurses and the least frequent contacts (0.64 contact) were within-patients.Average contact duration \(\left({{{T}}}_{{{i}}{{j}}}^{\#}\right)\) (Fig. 3b)The matrix of the average duration per contact \(\left({T}_{ij}^{\#}\right)\) between a susceptible individual in population \(i\) and a contagious individual in population \(j\) is reported in Fig. 3b. The maximum average duration of these contacts is found to be between contagious MD and susceptible PAT.The probability of transmission given contact \(\left({\mathrm{P}}_{\mathrm{ij}}\right)\) (Fig. 3c)This probability of transmission \(\left({P}_{ij}\right)\) during a contact between an \(i\)-susceptible individual and an \(j\)-contagious individual was the highest (\(1.64 .{10}^{-3}\)) when a contagious MD met a susceptible PAT (Fig. 3c). These contacts are among the less frequent and the longest. HCP are more likely to transmit infection to PAT than getting one from PAT (\(1.64 .{10}^{-3}\) vs \(1.49 .{10}^{-3}\) for MD; \(1.17 .{10}^{-3}\) vs \(1.49 .{10}^{-3}\) for NUR). Nurses are more likely infected by their peers \(\left(1.49 .{10}^{-3}\right)\), whereas patients do not tend to infect each other \(\left(0.86 .{10}^{-3}\right)\).Choice of parametersSusceptibility and infectivity. The \(\beta\) matrix depends on the susceptibility and the infectivity of individuals according to their category. Since no medical doctors became infected during the study period, we considered their susceptibility \(\left({\alpha }_{3}\right)\) 2 to 4 times lower than the 1 default value \(\left({\alpha }_{3}=\left\{0.\mathrm{25,0.5}\right\}\right)\). We considered 0.5 besides the 1 default value for nurse susceptibility \(\left({\alpha }_{2}=\left\{\mathrm{0.5,1.0}\right\}\right)\). Patient susceptibility \(\left({\alpha }_{1}\right)\) could be 6 times higher than the 1 default value as explained in "Method" section "Discussion about Patient susceptibility" \(\left({\alpha }_{1}=\left\{\mathrm{2.0,4.0,6.0}\right\}\right)\). The ILI symptom attack rate in a patient who was in contact with contagious patients has been shown to be three times higher than the attack rate in a patient who was in contact with contagious HCP22 (supplementary information page 4). We considered the infectivity \(\left({\upvarepsilon }_{11}\right)\) of contagious patients towards susceptible patients to be between 1 and 3 in step 1 \(\left({\xi }_{11}=\left\{\mathrm{1.0,2.0,3.0}\right\}\right)\). During an epidemic, precaution measures are time-consuming for HCP23. An excessive workload, especially with elderly patients, might modify transmissibility if HCP are becoming less adherent to precaution measures. Besides the 1 default value, we fixed at 2 the infectivity \(\left({\xi }_{12}\right)\) of contagious nurses towards susceptible patients and the infectivity \(\left({\xi }_{13}\right)\) of medical doctors towards susceptible patients (i.e. \({\xi }_{12}=\left\{\mathrm{1.0,2.0}\right\}, {\xi }_{13}=\left\{\mathrm{1.0,2.0}\right\}\))23. We tested two opposite behaviours nurses might display while gathering together during pauses: a protective behaviour \(\left({\varepsilon }_{22}=0.5\right)\) or a careless \(\left({\varepsilon }_{22}=2\right)\) behaviour \(\left({\varepsilon }_{22}=\left\{\mathrm{0.5,1.0,2.0}\right\}\right)\). We only considered protective behaviours between medical doctors besides 1 value \(\left({\varepsilon }_{33}=\left\{0.25, 0.5, 1\right\}\right)\).We fixed the latent period to 0.5 days to limit the number of possible model parameter combinations (Table 2). Carrat et al.24 reported a strong increase in viral shedding between 0.5 and 1 day and a consistent peak at 2 days after the experimental influenza infection of healthy volunteers. We allowed infectious periods to vary from 1 to 4 days in step 1 so that the generation interval of influenza remains inside the different 95% credible intervals which were estimated by Beest et al. in various settings25. We assumed here that infectious period for patients varied independently of HCP infectious period.We conducted a factorial design by testing all combinations of the possible parameter values with a multiplicative coefficient set at 3, 4 and 5 in turn. This led to 62,208 different scenarios.Because of the small population in this hospital setting (13 patients per day, 35 nurses and 15 medical doctors with only one-third of HCP on duty at the same time), events chance can have a substantial effect. As such, a stochastic approach is required to include the role of chance in the transmission process. Therefore, we chose an event-driven approach to simulate the evolution of an influenza epidemic during the study period. We relied on the Gillespie algorithm for investigating the parameter combinations using the R package GillespieSSA (function ssa) developed by Mario Pineda-Krch26. In this context, the probabilities of transitioning between states change over time. They depend on the current state of the populations and on the transition rate between states per day. The different transitions (Fig. 2 red lines) and their rates are reported in Table 3. These transition rates were deduced from the underlying differential equations that are reported in Supplementary Information page 7. Gillespie algorithm updates the probabilities of transitioning between states and allows simulating the evolution of the 3 populations. Successive simulations with similar parameters give different results due to the randomness. Then, we replicated them 2,000 times to report the mean of new infectious individuals appeared during the 10 days. We performed a total of 2,000 times 62,208 simulations (around 125 million).Table 3 Description of model transitions and their rates.Full size tableQuality of the predictionFor each simulation, we counted the number of incident cases per category (PAT, NUR, MD). We retained the mean number of incident cases over the 2,000 simulations for each scenario as the predicted value. The quality of the model prediction for a given scenario was appreciated by comparing the observed incident cases number for each individual category19 with the simulated ones. The relative error was computed for each scenario ("Method" section for details). The minimum relative error was 28.8%, 3.6% and 1.9% for patient susceptibility of 2, 4 and 6, respectively. We retained the 84 scenarios that gave a relative error of less than 5%. Only 8 best scenarios had patient susceptibility of 4.Average transmission rate \(\left({{{\upbeta}}}_{{i}{j}}\right)\) (Fig. 3d)The \(\beta\) matrix of the mean transmission rates matrix over these 84 scenarios is reported in Fig. 3d. Nurses appear to transmit infection to patients more often than medical doctors with a daily transmission rate of 1.04 days versus 0.38 for medical doctors. This means that a transmission would occur in average every 23 h during contact between contagious nurses and susceptible patients. This 1.04 rate was about three times higher than the transmissibility among nurses (rate of 0.34) and the transmissibility from contagious medical doctors towards susceptible patients. The mean reproduction number from an infectious nurse towards susceptible patients \(\left({R}_{12}\right)\) was the largest among the 9 possible reproduction numbers (Supplementary Fig. 3).DiscussionThe earliest publication, that modelled influenza in a hospital setting, estimated the parameters of contact from observed contact behaviour and the probability of transmission given contact using the modelling of an influenza epidemic in the community7. In this pilot study, the model we developed in the specific context of a short-stay geriatric unit allowed us to derive this probability of transmission from documented contacts between non-infected and infected individuals. Our results suggest that elderly patients have more frequent contacts, but of shorter duration, with nurses compared to medical doctors. Nurses also meet each other more often and for longer duration than medical doctors between themselves. The comparison with other reported studies may be considered carefully. Indeed, these patterns may vary according to the clinical specialty of the ward10.Our results suggest that, although medical doctors were implicated in the transmission, nurses appeared to be more involved in the transmission of influenza to patients during the epidemic. The nurses encompassed nurses’ aides, a social counsellor and paramedical staff. That finding must be balanced by their essential role towards elderly patients with a necessity of close contacts in care and for humanized reasons. Nurses were less vaccinated against influenza than medical doctors (30% vs 50%). Bianchi et al. reported a 2017–2018 influenza vaccine coverage of 7% and 26% in nurses and in medical doctors, respectively, in Italy27. Influenza vaccine coverage was lower for nurses (42.9%), nurses assistants (26.7%) and paramedical staff (34.0%) than for medical doctors (75.5%) in nursing homes in France during the 2018–2019 influenza season28. This confirms that medical doctors tend to be more sensitive to vaccination campaigns over time than other health staff. The link between vaccination of HCP and the risk of nosocomial influenza in patients was reported in observational studies in France with a protective effect for patients according to the rate of vaccine coverage in HCP27,29. Thus, vaccination of HCP reinforced with infection control measures appeared to be a crucial key for protecting patients29. Our results may provide additional arguments for encouraging nurses to be vaccinated for themselves and for patients.Some limitations should be addressed. Our model was not stratified by age as the populations were quite homogeneous. Patients were old (age > 75, mean ± SD, 90 ± \(6\) years) and the mean for all HCP was 33 years (SD = 12). The potential age-based transmission effects for influenza might be tied up in the free infectivity parameter of each group.This model disregarded vaccination status, asymptomatic patients and documented potential isolation procedure for infected patients. We had no exhaustive data available for HCP vaccination status with 23% of missing information. The vaccine effectiveness might have not been optimal during the 2011–2012 influenza epidemic in France due to a large proportion of circulating antigenic variants that differed from the vaccine strains30. In addition, the vaccine effectiveness differed by individual characteristics (i.e. among elderlies with underlying diseases compared to HCP in good health). Then adjustment on the vaccine composition and the individual health status as well would add complexities for transmission modelling. However, how to mitigate the viral spread in hospitals taking vaccine exposure in populations into account is an excellent question to explore further.We may have missed some asymptomatic infected individuals because only the individuals (HCP, PAT) with at least one ILI symptom during the study participation were laboratory diagnosed. However, at the initial and distal PCR testing performed among all individuals, no asymptomatic came out. The mean length of follow-up of the patients in the ward during the 10 days study was 3.8 days with a median of 3 days, and only one out of the 3-nosocomial incident infected patients appeared asymptomatic.This being mentioned, we believe that we did miss very few asymptomatic patients. Besides, in a systematic review including 11 studies of outbreak investigations, the asymptomatic fraction of influenza virus infections ranged from 4 to 28% with a pooled mean of 16%31.Furthermore, a recent study reported a cumulative incidence of asymptomatic HCP of 47% in HCP with laboratory confirmed influenza during the 2016–2017 influenza season32. If we missed 50% of the asymptomatic nosocomial HCP, we should have 2 nosocomial infected HCP instead of 1 with a low impact. In addition, a community-based study from 2008 to 2014 reports that the mean levels of influenza viral RNA shedding in asymptomatic cases was lower than in symptomatic cases, its duration was shorter and declined more rapidly as well33. These findings suggest that asymptomatic individuals had lower potential for transmitting the virus than symptomatic ones. We did not think that adding one infected HCP would change very much our results, and thus we did not take them into account.A more sophisticated model incorporating various ranges of percentages of asymptomatic cases24,34 should be considered in a future work. Indeed, the infectivity of a given subject varies with time and is proportional to the viral load35. Here, to keep the model simple, we did not take into account these variations and only conserved one compartment for contagious subjects.The isolation protocols for patients, the precaution measures (hand hygiene, mask) and their respect were not collected during the study. However, the surveillance of nosocomial influenza is ongoing in this unit since 200422. Then, HCP are well trained and very aware on this risk. Consequently, taking isolation protocols into account would not have changed our conclusions substantially.A fourth population involved in the pattern of transmission would be the visitors. Because of the complexity of collecting valid information on contacts for this population (no badges), they were not included in the model of this pilot analysis.These limitations had less impact on the results with our model than with the classical ones for which the transmission of infection given contact is fixed. Here, the transmission of infection was computed from several free parameters to take the various populations and their contact patterns into consideration. A future study should thus be planned with serological confirmation influenza completed by systematic collection of vaccination data status and the precise timetable of HCP. More data and more sophisticated models should be collected and performed to validate these results. In addition, nosocomial viral respiratory infection caused by influenza or more recently by SARS-COV-2 will have major consequences including morbidity, access and organisation of care, length of stay and financial costs36,37,38,39. The transmission model results may be considered as strong contributions for proposing adapted preventive measures aiming to control viral spread in hospitals.MethodIn this section, we explained how the viral data were collected. We detailed the steps that allowed us estimating the matrix of the per capita transmission rates. We discussed the patient susceptibility according to the estimation of the number of transmissions per hour of "contagious" contacts.Virological dataNasopharyngeal swabs were taken to confirm influenza infection. These swabs were sent to the Southern French National Reference Laboratory for Influenza (Lyon, France) and were analysed for influenza A and B viruses by real-time polymerase chain reaction (PCR; Respiratory Multi-Well system R-gene®, Argene, Verniolle, France)19.Matrix of the per capita transmission rate \(\left({{\varvec{\upbeta}}}_{\mathbf{i}\mathbf{j}}\right)\) The coefficient \({\beta }_{ij}\) is the probability that a contagious individual of population \(j\) infects a susceptible individual of population \(i\) per day, and is defined as follows11.$${\beta }_{ij}={\overline{c} }_{ij}\times {\alpha }_{i}\times {\xi }_{ij}\times {P}_{ij} , (1)$$with \({\overline{c} }_{ij}\) denoting the average number of contacts per time unit for an individual in population \(i\) with all individuals in population \(j\); \({\alpha }_{i}\) the susceptibility of individuals in population \(i\); \({\xi }_{ij}\) the infectivity of contagious individuals in population \(j\) towards susceptible individuals in population \(i\), and \({P}_{ij}\) the probability of transmission per contact between a susceptible individual in population \(i\) and a contagious individual in population \(j\)11The default values for susceptibility and infectivity were 1. Patient \(\left({\alpha }_{1}\right)\), nurse \(\left({\alpha }_{2}\right)\) and medical doctor \(\left({\alpha }_{3}\right)\) susceptibilities, patient-patient infectivity \(\left({\xi }_{11}\right)\) and HCP infectivity \(\left({\xi }_{12},{\xi }_{22},{\xi }_{13}, {\xi }_{33}\right)\) towards patients or HCP were allowed to vary during the calibration process. The computation of \({\overline{c} }_{ij}\) and \({P}_{ij}\) are detailed below.The average number \({\overline{\mathbf{c}} }_{\mathbf{i}\mathbf{j}}\) The daily average cumulative number of contacts for a patient with population \(j\) is given by the following formula:$${\overline{c} }_{1j}=\frac{\sum_{k=1}^{{Np}_{1}}\left(\frac{\sum_{t=1}^{{L}_{k}}\sum_{m=1}^{{Np}_{j}}{c}_{kmt}}{{L}_{k}}\right)}{{Np}_{1}},$$with \({Np}_{1}\) denoting the number of patients (n = 35) included in the study and \({Np}_{2}\) or \({Np}_{3}\) the number of nurses (n = 32) or medical doctors (n = 15) on duty in the ward during the study period; \({L}_{k}\) the length of stay in days of the k-th patient and \({c}_{kmt}\) the number of contacts between the k-th patient and the m-th individual in population \(j\) on day \(t\).In the case of nurses and medical doctors, the formula was:$${\overline{c} }_{ij}=\frac{\sum_{k=1}^{{Np}_{i}}\sum_{m=1}^{{Np}_{j}}{c}_{km}}{{Np}_{i}\times {T}_{study}},$$with \({Np}_{i}={N}_{i}\) and \({c}_{km}\) denoting the number of contacts between the k-th individual in the case of nurses and medical doctors \(i\) and the m-th individuals in population \(j\) during the whole study period.Estimation of the probability \({\mathbf{P}}_{\mathbf{i}\mathbf{j}}\) of contact transmission Definition The transmission probability matrix \(\left({P}_{ij}\right)\) renders the probabilities \({P}_{ij}\) that a susceptible individual in population \(i\) became infected after a contact of duration \({T}_{ij}^{\#}\) with any contagious individual of population \(j\). The probability \({P}_{ij}\) was considered as a function of the contact duration \({T}_{ij}^{\#}\).$${P}_{ij}=1-{e}^{-{\upsilon }_{T}{T}_{ij}^{\#}}\approx {{\varvec{\upsilon}}}_{{\varvec{t}}{\varvec{r}}}{{\varvec{T}}}_{{\varvec{i}}{\varvec{j}}}^{\#}.$$ The probability \(\left({P}_{ij}\right)\) that at least 1 transmission occurs during a contact in time interval \({T}_{ij}^{\#}\) is \(\left(1-{e}^{-{\upsilon }_{T}{T}_{ij}^{\#}}\right)\) assuming the number of transmissions during a contact of \({T}_{ij}^{\#}\) duration follows a Poisson distribution of mean \(\left({\upsilon }_{tr}{T}_{ij}^{\#}\right)\), with \({\upsilon }_{tr}\) being the average number of transmissions per unit of "contagious" contact duration (seconds) between a susceptible \(i\) and a contagious \(j.\)Estimation of \({{\varvec{T}}}_{{\varvec{i}}{\varvec{j}}}^{\#}\) The contact duration \({{\varvec{T}}}_{{\varvec{i}}{\varvec{j}}}^{\#}\). was estimated by the average duration for each contact between all susceptible individuals in population \(i\) and all contagious individuals in population \(j\) during their contagious period:$${T}_{ij}^{\#}=\frac{1}{\sum_{k=1}^{{Ns}_{i}}\sum_{q=1}^{{Nf}_{j}}{n}_{kq}}\left(\sum_{k=1}^{{Ns}_{i}}\sum_{q=1}^{{Nf}_{j}}\sum_{c=1}^{{n}_{kq}}{d}_{kqc}\right),$$with \({Ns}_{i}\) denoting the number of individuals in population \(i\) who were susceptible; \({Nf}_{j}\) the number of individuals in population \(j\) who were contagious during the study period \(T\); \({n}_{kq}\) the number of contacts between the k-th individual in population \(i\) when he or she is susceptible and the q-th individual in population \(j\) during his or her infectious period, and \({d}_{kqc}\) the duration of each c-th "contagious" contact.Estimation of \({{\varvec{\upsilon}}}_{{\varvec{T}}}\) The number of transmissions per hour of "contagious" contact was estimated as follows:$${\upsilon }_{T}=\frac{{Nf}^{\#}}{{\sum }_{i=1}^{3}{\sum }_{j=1}^{3}\sum_{k=1}^{{Ns}_{i}}\sum_{q=1}^{{Nf}_{j}}\sum_{c=1}^{{n}_{kq}}{d}_{kqc}},$$with \({Nf}^{\#}\) the number of incident cases that became contagious during the study period. The average number \({\upsilon }_{T}\) of transmissions per time unit of "contagious" contacts was supposed to be independent of the category of the population in this computation. This unrealistic hypothesis would be counteracted by the varying susceptibility \(\left({\alpha }_{i}\right)\) across the three populations.Only 4 nosocomial infections (3 patients and 1 nurse) occurred during the study period and the total cumulative "contagious" contacts over all populations were 152,200 s. The number \({\upsilon }_{tr}\) of transmissions per hour was therefore approximately 0.095 \(\left(\frac{4\times \mathrm{3,600}}{\mathrm{152,200}}\right)\).Discussion about PATIENT susceptibilityThis number \({{\varvec{\upsilon}}}_{{\varvec{t}}{\varvec{r}}}\) of transmissions per hour of "contagious" contacts of 0.095 was considerably lower than those reported in the literature for influenza. In comparison, this number \({\upsilon }_{tr}\) was taken at 0.20 transmissions per hour of contact by Del Valle et al.11 in case of an influenza epidemic in the community and estimated at 0.56 per hour by Salathé et al.40 because it approximates the time-dependent attack rate in an outbreak of influenza aboard a commercial airliner41. This latter \({\upsilon }_{tr}\) value is approximately 6 times higher than our own. Indeed, we considered that the self-protective behaviour against influenza transmission adopted by the passengers aboard the airliner might be similar to hospitalized patient behaviour and less careful than HCP behaviour. By default, all individual susceptibility was fixed at 1 but patient susceptibility \(\left({\mathrm{\alpha }}_{1}\right)\) can reach 6 according to Salathé et al.40 The 2, 4 and 6 values were tested as the potential patient susceptibility in the model.Relative error of prediction per scenarioWe assessed the prediction power of the model for a given parameter set by comparing the average number of incident cases over 2,000 simulations with the observed case number per category of individuals as follows:$$RE\left(\%\right)=100\times \frac{\sum_{i=1}^{3}\left|{O}_{i}-\frac{{\sum }_{k=1}^{\mathrm{2,000}}{PN}_{ik}}{\mathrm{2,000}}\right|}{\sum_{i=1}^{3}{O}_{i}},$$with \(i\) denoting population \(i\) (1:PAT; 2:NUR; 3:MD); \({O}_{i}\) the Observed number of incident cases in population \(i\) during the 10-day study period and \({PN}_{ik}\) the average of the Predicted Number of incident cases in population \(i\) for the simulation \(k\) over all 2,000 simulations.Data analysisData analysis was performed using R language version 4.1.0 freely available at https://cran.r-project.org and Octave version 4.2.1 freely available at http://www.octave.org.Ethics and PrivacyAll participants signed an informed consent form after having acknowledged the details and aims of the study as explained elsewhere19. All experimental protocols were approved by the French national bodies responsible for ethics and privacy: the National Commission for Information Technology and Civil Liberties (http://www.cnil.fr) and the Committee for the Protection of Individuals (http://www.cppsudest2.fr) of the hospital of Lyon. All methods were performed in accordance with the relevant guidelines and regulations. Data availability The data and the source code that support the findings of this study are available from the corresponding author upon reasonable request. AbbreviationsILI: Influenza-like illness HCP: Health care professional SEIR: Susceptible-exposed-infectious-removed PAT: Patients NUR: Nurses MD: Medical doctors ReferencesPockett, R. D., Watkins, J., McEwan, P. & Meier, G. Burden of illness in UK subjects with reported respiratory infections vaccinated or unvaccinated against influenza: a retrospective observational study. PLoS ONE 10, e0134928 (2015).Article PubMed PubMed Central Google Scholar Mitchell, R. et al. Understanding the burden of influenza infection among adults in Canadian hospitals: A comparison of the 2009–2010 pandemic season with the prepandemic and postpandemic seasons. Am. J. Infect. Control 41, 1032–1037 (2013).Article PubMed Google Scholar Beysard, N., Yersin, B., Meylan, P., Hugli, O. & Carron, P.-N. Impact of the 2014–2015 influenza season on the activity of an academic emergency department. Intern. Emerg. Med. 13, 251–256 (2018).Article PubMed Google Scholar Vanhems, P., Bénet, T. & Munier-Marion, E. Nosocomial influenza: encouraging insights and future challenges. Curr. Opin. Infect. Dis. 29, 366–372 (2016).Article PubMed Google Scholar Vanhems, P. et al. Detection of hospital outbreaks of influenza-like illness based on excess of incidence rates compared to the community. Am. J. Infect. Control 42, 1325–1327 (2014).Article PubMed Google Scholar van Kleef, E., Robotham, J. V., Jit, M., Deeny, S. R. & Edmunds, W. J. Modelling the transmission of healthcare associated infections: A systematic review. BMC Infect. Dis. 13, 294 (2013).Article PubMed PubMed Central Google Scholar van den Dool, C., Bonten, M. J. M., Hak, E., Heijne, J. C. M. & Wallinga, J. The effects of influenza vaccination of health care workers in nursing homes: Insights from a mathematical model. PLoS Med. 5, e200 (2008).Article PubMed PubMed Central Google Scholar van den Dool, C., Hak, E., Bonten, M. J. M. & Wallinga, J. A model-based assessment of oseltamivir prophylaxis strategies to prevent influenza in nursing homes. Emerg. Infect. Dis. 15, 1547–1555 (2009).Article PubMed PubMed Central Google Scholar Smith, D. R. M. et al. Optimizing COVID-19 surveillance in long-term care facilities: A modelling study. BMC Med. 18, 386 (2020).Article CAS PubMed PubMed Central Google Scholar Duval, A. et al. Measuring dynamic social contacts in a rehabilitation hospital: Effect of wards, patient and staff characteristics. Sci. Rep. 8, 1686 (2018).Article PubMed PubMed Central ADS Google Scholar Del Valle, S. Y., Hyman, J. M., Hethcote, H. W. & Eubank, S. G. Mixing patterns between age groups in social networks. Soc. Netw. 29, 539–554 (2007).Article Google Scholar Stehlé, J. et al. Simulation of an SEIR infectious disease model on the dynamic contact network of conference attendees. BMC Med. 9, 87 (2011).Article PubMed PubMed Central Google Scholar Vanhems, P. et al. Estimating potential infection transmission routes in hospital wards using wearable proximity sensors. PLoS ONE 8, e73970 (2013).Article CAS PubMed PubMed Central ADS Google Scholar Leecaster, M. et al. Estimates of social contact in a middle school based on self-report and wireless sensor data. PLoS ONE 11, e0153690 (2016).Article PubMed PubMed Central Google Scholar Mastrandrea, R., Fournet, J. & Barrat, A. Contact patterns in a high school: A comparison between data collected using wearable sensors, contact diaries and friendship surveys. PLoS ONE 10, e0136497 (2015).Article PubMed PubMed Central Google Scholar Smieszek, T. et al. Contact diaries versus wearable proximity sensors in measuring contact patterns at a conference: Method comparison and participants’ attitudes. BMC Infect. Dis. 16, 341 (2016).Article PubMed PubMed Central Google Scholar Vanhems, P., Von Raesfeldt, R., Ecochard, R. & Voirin, N. Emergence of Ebola virus disease in a French acute care setting: A simulation study based on documented inter-individual contacts. Sci. Rep. 6, 36301 (2016).Article CAS PubMed PubMed Central ADS Google Scholar Régis, C. et al. Five years of hospital based surveillance of influenza-like illness and influenza in a short-stay geriatric unit. BMC Res. Notes 7, 99 (2014).Article PubMed PubMed Central Google Scholar Voirin, N. et al. Combining high-resolution contact data with virological data to investigate influenza transmission in a tertiary care hospital. Infect. Control Hosp. Epidemiol. 36, 254–260 (2015).Article PubMed Google Scholar Cattuto, C. et al. Dynamics of person-to-person interactions from distributed RFID sensor networks. PLoS ONE 5, e11596 (2010).Article PubMed PubMed Central ADS Google Scholar Oussaid, N. et al. Contacts between health care workers and patients in a short-stay geriatric unit during the peak of a seasonal influenza epidemic compared with a nonepidemic period. Am. J. Infect. Control 44, 905–909 (2016).Article PubMed Google Scholar Vanhems, P. et al. Risk of influenza-like illness in an acute health care setting during community influenza epidemics in 2004–2005, 2005–2006, and 2006–2007: A prospective study. Arch. Intern. Med. 171, (2011).Hessels, A. J. et al. Impact of infectious exposures and outbreaks on nurse and infection preventionist workload. Am. J. Infect. Control 47, 623–627 (2019).Article PubMed PubMed Central Google Scholar Carrat, F. et al. A ‘small-world-like’ model for comparing interventions aimed at preventing and controlling influenza pandemics. BMC Med. 4, 26 (2006).Article PubMed PubMed Central Google Scholar te Beest, D. E., Wallinga, J., Donker, T. & van Boven, M. Estimating the generation interval of influenza A (H1N1) in a range of social settings. Epidemiol. Camb. Mass 24, 244–250 (2013).Article Google Scholar Pineda-Krch, M. GillespieSSA: Implementing the stochastic simulation algorithm in R. J. Stat. Softw. 25, (2008).Bianchi, F. P. et al. Two years of on-site influenza vaccination strategy in an Italian university hospital: Main results and lessons learned. Hum. Vaccines Immunother. 18, 1993039 (2022).Article Google Scholar Vaux, S. et al. Influenza vaccination coverage of professionals working in nursing homes in France and related determinants, 2018–2019 season: A cross-sectional survey. BMC Public Health 22, 1049 (2022).Article PubMed PubMed Central Google Scholar Amour, S. et al. Effect of influenza vaccination among healthcare workers on hospital-acquired influenza in short-stay hospitalized patients: a multicenter pilot study in France. Infect. Control Hosp. Epidemiol. 1–5 (2022). https://doi.org/10.1017/ice.2022.68.Belchior, E. Surveillance épidémiologique, clinique et virologique de la grippe en France métropolitaine: Saison 2011–2012. Bull Epidémiol Hebd 38, 424–427 (2012). Google Scholar Leung, N. H. L., Xu, C., Ip, D. K. M. & Cowling, B. J. Review article: the fraction of influenza virus infections that are asymptomatic. Epidemiology 26, 862–872 (2015).Article PubMed PubMed Central Google Scholar Bénet, T. et al. Incidence of asymptomatic and symptomatic influenza among healthcare workers: A multicenter prospective cohort study. Clin. Infect. Dis. 72, e311–e318 (2021).Article PubMed Google Scholar Ip, D. K. M. et al. Viral shedding and transmission potential of asymptomatic and pauci-symptomatic influenza virus infections in the community. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciw841 (2016).Article PubMed PubMed Central Google Scholar Chao, D. L., Halloran, M. E., Obenchain, V. J. & Longini, I. M. FluTE, a publicly available stochastic influenza epidemic simulation model. PLoS Comput. Biol. 6, e1000656 (2010).Article MathSciNet PubMed PubMed Central ADS Google Scholar Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590–7599 (2006).Article CAS PubMed PubMed Central Google Scholar Pires, S. M. et al. Disability adjusted life years associated with COVID-19 in Denmark in the first year of the pandemic. BMC Public Health 22, 1315 (2022).Article CAS PubMed PubMed Central Google Scholar Kopanczyk, R., Kumar, N. & Papadimos, T. Post-acute COVID-19 syndrome for anesthesiologists: A narrative review and a pragmatic approach to clinical care. J. Cardiothorac. Vasc. Anesth. 36, 2727–2737 (2022).Article CAS PubMed Google Scholar Ashraf, M., Rajaram, S. & English, P. M. How the COVID-19 pandemic will shape influenza public health initiatives: The UK experience. Hum. Vaccines Immunother. 18, 2056399 (2022).Article Google Scholar Lui, J. N. M., Andres, E. B. & Johnston, J. M. Does seasonal influenza related hospital occupancy surge impact hospital staff sickness presenteeism and productivity costs?. Int. J. Environ. Res. Public. Health 19, 769 (2022).Article PubMed PubMed Central Google Scholar Salathé, M. et al. A high-resolution human contact network for infectious disease transmission. Proc. Natl. Acad. Sci. USA 107, 22020–22025 (2010).Article PubMed PubMed Central ADS Google Scholar Moser, M. R. et al. An outbreak of influenza aboard a commercial airliner. Am. J. Epidemiol. 110, 1–6 (1979).Article CAS PubMed Google Scholar Download referencesFundingThe contact data collection has been supported in part by the FINOVI Foundation (Lyon) and the INSERM IMI Pandemic Program. Editing The authors thank Peter Tucker, Danaé Paultre and Professor Glenn F. Webb for editing the manuscript. The authors received a financial support from Inria for the publication of this article.Author informationAuthors and AffiliationsDepartment of Public Health, Institute of Pharmacy, CIRI-Centre International de Recherche en Infectiologie, Inserm, U1111, CNRS, UMR 5308, ENS Lyon, Equipe PHIE3D, University Lyon, University Claude Bernard Lyon 1, 7 Rue Guillaume Paradin, 69372, Lyon, FranceMarie-Paule GustinUniversity of Lyon, University Claude Bernard Lyon 1, CNRS UMR5208, Inria, Dracula Team, Institut Camille Jordan, 69622, Villeurbanne, FranceLaurent Pujo-MenjouetHospices Civils de Lyon, Service Hygiène, CIRI-Centre International de Recherche en Infectiologie, Université Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Lyon, FrancePhilippe VanhemsAuthorsMarie-Paule GustinView author publicationsYou can also search for this author in PubMed Google ScholarLaurent Pujo-MenjouetView author publicationsYou can also search for this author in PubMed Google ScholarPhilippe VanhemsView author publicationsYou can also search for this author in PubMed Google ScholarContributionsM.-P.G. and L.P.-M conceived this work, its methodology, analysed the data, interpreted the results, wrote and revised the manuscript. P.V. was responsible for the study protocol, the data acquisition and revised the manuscript critically. Corresponding authorCorrespondence to Laurent Pujo-Menjouet.Ethics declarations Competing interests The authors declare no competing interests. Additional informationPublisher's noteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary InformationSupplementary Information.Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissionsAbout this articleCite this articleGustin, MP., Pujo-Menjouet, L. & Vanhems, P. Influenza transmissibility among patients and health-care professionals in a geriatric short-stay unit using individual contact data. Sci Rep 13, 10547 (2023). https://doi.org/10.1038/s41598-023-36908-5Download citationReceived: 24 August 2022Accepted: 12 June 2023Published: 29 June 2023DOI: https://doi.org/10.1038/s41598-023-36908-5Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative Download PDF Advertisement Explore content Research articles News & Comment Collections Subjects Follow us on Facebook Follow us on Twitter Sign up for alerts RSS feed About the journal About Scientific Reports Contact Journal policies Guide to referees Calls for Papers Editor's Choice Journal highlights Open Access Fees and Funding Publish with us For authors Language editing services Submit manuscript Search Search articles by subject, keyword or author Show results from All journals This journal Search Advanced search Quick links Explore articles by subject Find a job Guide to authors Editorial policies Scientific Reports (Sci Rep) ISSN 2045-2322 (online) nature.com sitemap About Nature Portfolio About us Press releases Press office Contact us Discover content Journals A-Z Articles by subject protocols.io Nature Index Publishing policies Nature portfolio policies Open access Author & Researcher services Reprints & permissions Research data Language editing Scientific editing Nature Masterclasses Research Solutions Libraries & institutions Librarian service & tools Librarian portal Open research Recommend to library Advertising & partnerships Advertising Partnerships & Services Media kits Branded content Professional development Nature Careers Nature Conferences Regional websites Nature Africa Nature China Nature India Nature Italy Nature Japan Nature Middle East Privacy Policy Use of cookies Your privacy choices/Manage cookies Legal notice Accessibility statement Terms & Conditions Your US state privacy rights © 2024 Springer Nature Limited Close banner Close Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Email address Sign up I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close banner Close Get the most important science stories of the day, free in your inbox. Sign up for Nature BriefingMini-antibodies given mighty powers can stave off influenza Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement View all journals Search Log in Explore content About the journal Publish with us Subscribe Sign up for alerts RSS feed nature research highlights article RESEARCH HIGHLIGHT 30 June 2023 Mini-antibodies given mighty powers can stave off influenza Complexes formed from ‘nanobodies’ and an antiviral drug halt infection in its tracks. Twitter Facebook Email Mice fend off influenza A (red, artificially coloured) and its close relative, influenza B, when dosed with an antibody–drug pairing. Credit: Mike Miller/SPL Access through your institution Buy or subscribe A dynamic duo comprising an antiviral drug joined to an antibody fragment provides strong protection against the two main types of influenza that infect humans, according to research in mice1. Access options Access through your institution Access through your institution Change institution Buy or subscribe Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 24,99 € / 30 days cancel any time Learn more Subscription info for Korean customersWe have a dedicated website for our Korean customers. Please go to natureasia.com to subscribe to this journal.Go to natureasia.comRent or buy this articlePrices vary by article typefrom$1.95to$39.95Learn morePrices may be subject to local taxes which are calculated during checkout Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support Nature 619, 11 (2023) doi: https://doi.org/10.1038/d41586-023-02090-x ReferencesLiu, X., Balligand, T., Carpenet, C. & Ploegh, H. L. Sci. Immunol. 8, eadg9459 (2023).Article PubMed Google Scholar Download references Subjects Medical research Latest on: Medical research This scientist treated her own cancer with viruses she grew in the lab News 08 NOV 24 Should Alzheimer’s be diagnosed without symptoms? Proposal to rely on blood tests roils scientists News 08 NOV 24 Blood test could help diagnose bipolar disorder — but some researchers are sceptical News 06 NOV 24 Jobs Professor/Associate Professor/Assistant Professor/Senior Lecturer/Lecturer The School of Science and Engineering (SSE) at The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen) sincerely invites applications for mul... Shenzhen, China The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen) Professor/Associate Professor/Assistant Professor/Senior Lecturer/Lecturer The School of Science and Engineering (SSE) at The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen) sincerely invites applications for mul... Shenzhen, China The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen) High-level Talent Recruitment dedicated to teaching & research College of Water Sciences, Beijing Normal University Beijing, China College of Water Sciences, Beijing Normal University Independent junior research group leader registration number: ZE-0104-mikrokos-nwgl-2024 Entry date: as soon as possible Application deadline: 2024-12-15 Salary: E 15 TV-H Duration: 3 year... 35037, Marburg (DE) Philipps-Universität Marburg Research associate (Postdoc) Registration number: fb20-0239-wmz-2024 Entry date: as soon as possible Application deadline: 2024-12-01 Salary: E 13 TV-H Duration: 2 years Volume... Marburg, Hessen (DE) Philipps-Universität Marburg Access through your institution Buy or subscribe Access through your institution Change institution Buy or subscribe Subjects Medical research Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up Close banner Close Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Email address Sign up I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close banner Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content Research articles News Opinion Research Analysis Careers Books & Culture Podcasts Videos Current issue Browse issues Collections Subjects Follow us on Facebook Follow us on Twitter Subscribe Sign up for alerts RSS feed About the journal Journal Staff About the Editors Journal Information Our publishing models Editorial Values Statement Journal Metrics Awards Contact Editorial policies History of Nature Send a news tip Publish with us For Authors For Referees Language editing services Submit manuscript Search Search articles by subject, keyword or author Show results from All journals Search Advanced search Quick links Explore articles by subject Find a job Guide to authors Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio About us Press releases Press office Contact us Discover content Journals A-Z Articles by subject protocols.io Nature Index Publishing policies Nature portfolio policies Open access Author & Researcher services Reprints & permissions Research data Language editing Scientific editing Nature Masterclasses Research Solutions Libraries & institutions Librarian service & tools Librarian portal Open research Recommend to library Advertising & partnerships Advertising Partnerships & Services Media kits Branded content Professional development Nature Careers Nature Conferences Regional websites Nature Africa Nature China Nature India Nature Italy Nature Japan Nature Middle East Privacy Policy Use of cookies Your privacy choices/Manage cookies Legal notice Accessibility statement Terms & Conditions Your US state privacy rights © 2024 Springer Nature LimitedDoctors concerned over rise in influenza-associated encephalitis in children - The Hindu India World Elections Technology e-Paper Menu Science Data Opinion SEARCH FREE TRIALGIFT a Subscription Subscribe LOGIN ACCOUNT PREMIUM Open in The Hindu AppFREE TRIALLOGINGIFT a Subscription ACCOUNT PREMIUM Subscribe Science Data Opinion SEARCH India World Elections Technology e-Paper Science Data Opinion SEARCH News Business Entertainment Life & Style Society Technology Videos Sport Cities States Science Show More Chennai Delhi Bengaluru Hyderabad Movies Food Children Data Kochi Books Education Podcast Brandhub To enjoy additional benefitsFREE TRIALGIFT a Subscription Subscribe LOGIN ACCOUNT PREMIUM ShowcaseSubscribe to NewslettersCrossword+CONNECT WITH US Home News India Kerala Doctors concerned over rise in influenza-associated encephalitis in children Clinicians began recognising the increase in neurological involvement in influenza cases in the State, following the reporting of a few sudden and unexpected deaths in young children in the last two months. Published - July 01, 2023 08:42 pm IST - ThiruvananthapuramC Maya Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit READ LATER Remove SEE ALL PRINTThe surge in H1N1 cases this epidemic season, followed by reports of increasing incidence of influenza-associated encephalitis/encephalopathy (IAE) in young children from across the State is emerging as a serious concern.Clinicians began recognising the increase in neurological involvement in influenza cases in the State, following the reporting of a few sudden and unexpected deaths in young children in the last two months.Influenza primarily presents as a mild respiratory disease. But neurological manifestations of influenza, especially due to the sub type A H1N1, are known to occur during outbreaks, and young children are the most vulnerable. The reported frequency of neurological complications in hospitalised children with influenza ranges from 1.7 to 15% in different studies, according to literature.Once the neurological involvement happens (altered consciousness is the commonest symptom), the infection has a rapid course with some children going into complete brain herniation and death in a matter of hours. Some miraculously make full recovery after intensive and prolonged ICU care but many survivors are left with severe neurological sequelae. Paediatricians said that all clinicians and primary care physicians in the periphery need to be made aware that if a child with fever has febrile seizures or is showing signs of altered consciousness, then he/she should be evaluated for influenza-associated encephalitis, even in the absence of respiratory symptoms.“In 2019 also we had noticed the increase in IAE in children. It is possible that many of these cases are being underreported or missed because in the majority of cases, it is impossible to isolate the influenza virus from cerebrospinal fluid. This has been the pattern world over also,” pointed out Sheeja Sugunan, Associate Professor of Paediatrics, SAT Hospital.Rapid progressionThe rapid manner in which the disease progresses once the brain is affected leaves little room for early intervention and management. The median time from onset of respiratory signs to onset of neurological symptoms could be as short as 24 hours or within five days. In a study conducted at SAT Hospital during the seasonal epidemic flu in 2019, doctors had reported cases of 16 children who had influenza-associated neurological manifestations and 44% were children less than two years of age. Intensive care management was required for 81% of children and the cause specific mortality was 18.75%. Ten children recovered completely without any neurological deficit.Focus on disease prevention“The normal incidence of IAE is one in one lakh population and we expect a mortality rate of 10 to 40%. Given the fact that the general outcome of IAE in children is uncertain or poor and that even some survivors may be left with long-term neurological damage, there is a lot of emphasis on disease prevention. Wearing masks is protective against all respiratory infections and this practice should be promoted during this flu season,” Dr. Sugunan said.The Health department has taken cognisance of the emerging concerns and the uncertainties that clinicians are facing in the field, in the early recognition and optimised management of children presenting with IAE. “There is an increase in IAE this season but there is no need to be alarmed. We are collecting data and reports from across the State and evaluating the situation because there is a clear variance in the nature of influenza this season. A State-wide training session with the Health department is being organised soon to evolve a consensus on clinical management of cases,” the President of Indian Association of Paediatrics, Kerala, O. Jose, said. Published - July 01, 2023 08:42 pm IST Read Comments Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit READ LATER Remove SEE ALL PRINTTop News Today0 / 0 Read in App The Hindu About Us Code of Editorial Values News Archive Sitemap Print Subscription Digital Subscription Subscribe to Newsletters Rss Feeds Readers Editor-Terms of Reference Authors & Contributors Frame Front page Contact us Contact Us Social Media Advertise With Us Group News Sites Business Line BL on Campus Sportstar Frontline இந்து தமிழ் திசை The Hindu Centre Young World Club The Hindu ePaper Business Line ePaper Crossword + Free Games Other Products RoofandFloor STEP Images Classifieds - Print Bookstore & Special Publications Popular Sections Elections Israeli–Palestinian conflict 2023 Latest News National News International News Videos Life & Style Food Podcast Showcase Opinion Editorial Columns Comment Cartoon Letters Interview Lead Business Agri-Business Industry Economy Markets Budget Sport Cricket Football Hockey Tennis Athletics Motorsport Races Other Sports Sci-Tech Science Technology Health Agriculture Environment Gadgets Internet States Andhra Pradesh Karnataka Kerala Tamil Nadu Telangana Cities Bengaluru Chennai Coimbatore Delhi Hyderabad Kochi Kolkata Kozhikode Madurai Mangaluru Mumbai Puducherry Thiruvananthapuram Tiruchirapalli Vijayawada Visakhapatnam Trending on The Hindu News Hamas Chief Yahya Sinwar killing LIVE Full list of Haryana ministers Kolkatan who returns to Durga Puja after 20 years EC to announce schedule for Maharashtra, Jharkhand polls Waqf row Did not want to blow up India ties: Justin Trudeau RSS, Togadia decide to work together to ‘unite’ Hindus Five Eyes support Canada India Canada row Trending on Group sites Stock Market Live Updates Stocks to buy today Hockey Mogun Bagan Paralympics 2024 Gold Rate Today Silver Rate Today Sexual Harassment in Telugu Film Industry Mango: The Michael Jackson of Fruits Frontline Current Issue Terms of Use Privacy Policy Copyright© 2024, THG PUBLISHING PVT LTD. or its affiliated companies. All rights reserved. BACK TO TOPSign in to unlock member-only benefits!Access 10 free stories every monthSave stories to read laterAccess to comment on every storySign-up/manage your newsletter subscriptions with a single clickGet notified by email for early access to discounts & offers on our products✕Looks like you are already logged in from more than 3 devices!To continue logging in, remove at least one device from the below listLog outLog Out from all devicesTerms & conditions | Institutional SubscriberCommentsComments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments. We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.SK Bioscience, Peter Doherty Institute Partner On Influenza Research | Contract Pharma Login Join FOLLOW: Subscribe Free Magazine eNewsletter Checkout Menu Magazine News Manufacturing Packaging Development Compliance Top 20 Directory Solution Center Events More Magazine News Manufacturing Packaging Development Compliance Top 20 Directory Solution Center Events Current / Back Issue Features Editorial Columns Digital Edition eNewsletter Archive Our Team Editorial Guidelines Subscribe Now Advertise Now Top Features Sustainability in Pharma: CDMOs Move Fast to Cut Carbon Footprint 25th Anniversary Retrospective Top 50 Biopharma Products Drive Growth in Contract Manufacturing Single-Use Systems for Biomanufacturing CEO Spotlight: Thierry Van Nieuwenhove Breaking News Online Exclusives Industry News Collaborations & Alliances Promotions & Moves Trials & Filings Financial Reports Bio News & Views Custom Sourcing News Packaging & Tracking CRO News Live From Shows Top News GenScript Establishes Operations Site & Logistics Center in Sydney, Australia Altimmune Appoints Chief Financial Officer Koneksa Names Chief Business Officer J&J's 3Q Revenue up 5% Global API Market Expected to See Steady Growth Through 2029 APIs Aseptic Processing Cleaning Validation Clinical Trial Materials Cytotoxics and High Potency Manufacturing Equipment Excipients Extractables and Leachables Facilities Fill/Finish Lyophilization Parenterals Process Development Process Validation Risk Management Scale-up/ Technology Transfer Solid Dosage/ Creams/ Ointments GenScript Establishes Operations Site & Logistics Center in Sydney, Australia Global API Market Expected to See Steady Growth Through 2029 Effects of Residual Carbon Content Matrix on Determining Pharma Regulated Elemental Impurities Accurate Determination of Resin Substitution in Solid Phase Peptide Synthesis Impurity Level Confirmation by Nuclear Magnetic Resonance (NMR) Spectroscopy Summary Capsules Cold Chain Management Injectables Logistics Serialization Solid Dosage / Semi-solids Supply Chain Vials Peli BioThermal Unveils Crēdo Vault for Bulk Pharma Shipments SIRIO Opens €16M Packaging Facility on German Site Aptar CSP’s N-Sorb Accepted to FDA’s Emerging Tech Program Nipro Launches D2F Glass Vials Using Stevanato's EZ-fill Technology Securing Sustainability Throughout the Pharmaceutical Supply Chain Analytical Services Bioanalytical Services Bioassay Developement Biologics, Proteins, Vaccines Biosimilars Chemistry Clinical Trials Drug Delivery Drug Development Drug Discovery Formulation Development Information Technology Laboratory Testing Methods Development Microbiology Preclinical Outsourcing R&D Toxicology Citius' LYMPHIR Shows Potential to Boost Pembrolizumab Efficacy Longeveron Taps Devin Blass as CTO and SVP of CMC Maravai LifeSciences to Acquire DNA & RNA Business of Officinae Bio Huons Acquires Stake in PanGen to Bolster Biopharma Business Asymchem Leverages AI to Optimize Protein Design with STAR Platform Filtration & Purification GMPs/GCPs Inspections QA/QC Regulatory Affairs Validation From Ambiguity to Action: The FDA’s New Nitrosamine Guidance Abzena to Expand Microbiology Lab Space to Support Biologic Manufacturing Lonza Completes Drug Product Services Facility Expansion in Basel Rottendorf Pharma Selects ValGenesis VLMS Sustainability in Pharma: CDMOs Move Fast to Cut Carbon Footprint Companies Categories Corporate Capabilities Add New Company Contract Service Directory Companies UBI Pharma Inc. CMC Pharmaceuticals Vetter Pharma International UI Pharmaceuticals INCOG BioPharma Services Companies News Releases Posters Brochures Services Videos Case Study White Papers Jobs Contract Service Directory Companies UBI Pharma Inc. CMC Pharmaceuticals Vetter Pharma International UI Pharmaceuticals INCOG BioPharma Services Webinars Live From Shows Magazine Current / Back Issue Features Editorial Columns Editorial Guidelines Subscribe Now Advertise Now Enewsletter Archive Digital Edition Directory Companies Categories Corporate Capabilities Add Your Company Manufacturing APIs Aseptic Processing Cleaning Validation Clinical Trial Materials Cytotoxics and High Potency Manufacturing Equipment Excipients Extractables and Leachables Facilities Fill/Finish Lyophilization Parenterals Process Development Process Validation Risk Management Scale-up/ Technology Transfer Solid Dosage/ Creams/ Ointments cGMP Manufacture Packaging Capsules Cold Chain Management Injectables Logistics Serialization Solid Dosage / Semi-solids Supply Chain Vials Development Analytical Services Bioanalytical Services Bioassay Developement Biologics, Proteins, Vaccines Biosimilars Chemistry Clinical Trials Drug Delivery Drug Development Drug Discovery Formulation Development Information Technology Laboratory Testing Methods Development Microbiology Preclinical Outsourcing R&D Toxicology Compliance Filtration & Purification GMPs/GCPs Inspections QA/QC Regulatory Affairs Validation Top 20 Pharma & BioPharma Contract Pharma Direct Breaking News Online Exclusives Slideshows Experts Opinions Surveys Outsourcing Survey Salary Survey Glossary Videos White Papers Podcasts Infographics Microsites Companies News Releases Posters Brochures Services Videos Case Study White Papers Contract Pharma Conference Contract Pharma Conference Speakers Exhibitors Conference Sessions eBook Webinars Events Industry Events Live from Show Events Webinars Classifieds / Job Bank Classifieds Job Bank About Us About Us Contact Us Advertise With Us Privacy Policy Terms of Use Breaking News SK bioscience, Peter Doherty Institute Partner on Influenza Research The program will include testing of anti-influenza compounds to identify new antivirals and the development of a new influenza vaccine platform. 06.27.23 SK bioscience, a global innovative vaccine and biotech company, signed a research collaboration agreement with the Doherty Institute for influenza research. Under this agreement, SK bioscience and the Doherty Institute will work together to further research influenza biology, vaccines, and antivirals. The program will include testing of anti-influenza compounds to identify new antivirals, capacity building in low- and middle-income countries of the region, and the development of a new influenza vaccine platform. SK bioscience plans to establish a proactive response system against influenza, advancing influenza vaccine R&D capability to contribute to public health on a global scale. Professor Sharon Lewin, Director of the Doherty Institute said, "Our organizations joining forces through our influenza projects is a significant milestone in our shared commitment to tackling infectious diseases and promoting public health. By collaborating with SK bioscience, we will strengthen our ability to respond to global challenges through exchanging knowledge and fostering innovation. Together, we will make a lasting impact in the prevention and treatment of infectious diseases, like influenza, around the world." Jaeyong Ahn, CEO of SK bioscience said "We expect a synergy combined with our capability in developing the world's first quadrivalent cell culture-based influenza vaccine and the infrastructure of the Doherty Institute, a leading research institution on global infectious diseases. We will strengthen global partnerships with various organizations and continuously expand cooperative areas to establish a response system against infectious disease pandemics in the world." Currently, SK bioscience cooperates with various global organizations and research institutions, including the Bill & Melinda Gate Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the International Vaccine Institute (IVI), Wellcome Trust, Hilleman Laboratories, and the International AIDS Vaccine Initiative (IAVI) under the common goal of promoting human health. Based on these cooperations, SK bioscience plans to establish an innovative system for developing vaccines against new infectious diseases within 100 days and supply them within six months around the world. Related Searches Biologics, Proteins, Vaccines Drug Development R&D Breaking News GenScript Establishes Operations Site & Logistics Center in Sydney, Australia Altimmune Appoints Chief Financial Officer Koneksa Names Chief Business Officer J&J's 3Q Revenue up 5% Global API Market Expected to See Steady Growth Through 2029 View Breaking News > CURRENT ISSUE October/November 2024 Sustainability in Pharma: CDMOs Move Fast to Cut Carbon Footprint 25th Anniversary Retrospective Top 50 Biopharma Products Drive Growth in Contract Manufacturing Single-Use Systems for Biomanufacturing CEO Spotlight: Thierry Van Nieuwenhove C-Suite Spotlight: Navin Molecular Securing Sustainability Throughout the Pharmaceutical Supply Chain Greening the Supply Chain: A CDMO Perspective Pioneering Production Cell for the Pharmaceutical and Biotech Industry Strategies for More Effective Human Factors Engineering for Injectables View More > Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies on our website by clicking on "More information”. Got It About Us Privacy Policy Terms And Conditions Contact Us follow us Subscribe Latest Breaking News From Nutraceuticals World Givaudan Becomes Authorized Distributor of Comet’s Arrabina Upcycled Fiber Kerry Health and Nutrition Institute Release 2025 Trends on Food, Beverage, Supplement Innovation PanTheryx Launches GLP-1 Support Product Latest Breaking News From Coatings World Clariant Launches Melamine-free Flame Retardant for Intumescent Coatings Protech Group Acquires Caldwell Chemical Coatings Asian Paints Reports 2Q 2024-25 Fiscal Results Latest Breaking News From Medical Product Outsourcing StimLabs's Umbilical Cord-Derived Wound Care Product Released in U.S. New Medical-Grade Bio-Based PVC Compounds Introduced Croívalve Reports 1st Tricuspid Coaptation Valve Implant in U.S. Feasibility Study Latest Breaking News From Contract Pharma GenScript Establishes Operations Site & Logistics Center in Sydney, Australia Altimmune Appoints Chief Financial Officer Koneksa Names Chief Business Officer Latest Breaking News From Beauty Packaging L'Oréal Groupe Promotes Innovation in China—and Celebrates Beauty Tech Winners Succession Drama is Uncovered at Estée Lauder Companies Weekly Recap: Neutrogena’s Partners, NAD Claims, Coty’s Sustainability Report & More Latest Breaking News From Happi Cosmetify Names Nikkie de Jager the World’s Most Powerful Beauty Influencer Big Lips in the Small Wonder L’Oréal’s Bioprinted Skin & Dove’s Deodorant Launch Latest Breaking News From Ink World Lars Schuetzenmeister Appointed MCC APAC Leader Weekly Recap: MNYPIA Slideshow, INX Adds C&A Top This Week’s Stories DuPont Reports Third Quarter 2024 Results Latest Breaking News From Label & Narrow Web MCC appoints new APAC leader HP wins big at Canadian Printing Awards Gala MAPP introduces private-brand portfolio of parts and consumables Latest Breaking News From Nonwovens Industry Unicharm Earns Science Based Target Initiative Approval Weekly Recap: Berry Completes Spin-Off and Merger with Glatfelter, Lenzing Expands Nonwovens Range Ahlstrom Reports Growing Net Sales Latest Breaking News From Orthopedic Design & Technology David Thordarson Takes Charge of American Orthopaedic Foot & Ankle Society UPM Biomedicals Launches FibGel Injectable Nanocellulose Hydrogel for Medical Devices ONWARD Medical Attracts €50 Million in Capital Latest Breaking News From Printed Electronics Now TechBlick's Online Innovations Festival Set for Dec. 11, 2024 Canatu Ranked by Deloitte Technology Fast 50 JAS Jet Air Service SPA Achieves Zero Error Count with Zebra’s RFID Solutions Copyright © 2024 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media. AD BLOCKER DETECTED Our website is made possible by displaying online advertisements to our visitors.Please consider supporting us by disabling your ad blocker. FREE SUBSCRIPTION Already a subscriber? LoginHuman gene identified that prevents most bird flu viruses moving to people | Medical research | The Guardian Skip to main contentSkip to navigationClose dialogue1/1Next imagePrevious imageToggle captionSkip to navigationPrint subscriptionsSearch jobs Sign inIntInternational editionUK editionUS editionAustralia editionEurope editionThe Guardian - Back to homeThe GuardianNewsOpinionSportCultureLifestyleShow moreHide expanded menuNewsView all NewsWorld newsUS elections 2024UK newsClimate crisisUkraineEnvironmentScienceGlobal developmentFootballTechBusinessObituariesOpinionView all OpinionThe Guardian viewColumnistsCartoonsOpinion videosLettersSportView all SportFootballCricketRugby unionTennisCyclingF1GolfUS sportsCultureView all CultureBooksMusicTV & radioArt & designFilmGamesClassicalStageLifestyleView all LifestyleFashionFoodRecipesLove & sexHealth & fitnessHome & gardenWomenMenFamilyTravelMoneySearch input google-search SearchSupport usPrint subscriptionsSearch jobsHolidaysDigital ArchiveGuardian LicensingAbout UsThe Guardian appVideoPodcastsPicturesNewslettersToday's paperInside the GuardianThe ObserverGuardian WeeklyCrosswordsWordiplyCorrectionsSearch input google-search SearchSearch jobsHolidaysDigital ArchiveGuardian LicensingAbout UsWorldUS elections 2024UKClimate crisisUkraineEnvironmentScienceGlobal developmentFootballTechBusinessObituaries Free range laying hens on a farm in Shropshire, England. Photograph: Ian Hinchliffe/AlamyView image in fullscreenFree range laying hens on a farm in Shropshire, England. Photograph: Ian Hinchliffe/AlamyAnimals farmedMedical research This article is more than 1 year oldHuman gene identified that prevents most bird flu viruses moving to people This article is more than 1 year oldDiscovery means targeted solutions can be directed to avian flu viruses sooner to prevent spillover into humans, say scientistsSupported byAbout this contentSophie KevanyWed 28 Jun 2023 16.00 BSTLast modified on Thu 29 Jun 2023 02.30 BSTShareScientists have discovered that a gene present in humans is preventing most avian flu viruses moving from birds to people. The gene is present in all humans and can be found in the lungs and upper respiratory tract, where flu viruses replicate. It was already known to scientists, but the gene’s antiviral abilities are a new discovery.A six-year investigative study led by the MRC-University of Glasgow Centre for Virus Research found that the BTN3A3 gene is a powerful barrier against most avian flu viruses.Although relatively rare, some avian flu virus strains have periodically spilled over into humans. Two of the most recent H5N1 cases were reported in UK poultry farm workers in May this year. Human cases of H5N1 bird flu were first found in Hong Kong in 1997. Globally since 2003, 873 human H5N1 infections have been reported to the World Health Organization. Of those, 458 people died.The study found that some bird and swine flu viruses have a genetic mutation that allows them to escape the blocking effects of the BTN3A3 gene and infect people. By tracking the history of human influenza pandemics and linking resistance to the gene with key virus types, the researchers concluded that all human influenza pandemics, including the 1918 Spanish flu and the 2009 swine flu pandemics, were a result of BTN3A3-resistant strains.The findings suggest that resistance to the gene could help determine whether flu strains have human pandemic potential or not. That may lead to testing of wild birds, poultry and other animals susceptible to flu viruses such as pigs, for BTN3A3-resistant viruses.“The antiviral functions of the [BTN3A3] gene appeared 40m years ago in primates,” said Prof Massimo Palmarini who led the study and is director of Glasgow’s virology research centre. “Understanding the barriers that block avian flu in humans means better targeted solutions and better control measures to prevent the spillovers.He said that if a gene-resistant virus was identified, “we can direct preventative measures to those viruses, sooner, to prevent the spillover [into humans]”.Dr Rute Maria Pinto, the study’s lead author, said: “It’s pretty amazing, isn’t it? We are all fairly proud about the outcome. This gene had been identified before, and other functions were attributed to it, but we found that the gene is antiviral against avian flu. No one had found that before.”She said the discovery was expected to have immediate practical applications. “Now, when we find cases of bird flu, we can basically swab sick birds, carcasses or faeces and find out whether the virus can overcome the BTN3A3 gene, simply by looking at its sequence and determining if this virus is more or less likely to jump into humans. If the virus can in fact overcome BTN3A3 then stricter measurements should be put in place to prevent spillovers.”Bird flu: H5N1 virus in Brazil wild birds prompts animal health emergencyRead morePinto added: “As a scientist we are expected to find solutions to problems, to give back to the taxpayers that fund this [research], and to find something that can be used straight away is really impactful.”The study was also able to retrospectively identify increases in gene-resistant viruses ahead of previous human spillovers.Before the H7N9 bird flu virus outbreak, which first infected humans in China in 2013, the study found “an increased frequency of the BTN3A3-resistant genotype [in birds] in 2011-2012”. To date there have been almost 1,570 cases of H7N9 and at least 616 deaths.“I guess what these observations provide is a snapshot of what the frequency of the BTN3A3 resistant gene was at different period of times in the birds,” Palmarini said. “Because birds haven’t got BTN3A3, there is no evolutionary pressure to keep, or not, those traits.”He said certain mutations “might make the virus more or less fitter in the birds” but this had not yet been studied.Similarly, before the 2009 H1N1 swine flu pandemic, the study found H1N1 gene resistance in pigs occurring between 2002 and 2006. The swine flu pandemic is estimated to have killed between 150,000 and 575,400 people during the first year the virus circulated in humans.Explore more on these topicsMedical researchAnimals farmedGeneticsBird fluBiologynewsShareReuse this contentMore on this storyMore on this storyBird flu outbreak confirmed at East Yorkshire poultry farm6d agoBird flu in pheasants in England sparks concern over lax rearing rules17 Oct 2024Risk of bird flu spreading to humans is ‘enormous concern’, says WHO 18 Apr 2024Northumberland’s Farne Islands reopen to visitors after bird flu outbreak27 Mar 2024Avian flu outbreak confirmed at vital seabird colonies in Wales20 Jul 2023RSPB calls for suspension of game-bird releases over avian flu fears18 May 2023Two poultry workers test positive for bird flu in England16 May 2023‘We feel more prepared’: Farne Islands face another season battling avian flu4 May 2023Most viewedMost viewedWorldUS elections 2024UKClimate crisisUkraineEnvironmentScienceGlobal developmentFootballTechBusinessObituariesNewsOpinionSportCultureLifestyleOriginal reporting and incisive analysis, direct from the Guardian every morningSign up for our emailHelpComplaints & correctionsSecureDropWork for us Privacy policyCookie policyTerms & conditionsContact usAll topicsAll writersDigital newspaper archiveTax strategyFacebookYouTubeInstagramLinkedInXNewslettersAdvertise with usSearch UK jobsBack to top© 2024 Guardian News & Media Limited or its affiliated companies. All rights reserved. (dcr)Momentum for Poolbeg and CytoReason’s AI collaboration - PharmaTimes Subscribe Advertise About us FollowFollowFollowFollow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs Momentum for Poolbeg and CytoReason’s AI collaboration by John Pinching | 29th Jun 2023 | News Partnership establishes several influenza therapy targets using artificial intelligence Partnership establishes several influenza therapy targets using artificial intelligence Poolbeg Pharma – a company concentrating on infectious conditions with a high unmet medical need – has announced a notable breakthrough in its world-first influenza artificial intelligence (AI) programme with CytoReason. Poolbeg has been collabroating with CytoReason since last year. Poolbeg’s disease progression data from across influenza human challenge trials – combined with CytoReason’s wider repositories of curated disease data – was studied using the AI-led platform. This analysis has led to the establishing of several novel drug targets for treating influenza. The discovery of such targets from the data-sets has had some previous success – ‘p38 MAP kinase’, inhibited by Poolbeg’s POLB 001 programme, was identified as a driver of severe influenza. It did, however, require manual analysis – a process that takes several years. In contrast, the incorporation of CytoReason’s cutting-edge AI technology has allowed Poolbeg to identify multiple novel drug targets in just 15 months. Furthermore, CytoReason’s analysis further confirmed the significance of the p38 MAP kinase pathway in influenza, providing increased validation for POLB 001. It also marks Poolbeg’s second successful AI project, following the identification of potential new candidates for respiratory syncytial virus (RSV), announced at the end of 2022. Poolbeg is now exploring the most impactful way to develop significant novel drug targets. David Harel, chief executive officer at CytoReason, explained: “Once again, we’re pleased to see that leveraging CytoReason’s computational disease models to extract insights from Poolbeg’s unique human challenge data can optimise the target discovery process. More importantly, these impressive results would not be possible without the commitment, transparency, and reciprocity of both teams.” Jeremy Skillington, chief executive officer of Poolbeg Pharma, reflected: “Our collaboration with CytoReason has put Poolbeg at the forefront of AI drug discovery. CytoReason’s deep interrogation of the uniquely rich data derived from human challenge trials has deepened our knowledge of influenza, resulting in the identification of multiple novel influenza drug targets.” He added: “There is a significant unmet need for new and better treatments for vulnerable patients with influenza and this is a major milestone in the delivery of new therapies that can improve patient outcomes and global health.” Tags AI | CytoReason | Poolbeg Related posts SMC recommends Yselty for treating uterine fibroids Nov 11, 2024 Scottish medicines consortium approves CAR T-cell therapy for blood cancer Nov 11, 2024 New study to assess mpox vaccine in pregnant women and infants Nov 7, 2024 Elsevier backs Pistoia Alliance for AI in drug discovery Nov 7, 2024 News alerts This field is required. Submit Latest content SMC recommends Yselty for treating uterine fibroids Scottish medicines consortium approves CAR T-cell therapy for blood cancer New study to assess mpox vaccine in pregnant women and infants Elsevier backs Pistoia Alliance for AI in drug discovery Arcellx to present positive data on multiple myeloma treatments Contact details PharmaTimes Media Ltd.Mansard HouseChurch RoadLittle BookhamLeatherheadSurrey KT23 3JG E: editorial@pharmatimes.comE: subscriptions@pharmatimes.comT: +44 (0)20 7240 6999F: +44 (0)20 7240 4479 Get the latest pharma news delivered to your inbox A valid email address is required. Subscribe for free Latest jobs from #PharmaRole Territory Sales Manager - North London & East AngliaChief Business OfficerTerritory Sales Manager - North London & East AngliaKAM - Transplant (12 month FTC) - North West, North East or ScotlandAccount Manager - ManchesterPrimary Care Immunisation Facilitator - Home basedNational Account Manager - Anti-infectives - Midlands/YorkshireBrand Manager - Fertility Supplements - WatfordHealthcare Partnership Manager - Northern EnglandSales Specialist - London and South East What job are you looking for? This field is required. Find jobs Download our apps Go to the App Store or Google Play and search for ‘PharmaTimes’ to download our free app. Content NewsMagazineAdvertiseContactCompetitions Connect FollowFollowFollowFollowFollow Legal Privacy Policy Terms and Conditions Editorial policy Cookies RSS – feed subscriptions © Copyright PharmaTimes Media Limited 2023Heard of ‘kindy flu’? There’s no such thing. But kids are at risk this flu season for one simple reason Menu Close Home Edition Africa Australia Brasil Canada Canada (français) España Europe France Global Indonesia New Zealand United Kingdom United States Edition: Available editions Global Africa Australia Brasil Canada Canada (français) España Europe France Indonesia New Zealand United Kingdom United States Get newsletter Become an author Sign up as a reader Sign in Search Academic rigour, journalistic flair Shutterstock Heard of ‘kindy flu’? There’s no such thing. But kids are at risk this flu season for one simple reason Published: June 25, 2023 9.04pm BST Asha Bowen, The Kids Research Institute Australia, Christopher Blyth, The University of Western Australia Authors Asha Bowen Program Head, The Kids Research Institute Australia Christopher Blyth Paediatrician, Infectious Diseases Physician and Clinical Microbiologist, Telethon Kids Institute, The University of Western Australia Disclosure statement Asha Bowen receives funding from National Health and Medical Research Council of Australia, and Medical Research Futures Fund of Australia. Christopher Blyth receives funding from the National Health and Medical Research Council of Australia, and Medical Research Futures Fund of Australia. He is a member of the COVID-19 Vaccines and Treatments for Australia – Science and Industry Technical Advisory Group and past member of the Australian Technical Advisory Group on Immunisation. Partners University of Western Australia provides funding as a founding partner of The Conversation AU. View all partners Email X (Twitter) Facebook LinkedIn WhatsApp Messenger The 2023 flu season may be one of Australia’s largest flu seasons on record, and doctors are concerned about the impact on children. You may have seen headlines warning parents about “kindy flu”. These can be misleading. This year’s flu virus does not “target” children. But during the 2023 flu season, children are particularly vulnerable for one important reason – low vaccination rates. We are concerned that fewer children have received their annual flu vaccine in 2023, compared to previous years. And it leaves them, and the wider community, at risk of flu and its complications. Read more: Explainer: what is the flu? How bad is it? In 2023, we are on track for a similar influenza season to 2019 – the largest influenza season on record in Australia. That’s when there were more than 300,000 recorded influenza cases. At the time of writing, we’ve had 107,941 recorded flu cases so far in 2023, and the flu season still has months to go. Of these, 48,873 cases have been in children under 15 years and 22,365 in those aged five to nine years. Since the flu season started in late April, children have made up almost 80% of those admitted to hospital across the country at sentinel surveillance sites. Many children’s hospitals are reporting high numbers of children hospitalised with flu. Sadly, one child has died of influenza, a three year old in Perth. These large case numbers come after low influenza case numbers seen earlier in the pandemic. Read more: Kids are more vulnerable to the flu – here's what to look out for this winter Why is this happening? The 2023 flu strains do not seem to be any more severe than in other years, according to a number of measures. In hospitals, the number of those admitted directly to intensive care (currently 7%) is similar to previous seasons. In the community, the number of those with flu-like illnesses needing to take time off regular duties is also similar. There is also no evidence the current strains circulating are more likely to infect children, or for them to infect others, compared with strains circulating in previous years. So something else must be going on. Home sick from work? You’re not alone. Shutterstock So what’s different in 2023? The single thing different to pre-pandemic years is the number of younger Australians not getting an influenza vaccine. In 2020, at this stage of the season, nearly 40% of children aged from six months to under five years were vaccinated, compared with just 20% currently. In those aged five to under 15 years, 25% were vaccinated in 2020 compared with just 12% now. This makes us worried. Young children, particularly those under five years, are the group most likely to be hospitalised with flu. Although children with underlying medical conditions – including chronic disorders of the heart, lungs, nervous and immune system – are most susceptible, more than half of children admitted to hospital each year with flu are otherwise healthy. While rare, flu deaths also occur in previously healthy children. We are also worried about influenza making children more vulnerable to secondary bacterial infections. These include invasive group A streptococcus and pneumococccal disease. Complications from flu can include invasive group A streptococcus infection. Meredith Newlove/CDC/WHO Another reason to get vaccinated Children have large volumes of virus in their nasal secretions and, after infection, shed this for days. They also have poorer hygiene practices, often coughing and spluttering over those closest to them. So children will quickly infect their parents, grandparents and younger siblings. Some will be at higher risk of getting unwell and being hospitalised, such as the elderly, the very young, First Nations people, and those with underlying medical issues including heart, lung, kidney and immune problems. Primary school-age children are the group that most frequently transmits flu in the community. In 2023, we expect the largest number of cases in the community to be in five to nine-year-olds. Read more: Should I get a flu vaccine this year? Here's what you need to know When to seek medical attention Flu in children commonly causes high temperatures, sore throats, miserable kids and a non-stop runny nose and cough. Most cases can be safely managed at home. But if you’re worried about your child during the flu season, seek medical advice, particularly if your child: has difficulty breathing (breathing rapidly or drawing in chest or neck muscles) is vomiting and refusing to drink is more sleepy than normal has pain that doesn’t get better with simple pain relief medication. And right now, before they get sick, book in your children for their annual flu vaccine. It prevents more than half of flu infections. And even if infected, vaccinated children are less likely to be hospitalised with it. Read more: Thinking about getting your child the flu vaccine? Here's what you need to know Children Public health Infectious diseases Influenza Flu Child health Kids Flu season Flu vaccines Events More events Jobs Lecturer / Senior Lecturer in Indigenous Knowledges Student Academic Misconduct Officer Commissioning Editor Nigeria Professor in Physiotherapy Postdoctoral Research Associate More jobs Editorial Policies Community standards Republishing guidelines Analytics Our feeds Get newsletter Who we are Our charter Our team Partners and funders Resource for media Contact us ​ ​ ​ Privacy policy Terms and conditions Corrections Copyright © 2010–2024, The ConversationFrontiers | Changing patterns of infectious diseases in children during the COVID-19 pandemic Skip to main content Top bar navigation Frontiers in Cellular and Infection Microbiology About us About us Who we are MissionValuesHistoryLeadershipAwardsImpact and progress Frontiers' impactProgress Report 2022All progress reportsPublishing model How we publishOpen accessFee policyPeer reviewResearch integrityResearch TopicsServices SocietiesNational consortiaInstitutional partnershipsCollaboratorsMore from Frontiers Frontiers ForumFrontiers Planet PrizePress officeCarbon footprintCareer opportunitiesContact us All journalsAll articles Submit your research Search Frontiers in Cellular and Infection Microbiology Sections Sections Adaptive immunity in infectionAntibiotic Resistance and New Antimicrobial drugsBacteria and HostBiofilmsClinical Infectious DiseasesClinical MicrobiologyExtra-intestinal MicrobiomeFungal PathogenesisIntestinal MicrobiomeMicrobes and Innate ImmunityMicrobial VaccinesMolecular Bacterial PathogenesisMolecular Viral PathogenesisOral Microbes and HostParasite and HostVeterinary and Zoonotic InfectionVirus and Host ArticlesResearch TopicsEditorial board About journal About journal Scope Field chief editorsMission & scopeFactsJournal sectionsOpen access statementCopyright statementQualityFor authors Why submit?Article typesAuthor guidelinesEditor guidelinesPublishing feesSubmission checklistContact editorial office About us About us Who we are MissionValuesHistoryLeadershipAwardsImpact and progress Frontiers' impactProgress Report 2022All progress reportsPublishing model How we publishOpen accessFee policyPeer reviewResearch integrityResearch TopicsServices SocietiesNational consortiaInstitutional partnershipsCollaboratorsMore from Frontiers Frontiers ForumFrontiers Planet PrizePress officeCarbon footprintCareer opportunitiesContact us All journalsAll articles Submit your research Frontiers in Cellular and Infection Microbiology Sections Sections Adaptive immunity in infectionAntibiotic Resistance and New Antimicrobial drugsBacteria and HostBiofilmsClinical Infectious DiseasesClinical MicrobiologyExtra-intestinal MicrobiomeFungal PathogenesisIntestinal MicrobiomeMicrobes and Innate ImmunityMicrobial VaccinesMolecular Bacterial PathogenesisMolecular Viral PathogenesisOral Microbes and HostParasite and HostVeterinary and Zoonotic InfectionVirus and Host ArticlesResearch TopicsEditorial board About journal About journal Scope Field chief editorsMission & scopeFactsJournal sectionsOpen access statementCopyright statementQualityFor authors Why submit?Article typesAuthor guidelinesEditor guidelinesPublishing feesSubmission checklistContact editorial office Frontiers in Cellular and Infection Microbiology Sections Sections Adaptive immunity in infectionAntibiotic Resistance and New Antimicrobial drugsBacteria and HostBiofilmsClinical Infectious DiseasesClinical MicrobiologyExtra-intestinal MicrobiomeFungal PathogenesisIntestinal MicrobiomeMicrobes and Innate ImmunityMicrobial VaccinesMolecular Bacterial PathogenesisMolecular Viral PathogenesisOral Microbes and HostParasite and HostVeterinary and Zoonotic InfectionVirus and Host ArticlesResearch TopicsEditorial board About journal About journal Scope Field chief editorsMission & scopeFactsJournal sectionsOpen access statementCopyright statementQualityFor authors Why submit?Article typesAuthor guidelinesEditor guidelinesPublishing feesSubmission checklistContact editorial office Submit your research Search Download article Download PDF ReadCube EPUB XML (NLM) Share on Export citation EndNote Reference Manager Simple Text file BibTex 4,8K Total views 1,5K Downloads 24 Citations Citation numbers are available from Dimensions View article impact View altmetric score Share on Edited by Yasir Waheed Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU), Pakistan Reviewed by Victor Daniel Miron Carol Davila University of Medicine and Pharmacy, Romania Table of contents Abstract1 Introduction2 SARS-CoV-2 infection and reinfection in children3 "Declines" in infectious diseases in children during the early COVID-19 pandemic4 Immune debt and resurgence of infectious diseases during the current COVID-19 pandemic5 DiscussionAuthor contributionsFundingConflict of interestPublisher’s noteReferences Export citation EndNote Reference Manager Simple Text file BibTex Check for updates Download article Download Download PDF ReadCube EPUB XML (NLM) MINI REVIEW article Front. Cell. Infect. Microbiol., 29 June 2023 Sec. Clinical Microbiology Volume 13 - 2023 | https://doi.org/10.3389/fcimb.2023.1200617 This article is part of the Research Topic COVID-19 Crisis Creates Opportunity towards Global Monitoring & Surveillance View all 6 articles Changing patterns of infectious diseases in children during the COVID-19 pandemic Ming-Chun Yang1,2†Yu-Tsun Su1,3†Ping-Hong Chen1Ching-Chung Tsai1,3Ting-I Lin1Jiunn-Ren Wu1*1Department of Pediatrics, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan2School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan3School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, TaiwanEach infectious disease has had its own epidemic pattern and seasonality for decades. However, public health mitigation measures during the coronavirus disease 2019 (COVID-19) pandemic have resulted in changing epidemic patterns of infectious diseases. Stringent measures resulted in low incidences of various infectious diseases during the outbreak of COVID-19, including influenza, respiratory syncytial virus, pneumococcus, enterovirus, and parainfluenza. Owing to the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and subsequent immunity development, decreasing virulence of SARS-CoV-2, and worldwide immunization against SARS-CoV-2 in children beyond 6 months of age, mitigation measures are lifted country by country. Consequently, the immunity debt to infectious respiratory viruses other than SARS-CoV-2 contributed to the “off-season,” “see-saw,” and “upsurge” patterns of various infectious diseases in children. Moreover, apart from the persistence of SARS-CoV-2, the coexistence of other circulating viruses or bacterial outbreaks may lead to twindemics or tripledemics during the following years. Therefore, it is necessary to maintain hand hygiene and immunization policies against various pathogens to alleviate the ongoing impact of infectious diseases on children.1 IntroductionThe coronavirus disease 2019 (COVID-19) pandemic has increased worldwide since the beginning of 2020, resulting in devastating medical and economic impacts. Globally, countries have adopted various response strategies to slow the spread of COVID-19 (Su et al., 2021). These mitigation measures not only influenced transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also resulted in changing patterns of infectious diseases, especially those transmitted by respiratory pathogens. Since the beginning of the COVID-19 pandemic, severity of COVID-19-related illness, mutation of SARS-CoV-2 variants, and prevalence of other respiratory viruses and their relevant diseases change continuously. Here, we synthesized the current knowledge on epidemiological features regarding the trends of SARS-CoV-2 infection and other infectious diseases in children during the COVID-19 pandemic.2 SARS-CoV-2 infection and reinfection in children2.1 Changing severity in children with SARS-CoV-2 infectionAlthough the COVID-19-related symptoms and prognosis are better in children than in adults (Ludvigsson, 2020), COVID-19 has an unneglectable impact on children. The major SARS-CoV-2 variants evolved from pre-Alpha, Alpha, and Delta, to Omicron (Mattiuzzi and Lippi, 2022). The hospital admission rate in children with COVID-19 varies widely and is influenced by the evolving SARS-CoV-2 dominant variants, healthcare system availability, and different age groups and immunization status. At the beginning of the COVID-19 pandemic in 2020, multinational studies from Europe and China revealed that 51–62% of children required hospital admission, 7–8% required intensive care unit (ICU) admission, and 4% required mechanical ventilation (Götzinger et al., 2020; Bhuiyan et al., 2021). Clinical severity in children has considerably changed over time, after the initiation of immunization programs and evolution of SARS-CoV-2 variants. By 2021, most children had mild symptoms (58%) or were asymptomatic (36%) (Say et al., 2021). Following the extension of immunization to infants aged >6 months, hospitalization rates declined to 0.02–0.2% in fully vaccinated children (González et al., 2022; Tan et al., 2022). Thereafter, hospitalization rates stabilized and remain low to date.2.2 SARS-CoV-2 reinfection in childrenChildren who recovered from COVID-19 generated a robust immune response and developed protective immunity. A meta-analysis concluded an 87% reduction in SARS-CoV-2 reinfection in those previously infected compared to those who were never infected (Deng et al., 2022). Moreover, even though children and adolescents were either asymptomatic or experienced only mild symptoms during their first SARS-CoV-2 infections, all participants demonstrated seropositive SARS-CoV-2-specific antibodies. Although the antibody titer in these children was low compared to that in adults, 92% still exhibited virus-neutralizing activity, which may protect them from reinfections (Szépfalusi et al., 2021). Interestingly, SARS-CoV-2 antibody titers did not differ between asymptomatic and symptomatic children (Maier et al., 2022). In addition to humoral immunity, IgA antibodies play a role in mucosal immunity by eliminating viral replication and reducing the risk of reinfection (Zohar and Alter, 2020). Asymptomatic infections are more common in children (Yasuhara et al., 2020), and the trend of receiving SARS-CoV-2 testing is gradually decreasing (Park et al., 2023). As of August 2022, a national commercial laboratory seroprevalence study demonstrated that approximately 86% of children and adolescents in the US had serologic evidence of previous SARS-CoV-2 infection (Son et al., 2023).The risk and picture of SARS-CoV-2 reinfection are changing, and the emergence of new variants can partially evade immunity from previous infection or vaccination (Milne et al., 2021). The risk of reinfection increases with age in infants, children, and adolescents (Mensah et al., 2022; Medić et al., 2023). A previous study reported a J-shaped curve of antibody titers with respect to age after the first SARS-CoV-2 infection. Antibody titers were lowest among adolescents and young adults, higher in younger children, and highest among older adults (Maier et al., 2022). The J-shaped distribution of antibodies may partly explain the high risk of reinfection in adolescents.Fortunately, the risk of symptomatic COVID-19 reinfection was lower in seropositive children, whose relative risk of being symptomatic was reduced to 36–51% (Kubale et al., 2022). Although moderate and severe cases could still occur in reinfection, there was no difference in severity between first and second infections (Kubale et al., 2022). Therefore, recurrent infection was not a risk factor for severe COVID-19.3 "Declines" in infectious diseases in children during the early COVID-19 pandemic3.1 Declines in RSV, influenza, and other viral infectionsDuring the first wave of the COVID-19 pandemic, public health measures were strictly applied, including social distancing, increased awareness of wearing masks, reinforced hand hygiene, reduced contact between children, maintaining ventilation, containment, curfew, and closure of schools and daycare centers. Implementation of public health measures led to abrupt declines in human respiratory syncytial virus (RSV) and influenza infections worldwide in 2020 and 2021 due to a reduction in the circulation of respiratory viruses, with a reported reduction in infection rates of up to 98–99% (Baker et al., 2020; Feng et al., 2021; Stamm et al., 2021; Stera et al., 2021; van Summeren et al., 2021; Yeoh et al., 2021; Binns et al., 2022; Zhang et al., 2023). Declines in RSV and influenza and reduced transmission of other respiratory viral pathogens, including common human coronavirus, parainfluenza viruses, human metapneumovirus, adenovirus, rhinovirus, and enterovirus have been observed in the US (Olsen et al., 2021; Rankin et al., 2023).Bruggink et al. also reported a significant reduction in enterovirus infections during the 2020 early COVID-19 pandemic period in Australia. Mitigation measures resulted in an 84.2% reduction in enterovirus specimen positivity rate compared to previous decades, as the number of tested specimens did not differ appreciably in 2020 from that during 2010–2019 (Bruggink et al., 2021).3.2 Declines in pneumococcal and other bacterial infectionsThe incidence of invasive diseases due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis in early 2020 was significantly reduced in 26 countries (Brueggemann et al., 2021). Furthermore, the number of invasive pneumococcal disease (IPD) cases in children in Spain in 2020 decreased by 65% compared to 2018–2019 (Ciruela et al., 2022). Similarly, pneumococcal infections among children in China showed a decreasing trend during the 2020 early COVID-19 pandemic period (Li et al., 2022). Interestingly, studies from Israel, France, and Belgium reported that even though pneumococcal infection reduced strongly in 2020 and early 2021, pneumococcal carriage in young children declined only slightly during the pandemic (Willen et al., 2021; Danino et al., 2022; Rybak et al., 2022). Therefore, the major explanation for the reduced pneumococcal disease was the full suppression of co-pathogens that can lead to secondary pneumococcal infections, including RSV, influenza viruses, and human metapneumovirus, instead of the decreased number of pneumococcal carriages (Willen et al., 2021; Danino et al., 2022; Rybak et al., 2022). A reduction in Haemophilus influenzae infections in children has also been reported in China. The positivity rates of H. influenzae infection in children with respiratory tract infections in 2020 (6.21%) and 2021 (7.37%) were lower than those in 2018 (11.28%) and 2019 (10.16%) (Zhou et al., 2023).3.3 "Declines" in other infectious diseaseAn epidemiological and observational study in Northern Italy revealed a reduction in the prevalence of chickenpox, scarlet fever, pertussis, mumps, rubella, and measles in children (Belingheri et al., 2021). A report from the European Centre for Disease Prevention and Control also demonstrated that the number of measles cases declined in European Union countries and the United Kingdom in 2020 (Nicolay et al., 2020). Moreover, data from the China Disease Prevention and Control Information System showed a significant decrease in the number of varicella, measles, and rubella infections in 2020 (Wu et al., 2020).Furthermore, the annual number of community-acquired infectious diseases among children in France decreased by one-third in 2020 compared to 2018 and 2019, including scarlet fever, acute tonsillopharyngitis, enteroviral infections, acute bronchiolitis, and gastroenteritis (Cohen et al., 2022). The incidence of acute otitis media, acute bronchiolitis, and croup also decreased among children in the US during the 2020 COVID-19 pandemic (Kaur et al., 2021).The volume of pediatric emergency department visits and admissions also declined throughout the COVID-19 pandemic (DeLaroche et al., 2021; Moynihan et al., 2021; Miron et al., 2022b). A comprehensive systematic review further documented a 37% reduction in overall healthcare services, encompassing a 42% and 28% decrease in visits and admissions, respectively (Moynihan et al., 2021).3.4 Declines in infectious diseases in TaiwanCountry-based mitigation measures in Taiwan successfully delayed the COVID-19 epidemic until May 2022. Implementing mitigation measures also contributed to a decrease in the burden of other infectious diseases to hospitals. A report from Taiwan suggested an approximately 50% reduction in pediatric patient volume per hour at the emergency department between February 2020 and January 2021 compared with the pre-COVID-19 period (February 2019 to January 2020). The most obvious drop was noted for infectious diseases, especially influenza and enterovirus infections (Huang et al., 2022). The general population of Taiwan is approximately 23 million. According to the Taiwan CDC report (Figure 1), there was a 95–98% reduction in the rate of influenza-related critical illnesses in 2021–2022 compared to 2013–2019. The incidence of IPD, pertussis, enterovirus-related critical illness, measles, mumps, and rubella also decreased significantly during the COVID-19 pandemic. However, the tuberculosis incidence has declined annually since 2013 with a steady rate of de-escalation of 1,000 cases every two years, from 11,528 cases in 2013 to 6,387 in 2022; this change rate did not differ before and after the COVID-19 pandemic. Conversely, there was no decline in Legionella pneumonia infection rates, which steadily increased over the past decade, from 115 cases in 2013 to 382 in 2022 (Taiwan Centers for Disease).FIGURE 1 Figure 1 The incidence of various infectious diseases in Taiwan before (2013–2019) and during (2020–2022, light yellow box) the COVID-19 pandemic. (A, B) Annual reported cases of invasive pneumococcal diseases, influenza-associated critical illnesses, mumps, enterovirus-associated critical illnesses, pertussis, measles, and rubella in Taiwan from 2013–2022 are shown. The annual incidence dropped dramatically in 2020–2022 during the COVID-19 pandemic. (C) Annual tuberculosis cases decreased at a steady rate during the past 10 years, and the slope of 2020–2022 did not differ from the slope of 2013–2019 significantly. In contrast, the number of Legionella cases has steadily increased over the past 10 years. (D) Annual cumulative number of invasive pneumococcal diseases, influenza-associated critical illnesses, mumps, enterovirus-associated critical illnesses, pertussis, measles, and rubella significantly decreased from 2020 to 2022.4 Immune debt and resurgence of infectious diseases during the current COVID-19 pandemicThe lack of exposure to various infectious pathogens in children during the COVID-19 pandemic lockdown has an impact on their developing immunity. The paucity of protective immunity raises concerns regarding susceptibility to infectious diseases, the so-called immunity debt. Previously, an immunity debt was observed during the 2009 H1N1 influenza pandemic on RSV seasonality. Delayed onset of the RSV epidemic occurred initially, followed by a subsequent surge in the following year (Li et al., 2021).4.1 “Off-season,” “see-sawing,” and “upsurge” patterns of RSV infections in childrenImmunity debt leading to off-season resurgence of respiratory viral infections in several countries has been observed since 2021, after the wide-scale implementation of SARS-CoV-2 vaccination campaigns and easing of restrictive measures. Infants and children spent more time in daycare centers and schools than they did during the initial COVID-19 period; therefore, young children had a higher risk of infection. Previously RSV infections had a seasonal peak; however, the impact of COVID-19 mitigation measures contributed to “off-season” RSV bronchiolitis resurgence in France, England, and Israel (Casalegno et al., 2021; Delestrain et al., 2021; Rybak et al., 2021; Weinberger Opek et al., 2021; Billard and Bont, 2023). Furthermore, an alternating “see-sawing” pattern of COVID-19 and RSV infections in children has been observed in France, Italy, the US, and Australia (Agha and Avner, 2021; Delestrain et al., 2021; Eden et al., 2022; Rabbone et al., 2022). Strict restrictions during the COVID-19 outbreak periods flattened the RSV bronchiolitis epidemic; in contrast, unrestrained regulations after the cooldown of COVID-19 led to a resurgence of RSV infections (Figure 2).FIGURE 2 Figure 2 The schematic diagram showing the “off-season”, “see-sawing”, and “upsurge” patterns of respiratory syncytial viruses (RSV) infection in children. Previously RSV infections had a seasonal peak; however, the impact of COVID-19 mitigation measures contributed to the “off-season” resurgence of RSV. The “see-sawing” pattern of the RSV outbreak alternated with the COVID-19 epidemic. Strict restrictions during the COVID-19 outbreak periods result in the flattening of the RSV epidemic; in contrast, unrestrained regulations after the cooldown of COVID-19 led to resurgence of the RSV outbreak. Public health measures lead to immunity debt to RSV, which further results in RSV infections reaching the highest peak after the dismissal of public health mitigation policies (“upsurge” pattern).Other than the “off-season” and “see-sawing” features, “upsurge” pattern occurs as well in respiratory infectious diseases during the COVID-19 pandemic (Figure 2). Several countries reported that RSV infection reached its highest peak after dismissal of public health mitigation policies. In Japan, the largest increase in RSV bronchiolitis cases in children began in 2021. The cumulative number of RSV infections rose from 570 in 2020 to 10,327 in the early-to-middle 2021 (Ujiie et al., 2021). In New Zealand, a rapid increase in RSV bronchiolitis in children aged 0–4 years was observed after relaxation of the strict border closure policy in April 2021. The RSV incidence was three times higher than in 2015–2019, which contributed to more hospitalizations and ICU admissions due to RSV in this age group (Hatter et al., 2021). The RSV upsurge in Australia occurred from late September to November 2020, when RSV infections exceeded the median 2012–2019 seasonal peak. Considering the prior waning of population immunity to RSV from 2019 to mid-2020, there were more RSV-naïve older children. Thus, the median patient age in 2020 was 18.4 months, which was significantly higher than the upper range between 2012–2019 (7.3–12.5 months) (Foley et al., 2021). Because of the delayed first RSV infection during the COVID-19 pandemic, RSV-related hospital admissions were higher among children aged 24–59 months compared to younger ages (Nygaard et al., 2023; Rao et al., 2023a).A national population register in Norway revealed a surge in respiratory tract infection admissions from September to October 2021 among all children aged 0–5 years, which exceeded the numbers usually observed at the typical season peak in January. The major causes were RSV-related and lower respiratory tract infection-related admissions. Conversely, the number of influenza-related admissions remained low during this period (Methi et al., 2021). A study in Italy demonstrated an extensive epidemic of pediatric acute respiratory infections from June to October 2021. Compared to October 2019, RSV, parainfluenza, rhinoviruses/enteroviruses, metapneumoviruses, common coronaviruses, and adenoviruses were more frequently isolated from specimens in October 2021 (Mattana et al., 2022). It is worth noting that coinfections with two and three viruses were found in approximately 30% and 7% of all positive cases, respectively. This finding highlights the increasing circulation of these viruses by 2021 (Mattana et al., 2022).4.2 Surge in influenza infections in childrenThe “see-sawing” and “upsurging” patterns were also observed for influenza infections. Following two years of decline in influenza virus circulation during the early COVID-19 pandemic, influenza infection rates increased in 2022, coinciding with a decrease in SARS-CoV-2 infections (Miron et al., 2022a; Lei et al., 2023; Rao et al., 2023b). Relaxation of non-pharmacological interventions subsequently resulted in a significant accumulation of influenza infections, leading to a widespread influenza outbreak.4.3 Surge in IPD in childrenThe upsurge in infections after the COVID-19 pandemic also occurred in children with IPD. In a national enhanced surveillance in England, the children’s IPD incidence declined by 50% in 2020 but increased in 2021 after lifting COVID-19 social restrictions. Additionally, the 2021 children’s IPD incidence (1.96/100,000) was higher than that during the same period in pre-pandemic years 2017–2019 (1.43/100,000) (Bertran et al., 2022). A study in Germany also indicated that the children’s IPD incidence exceeded seasonal levels in 2021, concurrent with the dismissal of non-pharmaceutical interventions intended to lower the SARS-CoV-2 transmission. From April to June 2021, IPD among children exceeded 9% of the average monthly values for 2015–2019 (Perniciaro et al., 2022). Although large-scale IPD has not been reported in other countries, it is still necessary to pay attention to the surge after loosening public mitigation restrictions.4.4 Surge in enterovirus infection in childrenA similar upsurge was observed for enterovirus infections. Since there was a very low prevalence of enterovirus infection after hygiene reinforcement in France in 2020, reduced immune stimulation and greater susceptibility to enterovirus led to a large-scale outbreak of hand, foot, and mouth diseases (HFMDs) in children. A total of 3,403 cases were reported from January to September 2021, which was 47% higher than during the same period in 2018–2019 (Mirand et al., 2021). Likewise, after easing COVID-19 mitigation measures, enterovirus cases re-emerged in 18 European countries between January and October 2021. Although the number of samples tested monthly remained unchanged, the proportion of samples identified as enteroviruses increased from 2.5% in January to 8.2% in September. The positivity rate of enterovirus-D68 also increased from 0.2% in January to 14% in September 2021 (Benschop et al., 2021). Furthermore, soon after dismissal of non-pharmaceutical interventions in 2021, Brazil’s Information System for Notifiable Diseases reported a large-scale outbreak of HFMDs that was exclusively associated with the re-emergence of the Coxsackievirus A6 sublineage (Carmona et al., 2022). These outbreaks could be attributed to immunity debt to enteroviruses during the COVID-19 pandemic.5 DiscussionThe changing patterns of SARS-CoV-2, RSV, and influenza infections continuously evolve. It is worth noting that a tripledemic (COVID-19, RSV, and influenza) may occur following a low prevalence of RSV and influenza infections. Extensive adoption of molecular diagnostic tests, such as rapid multiplex PCR, has facilitated precise concurrent detection of various viral pathogens, offering potential advantages, including expedited patient discharge, targeted administration of antimicrobials, and efficient utilization of isolation facilities (Clark et al., 2023).However, patients may not afford such accurate diagnostic investigations for economic reasons (Kelleni, 2023). Even in countries with sufficient healthcare systems, a shortage of medical resources may also occur. The rates of RSV- and influenza-associated hospitalizations of infants and children in late-2022 were higher than those during the same period in 2010-2020 (Centers for Disease Control and Infection, 2022). The emerging tripledemic has led to shortages in pediatric inpatient capacity, drugs, and equipment in the US in late-2022 (Furlow, 2023).Fortunately, there are only a few reports on this tripledemic. Opinions have been proposed against the ongoing occurrence of a tripledemic. Based on the theory of viral interference, immune responses and virus-virus interactions at the host level may result in synergistic or antagonistic interactions. Fage et al. demonstrated that preceding infection with SARS-CoV-2 subsequently reduces the replication of influenza A (H1N1) and RSV in the human nasal airway epithelium. Furthermore, prior infection of the human nasal airway epithelium with influenza A (H1N1) also resulted in decreased SARS-CoV-2 viral load (Fage et al., 2022). Previous epidemiological surveillance revealed that RSV was detected less frequently during influenza epidemics (Anestad et al., 2007; Gröndahl et al., 2014; Meningher et al., 2014; van Asten et al., 2016). Chan et al. (2018) reported that infection of ferrets with influenza A (H1N1) induced a higher production of cytokines and immune mediators in the respiratory tract compared to RSV. Primary infection with influenza A (H1N1) prevented infection with RSV in ferrets, when infections were separated by seven days. However, both viruses induced minimal cross-reactive interferon-γ-producing cells, indicating that the reduced RSV infection was not caused by cross-reactive immunity between H1N1 and RSV. This suggests that innate immune mechanisms may be involved in the interference between H1N1 and RSV (Chan et al., 2018). Studies have also shown that sequential infection of human bronchial epithelial cells with human rhinovirus (48–72 h ahead) accelerates interferon-stimulated gene responses, which further impair SARS-CoV-2 replication (Cheemarla et al., 2021; Dee et al., 2021). Thus, the extent of the tripledemic might be limited by viral interference between these respiratory viruses. Although it is not necessary to panic, close attention should be paid to future viral dynamics. One way to prevent medical resources exhaustion is popularizing SARS-CoV-2 and influenza immunizations.Since April 2022, there have been widespread reports of severe cases of acute hepatitis of unknown etiology in children (Namakin et al., 2023). It is noteworthy that the affected children exhibited a potential immunological predisposition. The disruption of typical patterns of exposure and immunity resulting from population lockdowns enforced during the COVID-19 pandemic may have rendered these children susceptible to viral coinfections (Matthews et al., 2022). Consequently, it is imperative to establish international infectious disease monitoring and foster collaborative efforts in the post-COVID-19 period.The ever-changing patterns of infectious diseases have been influenced by public health mitigation measures during the COVID-19 pandemic, with stringent measures resulting in low incidence of various infectious diseases. Owing to the prevalence of SARS-CoV-2 infections and subsequent immunity development, decreasing virulence of SARS-CoV-2, and worldwide immunizations against SARS-CoV-2 in children aged >6 months, mitigation measures are lifted country-by-country. Consequently, immunity debt to respiratory viruses other than SARS-CoV-2 contributes to the “off-season,” “see-saw,” and “upsurge” patterns of infection in children. Apart from SARS-CoV-2 persistence, coexistence of other viruses or bacteria may lead to future twindemics or tripledemics. Therefore, maintaining hand hygiene and immunization policies against a variety of pathogens is necessary to alleviate the ongoing impacts of infectious diseases on children’s health.Author contributionsM-C Y and Y-T S contributed to conception and design of the study. M-C Y and Y-T S organized the database. M-C Y wrote the first draft of the manuscript. Y-T S, P-H C, C-C T, and T-I L wrote sections of the manuscript. J-R W coordinated and supervised data collection, collected data, and reviewed and revised the manuscript.All authors contributed to the article and approved the submitted version.FundingThis study was supported by intramural funding provided by the E-DA Hospital (EDAHP 112014, EDPJ 111048). The sponsor was not involved in the study design, collection, analysis, and interpretation of data, writing of the report, or decision to submit the manuscript for publication.Conflict of interestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher’s noteAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.References Agha, R., Avner, J. R. (2021). Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics 148 (3), e2021052089. doi: 10.1542/peds.2021-052089PubMed Abstract | CrossRef Full Text | Google Scholar Anestad, G., Vainio, K., Hungnes, O. (2007). Interference between outbreaks of epidemic viruses. Scand. J. Infect. Dis. 39 (6-7), 653–654. doi: 10.1080/00365540701253860PubMed Abstract | CrossRef Full Text | Google Scholar Baker, R. E., Park, S. W., Yang, W., Vecchi, G. A., Metcalf, C. J. E., Grenfell, B. T. (2020). The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc. Natl. Acad. Sci. U S A 117 (48), 30547–30553. doi: 10.1073/pnas.2013182117PubMed Abstract | CrossRef Full Text | Google Scholar Belingheri, M., Paladino, M. E., Piacenti, S., Riva, M. A. (2021). Effects of COVID-19 lockdown on epidemic diseases of childhood. J. Med. Virol. 93 (1), 153–154. doi: 10.1002/jmv.26253PubMed Abstract | CrossRef Full Text | Google Scholar Benschop, K. S., Albert, J., Anton, A., Andrés, C., Aranzamendi, M., Armannsdóttir, B., et al. (2021). Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021. Euro Surveill 26 (45), 2100998. doi: 10.2807/1560-7917.ES.2021.26.45.2100998PubMed Abstract | CrossRef Full Text | Google Scholar Bertran, M., Amin-Chowdhury, Z., Sheppard, C. L., Eletu, S., Zamarreño, D. V., Ramsay, M. E., et al. (2022). Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic, England. Emerg. Infect. Dis. 28 (8), 1669–1672. doi: 10.3201/eid2808.220304PubMed Abstract | CrossRef Full Text | Google Scholar Bhuiyan, M. U., Stiboy, E., Hassan, M. Z., Chan, M., Islam, M. S., Haider, N., et al. (2021). Epidemiology of COVID-19 infection in young children under five years: a systematic review and meta-analysis. Vaccine 39 (4), 667–677. doi: 10.1016/j.vaccine.2020.11.078PubMed Abstract | CrossRef Full Text | Google Scholar Billard, M. N., Bont, L. J. (2023). Quantifying the RSV immunity debt following COVID-19: a public health matter. Lancet Infect. Dis. 23 (1), 3–5. doi: 10.1016/S1473-3099(22)00544-8PubMed Abstract | CrossRef Full Text | Google Scholar Binns, E., Koenraads, M., Hristeva, L., Flamant, A., Baier-Grabner, S., Loi, M., et al. (2022). Influenza and respiratory syncytial virus during the COVID-19 pandemic: time for a new paradigm? Pediatr. Pulmonol 57 (1), 38–42. doi: 10.1002/ppul.25719PubMed Abstract | CrossRef Full Text | Google Scholar Brueggemann, A. B., Jansen van Rensburg, M. J., Shaw, D., McCarthy, N. D., Jolley, K. A., Maiden, M. C. J., et al. (2021). Changes in the incidence of invasive disease due to streptococcus pneumoniae, haemophilus influenzae, and neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the invasive respiratory infection surveillance initiative: a prospective analysis of surveillance data. Lancet Digit Health 3 (6), e360–e370. doi: 10.1016/S2589-7500(21)00077-7PubMed Abstract | CrossRef Full Text | Google Scholar Bruggink, L. D., Garcia-Clapes, A., Tran, T., Druce, J. D., Thorley, B. R. (2021). Decreased incidence of enterovirus and norovirus infections during the COVID-19 pandemic. Victoria, (Australia). 2020. Commun. Dis. Intell. 45, 1–8. doi: 10.33321/cdi.2021.45.5CrossRef Full Text | Google Scholar Carmona, R. C. C., Machado, B. C., Reis, F. C., Jorge, A. M. V., Cilli, A., Dias, A. M. N., et al. (2022). Hand, foot, and mouth disease outbreak by coxsackievirus A6 during COVID-19 pandemic in 2021, são paulo, Brazil. J. Clin. Virol. 154, 105245. doi: 10.1016/j.jcv.2022.105245PubMed Abstract | CrossRef Full Text | Google Scholar Casalegno, J. S., Ploin, D., Cantais, A., Masson, E., Bard, E., Valette, M., et al. (2021). Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, rhône Loire, France. Euro Surveill 26 (29), 2100630. doi: 10.2807/1560-7917.ES.2021.26.29.2100630PubMed Abstract | CrossRef Full Text | Google Scholar Centers for Disease Control and Infection (2022). Increased respiratory virus activity, especially among children, early in the 2022-2023 fall and winter. Health Alert Network (HAN-00479).Google Scholar Chan, K. F., Carolan, L. A., Korenkov, D., McCaw, J., Reading, P. C., Barr, I. G., et al. (2018). Investigating viral interference between influenza a virus and human respiratory syncytial virus in a ferret model of infection. J. Infect. Dis. 218 (3), 406–417. doi: 10.1093/infdis/jiy184PubMed Abstract | CrossRef Full Text | Google Scholar Cheemarla, N. R., Watkins, T. A., Mihaylova, V. T., Wang, B., Zhao, D., Wang, G., et al. (2021). Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J. Exp. Med. 218 (8), e20210583. doi: 10.1084/jem.20210583PubMed Abstract | CrossRef Full Text | Google Scholar Ciruela, P., Soldevila, N., García-Garcia, J. J., González-Peris, S. (2022). Diaz-conradi A.Effect of COVID-19 pandemic on invasive pneumococcal disease in children, Catalonia, Spain. Emerg. Infect. Dis. 28 (11), 2321–2325. doi: 10.3201/eid2811.211741PubMed Abstract | CrossRef Full Text | Google Scholar Clark, T. W., Lindsley, K., Wigmosta, T. B., Bhagat, A., Hemmert, R. B., Uyei, J., et al. (2023). Rapid multiplex PCR for respiratory viruses reduces time to result and improves clinical care: results of a systematic review and meta-analysis. J. Infect. 86 (5), 462–475. doi: 10.1016/j.jinf.2023.03.005PubMed Abstract | CrossRef Full Text | Google Scholar Cohen, P. R., Rybak, A., Werner, A., Béchet, S., Desandes, R., Hassid, F., et al. (2022). Trends in pediatric ambulatory community acquired infections before and during COVID-19 pandemic: a prospective multicentric surveillance study in France. Lancet Reg. Health Eur. 22, 100497. doi: 10.1016/j.lanepe.2022.100497PubMed Abstract | CrossRef Full Text | Google Scholar Danino, D., Ben-Shimol, S., van der Beek, B. A., Givon-Lavi, N., Avni, Y. S., Greenberg, D., et al. (2022). Decline in pneumococcal disease in young children during the coronavirus disease 2019 (COVID-19) pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: a prospective cohort study. Clin. Infect. Dis. 75 (1), e1154–e1164. doi: 10.1093/cid/ciab1014PubMed Abstract | CrossRef Full Text | Google Scholar Dee, K., Goldfarb, D. M., Haney, J., Herder, V., Stewart, M., Szemiel, A., et al. (2021). Human rhinovirus infection blocks severe acute respiratory syndrome coronavirus 2 replication within the respiratory epithelium: implications for COVID-19 epidemiology. J. Infect. Dis. 224 (1), 31–38. doi: 10.1093/infdis/jiab147PubMed Abstract | CrossRef Full Text | Google Scholar DeLaroche, A. M., Rodean, J., Aronson, P. L., Fleegler, E. W., Florin, T. A., Goyal, M., et al. (2021). Pediatric emergency department visits at US children’s hospitals during the COVID-19 pandemic. Pediatrics 147 (4), e2020039628. doi: 10.1542/peds.2020-039628PubMed Abstract | CrossRef Full Text | Google Scholar Delestrain, C., Danis, K., Hau, I., Behillil, S., Billard, M. N., Krajten, L., et al. (2021). Impact of COVID-19 social distancing on viral infection in France: a delayed outbreak of RSV. Pediatr. Pulmonol 56 (12), 3669–3673. doi: 10.1002/ppul.25644PubMed Abstract | CrossRef Full Text | Google Scholar Deng, L., Li, P., Zhang, X., Jiang, Q., Turner, D., Zhou, C., et al. (2022). Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis. Sci. Rep. 12 (1), 20763. doi: 10.1038/s41598-022-24220-7PubMed Abstract | CrossRef Full Text | Google Scholar Eden, J. S., Sikazwe, C., Xie, R., Deng, Y. M., Sullivan, S. G., Michie, A., et al. (2022). Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat. Commun. 13 (1), 2884. doi: 10.1038/s41467-022-30485-3PubMed Abstract | CrossRef Full Text | Google Scholar Fage, C., Hénaut, M., Carbonneau, J., Piret, J., Boivin, G. (2022). Influenza A(H1N1)pdm09 virus but not respiratory syncytial virus interferes with SARS-CoV-2 replication during sequential infections in human nasal epithelial cells. Viruses 14 (2), 395. doi: 10.3390/v14020395PubMed Abstract | CrossRef Full Text | Google Scholar Feng, L., Zhang, T., Wang, Q., Xie, Y., Peng, Z., Zheng, J., et al. (2021). Impact of COVID-19 outbreaks and interventions on influenza in China and the united states. Nat. Commun. 12 (1), 3249. doi: 10.1038/s41467-021-23440-1PubMed Abstract | CrossRef Full Text | Google Scholar Foley, D. A., Yeoh, D. K., Minney-Smith, C. A., Martin, A., Mace, A. O., Sikazwe, C. T., et al. (2021). The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin. Infect. Dis. 73 (9), e2829–e2830. doi: 10.1093/cid/ciaa1906PubMed Abstract | CrossRef Full Text | Google Scholar Furlow, B. (2023). Triple-demic overwhelms paediatric units in US hospitals. Lancet Child Adolesc. Health 7 (2), 86. doi: 10.1016/S2352-4642(22)00372-8PubMed Abstract | CrossRef Full Text | Google Scholar González, S., Olszevicki, S., Gaiano, A., Baino, A., Regairaz, L., Salazar, M., et al. (2022). Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the omicron outbreak in Argentina: a retrospective cohort study. Lancet Reg. Health Am. 13, 100316. doi: 10.1016/j.lana.2022.100316PubMed Abstract | CrossRef Full Text | Google Scholar Götzinger, F., Santiago-García, B., Noguera-Julián, A., Lanaspa, M., Lancella, L., Calò Carducci, F., et al. (2020). COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc. Health 4 (9), 653–661. doi: 10.1016/S2352-4642(20)30177-2PubMed Abstract | CrossRef Full Text | Google Scholar Gröndahl, B., Ankermann, T., von Bismarck, P., Rockahr, S., Kowalzik, F., Gehring, S., et al. (2014). The 2009 pandemic influenza A(H1N1) coincides with changes in the epidemiology of other viral pathogens causing acute respiratory tract infections in children. Infection 42 (2), 303–308. doi: 10.1007/s15010-013-0545-5PubMed Abstract | CrossRef Full Text | Google Scholar Hatter, L., Eathorne, A., Hills, T., Bruce, P., Beasley, R. (2021). Respiratory syncytial virus: paying the immunity debt with interest. Lancet Child Adolesc. Health 5 (12), e44–e45. doi: 10.1016/S2352-4642(21)00333-3PubMed Abstract | CrossRef Full Text | Google Scholar Huang, Y. B., Lin, Y. R., Hung, S. K., Chang, Y. C., Ng, C. J., Chen, S. Y. (2022). Pediatric training crisis of emergency medicine residency during the COVID-19 pandemic. Children (Basel) 9 (1), 32. doi: 10.3390/children9010032PubMed Abstract | CrossRef Full Text | Google Scholar Kaur, R., Schulz, S., Fuji, N., Pichichero, M. (2021). COVID-19 pandemic impact on respiratory infectious diseases in primary care practice in children. Front. Pediatr. 9. doi: 10.3389/fped.2021.722483PubMed Abstract | CrossRef Full Text | Google Scholar Kelleni, M. T. (2023). Real-life practice of the Egyptian kelleni’s protocol in the current tripledemic: COVID-19, RSV and influenza [letter]. J. Infect. 86 (2), 154–225. doi: 10.1016/j.jinf.2022.12.007CrossRef Full Text | Google Scholar Kubale, J., Balmaseda, A., Frutos, A. M., Sanchez, N., Plazaola, M., Ojeda, S., et al. (2022). Association of SARS-CoV-2 seropositivity and symptomatic reinfection in children in Nicaragua. JAMA Netw. Open 5 (6), e2218794. doi: 10.1001/jamanetworkopen.2022.18794PubMed Abstract | CrossRef Full Text | Google Scholar Lei, H., Yang, L., Yang, M., Tang, J., Yang, J., Tan, M., et al. (2023). Quantifying the rebound of influenza epidemics after the adjustment of zero-COVID policy in China. PNAS Nexus 2 (5), pgad152. doi: 10.1093/pnasnexus/pgad152PubMed Abstract | CrossRef Full Text | Google Scholar Li, Y., Guo, Y., Duan, Y. (2022). Changes in streptococcus pneumoniae infection in children before and after the COVID-19 pandemic in zhengzhou, China. J. Infect. 85 (3), e80–e81. doi: 10.1016/j.jinf.2022.05.040PubMed Abstract | CrossRef Full Text | Google Scholar Li, Y., Wang, X., Msosa, T., de Wit, F., Murdock, J., Nair, H. (2021). The impact of the 2009 influenza pandemic on the seasonality of human respiratory syncytial virus: a systematic analysis. Influ Other Respir. Viruses 15 (6), 804–812. doi: 10.1111/irv.12884CrossRef Full Text | Google Scholar Ludvigsson, J. F. (2020). Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 109 (6), 1088–1095. doi: 10.1111/apa.15270PubMed Abstract | CrossRef Full Text | Google Scholar Maier, H. E., Kuan, G., Saborio, S., Carillo, F. A., Plazola, M., Barilla, C., et al. (2022). Clinical spectrum of severe acute respiratory syndrome coronavirus 2 infection and protection from symptomatic reinfection. Clin. Infect. Dis. 75 (1), e257–e266. doi: 10.1093/cid/ciab717PubMed Abstract | CrossRef Full Text | Google Scholar Mattana, G., Albitar-Nehme, S., Cento, V., Colagrossi, L., Piccioni, L., Raponi, M., et al. (2022). Back to the future (of common respiratory viruses). J. Glob Antimicrob. Resist. 28, 223–225. doi: 10.1016/j.jgar.2022.01.010PubMed Abstract | CrossRef Full Text | Google Scholar Matthews, P. C., Campbell, C., Săndulescu, O., Matičič, M., Ruta, S. M., Rivero-Juárez, A., et al. (2022). Acute severe hepatitis outbreak in children: a perfect storm. what do we know, and what questions remain? Front. Pharmacol. 13. doi: 10.3389/fphar.2022.1062408CrossRef Full Text | Google Scholar Mattiuzzi, C., Lippi, G. (2022). Timeline analysis of clinical severity of COVID-19 in the general population. Eur. J. Intern. Med. S0953-6205 (22), 00435–00436. doi: 10.1016/j.ejim.2022.12.007CrossRef Full Text | Google Scholar Medić, S., Anastassopoulou, C., Lozanov-Crvenković, Z., Dragnić, N., Petrović, V., Ristić, M., et al. (2023). Incidence, risk, and severity of SARS-CoV-2 reinfections in children and adolescents between march 2020 and July 2022 in Serbia. JAMA Netw. Open 6 (2), e2255779. doi: 10.1001/jamanetworkopen.2022.55779PubMed Abstract | CrossRef Full Text | Google Scholar Meningher, T., Hindiyeh, M., Regev, L., Sherbany, H., Mendelson, E., Mandelboim, M. (2014). Relationships between A(H1N1)pdm09 influenza infection and infections with other respiratory viruses. Influ Other Respir. Viruses 8 (4), 422–430. doi: 10.1111/irv.12249CrossRef Full Text | Google Scholar Mensah, A. A., Campbell, H., Stowe, J., Seghezzo, G., Simmons, R., Lacy, J., et al. (2022). Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England. J. Adolesc. Health 6 (6), 384–392. doi: 10.1016/S2352-4642(22)00059-1CrossRef Full Text | Google Scholar Methi, F., Størdal, K., Telle, K., Larsen, V. B., Magnusson, K. (2021). Hospital admissions for respiratory tract infections in children aged 0-5 years for 2017/2023. Front. Pediatr. 9. doi: 10.3389/fped.2021.822985PubMed Abstract | CrossRef Full Text | Google Scholar Milne, G., Hames, T., Scotton, C., Gent, N., Johnsen, A., Anderson, R. M., et al. (2021). Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir. Med. 9 (12), 1450–1466. doi: 10.1016/S2213-2600(21)00407-0PubMed Abstract | CrossRef Full Text | Google Scholar Mirand, A., Cohen, R., Bisseux, M., Tomba, S., Sellem, F. C., Gelbert, N., et al. (2021). A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro Surveill 26 (43), 2100978. doi: 10.2807/1560-7917.ES.2021.26.43.2100978PubMed Abstract | CrossRef Full Text | Google Scholar Miron, V. D., Bar, G., Filimon, C., Craiu, M. (2022a). From COVID-19 to influenza-real-life clinical practice in a pediatric hospital. Diagnostics (Basel) 12 (5), 1208. doi: 10.3390/diagnostics12051208PubMed Abstract | CrossRef Full Text | Google Scholar Miron, V. D., Gunşahin, D., Filimon, C., Bar, G., Craiu, M. (2022b). Pediatric emergencies and hospital admissions in the first six months of the COVID-19 pandemic in a tertiary children’s hospital in Romania. Children (Basel) 9 (4), 513. doi: 10.3390/children9040513PubMed Abstract | CrossRef Full Text | Google Scholar Moynihan, R., Sanders, S., Michaleff, Z. A., Scott, A. M., Clark, J., To, E. J., et al. (2021). Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open 11 (3), e045343. doi: 10.1136/bmjopen-2020-045343PubMed Abstract | CrossRef Full Text | Google Scholar Namakin, K., Naserghandi, A., Allameh, S. F. (2023). Severe acute hepatitis of unknown etiology in children in 2022: a narrative review. New Microbes New Infect. 51, 101087. doi: 10.1016/j.nmni.2023.101087PubMed Abstract | CrossRef Full Text | Google Scholar Nicolay, N., Mirinaviciute, G., Mollet, T., Celentano, L. P., Bacci, S. (2020). Epidemiology of measles during the COVID-19 pandemic, a description of the surveillance data, 29 EU/EEA countries and the united kingdom, January to may 2020. Euro Surveill 25 (31), 2001390. doi: 10.2807/1560-7917.ES.2020.25.31.2001390PubMed Abstract | CrossRef Full Text | Google Scholar Nygaard, U., Hartling, U. B., Nielsen, J., Vestergaard, L. S., Dungu, K. H. S., Nielsen, J. S. A., et al. (2023). Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study. Lancet Child Adolesc. Health 7 (3), 171–179. doi: 10.1016/S2352-4642(22)00371-6PubMed Abstract | CrossRef Full Text | Google Scholar Olsen, S. J., Winn, A. K., Budd, A. P., Prill, M. M., Steel, J., Midgley, C. M., et al. (2021). Changes in influenza and other respiratory virus activity during the COVID-19 pandemic – united states, 2020-2021. MMWR Morb Mortal Wkly Rep. 70 (29), 1013–1019. doi: 10.15585/mmwr.mm7029a1PubMed Abstract | CrossRef Full Text | Google Scholar Park, S., Marcus, G. M., Olgin, J. E., Carton, T., Hamad, R., Pletcher, M. J. (2023). Unreported SARS-CoV-2 home testing and test positivity. JAMA Netw. Open 6 (1), e2252684. doi: 10.1001/jamanetworkopen.2022.52684PubMed Abstract | CrossRef Full Text | Google Scholar Perniciaro, S., van der Linden, M., Weinberger, D. M. (2022). Reemergence of invasive pneumococcal disease in Germany during the spring and summer of 2021. Clin. Infect. Dis. 75 (7), 1149–1153. doi: 10.1093/cid/ciac100PubMed Abstract | CrossRef Full Text | Google Scholar Rabbone, I., Monzani, A., Scaramuzza, A. E., Cavalli, C., See Rabbone, I., Monzani, A., et al. (2022). See-sawing COVID-19 and RSV bronchiolitis in children under 2 years of age in northern Italy. Acta Paediatr. 111 (11), 2174–2175. doi: 10.1111/apa.16512PubMed Abstract | CrossRef Full Text | Google Scholar Rankin, D. A., Spieker, A. J., Perez, A., Stahl, A., Rahman, H., Stewart, L., et al. (2023). Circulation of rhinoviruses and/or enteroviruses in pediatric patients with acute respiratory illness before and during the COVID-19 pandemic in the US. JAMA Netw. Open 6 (2), e2254909. doi: 10.1001/jamanetworkopen.2022.54909PubMed Abstract | CrossRef Full Text | Google Scholar Rao, S., Armistead, I., Messacar, K., Alden, N. B., Schmoll, E., Austin, E., et al. (2023a). Shifting epidemiology and severity of respiratory syncytial virus in children during the COVID-19 pandemic. JAMA Pediatr., e231088. doi: 10.1001/jamapediatrics.2023.1088PubMed Abstract | CrossRef Full Text | Google Scholar Rao, S., Armistead, I., Tyler, A., Lensing, M., Dominguez, S. R., Alden, N. B. (2023b). RSV, Influenza, and COVID-19 hospitalizations in children in Colorado during the 2021-2022 respiratory virus season. J. Pediatr., 113491. doi: 10.1016/j.jpeds.2023.113491PubMed Abstract | CrossRef Full Text | Google Scholar Rybak, A., Levy, C., Angoulvant, F., Auvrignon, A., Gembara, P., Danis, K., et al. (2022). Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral infections among children in France. JAMA Netw. Open 5 (6), e2218959. doi: 10.1001/jamanetworkopen.2022.18959PubMed Abstract | CrossRef Full Text | Google Scholar Rybak, A., Levy, C., Jung, C., Béchet, S., Batard, C., Hassid, F., et al. (2021). Delayed bronchiolitis epidemic in French primary care setting driven by respiratory syncytial virus: preliminary data from the oursyn study, march 2021. Pediatr. Infect. Dis. J. 40 (12), e511–e514. doi: 10.1097/INF.0000000000003270PubMed Abstract | CrossRef Full Text | Google Scholar Say, D., Crawford, N., McNab, S., Wurzel, D., Steer, A., Tosif, S. (2021). Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc. Health 5 (6), e22–e23. doi: 10.1016/S2352-4642(21)00124-3PubMed Abstract | CrossRef Full Text | Google Scholar Son, M. B. F., Burns, J. C., Newburger, J. W. (2023). A new definition for multisystem inflammatory syndrome in children. Pediatrics 151 (3), e2022060302. doi: 10.1542/peds.2022-060302PubMed Abstract | CrossRef Full Text | Google Scholar Stamm, P., Sagoschen, I., Weise, K., Plachter, B., Münzel, T., Gori, T., et al. (2021). Influenza and RSV incidence during COVID-19 pandemic-an observational study from in-hospital point-of-care testing. Med. Microbiol. Immunol. 210 (5-6), 277–282. doi: 10.1007/s00430-021-00720-7PubMed Abstract | CrossRef Full Text | Google Scholar Stera, G., Pierantoni, L., Masetti, R., Leardini, D., Biagi, C., Buosenso, D., et al. (2021). Impact of SARS-CoV-2 pandemic on bronchiolitis hospitalizations: the experience of an Italian tertiary center. Children (Basel) 8 (7), 556. doi: 10.3390/children8070556PubMed Abstract | CrossRef Full Text | Google Scholar Su, E. C., Hsiao, C. H., Chen, Y. T., Yu, S. H. (2021). An examination of COVID-19 mitigation efficiency among 23 countries. Healthc (Basel) 9 (6), 755. doi: 10.3390/healthcare9060755CrossRef Full Text | Google Scholar Szépfalusi, Z., Schmidthaler, K., Sieber, J., Kopanja, S., Götzinger, F., Schoof, A., et al. (2021). Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: a cross-sectional study. Pediatr. Allergy Immunol. 32 (4), 762–770. doi: 10.1111/pai.13459PubMed Abstract | CrossRef Full Text | Google Scholar Taiwan Centers for Disease Control. Available at: https:/idss.cdc.gov.tw/ (Accessed March 30, 2023).Google Scholar Tan, S. H. X., Cook, A. R., Heng, D., Ong, B., Lye, D. C., Tan, K. B. (2022). Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age. N Engl. J. Med. 387 (6), 525–532. doi: 10.1056/NEJMoa2203209PubMed Abstract | CrossRef Full Text | Google Scholar Ujiie, M., Tsuzuki, S., Nakamoto, T., Iwamoto, N. (2021). Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo, Japan. Emerg. Infect. Dis. 27 (11), 2969–2970. doi: 10.3201/eid2711.211565PubMed Abstract | CrossRef Full Text | Google Scholar van Asten, L., Bijkerk, P., Fanoy, E., van Ginkel, A., Suijkerbuijk, A., van der Hoek, W., et al. (2016). Early occurrence of influenza a epidemics coincided with changes in occurrence of other respiratory virus infections. Influ Other Respir. Viruses 10 (1), 14–26. doi: 10.1111/irv.12348CrossRef Full Text | Google Scholar van Summeren, J., Meijer, A., Aspelund, G., Casalegno, J. S., Erna, G., Hoang, U., et al. (2021). Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Euro Surveill 26 (29), 2100639. doi: 10.2807/1560-7917.ES.2021.26.29.2100639PubMed Abstract | CrossRef Full Text | Google Scholar Weinberger Opek, M., Yeshayahu, Y., Glatman-Freedman, A., Kaufman, Z., Sorek, N., Brosh-Nissimov, T. (2021). Delayed respiratory syncytial virus epidemic in children after relaxation of COVID-19 physical distancing measures, ashdod, Israel, 2021. Euro Surveill 26 (29), 2100706. doi: 10.2807/1560-7917.ES.2021.26.29.2100706PubMed Abstract | CrossRef Full Text | Google Scholar Willen, L., Ekinci, E., Cuypers, L., Theeten, H., Desmet, S. (2021). Infant pneumococcal carriage in Belgium not affected by COVID-19 containment measures. Front. Cell Infect. Microbiol. 11. doi: 10.3389/fcimb.2021.825427PubMed Abstract | CrossRef Full Text | Google Scholar Wu, D., Liu, Q., Wu, T., Wang, D., Lu, J. (2020). The impact of COVID-19 control measures on the morbidity of varicella, herpes zoster, rubella and measles in guangzhou, China. Immun. Inflam Dis. 8 (4), 844–846. doi: 10.1002/iid3.352CrossRef Full Text | Google Scholar Yasuhara, J., Kuno, T., Takagi, H., Sumitomo, N. (2020). Clinical characteristics of COVID-19 in children: a systematic review. Pediatr. Pulmonol 55 (10), 2565–2575. doi: 10.1002/ppul.24991PubMed Abstract | CrossRef Full Text | Google Scholar Yeoh, D. K., Foley, D. A., Minney-Smith, C. A., Martin, A., Mace, A., Sikazwe, C., et al. (2021). Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin. Infect. Dis. 72 (12), 2199–2202. doi: 10.1093/cid/ciaa1475PubMed Abstract | CrossRef Full Text | Google Scholar Zhang, M., Gao, J., Guo, Q., Zhang, X., Zhang, W. (2023). Changes of respiratory syncytial virus infection in children before and after the COVID-19 pandemic in henan, China. J. Infect. 86 (2), 154–225. doi: 10.1016/j.jinf.2022.12.011PubMed Abstract | CrossRef Full Text | Google Scholar Zhou, J., Zhao, P., Nie, M., Gao, K., Yang, J., Sun, J. (2023). Changes of haemophilus influenzae infection in children before and after the COVID-19 pandemic, henan, China. J. Infect. 86 (1), 66–117. doi: 10.1016/j.jinf.2022.10.019PubMed Abstract | CrossRef Full Text | Google Scholar Zohar, T., Alter, G. (2020). Dissecting antibody-mediated protection against SARS-CoV-2. Nat. Rev. Immunol. 20 (7), 392–394. doi: 10.1038/s41577-020-0359-5PubMed Abstract | CrossRef Full Text | Google ScholarKeywords: coronavirus disease 2019, immune debt, influenza, pediatric, pneumococcus, respiratory tract infection, respiratory syncytial virusCitation: Yang M-C, Su Y-T, Chen P-H, Tsai C-C, Lin T-I and Wu J-R (2023) Changing patterns of infectious diseases in children during the COVID-19 pandemic. Front. Cell. Infect. Microbiol. 13:1200617. doi: 10.3389/fcimb.2023.1200617Received: 05 April 2023; Accepted: 19 June 2023;Published: 29 June 2023.Edited by:Yasir Waheed, Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU), PakistanReviewed by:Victor Daniel Miron, Carol Davila University of Medicine and Pharmacy, RomaniaCopyright © 2023 Yang, Su, Chen, Tsai, Lin and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*Correspondence: Jiunn-Ren Wu, jirewu@gmail.com.tw†These authors have contributed equally to this work and share first authorship Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. Footer Guidelines Author guidelinesEditor guidelinesPolicies and publication ethicsFee policy Explore ArticlesResearch Topics Journals Outreach Frontiers Forum Frontiers Policy Labs Frontiers for Young Minds Connect Help centerEmails and alerts Contact us SubmitCareer opportunities Follow us © 2024 Frontiers Media S.A. All rights reserved Privacy policy | Terms and conditionsSK bioscience, GC go head-to-head to expand influenza vaccine market share < Pharma < Article - KBR 주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기 상단영역 UPDATE : 2024-11-12 12:00 (Tues) Home Log in Join 전체메뉴 기사검색 검색 본문영역 이전 기사보기 다음 기사보기 SK bioscience, GC go head-to-head to expand influenza vaccine market share 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 스크롤 이동 상태바 현재위치 Home Pharma SK bioscience, GC go head-to-head to expand influenza vaccine market share 기자명 Lee Han-soo Published 2023.06.26 14:09 바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기 SNS 기사보내기 Facebook(으)로 기사보내기 Twitter(으)로 기사보내기 Kakaostory(으)로 기사보내기 Copy url(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사스크랩하기 I share this article Facebook(으)로 기사보내기 Twitter(으)로 기사보내기 Kakaostory(으)로 기사보내기 Copy url(으)로 기사보내기 닫기 The global influenza vaccine market is experiencing a significant revival as the Covid-19 pandemic gradually subsides. SK bioscience's SKY Cellflu Inj. (right) and GC's GC Flu Multi Inj. are competing to win market share for influenza vaccines both at home and abroad. The influenza virus, which causes seasonal flu, poses a significant threat each year, resulting in substantial morbidity and mortality globally. With Covid-19 now relatively under control in many regions, healthcare authorities and professionals are urging individuals to get vaccinated against influenza to minimize the burden on healthcare systems already stretched thin due to the ongoing pandemic. In Korea, the market is also experiencing a tectonic shift with the return of SK bioscience, which was the leading influenza vaccine supplier until 2021, which is when the company left the market to develop a Covid-19 vaccine. During that time, GC had acquired most of the flu vaccines ordered by the government, which SK Bioscience used to almost monopolize. According to industry estimates, GC supplied over 60 percent of the 2.8 million doses of flu vaccines ordered by the government in 2022. While industry watchers speculated that SK bioscience will have a difficult time regaining the market that it had lost, SK bioscience, which returned to the national procurement market after a two-year hiatus, came on top in this year's National Immunization Program (NIP) procurement market by supplying the largest amount of doses. (Courtesy of KDCA) According to the Korea Disease Control and Prevention Agency, SK bioscience will supply 2.42 million influenza doses for the 2023-2024 NIP procurement for influenza, which accounts for a 21.6 percent share of the total 11.21 million doses purchased by the government. Compared to SK bioscience, GC will supply 1.74 million doses of its vaccine, ranking fourth among the six suppliers. Regarding the matter, a GC official said in the NIP market, bid price matters, and its competitors offered lower unit prices than what the company expected. "The government assigns the number of doses based on the bid price and then it's a matter of how many doses that a company can manufacture," a GC official told Korea Biomedical Review. GC winning influenza procurement markets abroad However, compared to the domestic situation, GC is leading the global procurement market for influenza vaccines at a time when the market is expected to grow. According to Evaluate Pharma, a global market research firm, the global influenza vaccine market is expected to grow from $5.8 billion in 2020 to $7.4 billion in 2025. Notably, GC maintained the largest flu market share in Latin America after winning a $43.38 million contract with Pan American Health Organization (PAHO) to supply its influenza vaccine to Latin America. The vaccines will be supplied to Latin American countries in the first half of the year. With the latest bidding win, GC maintained the top market share position for PAHO's southern hemisphere influenza supply for the past decade. GC's GC Flu Multi Inj. also has product approval in 23 countries, compared to 12 for SK bioscience's SKY Cellflu Inj. GC is also planning to develop a messenger ribonucleic acid (mRNA-based) flu vaccine in earnest through GC Biopharma, it's subsidiary. The company plans to develop this mRNA vaccine based on the lipid nanoparticle (LNP) development and option agreement signed with Canada-based bio company, Acuitas Therapeutics, in April last year and a recent non-exclusive licensing agreement involving LNP technologies. GC Biopharma aims to utilize its technology and experience in developing influenza vaccines together with the proven technology of Acuitas to enter phase 1 clinical trials by 2024. SK bioscience plans to expand its global market share based on the fact that SKY Cellflu Inj. is the world's first quadrivalent cell culture vaccine to receive WHO's prequalification (PQ) certification. The company received such a certification in 2020. tweet Related articles [Top K-Pharma Analysis ⑧] GC’s 2022 earnings expected to be largest in company's history [Top K-Pharma Analysis ④] SK Bioscience faces trouble as sales, operating profit fall drastically in 2022 SK bioscience, Australian institute collaborate to bolster global infectious disease ecosystem SK bioscience, Sanofi's pneumococcal vaccine shows strong efficacy in p2 study SK bioscience acquires 7% stake in cash-strapped Novavax, forging long-term partnership SK bioscience says cell-cultured influenza vaccine will become new norm Lee Han-soo corea022@docdocdoc.co.kr See Other Articles Copyright © KBR Unauthorized reproduction, redistribution prohibited News That You Haven't Seen Mediwhale wins 1st place in MICCAI’s medical AI competition Falls and trips, primary reasons for older adults’ injuries, while youngsters must be careful about electric scooters [Interview] ‘Pediatric care will revive, so don't give up and stay with us’ Potential new cure found for treating glioblastoma resistant to immunotherapy Macular degeneration cases mark a 2.5-fold increase in 5 years Huons to acquire PanGen Biotech to boost biopharma R&D, CDMO biz Philips Korea to launch digital pathology reference site at Seoul Clinical Laboratories Mediwhale wins 1st place in MICCAI’s medical AI competition Comments Log In 작성자 비밀번호 댓글 내용입력 0 / 400 Submit 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More Delete comments Deleted comments cannot be recovered. Do you still want to delete it? Password Delete 닫기 Modify the comments You can modify comments only within 1 minute after writing. Text / 400 Password Modify 닫기 My comment collection 닫기 Important News [SITC 2024] MD Anderson study shows Lunit SCOPE IO platform could transform immunotherapy selection Ovarian cancer linked to endometriosis can be detected earlier than typical ovarian cancer Recordati's Isturisa wins Korean approval to treat Cusing's disease Medical students abused by patients develop negative views on professional identity Huons reports 6.3% revenue growth in Q3, focuses on diabetes devices, biopharma expansion [Column] Intentions and misunderstandings: who is at fault? Recent News [SITC 2024] MD Anderson study shows Lunit SCOPE IO platform could transform immunotherapy selection Ovarian cancer linked to endometriosis can be detected earlier than typical ovarian cancer Recordati's Isturisa wins Korean approval to treat Cusing's disease Medical students abused by patients develop negative views on professional identity Huons reports 6.3% revenue growth in Q3, focuses on diabetes devices, biopharma expansion Photo News [SITC 2024] MD Anderson study shows Lunit SCOPE IO platform could transform immunotherapy selection Ovarian cancer linked to endometriosis can be detected earlier than typical ovarian cancer Recordati's Isturisa wins Korean approval to treat Cusing's disease Medical students abused by patients develop negative views on professional identity Most Viewed 1 Mediwhale wins 1st place in MICCAI’s medical AI competition 2 Falls and trips, primary reasons for older adults’ injuries, while youngsters must be careful about electric scooters 3 [Interview] ‘Pediatric care will revive, so don't give up and stay with us’ 4 Potential new cure found for treating glioblastoma resistant to immunotherapy 5 Macular degeneration cases mark a 2.5-fold increase in 5 years 6 Huons to acquire PanGen Biotech to boost biopharma R&D, CDMO biz 7 Philips Korea to launch digital pathology reference site at Seoul Clinical Laboratories 8 Hanmi Pharm boosts R&D spending amid Q3 profit decline and global headwinds 하단영역 Latest [SITC 2024] MD Anderson study shows Lunit SCOPE IO platform could transform immunotherapy selection Ovarian cancer linked to endometriosis can be detected earlier than typical ovarian cancer Recordati's Isturisa wins Korean approval to treat Cusing's disease Medical students abused by patients develop negative views on professional identity Huons reports 6.3% revenue growth in Q3, focuses on diabetes devices, biopharma expansion [Column] Intentions and misunderstandings: who is at fault? [SITC 2024] Abion presents data on antibody-interferon platform for cancer treatment Severance Hospital tops NCSI rankings for healthcare service for 14 consecutive years Women’s hesitation to seek menopause treatment risks long-term health Should Korea's obesity threshold be raised to BMI of 27 or higher? Important Neurophet teams up with AriBio to develop next-generation Alzheimer's diagnostic platform facebook twitter rss 하단메뉴 About KBR Tip off Advertising Site Feedback Privacy Policy Adolescent Protection Policy E-mail address privacy 매체정보 The Korean Doctors’ Weekly Co., Ltd 76-1, Dongmak-ro, Mapo-gu, Seoul, Korea Tel : 82-2-2646-0852 Fax : 82-2-703-3916 Title : KBR Online newspaper registration number : Seoul 아 04285 Date of registration : December 19, 2016 Publishing date : February 22, 2017 CEO & Publisher : Yang Kyung-cheol Managing Editor : Kim Yoon-mi Juvenile Protection Manager: Lim Woong Copyright © KBR. All rights reserved. 위로 전체메뉴 All Hospital Pharma Bio All Korea‘s Bio Industry Device/ICT Policy People Life science Special All Innovation for Survival Korea’s medical culture series Korea’s New Candidate Drug Watch List Special Series in Celebration of KBR's 1st Anniversary Interview with foreign envoys Special Series in Celebration of KBR’s 2nd Anniversary Interview with global pharma Special Series in Celebration of KBR’s 3rd Anniversary ASCO 2020 Highlights Special Series in Celebration of KBR’s 4th Anniversary KBR Covering RSNA 2021 Special Series in Celebration of KBR’s 5th Anniversary Special Report on EULAR 2022 [Top K-Pharma Analysis] BIO 2023 Opinion All Reporter’s Notebook Journalist’s Column Congratulatory Remarks Sponsored 전체메뉴닫기16 cats killed by bird flu in Poland as global outbreak continues - The Jerusalem Post Advertisement JP Newsletter Israel News Health & Wellness WORLD NEWS Middle East Business & Innovation Opinion JP Store Login Log Out Archaeology Israel Real Estate Judaism Kabbalah Environment Antisemitism JP Spanish Podcasts JP Shopping Aliyah Portal Premium Jerusalem Post Health & Wellness 16 cats killed by bird flu in Poland as global outbreak continues The infected cats were found in locations separated by hundreds of kilometers. By TZVI JOFFRE JUNE 27, 2023 18:04 Updated: JUNE 28, 2023 22:32 A cat in a basket (Illustrative) (photo credit: Vadim B/Pexels) 16 cats have been confirmed to be infected with the H5N1 subtype of avian influenza in Poland, the country's Chief Veterinary Officer announced this week, as reports of mammals being infected with the virus continue to increase.The infected cats were found in Poznań, the tri-city metropolitan area, Lublin, Gdańsk, Gdynia, Pruszcz Gdański, Warsaw, and Bydgoszcz locations separated by distances of hundreds of kilometers.According to the Chief Veterinary Officer, initial investigations found that the virus the cats were infected with is not the same strain as the virus that has been infecting gulls in the country in recent weeks. The source of infection for the cats had not been identified as of Monday.The Polish General Veterinary Inspectorate is working to establish a protocol for monitoring bird flu spread in cats and advised residents to keep cats indoors if possible, prevent contact between cats and wild animals, prevent cats from coming into contact with footwear, feed cats only with food from known sources, and wash their hands after coming into contact with animals.A swan angry with a cat (Illustrative) (credit: Emrecan Algül/Pexels)Mass die-offs of mammals continue due to bird fluThe reports from Poland come as reports of mammals being infected with avian influenza continue to spread across the globe, with mass die-offs of seals and sea lions reported in Russia and the Americas and dozens of foxes, skunks, dolphins, raccoons, cats, ferrets and other mammals found to be infected as well.Dogs, cats and other pets have been affected by the outbreak in multiple countries as well, including the US and Canada. In a recent interview with AFP, Ian Brown, virology head at the UK's Animal and Plant Health Agency, stated that it would take "two or three minor changes in one protein of the viruses" for the bird flu to become more adapted to humans.Since 2021, Europe and the Americas have been suffering from a continuous outbreak of H5N1 avian influenza which has been described as "the largest-ever" outbreak on all three continents. The outbreak, as well as other strains of the virus, has also spread to other locations around the globe.In South Africa, two outbreaks of the H7 subtype of avian influenza were found recently, Reuters reported on Monday. Stay updated with the latest news! Subscribe to The Jerusalem Post Newsletter Subscribe Now Thousands of wild birds, over 58 million domesticated birds, and nearly 200 mammals have been confirmed to have been affected by the bird flu in the US alone. In Europe, tens of thousands of wild and domestic birds were found to be infected in over 24 countries, with many sea birds affected.Human cases of H5N1 have been detected in the UK, US, Cambodia, Ecuador and Chile.European CDC advises hospitals on how to monitor patients for bird fluOn Monday, the European Centre for Disease Prevention and Control (ECDC) proposed new instructions for strengthening hospital surveillance for severe human bird flu infections, noting that "some epidemiological changes observed recently could contribute to a wider exposure of the general population to infected sick and dead wild birds (and mammalian species)." Russia claims bird flu may be spreading in Ukraine's KhersonAdditionally, on Tuesday, Russia’s Federal Service for Veterinary and Phytosanitary Supervision warned that avian influenza may be spreading in the Kherson Region of Ukraine as the conflict and the collapse of the Kakhovka dam complicate surveillance efforts, according to TASS.The Russian agency additionally accused Ukraine of "hiding the real situation, particularly in terms of cases of highly pathogenic avian influenza in gull colonies."Last week, the US Department of Agriculture announced that it would be providing $502 million to prepare for additional outbreaks of avian influenza in the US.Sign up for the Health & Wellness newsletter >> Related Tags Poland Russia health Ukraine mammals Cats bird flu Hot Opinion Change the climate: Israel’s environmental potential at COP29 and regional impact By JPOST EDITORIAL To recover, Democrats must expel anti-Zionist extremists who put off Middle America By AMOTZ ASA-EL Leaders of the Jewish enemies have always died as weak cowards By URI PILICHOWSKI How will the recent US election affect Iran, Russia, and North Korea? By LOUIS RENÉ BERES Israel cannot work with an organization that enables Hamas activities and terrorism By ZINA RAKHAMILOVA Most Read 1 Israel can't arm itself with 30,000-pound bombs in time against Iran 2 'We were ambushed': Pogrom in Amsterdam wounds several 3 102 years ago, one of the all-time greatest archaeological discoveries was made 4 Scientists unlock secrets of 3,000-year-old tablet revealing path to Noah's Ark 5 Trump’s victory throws diplomatic bombshell into Israel's multi-front war Advertisement Information About Us Contact us Feedback Terms Of Service Privacy Policy Subscriber Agreement JPost Jobs Cancel Subscription Sitemap פרסום בג'רוזלם פוסט Customer Service Advertise with Us The Jerusalem Post Group Breaking News World News Iran News MDA Heroes The Jerusalem Report Jerusalem Post Lite חדשות מעריב Real Estate Listings Hype Special Content JP Store BrandBlend Services Precious Metals Tools and services JPost Premium Ulpan Online JPost Newsletter Our Magazines Learn Hebrew RSS feed JPost.com Archive Digital Library Lists of Jewish holidays Law לוח חגים ומועדים 2024 זמני כניסת שבת Sites Of Interest Poalim Online JNF-USA The Jerusalem Post Customer Service Center can be contacted with any questions or requests: Telephone: *2421 * Extension 4 Jerusalem Post or 03-7619056 Fax: 03-5613699 E-mail: subs@jpost.com The center is staffed and provides answers on Sundays through Thursdays between 07:00 AM and 14:00 PM and Fridays only handles distribution requests between 7:00 AM and 12:30 PM For international customers: The center is staffed and provides answers on Sundays through Thursdays between 7AM and 14PM Israel time Toll Free number 1-800-448-9291 Telephone +972-3-761-9056 Fax: 972-3-561-3699 E-mail: subs@jpost.com Copyright © 2024 Jpost Inc. All rights reserved • Terms of Use • Privacy Policy Designed byImportant Things You Must Know About Influenza Important Things You Must Know About Influenza Influenza can cause serious problems. Read on to know everything about the flu. 26 Jun, 2023 The Health Site Web Desk Influenza A Cases With the onset of the monsoon, cases of Influenza A have surged in the city. Source: Thehealthsite Fever Symptom of influenza is fever. The flu virus triggers the body's immune system, leading to the release of chemicals that raise body temperature and help combat the infection. Source: Thehealthsite Cough Another symptom of influenza is cough. The virus infects the respiratory tract, causing irritation and inflammation, leading to a persistent cough. Source: Thehealthsite Body ache Third symptom of influenza is body ache. The immune system responses to the flu virus can cause muscle and joint inflammation, resulting in generalised pain. Source: Thehealthsite Fatigue Another symptom of influenza is fatigue. The body's immune response to the flu virus along with release of certain chemicals, can cause overwhelming fatigue and exhaustion. Source: Thehealthsite Headache Last symptom is headache. Inflammation of blood vessels in the brain and surrounding tissues due to the flu virus can result in headache. Source: Thehealthsite Antiviral medication Cure to flu is antiviral medication. Prescription to antiviral drugs like oseltamivir, which can help in reducing the severity and duration of influenza symptoms. Source: Thehealthsite Supportive care Another cure to this is supportive care. Rest, hydration, and over-the-counter pain relievers can alleviate symptoms and promote recovery. Source: Thehealthsite Influenza immunization Yearly influenza immunization is essential, especially for people who have lower immunity. Source: Thehealthsite Thanks For Reading! Next: Influenza: 6 At-Home Remedies For Faster Recovery Find Out MoreImportant Things You Must Know About Influenza Important Things You Must Know About Influenza Influenza can cause serious problems. Read on to know everything about the flu. 26 Jun, 2023 The Health Site Web Desk Influenza A Cases With the onset of the monsoon, cases of Influenza A have surged in the city. Source: Thehealthsite Fever Symptom of influenza is fever. The flu virus triggers the body's immune system, leading to the release of chemicals that raise body temperature and help combat the infection. Source: Thehealthsite Cough Another symptom of influenza is cough. The virus infects the respiratory tract, causing irritation and inflammation, leading to a persistent cough. Source: Thehealthsite Body ache Third symptom of influenza is body ache. The immune system responses to the flu virus can cause muscle and joint inflammation, resulting in generalised pain. Source: Thehealthsite Fatigue Another symptom of influenza is fatigue. The body's immune response to the flu virus along with release of certain chemicals, can cause overwhelming fatigue and exhaustion. Source: Thehealthsite Headache Last symptom is headache. Inflammation of blood vessels in the brain and surrounding tissues due to the flu virus can result in headache. Source: Thehealthsite Antiviral medication Cure to flu is antiviral medication. Prescription to antiviral drugs like oseltamivir, which can help in reducing the severity and duration of influenza symptoms. Source: Thehealthsite Supportive care Another cure to this is supportive care. Rest, hydration, and over-the-counter pain relievers can alleviate symptoms and promote recovery. Source: Thehealthsite Influenza immunization Yearly influenza immunization is essential, especially for people who have lower immunity. Source: Thehealthsite Thanks For Reading! Next: Influenza: 6 At-Home Remedies For Faster Recovery Find Out MoreEpidemic and emerging disease alerts in the Pacific as of 27 June 2023 - World | ReliefWeb Skip to main content Help Log in ReliefWeb Content Search What are you looking for? Search|t Updates Countries Disasters Organizations Topics Jobs Training Informing humanitarians worldwide 24/7 — a service provided by UN OCHA World + 15 more Epidemic and emerging disease alerts in the Pacific as of 27 June 2023 Format Map Source SPC Posted 27 Jun 2023 Originally published 27 Jun 2023 Attachments Download Map (PDF | 462.98 KB) Highlights/updates since the last map was sent on PacNet on 20 June 2023: Leptospirosis Fiji: As of 22 June 2023, the Eastern Division is currently experiencing a leptospirosis outbreak in Kadavu Medical Subdivision. Since the beginning of the outbreak, there have been 29 confirmed cases, 42 hospital admissions, and 1 death. Consequently, a red alert for leptospirosis is added.* -- *Source: Personal communication with country officials on 22 June 2023. Influenza and Influenza-Like Illness (ILI) **Federated States of Micronesia (FSM): **As of 18 June 2023, the number of Influenza-like Illness cases have gone below threshold in Pohnpei State. The number of ILI cases in Pohnpei State have decreased in the past 3 weeks with 145 cases reported in week 24 and 42 cases in week 25, as a result the red alert for influenza B is removed. *-- *Source: Communicable Disease Weekly Bulleting -- Pohnpei State Department of Health and Social Services (report for Epi week: 25, June 12 -- 18, 2023). **Palau: **As of 25 June 2023, the increase in Influenza cases has escalated to an outbreak. Enhanced precautionary measures are recommended by the Ministry of Health & Human Services to interrupt the further spread of Influenza B. The number of Influenza-Like Illness cases escalated from 18 in week 24 to 61 in week 25. *-- *Source: Ministry of Health & Human Services Syndromic Surveillance (Epi Week 25 of 2023 and report information through June 25, 2023). Typhoid Fever Fiji : As of 22 June 2023, 32 cases have been reported in the Northern Division. Since the beginning of the outbreak, there have been 18 cases reported in Macuata, 11 cases reported in Bua and 3 cases in Cakaudrove Subdivision. Consequently, a red alert for typhoid fever is added.* -- *Source: Personal communication with country officials on 22 June 2023. Coronavirus disease 2019 (COVID-19): Due to the evolving nature of COVID-19 testing, vaccination and reporting strategies across the pacific region, the data reported might not reflect the true situation in a number of countries. Australia: Over the last week, 17,204 cases of COVID-19 were reported across Australia, an average of 2,458 cases per day. This is down from 3,072 average daily cases the week prior. -- Source: Department of Health, Australian Government accessed on 27 June 2023. **Commonwealth of the Northern Marianas (CNMI): **As of 17 June 2023, 32 new cases were reported in week 24. A total of 13,999 COVID-19 cases and 43 deaths were recorded by Commonwealth Healthcare Corporation of CNMI. The number of new COVID-19 cases increased by 88% in week 24 compared to the previous three weeks. There was one COVID-19 hospital admission in week 24. -- Source: CNMI Weekly Syndromic Surveillance Report (Epi Week 24; Epi Week Date: June 11 -- June 17, 2023). **Cook Islands: **As of 15 June 2023, there were 5 new cases recorded since 12 June, which bring a total of 7,142 COVID-19 cases and 2 deaths reported by the Cook Islands Ministry of Health. -- Source: COVID-19 - Cook Island Response accessed on 27 June 2023. **Federated States of Micronesia (FSM): **As of 04 June 2023, a total of 26,460 COVID-19 cases and 65 deaths were reported by the FSM Department of Health and Social Affairs. -- Source: FSM weekly Surveillance report (report date: 09 June 2023; report week #23, May 29 -- Jun 04 2023). Fiji: As of 15 June 2023, there was a notable increase in COVID-19 cases over the past 3 weeks. There were 43 new cases reported since 08 June 2023. The national 7-day rolling average of cases as of the 11^th^ June was 8 daily cases. -- Source: COVID-19 Update 15-06-2023 -- MHMS Fiji (health.gov.fj) accessed on 27 June 2023. **French Polynesia: **As of 18 June 2023, a total of 78,784 COVID-19 cases and 650 deaths were reported in French Polynesia. One new case was reported in week 24. The test positivity rate is 1.7% and there were no hospital admissions in week 24. Given the current trend and with only 1 new confirmed case during week 24 out of 59 reported test results, the blue alert for COVID-19 is removed. -- Source: Bulletin de surveillance sanitaire Polynésie Française n° 23 -- 2023. **Guam: As of 27 June 2023, a total of 62,185 COVID-19 cases and 413 deaths were reported by the Guam Department of Public Health and Social Services (DPHSS). In the past 7 days, 87 new cases were recorded. -- **Source: COVID-19 Surveillance Summary & Situation Report 27 June 2023. Hawaii: As of 21 June 2023, a total of 391,379 COVID-19 cases and 1,927 deaths were reported by the Hawaii Department of Health. There were 685 new cases since 14 June 2023.-- Source: State of Hawaii, Department of Health accessed on 27 June 2023. Kiribati: As of 14 June 2023, a total of 5,067 COVID-19 confirmed community cases and 24 deaths were reported by the Kiribati Government. There were 30 new cases since 30 May 2023**.** **-- **Source: Personal communication with country officials on 16 June 2023. New Zealand: As of 26 June 2023, a total of 2,413,279 COVID-19 cases and 3,117 deaths were reported by the New Zealand Ministry of Health. The 7-day rolling new case average is 1,096, compared to 1,217 the week prior. -- Source : New Zealand Ministry of Health accessed on 27 June 2023. **Niue: **As of 20 June 2023, a total of 820 COVID-19 cases and no deaths were reported by the Niue Government. No new cases have been reported since 02 June 2023. -- Source: Niue Government accessed on 27 June 2023. **Palau: **As of 25 June 2023, a total of 6,017 COVID-19 cases and 9 deaths were reported by the Republic of Palau. There were 2 new cases reported since the 16 June 2023. -- Source: Ministry of Health & Human Services Syndromic Surveillance (Epi Week 25 of 2023 and report information through June 25, 2023). Solomon Islands: As of 25 June 2023, a total of 25,945 COVID-19 cases and 199 deaths were reported by the Ministry of Health & Medical Services. There have been 2 new imported cases since the 24 May 2023**. Consequently, the blue alert for COVID-19 is removed. ***-- *Source: Personal communication with country officials on 25 June 2023. Tokelau: As of 21 June 2023, Tokelau has a total of 19 COVID-19 cases., 13 cases were imported and 6 were community cases. Five cases were reported in November 2022, 9 cases reported in May and 5 imported cases reported in. There are 2 cases still in isolation. -- Source: Personal communication with country officials on 22 June 2023. Tuvalu: As of 16 June 2023, a total of 3,243 COVID-19 cases and 1 death were reported by the Ministry of Health, Social Welfare, and Gender Affairs. Between 26 May -- 16 June 2023, there was a total of 166 confirmed cases with 32 cases between the period of 03 -- 16 June 2023. One death has been reported on the 03 June 2023. -- Source: SARS-CoV-2 Outbreak Situational Report #2, 19^th^ June 2023 (03^rd^ -- 16^nd^ June). MORE information and data visualization products on COVID-19 morbidity and mortality in the Pacific Islands can be accessed on SPC website at https://www.spc.int/updates/blog/2021/03/covid-19-pacific-community-updates. Outside of the Pacific Coronavirus disease 2019 (COVID-19): A total of 768,187,096 cases of COVID-19 and 6,945,714 deaths were reported globally as 14 June 2023.-- Source: WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data accessed on 27 June 2023. Other updates and information on Coronavirus disease 2019 (COVID-19) can be accessed at WHO Coronavirus disease 2019 (COVID-19) situation reports and WPRO COVID-19 Dashboard_bk (arcgis.com). **Other information: ** Dengue **French Polynesia: **As of 21 June 2023, an imported case of dengue was detected in Fenua. The patient, who arrived from Asia, was promptly treated in Moorea to prevent the spread of an epidemic. The identified serotype is Type 3. The last DENV-3 outbreak in French Polynesia was 10 years ago. -- Source: Bulletin de surveillance sanitaire Polynésie Française n° 23 -- 2023. Meningococcal Meningitis Australia: As of 20 June 2023, a case of invasive meningococcal disease was notified in a 25-year-old man from metropolitan Adelaide. The strain has been identified as serotype B. South Australia Health identified multiple people who had contact with the patient, of whom two people have been directed to receive clearance antibiotics. There have been ten cases of invasive meningococcal disease reported in South Australia this year, compared to six cases recorded by the same time last year. Of the ten cases reported so far this year, nine are serogroup B and one is serogroup W.-- Source: Meningococcal case 20 June 2023 | SA Health accessed on 27 June 2023. Tuberculosis Australia: As of 21 June 2023, Health professionals are reminded to consider Tuberculosis when patients present within the Northern Territory (NT). There have now been two Tuberculosis-related deaths reported in the NT since the beginning of 2023. -- Source: Tuberculosis (TB) | NT Healthaccessed on 27 June 2023. Report details Primary country World Other countries AustraliaCook IslandsFijiFrench Polynesia (France)GuamKiribatiMarshall IslandsMicronesia (Federated States of)New ZealandNiue (New Zealand)PalauSolomon IslandsTokelauTuvaluWallis and Futuna (France) Source Pacific Community Format Map Theme Health Disaster type Epidemic Language English Share Share this on Facebook Share this on X Post this on LinkedIn Related Content World Navigating the climate-health nexus: linking health data with climate data to advance public health interventions Format Analysis Source BMC Posted 12 Nov 2024 Originally published 11 Nov 2024 World + 7 more Polio Transition Independent Monitoring Board Seventh Report - The struggle for progress: Does system strengthening always have to be slow? (October 2024) Format Analysis Source GPEI Posted 12 Nov 2024 Originally published 7 Nov 2024 World Prioritising health in humanitarian work: the need for comprehensive and inclusive research Format News and Press Release Source ODI - HPN Posted 11 Nov 2024 Originally published 11 Nov 2024 World Joint Brief: the Lancet Countdown on Health and Climate Change & Médecins Sans Frontières 2024 - Every Climate Action Counts: the Ripple Effect of Each Failure on Health Care in Humanitarian Settings Format Analysis Sources MSFThe Lancet Posted 11 Nov 2024 Originally published 11 Nov 2024 Blog Labs About Us Terms Contact Facebook X LinkedIn Instagram Telegram OCHA Services Related Platforms Humanitarian Action Central Emergency Response Fund Other OCHA Services Financial Tracking Service Humanitarian Data Exchange Humanitarian ID ReliefWeb Response Inter-Agency Standing Committee OCHA website ReliefWeb Virtual OSOCC More OCHA Services Opens in a new window Service provided by United Nations Office for the Coordination of Humanitarian Affairs UN OCHA United Nations Office for the Coordination of Humanitarian Affairs OCHA coordinates the global emergency response to save lives and protect people in humanitarian crises. We advocate for effective and principled humanitarian action by all, for all. ReliefWeb's Terms & Conditions. © 2024 all rights reserved.Influenza, COVID-19 and RSV cases jump in Qld, parents and carers warned to remain cautious - ABC NewsSkip to main contentABC NewsJust InFor YouPoliticsUS ElectionWorldBusinessAnalysisSportLifestyleEntertainmentMoreSearch the news, stories & peopleLog inNews HomeJust InFor YouAnalysisRuralWatch LiveHealthIndigenousPoliticsUS ElectionScienceElectionsWorldEnvironmentInvestigationsBusinessFact CheckLocal newsSportAFLNRLFootballTennisCricketNetballLifestyleWellbeingRelationships & FamilyFood & RecipesPersonal FinanceHome & GardenEntertainmentTV & MoviesBooksMusicPop CultureArtsYour ABC AccountPersonalise the news andstay in the knowLog in to personaliseFacebookYouTubeInstagramTwitterEmergencyBackstoryNewsletters中文新闻BERITA BAHASA INDONESIATOK PISINABCABC iViewABC ListenTriple JABC KidsABC NewsABC News News HomeLatest updatesAsk a questionShare Influenza, COVID-19 and RSV cases jump in Qld, parents and carers warned to remain cautiousBy Michelle GatelyABC CapricorniaTopic:HealthWed 28 Jun 2023Wednesday 28 June 2023Wed 28 Jun 2023 at 8:06pmMontana Shortland wants other parents to know about the high risks of RSV in infants. (ABC Capricornia: Michelle Gately)abc.net.auewssv-covid-influenza-cases-spike-queensland/102536682Link copiedShareShare articleAs Montana Shortland's son Griffin giggles and hiccups from his rocker, he looks like a healthy newborn baby.Key points:RSV is one of about 200 viruses that can cause a cold, but can lead to life-threatening illnesses in infants and the elderlyThere have been more than 15,387 cases in Queensland so far this yearDoctors say the combination of influenza, RSV and COVID-19 have created a "robust" and prolonged winter illness seasonBut a month ago, things looked very different. Ms Shortland thought Griffin "would not be coming home" after what seemed like a common cold saw him airlifted for specialist intensive care."I didn't sleep at all. I didn't eat," she said."I was so scared if I took my eyes off him for one second, he may be dead."Now 10 weeks old, Griffin still has a lingering cough but has otherwise recovered from a serious bout of respiratory syncytial virus (RSV).The virus is common among children. According to Queensland Health, most children will catch RSV at least once before they turn two.The symptoms of RSV, COVID-19 and influenza (the flu) can all overlap and health officials are warning that this year's wave of winter respiratory illnesses may be the worst in several years.Baby Griffin deteriorated rapidly while in Rockhampton Hospital and was airlifted to the Sunshine Coast. (Supplied: Montana Shortland)Life-threatening virusMs Shortland believes Griffin may have caught RSV from his 18-month-old brother Archer who attends day care.She said Griffin, then six weeks old, went from having a runny nose one day to "gasping for air" the next.He was admitted to Rockhampton Hospital where laboratory tests confirmed RSV."The ED doctor told me that if I hadn't brought him in when I did, I could very possibly have woken up with a baby that wasn't breathing the next morning," Ms Shortland said.Heard a lot about RSV lately? Let's unpack the symptomsPhoto shows Person leaning over a table wearing a hooded gown, with a box of tissues and a mug on the table.This respiratory virus is so common that most children will have had it at least once it before they turn two.Data from Queensland Health reported 449 cases of RSV in central Queensland in the year to June 18, with 15,387 cases state-wide in the same period.Young children and infants are susceptible to developing bronchiolitis from RSV, said Margaret Young from the Central Queensland Hospital and Health Service's public health unit."They develop wheezing and can develop difficulty breathing," she said."Unlike influenza, where there is a community-wide funded program for influenza vaccine, the prevention of RSV is really through making sure that transmission is restricted."A newly developed vaccine for RSV is yet to be approved in Australia.Dr Young said the combination of influenza, RSV and COVID-19 created a "robust" and prolonged winter illness season.But she said it was not too late in the season to get a flu vaccine and encouraged those at risk of complications to take advantage of subsidised immunisations.Airlifted for critical careMs Shortland said Griffin was admitted to Rockhampton Hospital's paediatric ward and placed on high-flow oxygen and a feeding tube.After three days in the hospital, Griffin was improving and plans were being made to take him home.Griffin spent more than a week in hospital, but has now recovered. (Supplied: Montana Shortland)But that evening he rapidly deteriorated."There were about 10 doctors in there, there were nurses everywhere," Ms Shortland said."The decision was made that we would be flown to the Sunshine Coast University Hospital where he would be placed in critical care."After another four days in intensive care, Ms Shortland was able to take Griffin home."We never imagined that a slight cold or a slight cough could have turned into something so serious," she said.Complacency after COVID-19With COVID-19 restrictions broadly eased over the past year, Michael Clements from the Royal Australian College of General Practitioners says people have become complacent. What are the differences between COVID-19, RSV and the flu? Photo shows A woman lying in bed with medications next to herIs it COVID-19, RSV or the flu? Let's unpack their differences in symptoms."I think there's certainly complacency around COVID-19 … and then that has led into a complacency around normal viruses," he said."I guess we've had it good for the last few years because people have been respecting all of the viruses."We can see people are really just trying to get back into their normal activities and perhaps go back to some of our pre-COVID habits that did see the growth of the normal influenza and viral seasons."ABC Capricornia — local news in your inboxGet our local newsletter, delivered free each FridayYour information is being handled in accordance with the ABC Privacy Collection Statement.Email addressSubscribePosted Wed 28 Jun 2023 at 8:06pmWednesday 28 Jun 2023 at 8:06pmWed 28 Jun 2023 at 8:06pmShare optionsCopy linkFacebookX (formerly Twitter)Top StoriesFamily of teacher's aide killed in preschool crash pay tribute to 'cherished mother, wife, daughter'Topic:Road Accidents and IncidentsPhoto shows Eleanor Bryant, who was killed when a truck crashed into a Victorian preschool, pictured smiling at the races.Barron Trump and AOC expose the problems with the Democratic campaignTopic:US ElectionsPhoto shows Barron Trump and Alexandria Ocasio-Cortez in a split screen image. Four foreign nationals found on remote NT island say they paid money to be taken to AustraliaTopic:Indigenous (Aboriginal and Torres Strait Islander)Photo shows Four people walk in the shallows of a coastline, with white backs slung over their shouldersRex given $80m lifeline, as ACCC warns Qantas controls 65pc of market and prices are upLIVEPhoto shows A Regional Express (REX) aircraft unloads at Charleville Airport in south-west Queensland.Donald Trump and the one big threat to Australia's almost $4 trillion superannuation systemDAnalysis by David TaylorPhoto shows SuperannuationRelated storiesQueensland hit hard by outbreaks of RSV ahead of winterTopic:Infectious DiseasesPhoto shows Close up of an adult's hand holding an in-ear thermometer to a child's ear.Researchers hope to develop vaccine to eliminate childhood virus RSVTopic:Infant HealthPhoto shows A little boy sits in a chair in an ambulanceAustralia is having a bad flu season and vaccination rates are fallingTopic:Respiratory DiseasesPhoto shows A woman blows a young child's nose.Related topicsBabiesCOVID-19ChildrenHealthInfectious DiseasesInfluenzaRespiratory DiseasesRockhamptonVaccines and ImmunityTop StoriesFamily of teacher's aide killed in preschool crash pay tribute to 'cherished mother, wife, daughter'Topic:Road Accidents and IncidentsPhoto shows Eleanor Bryant, who was killed when a truck crashed into a Victorian preschool, pictured smiling at the races.Barron Trump and AOC expose the problems with the Democratic campaignTopic:US ElectionsFour foreign nationals found on remote NT island say they paid money to be taken to AustraliaTopic:Indigenous (Aboriginal and Torres Strait Islander)Rex given $80m lifeline, as ACCC warns Qantas controls 65pc of market and prices are upTopic:Stock MarketDonald Trump and the one big threat to Australia's almost $4 trillion superannuation systemDAnalysis by David TaylorJust InCosmic coincidence leads NASA scientists to believe Uranus could support lifeTopic:Planets and Asteroids15m ago15 minutes agoTue 12 Nov 2024 at 2:50amLED lighting on surfboards may deter great white sharks from attacking surfersTopic:Shark Attacks28m ago28 minutes agoTue 12 Nov 2024 at 2:38am'Today was the day': Almost eight years after Abby and Libby were murdered, a jury hands down a guilty verdictTopic:Homicide40m ago40 minutes agoTue 12 Nov 2024 at 2:25amPlans to extend anti-protest laws in NSW labelled 'a rampage against free speech' by climate activistsTopic:Demonstrations4m ago4 minutes agoTue 12 Nov 2024 at 3:01amMore Just InBack to topFooterABC News homepageMore From ABC NEWSWe acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the lands where we live, learn, and work.SectionsABC NEWSJust InWatch LivePoliticsWorldBusinessAnalysisSportScienceHealthEntertainmentLifestyleFact CheckOtherNews in language中文Berita Bahasa IndonesiaTok PisinConnect with ABC NewsFacebookInstagramYouTubeApple NewsX (formerly Twitter)More from ABC NewsContact ABC NEWSThis service may include material from Agence France-Presse (AFP), APTN, Reuters, AAP, CNN and the BBC World Service which is copyright and cannot be reproduced.AEST = Australian Eastern Standard Time which is 10 hours ahead of GMT (Greenwich Mean Time)Editorial PoliciesAccessibilityHelpContact UsAbout the ABCPrivacy PolicyTerms of Use© 2024 ABCTechnology app to help farmers get ahead of bird flu - Poultry World × PoultryGeneticsLayersBroilersOther speciesHealth/NutritionHealth ToolHealthNutritionAvian influenzaGut HealthWorld of PoultryFarm visitsBest practicesSpecialsEditor’s PickInnovative farmingProcessingDigital magazineWebinarsVideosOur sitesAll About FeedPig ProgressDairy GlobalFuture FarmingNewsletter Login/Register SubscribeVideosseminarsWebinarsDigital magazineNewsletterSubscribe PoultryGeneticsLayersBroilersOther speciesMarketsProcessingInnovative farmingMarket trends/analysisPoultry insightsHealth/NutritionGut HealthHealth ToolAvian influenzaHigher welfareNutritionHealthWorld of PoultryFarm visitsCountry FocusBest practicesSpecialsEditor’s PickOur sitesAll About FeedPig ProgressDairy GlobalFuture Farming Logout Gateway to the global poultry industry Technology app to help farmers get ahead of bird flu 30-06-2023 | Health | NewsThe real-time outbreak notifications alert farmers if their business is located within an identified outbreak zone and provide guidance on the measures to be taken immediately to protect their flocks. Photo: Livetec Systems AppPoultry farmers and backyard flock keepers are being given a helping hand in their battle against avian influenza in the form of a new, free app.The app is designed to improve disease reporting and tracking to help limit the spread of disease. It comes as the UK government continues to impose strict rules amid the worst bird flu outbreak.The Livetec Systems App empowers early detection and quick response to animal health issues with a wealth of intuitive, practical features, including real-time outbreak notifications and reporting.ALSO READ: Living with the risk of bird flu – a reportThe real-time outbreak notifications alert farmers if their business is located within an identified outbreak zone and provide guidance on the measures to be taken immediately to protect their flocks.Outbreak reporting and monitoringOutbreak reporting is also simplified, and the built-in reporting tool enables any poultry keeper identifying suspicious symptoms to use the app to quickly and compliantly alert relevant authorities, helping to prevent further spread.ALSO READ: Avian influenza: No one size fits all, says WOAHIt also includes disease outbreak monitoring, giving users visibility to the national outbreak status, so they can see the location of their property and the proximity to current outbreaks and the zones around them.“Preparedness is key”Gordon Samet, Livetec Systems commercial director, said: “Preparedness is key to protecting poultry. The Livetec Systems App has been created to help farmers and backyard keepers to avoid unnecessary expenses, prevent disease outbreaks, and protect their birds, revenue streams and reputation.ALSO READ: Impact of the 2022 avian influenza epidemic in the US“With avian influenza becoming harder to stem and cases continuing way past the traditional window, it’s more important than ever to stay on top of disease management. Downloading the app delivers real-time updates on avian influenza outbreaks directly to the palm of the hand, makes it easy to report suspicious symptoms and simplifies the task of knowing what to do should bird keepers be caught in a disease zone.”The app is available to download for free on the App Store (Apple) and Google Play (Android).Join 31,000+ subscribers Subscribe to our newsletter to stay updated about all the need-to-know content in the poultry sector, three times a week. "*" indicates required fieldsEmail* First name*CommentsThis field is for validation purposes and should be left unchanged. Tony Mcdougal Freelance JournalistMore aboutavian influenzabird flutechnologyRelated articles05-11 | Expert opinionDoes the poultry industry have a workforce problem?01-11 | NewsBackyard pig in US found infected with H5N125-10 | NewsOne year of avian influenza vaccination in France15-10 | NewsStrengthening poultry research collaboration between Britain and China Health tool Focus topicsSpecial editionsHealth ToolGut HealthAvian influenzaEditor’s PickProductsWebinarsEventsNewsletterDigital magazineOur content partnersSocialFacebookLinkedInTwitterYouTubeInstagramWhatsappServicesContactAdvertisingOur sitesNewsletter "*" indicates required fieldsEmail* First name*EmailThis field is for validation purposes and should be left unchanged. Misset Uitgeverij B.V. Copyright reserved.The following rules apply to the use of this site: Terms of Use, Privacy Policy and Cookie Policy.RFK Jr. Hosts Conspiracy Riddled Panel With Anti-Vaxxers × × Skip to main content Rollingstone Logo Click to expand the Mega Menu Click to Expand Search Input Music Politics TV & Movies Culture RS Recommends Got A Tip? Account Welcome Manage Account Manage Print Account Sign Out Log In Click to expand the Mega Menu Click to Expand Search Input Rollingstone Logo Politics RFK Jr. Claims ‘Vaccine Research’ Likely Responsible for HIV and the Spanish Flu Facebook X email Got A Tip? Account Welcome Manage Account Manage Print Account Sign Out Log In Trust Me Bro RFK Jr. Claims ‘Vaccine Research’ Likely Responsible for HIV and the Spanish Flu The 2024 presidential hopeful hosted a panel with some of the loudest vaccine skeptics in the nation By Nikki McCann Ramirez, Miles Klee June 27, 2023 Presidential hopeful Robert F. Kennedy Jr. at the State House in Concord, New Hampshire. JOSEPH PREZIOSO/AFP/Getty Images Robert F. Kennedy Jr. convened a panel of health misinformation superstars on Tuesday evening for a roundtable discussion that suggested his medical conspiracism will be a key component of his 2024 presidential run. During the unfiltered conversation, he falsely suggested that millions of deaths in the Great Influenza (or “Spanish flu”) epidemic of 1918 could be attributed to vaccine experiments. The long-shot candidate — known for promoting the debunked link between vaccines and autism, and opposing Covid-19 vaccination efforts — was joined in conversation by four doctors as well as several influencers and alternative medicine promoters, all of whom have gained notoriety for false claims about the dangers of vaccination. The live event aired on Rumble, a video streaming site favored by far-right extremists and conspiracy theorists, particularly those who have been banned by other platforms. During the discussion, Kennedy made several unfounded claims regarding the origins of infectious diseases and their relationships to vaccines. At one point, he baselessly asserted that vaccine research had been responsible for the creation of some of the deadliest diseases in human history, including HIV, the Spanish flu, and Lyme disease. “I will end all gain-of-function research [as president],” Kennedy said. “It’s just a disaster, it’s given us no benefits. It’s given us everything from Lyme disease to Covid, and many many other diseases. RSV, which is now one of the biggest killers of children, came out of a vaccine lab.” “We can go down the whole list of diseases,” he added. “There’s even good evidence that even Spanish flu came from vaccine research.” Kennedy then claimed that “the medical research on these diseases and vaccine research has actually created some of the worst plagues in our history. Anybody who reads The River will come away pretty much convinced that HIV also came from a vaccine program, there’s plenty of evidence on that as well.” Editor’s picks The 100 Best TV Episodes of All Time The 250 Greatest Guitarists of All Time The 500 Greatest Albums of All Time The 200 Greatest Singers of All Time Kennedy has previously claimed, without evidence, that AIDS was not caused by HIV (human immunodeficiency virus) but “a gay lifestyle” and the use of alkyl nitrites, or poppers. His 2021 book The Real Anthony Fauci included similar AIDS denialism — including the falsehood that the disease is not caused by HIV — views that he repeated this month on Joe Rogan’s podcast, which commands an audience of millions. RFK Jr. baselessly claims there's "good evidence" that "vaccine research" is the cause of diseases like HIV, RSV, Lyme disease, and even the Spanish flu pic.twitter.com/iPRpxrm8M6— nikki mccann ramírez (@NikkiMcR) June 27, 2023 “I do not believe that infectious disease is an enormous threat to human health,” Kennedy added. The presidential hopeful stated that if he assumed office, he would target medical journals and redirect funding grants away from epidemiology. Further along in the discussion, Kennedy discussed his proposal for a “corporate death penalty” to be leveled against companies found to be defrauding the public. He suggested that some institutes “associated with promoting vaccines” could be subjected to it. RFK Jr. suggests that some institutes "associated with promoting vaccines" be subjected to a "corporate death penalty." pic.twitter.com/FpjEchC3ZL— nikki mccann ramírez (@NikkiMcR) June 28, 2023 Kennedy and three of Tuesday’s roundtable guests — Dr. Sherri Tenpenny, Dr. Joseph Mercola, and Sayer Yi — were named as members of the “Disinformation Dozen” by the Center for Countering Digital Hate in 2020. After analyzing a sample of anti-vaccine content shared or posted on Facebook or Twitter a total of 812,000 times in early 2021, researchers at the organization found that 65 percent of it could be traced back to this small group. Tenpenny and Mercola are both osteopathic physicians. Tenpenny has claimed that the Covid-19 vaccine makes people magnetic and may connect them to 5G towers. Suspended from Twitter in 2021, she was reinstated under Elon Musk. She’s also under investigation for unspecified reasons by the State Medical Board of Ohio as of October 2022, and may lose her license simply for failing to cooperate with the probe. Mercola, a kingpin of “natural health” products who was boosted by Dr. Oz, has peddled quack cures for Covid, earning a warning from the FDA in 2021. He has also claimed the Covid jab will “alter your genetic coding, turning you into a viral protein factory that has no off-switch,” and platformed medical conspiracists who claim that HIV does not cause AIDS. Related Content Trump's Cabinet Could Include Senator Who Tried to Fight Hearing Witness: Report Trump Taps Family Separation Mastermind to Be ‘Border Czar’ Americans Didn’t Vote for What Donald Trump Is About to Give Them From a High-Schooler to the Democrats: We Must Keep Fighting Also questioning Kennedy was Sayer Yi, whose alternative medicine website was banned from Twitter and Instagram in 2020. Ji has promoted the baseless link between vaccines and autism and falsely claimed the Pfizer vaccine killed more people than Covid itself. Mikki Willis, producer of the 2020 film Plandemic — one of the most notorious pieces of anti-vaccine propaganda made in response to the Covid pandemic — interrogated Kennedy on his beliefs around climate change. Plandemic 3, a sequel to Willis’ original film, argued that the HIV antiviral treatment drug AZT was actually responsible for the AIDS epidemic of the Eighties and Nineties. Kennedy’s conspiratorial views on vaccines long predate those stemming from the Covid pandemic. In 2005, he published the article “Deadly Immunity,” which falsely claimed a link between childhood vaccines and autism, in Rolling Stone. Following repeated debunkings of the claim by members of the scientific community, Rolling Stone retracted the article in 2011. Trending Stories Americans Didn’t Vote for What Donald Trump Is About to Give Them Trump Tells GOP to Bypass Senate Confirmation Process, Block Biden Judicial Appointments The Edge Looks Back on 'Atomic Bomb,' Ahead to U2's Next Album House Fast-Tracks Bill That Would Give Trump Power to Target Nonprofits But scientific advancement has not deterred Kennedy from his position. In 2014, Kennedy published the book Thimerosal: Let the Science Speak: The Evidence Supporting the Immediate Removal of Mercury—a Known Neurotoxin—from Vaccines, which claimed certain ingredients used in vaccine preservation were toxic. No evidence has been found to substantiate his assertions. In recent years, Kennedy’s stance has only grown more radical. Last January, he compared vaccination requirements to the plight of the Jewish people in Nazi Germany. In January of this year, he joined a lawsuit with several other vaccine conspiracy theorists, alleging that the labeling of their claims by journalistic publications as “misinformation” constitutes a violation of antitrust laws. In this article: 2024 Election, anti-vaccine, Robert F. Kennedy Jr., vaccines Politics Politics News More News Trump to Tap Marco Rubio for Secretary of State: Report Little Marco By Charisma Madarang Trump's Cabinet Could Include Senator Who Tried to Fight Hearing Witness: Report Agressive Policy By Nikki McCann Ramirez Trump Taps Family Separation Mastermind to Be ‘Border Czar’ Deportation Nation By Nikki McCann Ramirez Americans Didn’t Vote for What Donald Trump Is About to Give Them Commentary By Jay Michaelson Trump Tells GOP to Bypass Senate Confirmation Process, Block Biden Judicial Appointments sore winner By Peter Wade Read more Trump to Tap Marco Rubio for Secretary of State: Report Little Marco 46 mins ago Dwayne Johnson Says He's Now Open to 'Deeper' Films: 'I've Evolved' Wanting More 2 hours ago Sting Says Diddy Allegations Don't 'Taint' Police Hit 'Every Breath You Take' 'Still My Song' 2 hours ago Former Iron Maiden Frontman Paul Di'Anno's Cause of Death Revealed Update 4 hours ago Top stories newsletter A Cultural Force That Transcends Generations Enter your Email By providing your information, you agree to our Terms of Use and our Privacy Policy. We use vendors that may also process your information to help provide our services. Go to PMC.com Most Popular Grammy Nominations 2025: Beyonce Leads With 11 Nods as Taylor Swift, Chappell Roan, Sabrina Carpenter and Charli XCX Are Among Top Nominees 'Yellowstone' Premiere Quickly Reveals Fate of Kevin Costner's Character: "We Let the Cat Out of the Bag" 178 Amazon Favorites That Have Earned a Spot In Everyone's Cart British Artist Sarah Cunningham Dies at 31, Trio Charged for Vandalizing Homes of Brooklyn Museum Execs, and More: Morning Links for November 5, 2024 You might also like ‘Yellowstone’ Director on John Dutton’s Bloody Crime Scene, Beth’s Primal Wail and More Secrets 3 hours ago Naiomi Glasses and David Lauren Talk About Her Collaboration With Ralph Lauren 5 hours ago The Best Yoga Mats for Any Practice, According to Instructors 8 months ago Jeff Goldblum Isn’t Worried About ‘Wicked’ Competing with ‘Gladiator II’: There’s ‘Enough to Go Around’ 3 hours ago Endeavor CEO Buys Endeavor Betting Biz for $450 Million 3 mins ago Rolling Stone Music Politics TV & Movies Culture Staff Contact Advertise Shop Legal Privacy Policy Terms of Use AdChoices PMC Entertainment California Privacy Rights Your Privacy Choices EU Privacy Preferences Accessibility Policy on Anonymous Sources Follow Us Facebook Instagram TikTok X YouTube Newsletter Signup Enter Your Email Subscribe Got a Hot News Tip? We want to hear it. Send us a tip using our anonymous form. Send Us a Tip By providing your information, you agree to our Terms of Use and our Privacy Policy. We use vendors that may also process your information to help provide our services. Rolling Stone is a part of Penske Media Corporation. © 2024 Rolling Stone, LLC. All rights reserved. Powered by WordPress.com VIP Our Sites Art in America Artforum Artnews ATX TV ATX TV Festival BGR Billboard BlogHer Deadline Flow Space Footwear News GoldDerby IndieWire LA3C Life is Beautiful Robb Report Rolling Stone SheKnows Soaps Sourcing Journal Sportico Spy StyleCaster The Hollywood Reporter TVLine Variety Vibe WWD Log In Welcome Manage Account Manage Print Account Sign Out Music News Features Lists Album Reviews Live Reviews Artists You Need To Know Songs You Need To Know RS Country RS Latin Politics News Features Lists Shop TV & Movies News Features Lists Recaps Reviews Video & Photos Photos Videos The Cover Musicians on Musicians Culture News Features Lists Creators RS Gaming RS Films RS Recommends Reviews RS Essentials RS Audio Awards Gift Guides Culture Council Subscription Icon Follow Us Facebook Instagram TikTok X YouTube Alerts & Newsletters Email Address By providing your information, you agree to our Terms of Use and our Privacy Policy. We use vendors that may also process your information to help provide our services. adHybrid immunity and vaccine Imprinting: Powerful defenses against Omicron reinfection Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About COVID-19 News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge Newsletters Health & Personal Care eBooks Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Cold, Flu & Cough Eating Disorders Eye Health Gastrointestinal Health Heart Disease High Blood Pressure Lung Cancer Mental Health Mpox Pregnancy Type 1 Diabetes Type 2 Diabetes Sexual Health Sleep View Health A-Z ×Top Health Categories Coronavirus Disease COVID-19 Heart Disease Diet & Nutrition High Blood Pressure Artificial Intelligence Lung Cancer Allergies Mental Health Alzheimer's & Dementia Mpox Arthritis & Rheumatology Pregnancy Breast Cancer Type 1 Diabetes Cold, Flu & Cough Type 2 Diabetes Eating Disorders Sexual Health Eye Health Sleep Gastrointestinal Health View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge Newsletters Health & Personal Care eBooks Contact Meet the Team Advertise Search Become a Member Webinars eBooks Contact Meet the Team Advertise Search Become a Member Hybrid immunity and vaccine Imprinting: Powerful defenses against Omicron reinfection Download PDF Copy By Dr. Priyom Bose, Ph.D.Reviewed by Benedette Cuffari, M.Sc.Jun 25 2023 To date, the ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has claimed more than 6.94 million lives worldwide. Study: Humoral immune response to omicron infection in long-term Wuhan-Hu-1-imprinted population. Image Credit: visualstock / Shutterstock.com*Important notice: Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. Background In contrast to prior recommendations, the recent World Health Organization (WHO) guidance indicated no need for annual booster COVID-19 vaccination for low-risk populations. This updated WHO guidance has triggered a debate on the effectiveness of regular booster vaccination, particularly because of the lack of impressive serum neutralization against SARS-CoV-2 Omicron sub-variants. The abrupt withdrawal of COVID-19 booster recommendations could also be due to incomplete evidence regarding the persistence and effectiveness of natural infection-elicited immune protection against re-infection caused by emerging variants with different antigenic characteristics. The majority of studies have indicated that prior infection of Wuhan-Hu-1(WH1), which is the ancestral SARS-CoV-2 strain, and WH1-based vaccination have weakened humoral immune responses to Oubsequent omicron infection. These findings are consistent with immune imprinting in influenza virus infection. Antigenic cartography studies have demonstrated that antigenic distances between SARS-CoV-2 variants and Omicron sub-variants were only of 103-fold change in neutralization titer levels. Thus, as compared to influenza infection, SARS-CoV-2 infection manifests smaller imprinting effects. Most of the world population was exposed to SARS-CoV-2 antigens through WH1-based vaccines. As a result, a new study under review at Nature Portfolio and currently posted to the Research Square preprint server evaluates the effects of long-term WH1 imprinting on the humoral immune response to an antigenically distant SARS-CoV-2 variant to determine the maximal imprinting effects in the current SARS-CoV-2 variant landscape. About the study The Hubei province of China, which was the main epicenter of the first COVID-19 outbreak in the world, successfully avoided all pre-Omicron variants due to the implementation of strict public health measures. Most people in Hubei were vaccinated with several rounds of WH1-based COVID-19 vaccines; therefore, the majority of this population was exclusively WH1 imprinted. Related StoriesFrequent infections and pathobionts boost children's nasal immunity, study revealsVaccines and virus changes cut long COVID risk by 50%, but Omicron still poses a threatNew single-chain mRNA vaccines offer enhanced immunity and protection against mpoxHubei experienced a population-wide Omicron outbreak in December 2022, with about 90% of the population infected by the BF.7 sub-variant and its derivates. Scientists took the opportunity of this sweeping outbreak to study immune imprinting in re-infected participants. The study cohort comprised WH1-infected participants from Xiangyang City of Hubei province. Study participants reinfected with the Omicron variant provided serum samples two months following the infection. Some of the participants were vaccinated with three doses of whole-inactivated virus (WIV) vaccines. Serum samples collected from WH1-infected and triple-vaccinated participants at three to four months before Omicron infection were used as pre-infection controls. Other cohorts from the same region were studied. One cohort included vaccinated participants, whereas another cohort contained unvaccinated participants. Pre- and post-Omicron infection serum samples from the vaccinated and unvaccinated cohorts were obtained. Importantly, all participants did not have any history of immunological disorders or were under any medication that could affect the immune system. Humoral immune responses were measured using pseudovirus neutralization assays, which were based on non-replicative vesicular stomatitis viruses (VSV) pseudotyped with spike proteins of WH1, Omicron BF.7, BQ.1.1, or XBB.1.5. Study findings The current study used pre-and post-Omicron infection sera from an exclusively WH1-imprinted population to determine long-term and long antigenic distance immune imprinting on the humoral immune system. Based on the pseudovirus neutralization assays, an increase in WH1 and Omicron sub-variants neutralization was observed in WH1 imprinting as compared to naïve sera. Mechanistically, antibody feedback limited the magnitude of WH1 back-boost through antibody diversity enhancement. In addition, antigenic seniority caused a rapid upregulation of Omicron neutralization titers by recalling cross-reactive B-cells upon Omicron infection. Only hybrid WH1 imprinting marginally reduced forward neutralization breadth without affecting the overall neutralization titers after Omicron infection. Importantly, the imprinting effects collectively increased the protection levels against reinfection. Therefore, it could be beneficial to support immune imprinting for humoral immunity. Conclusions The current study supports the WHO recommendation against the COVID-19 booster vaccination in low-risk populations. In fact, the study findings strongly indicate that Omicron infection will confer immune protection in imprinted populations. However, SARS-CoV-2 variants with more antigenic drift will induce immune protection less effectively, irrespective of the imprinting status. The effect of immune imprinting depends on the quality and quantity of cross-reactive antibodies. Taken together, long-term WH1 immune imprinting enhances the humoral immune response against Omicron infection with negligible adverse effects, thereby protecting against reinfection. In contrast to the findings of previous studies, the current study concluded that immune imprinting is a beneficial mechanism. *Important notice: Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. Journal reference: Preliminary scientific report. Liu, Y., Zhu, Y., Tang, L., et al. (2023) Humoral immune response to omicron infection in long-term Wuhan-Hu-1-imprinted population. Research Square. doi:10.21203s.3.rs-3024491/v Posted in: Medical Science News | Medical Research News | Disease/Infection News Tags: Antibodies, Antibody, Coronavirus, covid-19, Efficacy, Immune Response, Immune System, immunity, Influenza, Omicron, Pandemic, Pseudovirus, Public Health, Research, Respiratory, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Stomatitis, Syndrome, Virus Comments (0) Written byDr. Priyom BosePriyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer. Download PDF Copy Citations Please use one of the following formats to cite this article in your essay, paper or report:APABose, Priyom. (2023, June 25). Hybrid immunity and vaccine Imprinting: Powerful defenses against Omicron reinfection. News-Medical. Retrieved on November 11, 2024 from https://www.news-medical.netews/20230625/Hybrid-immunity-and-vaccine-Imprinting-Powerful-defenses-against-Omicron-reinfection.aspx.MLABose, Priyom. "Hybrid immunity and vaccine Imprinting: Powerful defenses against Omicron reinfection". News-Medical. 11 November 2024. <https://www.news-medical.netews/20230625/Hybrid-immunity-and-vaccine-Imprinting-Powerful-defenses-against-Omicron-reinfection.aspx>.ChicagoBose, Priyom. "Hybrid immunity and vaccine Imprinting: Powerful defenses against Omicron reinfection". News-Medical. https://www.news-medical.netews/20230625/Hybrid-immunity-and-vaccine-Imprinting-Powerful-defenses-against-Omicron-reinfection.aspx. (accessed November 11, 2024).HarvardBose, Priyom. 2023. Hybrid immunity and vaccine Imprinting: Powerful defenses against Omicron reinfection. News-Medical, viewed 11 November 2024, https://www.news-medical.netews/20230625/Hybrid-immunity-and-vaccine-Imprinting-Powerful-defenses-against-Omicron-reinfection.aspx. Suggested Reading Transcendental Meditation empowers female youth in Uganda with improved self-esteem and resilienceThe efficacy of the Mediterranean diet on health outcomes in adults with cancerTwincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes managementSemaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetesInnovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies showOctavalent intranasal flu vaccine proves effective in neutralizing both existing and emerging strainsEfficacy of acupuncture in improving sleep quality for Parkinson's patientsNovel vaccination strategy shows promise in boosting immunity and controlling influenza spread in pigs Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post TrendingStories LatestInterviews Top HealthArticles Traditional Chinese herb shows promise against Alzheimer’s and Parkinson’sAncient herb shows promise in fighting dementiaBreakthrough research reveals how to target malignant DNA in aggressive cancersLink between COVID-19 and long-term risk of autoimmune and autoinflammatory connective tissue disordersCDC updates pain care guidelines for clinicians Exploring the G:Box and for high-quality imaging Dr Martin Biggs In this interview, News Medical speaks with Dr Martin Biggs from Synoptics about Syngene's G:Box, a high-quality imaging and gel documentation system. Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024 Carolyn Marks and Joel Svensson In this interview, conducted at SfN 2024 in Chicago, News Medical speaks with Joel Svensson and Carolyn Marks of Atlas Antibodies, about their new launch, the MolBoolean™, as well as how conferences like SfN are helping shape the future of neuroscience research. How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics Susan Magsamen The intersection of arts and neuroscience reveals transformative effects on health and learning, as discussed by Susan Magsamen in her neuroaesthetics research. Why You Might Feel Tired After Drinking CoffeeMythbusting: The 10,000 Steps Per Day TrendCan Magnesium Supplements Help You Sleep Better?Challenges in the Global ADHD Medication Supply ChainHow Does Semaglutide Work to Lose Weight? Latest NewsEarly RSV vaccination in pregnancy provides best protection for newbornsBloodletting therapy offers promising treatment for heat strokeTime-restricted eating shows promising weight and metabolic benefits, study revealsProlonged mental fatigue can impair self-control and increase aggressionAI tool tracks infant movement to predict neurologic changes in NICU Newsletters you may be interested in COVID-19 (Subscribe or Preview) Infectious Diseases (Subscribe or Preview) Epilepsy (Subscribe or Preview) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home COVID-19 News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Monday 11 Nov 2024 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2024 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI. Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy. Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms. Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions. Provide Feedback Submit Cancel You might also like... × Evaluating the efficacy of harmol in treating herpes simplex virus-induced keratitisMysterious cat disease in Poland turned out to be avian influenza? — What we know so far [Text updated] - Fakenews.pl Hold on!Creating content like this costs us a lot of time and effort. Could you please consider a small donation? Donate now! Close that window Foundation “Counteracting Disinformation” Report fake news Support us Contact us EN PL Toggle navigation Home Politics General Tech Health Analyzes Foundation Foundation “Counteracting Disinformation” Support us Contact us Wersja PolskaMysterious cat disease in Poland turned out to be avian influenza? — What we know so far [Text updated] Published: 2023-06-30 Modified: 2023-11-04 by Katarzyna Lipka Komentarze A mysterious cat disease in Poland took over social media early last week. The lack of publicly available verified data and the late announcements of the Chief Veterinary Officer were very noticeable in the first days. The resulting information gap and the emotions accompanying these reports created ideal conditions for spreading unproven theories. Official data is very scarce. Here’s what we’ve found so far — we’ll update this article as soon as we get any new and relevant information.Recommendations for cat ownersDo not feed cats raw meat;Keep cats indoors, whenever possible;Any release of the animal to the balcony or terrace should be preceded by cleaning the floor with standard detergents;Prevent contacts between cats and other wild animals, including birds;Prevent cats from coming into contact with footwear that is used outside;Only feed your cats food coming from reliable sources;Wash your hands after touching other animals (follow standard hygiene rules after coming back home).It is likely that infected cats would shed virus via the gut and respiratory tract, so any suspected cases should be isolated from other pets.Cat disease — symptomsIf you notice disturbing symptoms, such as loss of appetite, listlessness, stiffness of the limbs, shortness of breath, pupils of different sizes, pupils that do not react to light, convulsions or epileptic seizures, take your cat to the veterinarian immediately.Cat disease — first reportsThe first information about the observed cases surfaced on a closed veterinary group, where doctors exchanged observations about an unexplained cat disease. On 19 June, the information spread beyond the group thanks to a behaviourist who published a screenshot of one of the posts on her profile and warned Internet users against feeding poultry meat to cats. Understandably, this has caused concern among cat owners.In response to numerous inquiries, veterinary clinics began to publish information on their profiles, urging people to apply basic safety rules, including, above all, not letting cats outside. According to doctors’ observations, the disease attacks both young and old cats, living indoors or outside, fed wet or dry food. The disease is characterized by a rapid course and high mortality rates.Cat disease — official information20 June 2023On Tuesday, the news was addressed by Chief Veterinary officer who stated that at the moment, there is no evidence that the symptoms observed in cats are caused by an infection with the avian influenza virus. The CVO did not have data on the number of sick cats or the results of samples taken from them on that day.On the same day, the Deputy Chief Veterinary Officer sent a letter to the President of the Polish National Veterinary Chamber. In it, he appealed for immediate reporting to district veterinarians of positive results of laboratory tests for avian influenza obtained from animals other than birds, in particular from companion animals. At the same time, they expressed concern about “veterinarians casually and publicly expressing unsubstantiated judgments that the symptoms found in cats are probably the result of infection with avian influenza virus after feeding animals raw poultry or pork.” In the opinion of the CVO, such statements pose a risk of being perceived by the public as a result of the lack of proper supervision over the breeding and slaughter of farm animals and as a threat to food safety.21 June 2023On Wednesday, the Pomeranian Voivodeship Veterinary Officer informed that in the last two weeks, 28 cats with neurological and respiratory symptoms were treated in Gdańsk. Unfortunately, 25 of them did not survive. 22 June 2023On Thursday, Animallab informed that the total number of cases in Poland reached 86.23 June 2023On Friday, the CVO published information about the first results of research conducted at the Veterinary Institute in Puławy. The results of the Tri-City samples indicated an influenza virus. However, the message did not specify the type of virus — research to determine this information was ongoing.24 June 2023On Saturday, a team of the Institute of Veterinary Medicine of the Warsaw University of Life Sciences in cooperation with Dr. hab. Tomasz Dzieciątkowski from the Medical University of Warsaw confirmed an infection with the H5N1 influenza virus in a cat from the Mazowieckie Voivodeship.source: Facebook26 June 2023On 26 June, the CVO issued another announcement. The Institute in Puławy finished examining samples from Lublin and Poznań. In total, 11 samples were tested at the institute, together with the material from Tri-City cats. 9 of them tested positive for H5N1. However, the source of infection remains unknown.source: wetgiw.gov.pl28 June 2023On Wednesday, the CVO informed that the National Veterinary Institute in Puławy received a total of 33 samples from cats from Gdańsk, Gdynia, Poznań, Lublin, Pruszcz Gdański, Nowy Dwór Mazowiecki, Bydgoszcz, Wrocław and the vicinity of Zamość. As of that day, 19 of them were tested and 15 gave positive results for the H5N1 influenza virus. Positive samples came from Gdańsk, Gdynia, Pruszcz Gdański, Lublin, Bydgoszcz and Poznań. With the sample from Warsaw tested earlier at the Warsaw University of Life Sciences, we have a total of 16 confirmed foci of the disease.30 June 2023The University of Gdańsk informed about the results of the cooperation between three research groups led by dr. Łukasz Rąbalski (University of Gdańsk and the Military Institute of Hygiene and Epidemiology), dr. hab. Maciej Grzybek (Medical University of Gdańsk), and prof. dr. hab. Krzysztof Pyrć (Jagiellonian University). The researchers have managed to obtain the first sequence of the H5N1 influenza virus that infects cats in Poland. The sequence has been made public in the GISAID database under the number EPI_ISL_17949824. The abovementioned institutions are conducting further research on the biology, genetics and origin of the virus.3 July 2023 The National Veterinary Research Institute (NVRI) reported the results of the analysis of H5N1 virus genome sequences detected in nine cats from Poznań, the Tri-City and Lublin. All analysed sequences show very close affinity between each other and belong to the CH genotype. This genotype was predominant during the peak of the current avian influenza season (2022/23) and was mainly found in poultry in the Wielkopolskie Voivodship, as well as in wild birds in different regions of the country. The viruses identified in cats are most closely related to the CH genotype virus detected in early June in a white stork in the Tarnów district (outbreak no. 119/2023).The close relatedness of the viruses detected in cats indicates that they originate from a single source linked to the H5N1 viruses circulating in wild birds in Poland in recent weeks. This source remains unidentified for the time being. In addition, molecular analysis indicates the presence of mutations that increase the adaptation of the virus to mammals.Statement by scientists regarding the Gazeta Wyborcza publicationIn connection with the publication scheduled for the next day in Gazeta Wyborcza, a statement by the scientists leading the research teams analysing the recent cat infections — prof. dr. hab. Krzysztof Pyrć, dr. hab. Maciej Grzybek and dr. Łukasz Rąbalski — was published on social media on Monday evening. The text prepared by the Wyborcza newspaper is written in a sensationalist tone, and the scientists express concern about the overinterpretation of the results of their research. In their opinion, it distorts the meaning of the results obtained and may lead to panic as well as economic losses and reputational damages. In view of the situation, the scientists have decided to publish their position and their interpretation of the data obtained.source: TwitterBased on their assessment of the situation, the researchers believe that one of the likely routes of transmission of the pathogen is through food. This conclusion is supported by the following findings:sudden outbreak of the virus in both outdoor and indoor cats in different parts of the country;no outbreaks of infection with cat-to-cat transmission;the analysis of the genome sequence of the virus collected from the cat did not reveal drastic changes compared to reference sequences, which could suggest the emergence of a new influenza virus strain efficiently infecting cats;the similarity of virus sequences that have been isolated from cats in different parts of Poland is very high, suggesting a single source of infection;interviews with cat owners suggested that the source may be raw meat.The researchers asked the caretakers of the sick cats to send in samples of the meat they fed the animals. As a result, they obtained five samples, which they subjected to molecular tests for the virus. One of the five samples tested positive.Further analysis showed that the meat contained not only the genetic material of the virus, but also the infectious virus – we were able to isolate the virus in cell cultures. Although it cannot be ruled out that the virus found its way into the meat samples later, or even that the meat was contaminated by the owners with the virus developing in the cat’s body, it also cannot be ruled out that the raw meat was the source of the infection. In fact, this would not be surprising, as a case of contamination of frozen duck meat with the H5N1 virus was already reported in 2007 [1], resulting in disease outbreaks in Germany. In view of the above, an appeal to the veterinary services and the health inspectorate to examine the meat available in Poland and to consider including meat testing for H5N1 influenza seems justified. This is crucial not only because of the cats, but also because this virus is a threat to human life. In addition, the Polish poultry industry accounts for almost 20% of the EU market and the estimated value of meat exports is over €3 billion. It is worth envisaging the consequences for this sector of the economy if it were to turn out that contaminated meat had found its way to France, Italy or Germany.4 July 2023On Tuesday, Gazeta Wyborcza published the aforementioned text on its website with the corrections sought by the scientists. However, the pre-authorization version of the text was available in the paper edition. The article incorrectly suggested that scientists had confirmed the presence of the avian flu virus in meat available in Polish stores.Wyborcza’s material met with an immediate response from the National Poultry Council – Chamber of Commerce. In an official statement, the Council demands the cessation of publishing information that is not confirmed in official announcements of state services. The poultry industry also expresses interest in a reliable explanation of the case, but believes that the research should be conducted by veterinary and sanitary services. Wild birds are the most likely source of infection, according to poultry farmers. The Council also condemns “any attempt to discredit the quality of Polish meat” and claims that Polish poultry meat “was, is and will be safe.”On that day, the Chief Veterinary Officer decided that infections of companion animals with avian influenza viruses will be subject to the supervision of the Veterinary Inspectorate. Therefore, the CVO prepared templates of documents for the Veterinary Inspectorate and veterinarians: medical and veterinary interview and a letter attached to the samples.An official statement was also released by the Chief Sanitary Inspector. It informs that the State Sanitary Inspectorate has taken preventive measures to prevent the occurrence of the disease in humans, among others by extending epidemiological supervision to the owners of cats confirmed to be infected with the avian influenza virus. These people will be contacted by employees of district sanitary and epidemiological stations. However, the Chief Sanitary Inspector reassures that the risk of infection transmission from a sick cat to a human is negligible.5 July 2023On Wednesday morning, a press conference was held at the Ministry of Agriculture and Rural Development. During the meeting, Deputy Minister Krzysztof Ciecióra assured that there was no threat to consumers. In his opinion, Polish poultry is of high quality, and the information about the avian flu virus in poultry meat is the result of manipulation by the reporters of Gazeta Wyborcza. In his speech, he praised the successes of the Polish poultry sector, including its export value.Next, the director of the Veterinary Institute in Puławy, prof. dr hab. Stanisław Winiarczyk, stated that infections of cats with the H5N1 virus are nothing new and usually outbreaks of infection self-extinguish. A total of 43 samples were tested at the institute and 22 tested positive for H5N1.The Chief Veterinary Officer, Paweł Niemczuk, stated that the numbers of both the samples and the cases of cat diseases are decreasing. Though he did not provide any specific figures. The conference was also attended by the president of the Polish Meat Association — Witold Choiński, whose speech focused on how profitable the Polish poultry industry is.Referring to the appeal of prof. Krzysztof Pyrć to the services to consider including meat testing for H5N1, RMF journalist Maciej Sztykiel asked whether meat is tested in this direction on a daily basis. The question was answered by Paweł Niemczuk:Not every meat is tested on a daily basis. Poultry is. There is a national avian influenza control program and flocks to be sampled are identified. The plan includes over 10,000 flocks, and more than 8,000 have been tested. If the poultry is infected, it shows signs of the disease and you can see it immediately because there are high deaths. But prior to that, animals stop eating, stop drinking, they show symptoms of illness – it shows. Doctors and breeders know very well what avian influenza looks like in poultry; therefore, only healthy poultry can go to the slaughterhouse.Although the situation regarding cat infections has been supervised by the Veterinary Inspectorate, cat owners or veterinary clinics ordering the tests must pay for testing samples from infected animals (1, 2). According to Minister Ciecióra, the only laboratory in Poland that can detect the presence of the virus in meat is the National Veterinary Institute in Puławy. However, the NVI has not tested any meat samples fed to the animals so far.The content of the initially uninformative statement released on 30 June was updated on the CVO’s website. After the update, it provides the results for the samples tested in the NVI (out of 29 samples, 20 tested positive for the H5N1 virus), and the locations the positive samples came from (Gdańsk, Gdynia, Poznań, Lublin, Pruszcz Gdański, Nowy Dwór Mazowiecki, Bydgoszcz and Wrocław). However, it is worth noting that the information was current as of 30 June, 2023.Social mediaAn “investigative” group has been created on Facebook, associating over 9.7 thousand Internet users looking for answers. We understand that this topic evokes great emotions. However, we warn against uncritical faith in information shared on social media. Cases described in such groups can be multiplied, which gives a false impression of the scale of the problem and unnecessarily fuels emotions. Various medicines are also recommended in the group — we urge you not to give medicines to cats without consulting a veterinarian.What is more, numerous narratives relating to the war in Ukraine or vaccines against COVID-19 can be observed in comments on social media. Remember to get information only from reliable sources. Support us This article was created with the support from our donors. Join them and help us post more verifications that will make the internet and media a better place. I decided to support: Sign up to our newsletter. Comments Tagi: animals cats h5n1 influenza False The beating in the school toilet happened in Russia 2023-06-30 False Recent military movements in the U.S. are nothing unusual 2023-07-10 About the Author More from the author Katarzyna Lipka Z wykształcenia biolożka ze szczególną pasją do genetyki. Po godzinach aktywistka prozwierzęca. Zagorzała orędowniczka nauki - szkiełko i oko silniej mówią do niej niż czucie i wiara. Prywatnie interesuje się kryminalistyką. Swoje zapędy śledcze spełniała pracując w trakcie studiów w agencji detektywistycznej. Energię czerpie z kontaktu z dziką przyrodą. Email: klipka(at)fakenews.pl False Iceland has not banned COVID-19 vaccinations 2024-01-02 Adrenochrome, QAnon and Pizzagate 2023-09-04 Waxwings visible in the photo are dead, not drunk with alcohol 2023-01-24 False Joseph Ladapo, Surgeon General of Florida, cites an unreliable analysis of the mRNA vaccine 2022-10-21 You may also likeAbout usThe fakenews.pl portal is a website dedicated to a subject of fake news. You will find here a collection of the latest and archival fake news verifications, interesting publications and articles.Social media Random False No Ukrainians were involved in the beating of young Poles on the Vistulan Boulevards 2023-08-29 False Swiss poster “Snitch on your neighbour, earn 200 francs” is a photo manipulation 2022-09-13 False No, SeaFox was not used by NATO in an attempt to destroy the Nord Stream gas pipeline in 2015 2022-10-21Categories Analyzes 14 Environment 1 General 62 Health 9 Politics 16 Tech 3 © COPYRIGHT 2024 fakenews.pl Foundation “Counteracting Disinformation” Support us Contact us Wersja PolskaPacific Syndromic Surveillance System Weekly Bulletin / Système de Surveillance Syndromique dans le Pacifique - Bulletin Hebdomadaire: W25 2023 (Jun 19 - Jun 25) - Fiji | ReliefWeb Skip to main content Help Log in ReliefWeb Content Search What are you looking for? Search|t Updates Countries Disasters Organizations Topics Jobs Training Informing humanitarians worldwide 24/7 — a service provided by UN OCHA Fiji + 22 more Pacific Syndromic Surveillance System Weekly Bulletin / Système de Surveillance Syndromique dans le Pacifique - Bulletin Hebdomadaire: W25 2023 (Jun 19 - Jun 25) Format Situation Report Source WHO Posted 30 Jun 2023 Originally published 30 Jun 2023 Attachments Download Report (PDF | 500.51 KB) Download Report (PDF | 1.17 MB | Pacific COVID-19 Weekly Epidemiological Update) Download Report (PDF | 102.67 KB) Alerts : AFR: Fiji (21), Wallis & Futuna (1). COVID-19 : Cook Islands (2), CNMI (13), Solomon Islands (1). Influenza-like Illness (ILI) : RMI. Influenza-like Illness (ILI). PSSS, EPI – WK 25, 2023 Influenza-like Illness (ILI) cases compared to WK 24, 2023 ILI cases are as tabulated as below for comparison. For an added perspective on the figures and trends percentage, country sentinel sites reporting for WKs 24 & 25 are also shown. Please refer Seasonal Influenza for Pacific Island Countries and Territories (PICTs) - ILI Surveillance. Actual increase in the number of ILI cases has been seen in RMI and Fiji. The increased ILI cases seen in Vanuatu may be to the increased number of sites reporting for the week. The reduction in the number of ILI cases has been seen in French Polynesia, Solomon Islands, Samoa, New Caledonia, CNMI, and Wallis & Futuna. The decreased ILI cases seen in Tonga may be due to the decreased number of sites reporting for the week. No ILI cases were reported from Cook Islands, Pitcairn Islands and Niue for the week. No reports were available from FSM, Kiribati, Tokelau, Palau, and Tuvalu for the week. American Samoa and Nauru have not participated in the surveillance. Surveillance figures are not intended to capture all country cases but to describe trends over time and are invaluable when trends rise beyond country baselines which should then trigger alerts and timely actions to characterize the actual nature and magnitude of the disease. Avian Influenza Weekly Update: Report details Primary country Fiji Other countries American SamoaCook IslandsFrench Polynesia (France)GuamKiribatiMarshall IslandsMicronesia (Federated States of)NauruNew Caledonia (France)New ZealandNiue (New Zealand)Northern Mariana Islands (The United States of America)PalauPapua New GuineaPitcairn IslandsSamoaSolomon IslandsTokelauTongaTuvaluVanuatuWallis and Futuna (France) Source World Health Organization Format Situation Report Theme Health Disaster type Epidemic Languages EnglishFrench Share Share this on Facebook Share this on X Post this on LinkedIn Related Content Fiji + 29 more Pacific Syndromic Surveillance System Weekly Bulletin / Système de Surveillance Syndromique dans le Pacifique - Bulletin Hebdomadaire: W44 2024 (Oct 28-Nov 8) [EN/FR] Format Situation Report Source WHO Posted 11 Nov 2024 Originally published 11 Nov 2024 Vanuatu Vanuatu: Watery Diarrhoea in Efate- Situation Update 02 - Report Date: 08 November 2024 I Covering Period from 01 January - 03 November 2024 Format News and Press Release Source Govt. Vanuatu Posted 8 Nov 2024 Originally published 8 Nov 2024 PNG DTM Aiya Local Level Government, Southern Highlands Province, Papua New Guinea - Round 01 - Flooding and Landslip Rapid Assessment Report | 01-Nov-2024 Format Assessment Source IOM Posted 8 Nov 2024 Originally published 1 Nov 2024 Kiribati + 3 more AUD 4.9 million to fortify Pacific region against health impacts of climate change Format News and Press Release Source SPREP Posted 8 Nov 2024 Originally published 8 Nov 2024 Blog Labs About Us Terms Contact Facebook X LinkedIn Instagram Telegram OCHA Services Related Platforms Humanitarian Action Central Emergency Response Fund Other OCHA Services Financial Tracking Service Humanitarian Data Exchange Humanitarian ID ReliefWeb Response Inter-Agency Standing Committee OCHA website ReliefWeb Virtual OSOCC More OCHA Services Opens in a new window Service provided by United Nations Office for the Coordination of Humanitarian Affairs UN OCHA United Nations Office for the Coordination of Humanitarian Affairs OCHA coordinates the global emergency response to save lives and protect people in humanitarian crises. We advocate for effective and principled humanitarian action by all, for all. ReliefWeb's Terms & Conditions. © 2024 all rights reserved.What is 'air con flu'? How staying cool may make you sick Primary Menu Sections US News Metro Politics Swing States 2024 World News Page Six Sports NFL MLB Olympics NBA NHL College Football College Basketball WNBA Post Sports+ Sports Betting Business Personal Finance Opinion Entertainment TV Movies Music Celebrities Awards Theater Shopping Lifestyle Weird But True Health Sex & Relationships Viral Trends Human Interest Parenting Fashion & Beauty Food & Drink Travel Real Estate Alexa Media Tech Science Space Environment Wildlife Archaeology Astrology Video Photos Visual Stories Today’s Paper Covers Columnists Horoscopes Crosswords & Games Sports Odds Podcasts Careers Email Newsletters Official Store Home Delivery Tips Search Email New York Post Open main lifestyle navigation Lifestyle Lifestyle Weird But True Health Sex & Relationships Viral Trends Human Interest Astrology Parenting Shopping Fashion & Beauty Food & Drink Travel Health Fitness Health Care Medicine Men’s Health Women’s Health Mental Health Nutrition Health & Wellness Products Personal Care Products Search Search trending now in Lifestyle Skip to main content Miss Universe contestant expelled from competition over... Doctor's 'pizza topping' trick to tell the difference between... I'm a sociopath — here's my one rule in the bedroom Dear Abby: My husband doesn't care about my needs — and refuses... Veterans Day 2024 deals: All the restaurant and retail stores... Millennials defend wearing 'classic' ’50s outerwear — despite... I'm a doctor — beware these foods that may be giving you acid... Mathematicians claim to know the formula for the 'perfect' female... Health What is ‘air con flu’? How staying cool may make you sick By Emily Lefroy Published June 28, 2023 Updated June 28, 2023, 6:13 p.m. ET Explore More I’m a doctor — 5 weird but proven ways to avoid colds and reduce the ‘yuck load’ Apple Watch Vitals app predicts colds, flu, COVID days before they hit, users claim This one simple habit can slash your chances of getting sick this season Keeping cool can make you sick. If you’ve ever felt a sniffle coming on in the summer months — particularly when you’re on vacation — then air conditioning could be to blame. The phenomenon has been widely documented on TikTok, with a few different names coined for the illness, such as “Ayia Napa Flu,” “Air Con Cough” and “Magaluf Flu.” But what is it, and is it a real illness? According to a 2004 study in the Journal of Epidemiology, there is some science to support “air con sickness.” Researchers found that being in air conditioning — if the unit has not been maintained or is in a poorly ventilated building — can cause health problems. Working or living in a poorly ventilated building with air conditioning can raise your risk of “sick building syndrome,” a term used to describe collective symptoms experienced by a building’s occupants, according to the EPA. Symptoms may include headaches, dry cough, dizziness, nausea, trouble concentrating, fatigue and odor sensitivity. Air conditioning can make you sick. Getty Images Researchers found that being in air conditioning — if the unit has not been maintained or is in a poorly ventilated building — can cause health problems. Getty Images/iStockphoto Science ABC reported that when air conditioners are not properly maintained or cleaned, they are potentially filled with bacteria and mold. This can mean that the unit may circulate infected air. Heating, ventilation and air conditioning units are designed to filter air pollutants and contaminants from indoor air, however, if the filters are not cleaned properly they become prime space for air particles and microorganisms to breed. This may trigger asthma, allergies and other respiratory symptoms. “Dirty air conditioning filters may be contaminated with mold, fungus or other microorganisms,” a representative for the California Department of Public Health told Verywell. “This may lead some occupants, especially if sensitive to molds, to have breathing problems.” @drnathanspence #stitch with @younghstuds Hope you all feel better soon 🥺 #flu #holiday #ayia #medicine ♬ original sound – Dr Nathan Spence Last year, Dr. Nathan Spence posted a video to TikTok about why the phenomenon occurs. In the video, he explained there is a type of pneumonia that can be caused by air conditioning. Dirty air conditioning units in hotel rooms can trigger a condition known as Legionnaires’ disease, which causes “an atypical chest infection that requires antibiotics.” The disease is a serious type of pneumonia caused by the Legionella bacteria, which can be contracted by inhaling droplets of water from things like air conditioning or hot tubs, according to the CDC. Filed under air conditioning flu legionnaires’ disease summer TikTok 6/28/23 Read Next US 'ill prepared for a global pandemic,' outgoing CDC chie... The Latest Deals Madden 25 for the PS5 is 50% off while this Early Black Friday deal lasts on Amazon Walmart’s early Black Friday sale is live today: 38 best deals I’d shop now Get ready for Wayfair’s Black Friday sale with the 24 best early deals Veterans Day 2024 deals: All the restaurant and retail stores offering discounts Target’s early Black Friday sale kicks off with up to $200 off vacuums, TVs, more Top Concerts Vividseats: Official Ticketing Partner of New York Post Get seats. Earn rewards. Experience it live. Taylor Swift 9 Shows | Get Tickets Coldplay 30 Shows | Get Tickets George Strait 1 Shows | Get Tickets Adele 4 Shows | Get Tickets The Eagles 16 Shows | Get Tickets See More Shows Trending Now ON NYPOST.COM This story has been shared 59,149 times. 59,149 Atlanta Falcons owner gave younger lover a cushy job on his private jet -- while forcing other flight attendants to work overtime: suit This story has been shared 58,766 times. 58,766 Sean 'Diddy' Combs housed in low-security jail dorm alongside SBF— where inmates can spy on female convicts: sources This story has been shared 55,371 times. 55,371 Hackers are targeting people who type these six words into their computer This story has been shared 51,013 times. 51,013 Trump set to select Sen. Marco Rubio to serve as secretary of state in historic appointment: report This story has been shared 44,573 times. 44,573 Prince Harry and Meghan Markle share new video message: 'We are at a crossroads' What to Shop Now Ruggable splashes its rugs with festive flair: Shop the holiday collection now Celebrate with savings: 30 businesses offering military discounts and sales for Veteran's Day 2024 Step into Dutton style: Ariat teams up with 'Yellowstone' to create a new Western collection You can already shop Target's early Black Friday deals: Our top 35 picks are up to 62% off now Celebrate Black Friday all month long! Shop 35 expert-picked Amazon early Black Friday deals on sell-out-risk gifts Now on Page Six Chris Wallace quits CNN after three years to explore streaming and podcasting Why Kevin Costner is not in a ‘rush’ to see his final ‘Yellowstone’ episode Fans think Jessica Simpson’s cryptic post is hint at Eric Johnson split See All Now on Decider Ana Navarro Delivers Spiteful Warning To Trump Voters On ‘The View’: “You Screwed Around And You’re About To Find Out” See All More Stories Page Six 'Yellowstone' Season 5 Part 2 is finally here—Here's how to watch for free NYPost Sean 'Diddy' Combs housed in low-security jail dorm alongside SBF— where inmates can spy on female convicts: sources Facebook Twitter Instagram LinkedIn Email YouTube Sections & Features US News Metro World News Sports Sports Betting Business Opinion Entertainment Fashion & Beauty Shopping Lifestyle Real Estate Media Tech Science Health Travel Astrology Video Photos Visual Stories Alexa Covers Horoscopes Sports Odds Podcasts Crosswords & Games Columnists Classifieds Post Sports+ Subscribe Articles Manage Newsletters & Feeds Email Newsletters RSS Feeds NY Post Official Store Home Delivery Subscribe Manage Subscription Delivery Help Help/Support About New York Post Customer Service Apps Help Community Guidelines Contact Us Tips Newsroom Letters to the Editor Licensing & Reprints Careers Vulnerability Disclosure Program Apps iPhone App iPad App Android Phone Android Tablet Advertise Media Kit Contact © 2024 NYP Holdings, Inc. All Rights Reserved Terms of Use Membership Terms Privacy Notice Sitemap Your California Privacy Rights Do Not Sell My Personal Information